No., subject, TM-score, RMSD, Sequence Identity, Subject length, Aligned length, Description
1, 3ikaB, 1.0000, 0.00, 1.000, 310, 310, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
2, 4wd5B, 0.9712, 0.75, 0.993, 304, 304, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH QL-X138
3, 2jitB, 0.9691, 1.19, 0.987, 312, 308, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
4, 5xgnB, 0.9614, 1.10, 0.997, 308, 304, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
5, 2jiuB, 0.9562, 0.75, 0.993, 309, 300, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
6, 4g5pB, 0.9483, 1.16, 0.993, 303, 301, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
7, 3w2rA, 0.8823, 1.73, 0.872, 297, 290, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 4
8, 2jitA, 0.8814, 1.89, 0.880, 299, 292, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
9, 3w32A, 0.8782, 2.49, 0.836, 317, 299, EGFR KINASE DOMAIN COMPLEXED WITH COMPOUND 20A
10, 3ikaA, 0.8746, 2.35, 0.834, 310, 296, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
11, 4g5pA, 0.8724, 2.05, 0.863, 299, 292, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
12, 3pp0B, 0.8716, 2.10, 0.704, 296, 291, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
13, 2jiuA, 0.8710, 2.02, 0.862, 303, 290, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
14, 5xgnA, 0.8662, 2.26, 0.842, 302, 292, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
15, 4ll0A, 0.8590, 2.18, 0.857, 291, 287, EGFR L858R/T790M IN COMPLEX WITH PD168393
16, 3gopA, 0.8542, 1.64, 0.986, 300, 278, CRYSTAL STRUCTURE OF THE EGF RECEPTOR JUXTAMEMBRANE AND KINASE DOMAINS
17, 4wd5A, 0.8514, 2.44, 0.846, 307, 292, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH QL-X138
18, 1xkkA, 0.8489, 2.34, 0.829, 289, 286, EGFR KINASE DOMAIN COMPLEXED WITH A QUINAZOLINE INHIBITOR- GW572016
19, 4ll0B, 0.8465, 1.69, 0.863, 281, 278, EGFR L858R/T790M IN COMPLEX WITH PD168393
20, 3w2sA, 0.8450, 2.60, 0.856, 307, 291, EGFR KINASE DOMAIN WITH COMPOUND4
21, 4i21B, 0.8444, 2.30, 0.834, 302, 283, CRYSTAL STRUCTURE OF L858R + T790M EGFR KINASE DOMAIN IN COMPLEX WITH MIG6 PEPTIDE
22, 4i20A, 0.8414, 2.00, 0.821, 287, 280, CRYSTAL STRUCTURE OF MONOMERIC (V948R) PRIMARY ONCOGENIC MUTANT L858R EGFR KINASE DOMAIN
23, 4lrmA, 0.8410, 2.78, 0.788, 307, 293, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
24, 4i1zA, 0.8408, 2.02, 0.836, 287, 280, CRYSTAL STRUCTURE OF THE MONOMERIC (V948R) FORM OF THE GEFITINIB/ERLOTINIB RESISTANT EGFR KINASE DOMAIN L858R+T790M
25, 3w33A, 0.8408, 2.28, 0.883, 297, 283, EGFR KINASE DOMAIN COMPLEXED WITH COMPOUND 19B
26, 4i21A, 0.8405, 2.00, 0.842, 290, 279, CRYSTAL STRUCTURE OF L858R + T790M EGFR KINASE DOMAIN IN COMPLEX WITH MIG6 PEPTIDE
27, 5jebA, 0.8397, 2.56, 0.817, 299, 289, CRYSTAL STRUCTURE OF EGFR TYROSINE KINASE DOMAIN WITH NOVEL INHIBITOR OF ACTIVE STATE OF HER2
28, 3pozA, 0.8392, 2.47, 0.877, 293, 285, EGFR KINASE DOMAIN COMPLEXED WITH TAK-285
29, 2rgpA, 0.8382, 2.20, 0.843, 284, 280, STRUCTURE OF EGFR IN COMPLEX WITH HYDRAZONE A POTENT DUAL INHIBITOR
30, 5hg5A, 0.8379, 2.43, 0.806, 302, 284, EGFR (L858R T790M V948R) IN COMPLEX WITH N-{3-[(2-{[4-(4- METHYLPIPERAZIN-1-YL)PHENYL]AMINO}-7H-PYRROLO[23-D]PYRIMIDIN-4-YL) OXY]PHENYL}PROP-2-ENAMIDE
31, 4zjvA, 0.8376, 1.83, 0.841, 282, 276, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH MITOGEN- INDUCIBLE GENE 6 PROTEIN
32, 5hg8A, 0.8371, 2.56, 0.804, 300, 285, EGFR (L858R T790M V948R) IN COMPLEX WITH N-[3-({2-[(1-METHYL-1H- PYRAZOL-4-YL)AMINO]-7H-PYRROLO[23-D]PYRIMIDIN-4-YL}OXY)PHENYL]PROP- 2-ENAMIDE
33, 5u8lA, 0.8360, 2.43, 0.809, 289, 283, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH A SULFONYL FLUORIDE PROBE XO44
34, 3pp0A, 0.8347, 2.21, 0.707, 286, 280, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
35, 5x2fD, 0.8334, 2.43, 0.854, 309, 281, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(6)
36, 2rfeA, 0.8286, 2.35, 0.821, 286, 279, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
37, 5cnnB, 0.8282, 2.35, 0.842, 304, 279, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT I682Q
38, 5x2aB, 0.8276, 2.42, 0.846, 322, 279, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(3)
39, 3belA, 0.8273, 2.19, 0.844, 280, 276, X-RAY STRUCTURE OF EGFR IN COMPLEX WITH OXIME INHIBITOR
40, 4lrmE, 0.8263, 2.29, 0.861, 290, 281, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
41, 2r4bA, 0.8261, 2.00, 0.696, 292, 273, ERBB4 KINASE DOMAIN COMPLEXED WITH A THIENOPYRIMIDINE INHIBITOR
42, 5x2fB, 0.8260, 2.40, 0.849, 312, 279, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(6)
43, 4zseA, 0.8258, 2.40, 0.828, 297, 279, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
44, 5d41B, 0.8251, 2.30, 0.830, 302, 277, EGFR KINASE DOMAIN IN COMPLEX WITH MUTANT SELECTIVE ALLOSTERIC INHIBITOR
45, 4lrmC, 0.8244, 2.34, 0.836, 293, 281, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
46, 2rfdB, 0.8241, 2.49, 0.864, 286, 279, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
47, 2gs7B, 0.8241, 2.36, 0.812, 288, 277, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
48, 2r4bB, 0.8236, 1.99, 0.699, 291, 272, ERBB4 KINASE DOMAIN COMPLEXED WITH A THIENOPYRIMIDINE INHIBITOR
49, 4zseB, 0.8234, 2.68, 0.839, 313, 280, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
50, 4i24B, 0.8230, 2.38, 0.855, 304, 276, STRUCTURE OF T790M EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH DACOMITINIB
51, 5ugaA, 0.8229, 2.22, 0.819, 283, 277, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH 4-(4-{[2-{[(3S)-1-ACETYLPYRROLIDIN-3-YL]AMINO}-9- (PROPAN-2-YL)-9H-PURIN-6-YL]AMINO}PHENYL)-1-METHYLPIPERAZIN-1-IUM
52, 4tksA, 0.8223, 3.02, 0.845, 307, 291, NATIVE-SAD PHASING FOR HUMAN EGFR KINASE DOMAIN.
53, 5x2cB, 0.8220, 2.38, 0.834, 303, 277, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(5)
54, 5x2cA, 0.8219, 2.41, 0.827, 304, 278, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(5)
55, 4riyD, 0.8216, 2.43, 0.854, 297, 281, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
56, 2rfdA, 0.8212, 2.61, 0.849, 288, 279, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
57, 5x2fA, 0.8209, 2.34, 0.855, 301, 275, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(6)
58, 5x2aA, 0.8206, 2.34, 0.840, 297, 275, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(3)
59, 5hg7A, 0.8203, 2.02, 0.864, 280, 273, EGFR (L858R T790M V948R) IN COMPLEX WITH 1-{(3R4R)-3-[5-CHLORO-2- (1-METHYL-1H-PYRAZOL-4-YLAMINO)-7H-PYRROLO[23-D]PYRIMIDIN-4- YLOXYMETHYL]-4-METHOXY-PYRROLIDIN-1-YL}PROPENONE (PF-06459988)
60, 4zjvB, 0.8201, 1.86, 0.848, 273, 270, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH MITOGEN- INDUCIBLE GENE 6 PROTEIN
61, 2j5eA, 0.8195, 3.03, 0.849, 309, 291, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 13-JAB
62, 5x2aD, 0.8194, 2.31, 0.843, 297, 274, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(3)
63, 4rixD, 0.8194, 2.49, 0.854, 297, 281, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
64, 2gs6A, 0.8194, 3.14, 0.842, 311, 292, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AN ATP ANALOG-PEPTIDE CONJUGATE
65, 4riwD, 0.8189, 2.48, 0.854, 297, 281, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
66, 5hg9A, 0.8188, 2.06, 0.868, 280, 273, EGFR (L858R T790M V948R) IN COMPLEX WITH 1-[(3R4R)-3-[({2-[(1- METHYL-1H-PYRAZOL-4-YL)AMINO]-7H-PYRROLO[23-D]PYRIMIDIN-4-YL}OXY) METHYL]-4-(TRIFLUOROMETHYL)PYRROLIDIN-1-YL]PROP-2-EN-1-ONE
67, 5d41A, 0.8187, 2.28, 0.818, 300, 275, EGFR KINASE DOMAIN IN COMPLEX WITH MUTANT SELECTIVE ALLOSTERIC INHIBITOR
68, 5gnkA, 0.8186, 2.06, 0.867, 277, 271, CRYSTAL STRUCTURE OF EGFR 696-988 T790M IN COMPLEX WITH LXX-6-34
69, 3gt8C, 0.8186, 2.37, 0.851, 296, 275, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
70, 5hibA, 0.8184, 3.27, 0.791, 314, 296, EGFR KINASE DOMAIN MUTANT TMLR WITH A PYRAZOLOPYRIMIDINE INHIBITOR
71, 5x2fC, 0.8179, 2.40, 0.840, 302, 275, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(6)
72, 5wnoA, 0.8174, 2.98, 0.343, 302, 289, CRYSTAL STRUCTURE OF C. ELEGANS LET-23 KINASE DOMAIN COMPLEXED WITH AMP-PNP
73, 5cnoA, 0.8169, 2.32, 0.839, 300, 274, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT V924R
74, 5yu9D, 0.8167, 2.33, 0.850, 300, 274, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH IBRUTINIB
75, 4zseD, 0.8167, 2.37, 0.836, 297, 275, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
76, 4zseC, 0.8166, 2.41, 0.840, 301, 275, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
77, 3gt8A, 0.8166, 2.33, 0.829, 300, 275, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
78, 5ug9A, 0.8163, 2.11, 0.868, 280, 273, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH A COVALENT INHIBITOR N-[(3R4R)-4-FLUORO-1-{6-[(3- METHOXY-1-METHYL-1H-PYRAZOL-4-YL)AMINO]-9-(PROPAN-2-YL)-9H-PURIN-2- YL}PYRROLIDIN-3-YL]PROPANAMIDE
79, 3gt8B, 0.8158, 2.31, 0.825, 292, 274, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
80, 2itpA, 0.8158, 3.18, 0.777, 305, 291, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AEE788
81, 5xdkA, 0.8155, 3.17, 0.856, 307, 291, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH CO-1686
82, 5cnoB, 0.8155, 2.50, 0.833, 302, 276, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT V924R
83, 5cnnA, 0.8153, 2.41, 0.840, 300, 275, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT I682Q
84, 5em8A, 0.8152, 3.14, 0.841, 303, 290, EGFR KINASE DOMAIN WITH PYRIDONE COMPOUND 13: 4-[(2-METHOXYPHENYL) AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2-OXIDANYLIDENE-1~{H}- PYRIDINE-3-CARBOXAMIDE
85, 2rf9A, 0.8151, 2.11, 0.864, 280, 272, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
86, 4li5A, 0.8150, 2.66, 0.812, 306, 282, EGFR-K IN COMPLEX WITH N-[3-[[5-CHLORO-4-(1H-INDOL-3-YL)PYRIMIDIN-2- YL]AMINO]-4-METHOXY-PHENYL] PROP-2-ENAMIDE
87, 2j6mA, 0.8150, 3.10, 0.772, 306, 289, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AEE788
88, 5x2aC, 0.8149, 2.47, 0.840, 303, 275, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(3)
89, 5yu9C, 0.8148, 2.47, 0.861, 306, 274, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH IBRUTINIB
90, 5ug8A, 0.8148, 2.14, 0.868, 280, 273, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH A COVALENT INHIBITOR N-[(3R4R)-4-FLUORO-1-{6-[(1- METHYL-1H-PYRAZOL-4-YL)AMINO]-9-(PROPAN-2-YL)-9H-PURIN-2- YL}PYRROLIDIN-3-YL]PROPANAMIDE
91, 5ugcA, 0.8147, 2.14, 0.868, 280, 273, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH A COVALENT INHIBITOR N-[(3R4R)-4-FLUORO-1-{6-[(3- METHOXY-1-METHYL-1H-PYRAZOL-4-YL)AMINO]-9-METHYL-9H-PURIN-2- YL}PYRROLIDIN-3-YL]PROPANAMIDE
92, 4r3pA, 0.8147, 3.32, 0.840, 310, 294, CRYSTAL STRUCTURES OF EGFR IN COMPLEX WITH MIG6
93, 3gt8D, 0.8137, 2.21, 0.845, 295, 271, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
94, 5gtyA, 0.8128, 2.31, 0.861, 300, 273, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
95, 5gtzA, 0.8127, 3.46, 0.826, 317, 298, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH JTS-1-39
96, 2gs2A, 0.8121, 3.23, 0.849, 305, 291, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN
97, 5czhA, 0.8113, 3.40, 0.772, 311, 294, EGFR L858R MUTANT IN COMPLEX WITH AN OPTIMAL PEPTIDE SUBSTRATE
98, 3w2qA, 0.8110, 3.28, 0.808, 307, 292, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH HKI-272
99, 4lrmB, 0.8109, 2.77, 0.783, 293, 281, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
100, 5cziA, 0.8108, 3.37, 0.840, 310, 293, EGFR L858R MUTANT IN COMPLEX WITH A SHC PEPTIDE SUBSTRATE
101, 5cavA, 0.8108, 3.17, 0.786, 306, 290, EGFR KINASE DOMAIN WITH COMPOUND 41A
102, 4lrmD, 0.8108, 2.43, 0.842, 289, 278, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
103, 5gtyB, 0.8107, 2.33, 0.853, 299, 272, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
104, 4riyB, 0.8105, 2.41, 0.852, 293, 277, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
105, 2itxA, 0.8105, 3.34, 0.829, 307, 292, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AMP- PNP
106, 3rcdC, 0.8098, 2.39, 0.699, 281, 276, HER2 KINASE DOMAIN COMPLEXED WITH TAK-285
107, 4lqmA, 0.8097, 3.14, 0.828, 305, 290, EGFR L858R IN COMPLEX WITH PD168393
108, 3rcdA, 0.8096, 2.39, 0.699, 281, 276, HER2 KINASE DOMAIN COMPLEXED WITH TAK-285
109, 5gtyH, 0.8093, 2.32, 0.867, 300, 271, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
110, 2j5fA, 0.8093, 3.19, 0.814, 308, 291, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 34-JAB
111, 5yu9A, 0.8092, 2.32, 0.867, 302, 271, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH IBRUTINIB
112, 5ugbA, 0.8092, 2.94, 0.837, 307, 283, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN IN COMPLEX WITH 4-(4-{[2- {[(3S)-1-ACETYLPYRROLIDIN-3-YL]AMINO}-9-(PROPAN-2-YL)-9H-PURIN-6- YL]AMINO}PHENYL)-1-METHYLPIPERAZIN-1-IUM
113, 5gtyG, 0.8091, 2.39, 0.867, 299, 271, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
114, 4i22A, 0.8085, 2.33, 0.852, 297, 271, STRUCTURE OF THE MONOMERIC (V948R)GEFITINIB/ERLOTINIB RESISTANT DOUBLE MUTANT (L858R+T790M) EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH GEFITINIB
115, 4r3rA, 0.8083, 3.37, 0.818, 309, 292, CRYSTAL STRUCTURES OF EGFR IN COMPLEX WITH MIG6
116, 4rixB, 0.8082, 2.47, 0.852, 293, 277, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
117, 2eb2A, 0.8081, 3.14, 0.854, 305, 288, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (G719S)
118, 5x28A, 0.8080, 3.24, 0.829, 310, 292, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH SKLB(6)
119, 2itqA, 0.8074, 3.09, 0.819, 300, 287, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AFN941
120, 2gs7A, 0.8073, 2.33, 0.819, 281, 271, CRYSTAL STRUCTURE OF THE INACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AMP-PNP
121, 3w2oA, 0.8070, 3.32, 0.808, 305, 292, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH TAK-285
122, 5gtyF, 0.8069, 2.31, 0.856, 297, 270, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
123, 4hjoA, 0.8069, 2.16, 0.825, 278, 268, CRYSTAL STRUCTURE OF THE INACTIVE EGFR TYROSINE KINASE DOMAIN WITH ERLOTINIB
124, 4riwB, 0.8068, 2.48, 0.852, 293, 277, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
125, 3w2pA, 0.8064, 3.33, 0.810, 308, 290, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 2
126, 5j9yA, 0.8058, 3.02, 0.856, 300, 285, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1B
127, 5x2kA, 0.8047, 3.35, 0.817, 314, 295, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH WZ4003
128, 4wkqA, 0.8045, 2.77, 0.871, 296, 280, 1.85 ANGSTROM STRUCTURE OF EGFR KINASE DOMAIN WITH GEFITINIB
129, 3ug2A, 0.8043, 3.03, 0.874, 299, 285, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH GEFITINIB
130, 3bceB, 0.8042, 2.62, 0.705, 286, 278, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
131, 3bceC, 0.8038, 2.63, 0.698, 286, 278, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
132, 6d8eA, 0.8037, 3.23, 0.758, 304, 289, DISCOVERY OF A HIGHLY POTENT AND BROADLY EFFECTIVE EGFR AND HER2 EXON 20 INSERTION MUTANT INHIBITOR 
133, 5yu9B, 0.8036, 2.44, 0.870, 295, 270, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH IBRUTINIB
134, 2rf9B, 0.8036, 1.95, 0.823, 269, 266, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
135, 4i24A, 0.8034, 2.24, 0.869, 295, 267, STRUCTURE OF T790M EGFR KINASE DOMAIN CO-CRYSTALLIZED WITH DACOMITINIB
136, 5gtyC, 0.8031, 2.26, 0.859, 295, 269, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
137, 2itwA, 0.8028, 3.16, 0.815, 300, 287, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AFN941
138, 5gtyE, 0.8022, 2.35, 0.859, 297, 270, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
139, 3vjnA, 0.8020, 3.13, 0.863, 297, 285, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH AMPPNP.
140, 5gtyD, 0.8018, 2.31, 0.862, 297, 269, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
141, 4i23A, 0.8017, 3.00, 0.851, 304, 281, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH DACOMITINIB (SOAKED)
142, 3ug1A, 0.8017, 3.01, 0.799, 296, 283, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN THE APO FORM
143, 5x26A, 0.8008, 3.17, 0.833, 302, 287, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH SKLB(3)
144, 2itoA, 0.8008, 3.21, 0.771, 303, 288, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH IRESSA
145, 2itzA, 0.8002, 3.28, 0.765, 302, 289, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH IRESSA
146, 5x27A, 0.8000, 3.19, 0.833, 302, 287, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH SKLB(5)
147, 1m17A, 0.7999, 2.90, 0.807, 312, 280, EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE DOMAIN WITH 4-ANILINOQUINAZOLINE INHIBITOR ERLOTINIB
148, 3vjoA, 0.7998, 2.99, 0.873, 298, 283, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH AMPPNP.
149, 4jq8A, 0.7996, 2.87, 0.796, 303, 279, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4B
150, 3bceA, 0.7984, 2.67, 0.697, 285, 277, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
151, 5y9tA, 0.7981, 3.19, 0.789, 300, 285, CRYSTAL STRUCTURE OF EGFR T790M MUTANT IN COMPLEX WITH NAQUOTINIB 
152, 5feqA, 0.7974, 2.89, 0.864, 290, 280, EGFR KINASE DOMAIN IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE
153, 2jivA, 0.7970, 2.06, 0.876, 270, 266, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPEX WITH HKI-272
154, 4jrvA, 0.7967, 2.81, 0.853, 300, 278, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4C
155, 2rfeB, 0.7962, 2.27, 0.820, 273, 267, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
156, 2jivB, 0.7959, 2.17, 0.865, 272, 266, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPEX WITH HKI-272
157, 3kexA, 0.7958, 2.35, 0.504, 292, 270, CRYSTAL STRUCTURE OF THE CATALYTICALLY INACTIVE KINASE DOMAIN OF THE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
158, 4jr3A, 0.7957, 2.99, 0.800, 303, 280, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 3G
159, 2ittA, 0.7957, 3.26, 0.767, 302, 287, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AEE788
160, 4jq7A, 0.7956, 2.99, 0.800, 303, 280, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 2A
161, 3kexB, 0.7955, 2.36, 0.504, 283, 270, CRYSTAL STRUCTURE OF THE CATALYTICALLY INACTIVE KINASE DOMAIN OF THE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
162, 2rfeD, 0.7935, 2.55, 0.867, 278, 270, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
163, 5gmpA, 0.7934, 3.47, 0.769, 305, 290, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH XTF-262
164, 5fedA, 0.7932, 2.91, 0.875, 288, 279, EGFR KINASE DOMAIN IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
165, 2itnA, 0.7932, 3.36, 0.767, 304, 288, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AMP-PNP
166, 4g5jA, 0.7931, 2.58, 0.867, 307, 271, CRYSTAL STRUCTURE OF EGFR KINASE IN COMPLEX WITH BIBW2992
167, 2ityA, 0.7923, 3.23, 0.849, 300, 285, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH IRESSA
168, 5uwdA, 0.7920, 2.34, 0.831, 271, 267, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH THE COVALENT INHIBITOR CO-1686
169, 1m14A, 0.7920, 2.96, 0.802, 307, 278, TYROSINE KINASE DOMAIN FROM EPIDERMAL GROWTH FACTOR RECEPTOR
170, 2itvA, 0.7918, 3.37, 0.764, 303, 288, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AMP-PNP
171, 5hicA, 0.7917, 3.13, 0.859, 302, 283, EGFR KINASE DOMAIN MUTANT TMLR WITH A IMIDAZOPYRIDINYL- AMINOPYRIMIDINE INHIBITOR
172, 5hczA, 0.7913, 2.98, 0.854, 300, 280, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-AZETIDINYL AZAINDAZOLE COMPOUND 21
173, 5hcyA, 0.7912, 3.03, 0.854, 302, 281, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-CARBOXAMIDE AZAINDOLE COMPOUND 13
174, 6gl9B, 0.7904, 2.34, 0.294, 291, 269, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 10 (FM475) 
175, 6gl9A, 0.7901, 2.34, 0.294, 292, 269, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 10 (FM475) 
176, 5hcxA, 0.7900, 2.92, 0.860, 298, 279, EGFR KINASE DOMAIN MUTANT TMLR WITH AZABENZIMIDAZOLE COMPOUND 7
177, 4otwA, 0.7898, 2.15, 0.519, 272, 264, HER3 PSEUDOKINASE DOMAIN BOUND TO BOSUTINIB
178, 3bbwB, 0.7897, 2.36, 0.691, 275, 265, CRYSTAL STRUCTURE OF THE ERBB4 KINASE IN ITS INACTIVE CONFORMATION
179, 6bbvA, 0.7893, 2.07, 0.306, 289, 265, CRYSTAL STRUCTURE OF JAK2 IN COMPLEX WITH COMPOUND 25
180, 5zwjA, 0.7891, 1.98, 0.859, 267, 262, CRYSTAL STRUCTURE OF EGFR 675-1022 T790M/C797S/V948R IN COMPLEX WITH EAI045 
181, 5lwmA, 0.7891, 2.27, 0.295, 290, 268, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 4 (FM381)
182, 2ituA, 0.7890, 3.45, 0.765, 304, 289, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AFN941
183, 5lwnA, 0.7889, 2.27, 0.295, 290, 268, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 5 (FM409)
184, 3bbtB, 0.7888, 2.34, 0.675, 274, 265, CRYSTAL STRUCTURE OF THE ERBB4 KINASE IN COMPLEX WITH LAPATINIB
185, 3bbwA, 0.7886, 2.31, 0.679, 268, 265, CRYSTAL STRUCTURE OF THE ERBB4 KINASE IN ITS INACTIVE CONFORMATION
186, 3q32B, 0.7877, 2.29, 0.307, 294, 267, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
187, 5em6A, 0.7871, 3.02, 0.793, 301, 280, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 19: 4-[(2- AZANYLPYRIMIDIN-4-YL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]- 2-OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
188, 5calA, 0.7868, 3.16, 0.851, 300, 281, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 24
189, 5casA, 0.7866, 3.03, 0.861, 299, 280, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41A
190, 5canA, 0.7866, 3.07, 0.819, 301, 281, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 27
191, 4rixA, 0.7866, 2.29, 0.502, 269, 265, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
192, 3rcdB, 0.7864, 2.30, 0.682, 271, 267, HER2 KINASE DOMAIN COMPLEXED WITH TAK-285
193, 3rcdD, 0.7860, 2.30, 0.682, 271, 267, HER2 KINASE DOMAIN COMPLEXED WITH TAK-285
194, 5tq5A, 0.7859, 2.19, 0.294, 291, 265, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
195, 5feeA, 0.7859, 2.90, 0.888, 287, 276, EGFR KINASE DOMAIN T790M MUTANT IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
196, 4rj7A, 0.7858, 2.95, 0.863, 295, 278, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 1
197, 5cauA, 0.7857, 3.00, 0.864, 297, 279, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41B
198, 4zauA, 0.7857, 2.70, 0.861, 283, 273, AZD9291 COMPLEX WITH WILD TYPE EGFR
199, 5caqA, 0.7856, 3.16, 0.851, 301, 282, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 33
200, 5tq8A, 0.7855, 2.19, 0.306, 291, 265, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
201, 4riyA, 0.7854, 2.27, 0.498, 269, 265, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
202, 5cf5B, 0.7852, 2.33, 0.307, 294, 267, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
203, 5c8nA, 0.7849, 3.21, 0.855, 300, 282, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 23
204, 4rj6A, 0.7848, 3.29, 0.858, 297, 282, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 4
205, 6glbB, 0.7846, 2.33, 0.292, 288, 267, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 20 (FM484) 
206, 5cf6B, 0.7846, 2.28, 0.308, 290, 266, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
207, 5em7A, 0.7844, 3.05, 0.796, 300, 279, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 13: 4-[(2- METHOXYPHENYL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
208, 4riwA, 0.7842, 2.30, 0.506, 269, 265, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
209, 6glbA, 0.7841, 2.33, 0.292, 288, 267, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 20 (FM484) 
210, 5cf4B, 0.7840, 2.35, 0.307, 291, 267, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
211, 5capA, 0.7840, 3.27, 0.813, 303, 284, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 30
212, 5c8kA, 0.7840, 3.35, 0.845, 300, 284, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 1
213, 4e6qB, 0.7839, 2.43, 0.297, 296, 269, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
214, 4aqcB, 0.7837, 2.31, 0.301, 295, 266, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
215, 3lmgB, 0.7834, 2.20, 0.521, 268, 263, CRYSTAL STRUCTURE OF THE ERBB3 KINASE DOMAIN IN COMPLEX WITH AMP-PNP
216, 2rfeC, 0.7833, 2.10, 0.869, 262, 259, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
217, 3pjcA, 0.7832, 2.31, 0.321, 286, 265, CRYSTAL STRUCTURE OF JAK3 COMPLEXED WITH A POTENT ATP SITE INHIBITOR SHOWING HIGH SELECTIVITY WITHIN THE JANUS KINASE FAMILY
218, 2fo0A, 0.7832, 2.96, 0.325, 465, 277, ORGANIZATION OF THE SH3-SH2 UNIT IN ACTIVE AND INACTIVE FORMS OF THE C-ABL TYROSINE KINASE
219, 3fupB, 0.7831, 2.31, 0.297, 287, 266, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
220, 6glaA, 0.7830, 2.33, 0.297, 288, 266, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 11 (FM481) 
221, 3lzbB, 0.7829, 1.84, 0.857, 265, 258, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
222, 6glaB, 0.7828, 2.34, 0.293, 286, 266, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 11 (FM481) 
223, 3q32A, 0.7828, 2.45, 0.301, 291, 269, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
224, 4rj4A, 0.7827, 3.10, 0.792, 299, 279, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 6
225, 4ivaA, 0.7823, 2.40, 0.297, 290, 269, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-[(8AS)- 2-[(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(8AH)- YL]CYCLOHEXANECARBONITRILE
226, 2b7aB, 0.7823, 2.34, 0.308, 287, 266, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
227, 4zimB, 0.7821, 2.39, 0.307, 294, 267, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
228, 4rj8A, 0.7821, 3.04, 0.860, 298, 279, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 8
229, 4e6qA, 0.7817, 2.48, 0.297, 296, 269, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
230, 3lmgA, 0.7817, 2.18, 0.515, 268, 262, CRYSTAL STRUCTURE OF THE ERBB3 KINASE DOMAIN IN COMPLEX WITH AMP-PNP
231, 4p7eB, 0.7816, 2.34, 0.308, 285, 266, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
232, 5cf6A, 0.7814, 2.22, 0.306, 285, 265, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
233, 4wrgA, 0.7812, 2.83, 0.883, 289, 273, 1.9 ANGSTROM STRUCTURE OF EGFR KINASE DOMAIN
234, 3tjcB, 0.7811, 2.35, 0.308, 287, 266, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
235, 4ji9B, 0.7810, 2.33, 0.308, 288, 266, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
236, 4hvgA, 0.7807, 2.35, 0.303, 281, 267, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-2-HYDROXY-12-DIMETHYL-PROPYL)- AMIDE
237, 4e6dB, 0.7803, 2.37, 0.300, 286, 267, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
238, 4aqcA, 0.7803, 2.37, 0.303, 289, 267, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
239, 4riyC, 0.7800, 2.11, 0.513, 275, 261, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
240, 4f08B, 0.7800, 2.35, 0.300, 288, 267, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
241, 5cf5A, 0.7799, 2.30, 0.309, 287, 265, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
242, 5c8mA, 0.7799, 3.27, 0.777, 302, 282, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 17
243, 4rixC, 0.7798, 2.12, 0.513, 275, 261, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
244, 4f08A, 0.7798, 2.34, 0.300, 288, 267, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
245, 3tjdB, 0.7798, 2.38, 0.308, 287, 266, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
246, 3krrA, 0.7798, 2.36, 0.308, 291, 266, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT QUINOXALINE ATP SITE INHIBITOR
247, 3e62A, 0.7795, 2.44, 0.303, 291, 267, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
248, 5aepA, 0.7794, 2.32, 0.302, 287, 265, NOVEL PYRROLE CARBOXAMIDE INHIBITORS OF JAK2 AS POTENTIAL TREATMENT OF MYELOPROLIFERATIVE DISORDERS
249, 3lzbA, 0.7792, 1.92, 0.860, 265, 258, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
250, 4riwC, 0.7791, 2.18, 0.523, 275, 262, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
251, 4hgeB, 0.7791, 2.37, 0.308, 288, 266, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
252, 3e64A, 0.7788, 2.39, 0.308, 291, 266, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
253, 4r5sA, 0.7787, 3.44, 0.761, 299, 285, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH FIIN-3
254, 5cf8B, 0.7786, 2.35, 0.309, 288, 265, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
255, 4e6dA, 0.7785, 2.39, 0.300, 286, 267, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
256, 3e63A, 0.7783, 2.39, 0.308, 290, 266, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
257, 4qpsC, 0.7782, 2.01, 0.304, 276, 260, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
258, 3hmiA, 0.7782, 2.14, 0.351, 268, 262, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
259, 5caoA, 0.7779, 3.17, 0.850, 300, 280, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 29
260, 4f09A, 0.7778, 2.44, 0.300, 288, 267, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
261, 1yvjA, 0.7778, 2.42, 0.300, 288, 267, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN IN COMPLEX WITH A STAUROSPORINE ANALOGUE
262, 4zimA, 0.7777, 2.25, 0.311, 285, 264, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
263, 4d0xA, 0.7777, 2.40, 0.308, 291, 266, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
264, 2eb3A, 0.7776, 3.23, 0.804, 294, 280, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (L858R) IN COMPLEX WITH AMPPNP
265, 3dkcA, 0.7775, 2.93, 0.331, 312, 269, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH ATP
266, 4qt1A, 0.7771, 2.23, 0.312, 277, 263, JAK3 KINASE DOMAIN IN COMPLEX WITH 1-[(3S)-1-ISOBUTYLSULFONYL-3- PIPERIDYL]-3-(5H-PYRROLO[23-B]PYRAZIN-2-YL)UREA
267, 4hvhA, 0.7771, 2.24, 0.312, 278, 263, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-2-HYDROXY-12-DIMETHYL-PROPYL
268, 4gfmA, 0.7770, 2.35, 0.309, 289, 265, JAK2 KINASE (JH1 DOMAIN) WITH 26-DICHLORO-N-(2-OXO-25- DIHYDROPYRIDIN-4-YL)BENZAMIDE
269, 5tq3B, 0.7769, 2.32, 0.311, 285, 264, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
270, 5xdlA, 0.7766, 3.24, 0.864, 292, 280, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH CO-1686
271, 4ythA, 0.7758, 2.34, 0.306, 287, 265, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
272, 4e4mE, 0.7757, 2.43, 0.301, 296, 266, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
273, 4e4mA, 0.7757, 2.42, 0.301, 296, 266, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
274, 4py1A, 0.7754, 2.45, 0.300, 289, 267, CRYSTAL STRUCTURE OF TYK2 IN COMPLEX WITH COMPOUND 15 6-((25- DIMETHOXYPHENYL)THIO)-3-(1-METHYL-1H-PYRAZOL-4-YL)-[124]TRIAZOLO[4 3-B]PYRIDAZINE
275, 3bbtD, 0.7752, 1.98, 0.693, 259, 257, CRYSTAL STRUCTURE OF THE ERBB4 KINASE IN COMPLEX WITH LAPATINIB
276, 3bkbA, 0.7751, 2.47, 0.275, 373, 265, CRYSTAL STRUCTURE OF HUMAN FELINE SARCOMA VIRAL ONCOGENE HOMOLOGUE (V- FES)
277, 5j9zA, 0.7750, 3.04, 0.830, 291, 276, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1A
278, 4ji9A, 0.7748, 2.38, 0.302, 284, 265, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
279, 5y25A, 0.7747, 3.14, 0.849, 292, 278, EGFR KINASE DOMAIN MUTANT (T790M/L858R) WITH COVALENT LIGAND NS-062 
280, 4rj5A, 0.7747, 3.02, 0.862, 296, 275, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 5
281, 3lpbA, 0.7746, 2.27, 0.308, 278, 263, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
282, 4fk6B, 0.7745, 2.27, 0.312, 284, 263, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
283, 4ytiA, 0.7742, 2.37, 0.302, 284, 265, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
284, 4p7eA, 0.7740, 2.33, 0.307, 281, 264, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
285, 3tjcA, 0.7740, 2.37, 0.306, 284, 265, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
286, 4d0wA, 0.7739, 2.35, 0.311, 289, 264, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
287, 3plsA, 0.7736, 2.78, 0.310, 298, 268, RON IN COMPLEX WITH LIGAND AMP-PNP
288, 4rioA, 0.7731, 2.27, 0.304, 285, 263, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE CARBOXAMIDE INHIBITOR
289, 3nyxA, 0.7731, 2.32, 0.297, 287, 263, NON-PHOSPHORYLATED TYK2 JH1 DOMAIN WITH QUINOLINE-THIADIAZOLE- THIOPHENE INHIBITOR
290, 4i6qA, 0.7730, 2.27, 0.313, 277, 262, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-PHENOXY-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-1-CYCLOPROPYL-ETHYL)-AMIDE
291, 5cf8A, 0.7727, 2.38, 0.307, 285, 264, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
292, 3tjdA, 0.7727, 2.39, 0.306, 284, 265, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
293, 4hvdA, 0.7726, 2.19, 0.314, 276, 261, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-122-TRIMETHYL-PROPYL)-AMIDE
294, 4bbfD, 0.7725, 2.28, 0.300, 288, 263, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
295, 4bbfA, 0.7725, 2.29, 0.300, 288, 263, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
296, 3lzbD, 0.7725, 1.80, 0.874, 261, 254, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
297, 5edqA, 0.7721, 3.41, 0.812, 298, 282, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 15: ~{N}-(7- CHLORANYL-1~{H}-INDAZOL-3-YL)-77-DIMETHYL-2-(1~{H}-PYRAZOL-4-YL)- 5~{H}-FURO[34-D]PYRIMIDIN-4-AMINE
298, 6bbuA, 0.7720, 2.16, 0.296, 279, 260, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH COMPOUND 25
299, 3fupA, 0.7719, 2.45, 0.301, 284, 266, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
300, 3dk7B, 0.7719, 2.28, 0.331, 268, 263, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
301, 2qohB, 0.7719, 2.69, 0.335, 281, 266, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
302, 5tq3A, 0.7717, 2.27, 0.303, 282, 261, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
303, 4hgeA, 0.7716, 2.43, 0.302, 284, 265, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
304, 3cblA, 0.7716, 2.50, 0.275, 356, 265, CRYSTAL STRUCTURE OF HUMAN FELINE SARCOMA VIRAL ONCOGENE HOMOLOGUE (V- FES) IN COMPLEX WITH STAUROSPORINE AND A CONSENSUS PEPTIDE
305, 3lzbC, 0.7713, 1.77, 0.877, 259, 253, EGFR KINASE DOMAIN COMPLEXED WITH AN IMIDAZO[21-B]THIAZOLE INHIBITOR
306, 4e4mD, 0.7710, 2.71, 0.301, 296, 269, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
307, 4e4mB, 0.7709, 2.71, 0.301, 296, 269, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
308, 5cf4A, 0.7708, 2.38, 0.303, 283, 264, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
309, 3dk3B, 0.7708, 2.30, 0.335, 269, 263, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
310, 2g2hB, 0.7706, 2.59, 0.333, 272, 267, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
311, 2b7aA, 0.7705, 2.46, 0.302, 284, 265, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
312, 2g2fA, 0.7702, 2.74, 0.347, 275, 268, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
313, 1u59A, 0.7701, 2.96, 0.301, 282, 272, CRYSTAL STRUCTURE OF THE ZAP-70 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
314, 4hzsB, 0.7699, 3.01, 0.337, 319, 270, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN WITH C-TERMINAL SH3 DOMAIN
315, 4hzsA, 0.7699, 3.01, 0.337, 319, 270, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN WITH C-TERMINAL SH3 DOMAIN
316, 4hzsC, 0.7698, 3.01, 0.337, 319, 270, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN WITH C-TERMINAL SH3 DOMAIN
317, 4hzsD, 0.7697, 3.01, 0.337, 319, 270, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN WITH C-TERMINAL SH3 DOMAIN
318, 3lpbB, 0.7697, 2.29, 0.299, 284, 261, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
319, 5edrA, 0.7696, 3.21, 0.849, 299, 278, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 27: ~{N}-(1~{H}- INDAZOL-3-YL)-77-DIMETHYL-2-(2-METHYLPYRAZOL-3-YL)-5~{H}-FURO[34- D]PYRIMIDIN-4-AMINE
320, 5edpA, 0.7693, 3.36, 0.804, 295, 280, EGFR KINASE (T790M/L858R) APO
321, 4fk6A, 0.7693, 2.28, 0.314, 285, 261, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
322, 4e1zA, 0.7692, 2.49, 0.282, 288, 266, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
323, 5eg3A, 0.7690, 3.20, 0.296, 301, 274, CRYSTAL STRUCTURE OF THE ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH THE CSH2 DOMAIN OF PHOSPHOLIPASE C GAMMA (PLCGAMMA)
324, 5cy3A, 0.7686, 2.80, 0.330, 276, 270, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT AND ORALLY BIOAVAILABLE BENZISOTHIAZOLE INHIBITOR
325, 4ehzD, 0.7686, 2.26, 0.307, 280, 261, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
326, 5e1eB, 0.7684, 2.25, 0.307, 280, 261, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
327, 5wo4A, 0.7682, 2.33, 0.305, 292, 262, JAK1 COMPLEXED WITH COMPOUND 28
328, 1opkA, 0.7682, 3.12, 0.326, 449, 276, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
329, 4e5wA, 0.7680, 2.26, 0.307, 292, 261, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
330, 3r7oA, 0.7679, 3.02, 0.325, 299, 271, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG
331, 2w1iA, 0.7679, 2.47, 0.307, 284, 264, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
332, 3rvgA, 0.7678, 2.32, 0.290, 285, 262, CRYSTALS STRUCTURE OF JAK2 WITH A 1-AMINO-5H-PYRIDO[43-B]INDOL-4- CARBOXAMIDE INHIBITOR
333, 4ivbB, 0.7677, 2.28, 0.307, 280, 261, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
334, 4gmyA, 0.7676, 2.60, 0.307, 298, 267, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH 26-DICHLORO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
335, 2w1iB, 0.7675, 2.48, 0.307, 284, 264, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
336, 5tozA, 0.7674, 2.38, 0.309, 278, 262, JAK3 WITH COVALENT INHIBITOR PF-06651600
337, 3dqwD, 0.7674, 2.96, 0.293, 276, 273, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
338, 1oplA, 0.7674, 3.14, 0.326, 451, 276, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
339, 3q6wA, 0.7673, 3.07, 0.320, 297, 272, STRUCTURE OF DUALLY-PHOSPHORYLATED MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG WITH SPECIFICITY FOR THE ACTIVATED RECEPTOR
340, 5ttvA, 0.7671, 2.30, 0.318, 280, 261, JAK3 WITH COVALENT INHIBITOR 6
341, 3dqwC, 0.7671, 2.88, 0.280, 275, 271, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
342, 4ehzB, 0.7670, 2.29, 0.310, 280, 261, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
343, 4ytcA, 0.7669, 2.36, 0.298, 284, 262, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
344, 5wo4B, 0.7668, 2.30, 0.307, 280, 261, JAK1 COMPLEXED WITH COMPOUND 28
345, 3jy9A, 0.7668, 2.31, 0.303, 282, 261, JANUS KINASE 2 INHIBITORS
346, 5hx8A, 0.7666, 2.37, 0.305, 291, 262, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
347, 3clyA, 0.7666, 3.12, 0.293, 289, 273, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAINS TRAPPED IN TRANS-PHOSPHORYLATION REACTION
348, 4z16B, 0.7665, 2.46, 0.312, 276, 263, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
349, 4gvjA, 0.7665, 2.49, 0.303, 290, 264, TYK2 (JH1) IN COMPLEX WITH ADENOSINE DI-PHOSPHATE
350, 4hviA, 0.7662, 2.21, 0.317, 274, 259, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-1-METHYL-2-OXO-2-PIPERIDIN-1-YL- ETHYL)-AMIDE
351, 4ei4B, 0.7662, 2.31, 0.307, 280, 261, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 20
352, 2z60A, 0.7662, 2.86, 0.326, 281, 267, CRYSTAL STRUCTURE OF THE T315I MUTANT OF ABL KINASE BOUND WITH PPY-A
353, 5tq6A, 0.7661, 2.34, 0.303, 274, 261, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
354, 4ehzA, 0.7658, 2.31, 0.310, 290, 261, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
355, 4ivcB, 0.7657, 2.30, 0.307, 280, 261, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
356, 4ytfA, 0.7656, 2.37, 0.309, 283, 262, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
357, 3lxnA, 0.7656, 2.43, 0.300, 287, 263, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
358, 3nz0A, 0.7655, 2.63, 0.305, 285, 266, NON-PHOSPHORYLATED TYK2 KINASE WITH CMP6
359, 3lxlA, 0.7655, 2.44, 0.309, 281, 262, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
360, 4gj2A, 0.7653, 2.51, 0.299, 288, 264, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
361, 3gqiA, 0.7653, 2.85, 0.311, 304, 267, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
362, 5flfD, 0.7652, 2.89, 0.310, 290, 268, DISEASE LINKED MUTATION IN FGFR
363, 3io7A, 0.7652, 2.41, 0.304, 282, 263, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
364, 4e4lD, 0.7651, 2.26, 0.312, 281, 260, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
365, 5tq7A, 0.7650, 2.39, 0.302, 275, 262, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
366, 4ivbA, 0.7650, 2.28, 0.308, 291, 260, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
367, 4k77A, 0.7647, 2.39, 0.305, 282, 262, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
368, 3lxkA, 0.7645, 2.32, 0.319, 279, 260, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
369, 4jiaA, 0.7644, 2.65, 0.311, 298, 267, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 9
370, 4ivdB, 0.7644, 2.33, 0.307, 280, 261, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
371, 4ewhA, 0.7644, 2.78, 0.335, 274, 266, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
372, 4gl9D, 0.7643, 2.41, 0.305, 282, 262, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS3 IN COMPLEX WITH JAK2 KINASE DOMAIN AND FRAGMENT OF GP130 INTRACELLULAR DOMAIN
373, 4gihA, 0.7643, 2.57, 0.302, 288, 265, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}BENZAMIDE
374, 4ehzC, 0.7643, 2.29, 0.315, 278, 260, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
375, 5em5A, 0.7642, 3.22, 0.830, 298, 276, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 2: 4-[2-(4- CHLOROPHENYL)ETHYLAMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
376, 4e4lE, 0.7641, 2.29, 0.312, 280, 260, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
377, 4bbeC, 0.7641, 2.44, 0.300, 288, 263, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
378, 5ttsA, 0.7639, 2.27, 0.313, 274, 259, JAK3 WITH COVALENT INHIBITOR 4
379, 4zogB, 0.7638, 2.38, 0.332, 268, 262, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
380, 2x2kA, 0.7638, 2.70, 0.332, 289, 265, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
381, 4e20A, 0.7637, 2.47, 0.293, 282, 263, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
382, 5hx8B, 0.7634, 2.31, 0.312, 279, 260, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
383, 4e4lB, 0.7634, 2.24, 0.313, 279, 259, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
384, 1m52A, 0.7634, 2.76, 0.335, 271, 266, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
385, 3kulA, 0.7633, 2.53, 0.304, 267, 263, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
386, 3kckA, 0.7633, 2.46, 0.304, 285, 263, A NOVEL CHEMOTYPE OF KINASE INHIBITORS
387, 3cd3A, 0.7633, 2.46, 0.282, 352, 262, CRYSTAL STRUCTURE OF PHOSPHORYLATED HUMAN FELINE SARCOMA VIRAL ONCOGENE HOMOLOGUE (V-FES) IN COMPLEX WITH STAUROSPORINE AND A CONSENSUS PEPTIDE
388, 3iokA, 0.7631, 2.40, 0.309, 285, 262, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
389, 5walA, 0.7630, 2.57, 0.306, 286, 265, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
390, 5flfA, 0.7630, 2.91, 0.311, 296, 267, DISEASE LINKED MUTATION IN FGFR
391, 4ivcA, 0.7630, 2.30, 0.308, 291, 260, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
392, 4gj3A, 0.7630, 2.55, 0.299, 288, 264, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
393, 4bbeB, 0.7630, 2.46, 0.300, 288, 263, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
394, 4k77B, 0.7629, 2.37, 0.310, 280, 261, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
395, 2g1tC, 0.7628, 2.90, 0.328, 276, 265, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
396, 4e5wB, 0.7626, 2.26, 0.297, 278, 259, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
397, 4e4lA, 0.7626, 2.20, 0.314, 277, 258, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
398, 3kulB, 0.7625, 2.65, 0.295, 271, 264, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
399, 2ivuA, 0.7625, 2.77, 0.332, 288, 265, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR ZD6474
400, 4giiA, 0.7624, 2.64, 0.305, 289, 266, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
401, 6bl8A, 0.7623, 2.74, 0.338, 270, 266, PREDICTING THE CONFORMATIONAL VARIABILITY OF ABL TYROSINE KINASE USING MOLECULAR DYNAMICS SIMULATIONS AND MARKOV STATE MODELS
402, 4e4nB, 0.7623, 2.40, 0.310, 280, 261, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
403, 5u6bB, 0.7618, 2.85, 0.327, 291, 266, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
404, 1y57A, 0.7618, 3.09, 0.278, 452, 273, STRUCTURE OF UNPHOSPHORYLATED C-SRC IN COMPLEX WITH AN INHIBITOR
405, 5f1zA, 0.7615, 2.18, 0.311, 281, 257, STRUCTURE OF TYK2 WITH INHIBITOR 16: 3-AZANYL-5-[(2~{S})-3- METHYLBUTAN-2-YL]-7-[1-METHYL-5-(2-OXIDANYLPROPAN-2-YL)PYRAZOL-3-YL]- 1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
406, 4i5cA, 0.7615, 2.32, 0.304, 279, 260, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
407, 5tq6B, 0.7612, 2.22, 0.306, 271, 258, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
408, 1m52B, 0.7612, 2.81, 0.335, 272, 266, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
409, 5tq7B, 0.7611, 2.17, 0.305, 269, 256, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
410, 4bbfB, 0.7611, 2.49, 0.300, 288, 263, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
411, 5e1eA, 0.7610, 2.32, 0.308, 279, 260, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
412, 5u6bD, 0.7609, 2.96, 0.326, 291, 267, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
413, 4gl9B, 0.7608, 2.48, 0.305, 280, 262, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS3 IN COMPLEX WITH JAK2 KINASE DOMAIN AND FRAGMENT OF GP130 INTRACELLULAR DOMAIN
414, 5tq4A, 0.7607, 2.63, 0.308, 290, 266, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
415, 4ckjA, 0.7606, 2.85, 0.331, 292, 266, CRYSTAL STRUCTURE OF RET TYROSINE KINASE DOMAIN BOUND TO ADENOSINE
416, 3zc6B, 0.7606, 2.31, 0.314, 276, 258, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH AN INDAZOLE SUBSTITUTED PYRROLOPYRAZINE INHIBITOR
417, 4bbeD, 0.7605, 2.50, 0.300, 288, 263, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
418, 2ivtA, 0.7605, 2.70, 0.333, 288, 264, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
419, 4bbfC, 0.7604, 2.50, 0.300, 288, 263, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
420, 4iwdA, 0.7603, 3.18, 0.320, 299, 272, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-8033 ANALOG
421, 4wa9B, 0.7602, 2.80, 0.338, 276, 266, THE CRYSTAL STRUCTURE OF HUMAN ABL1 WILD TYPE KINASE DOMAIN IN COMPLEX WITH AXITINIB
422, 4ckiA, 0.7601, 2.72, 0.326, 293, 264, CRYSTAL STRUCTURE OF ONCOGENIC RET TYROSINE KINASE M918T BOUND TO ADENOSINE
423, 5l3aA, 0.7600, 2.60, 0.298, 290, 265, FRAGMENT-BASED DISCOVERY OF 6-ARYLINDAZOLE JAK INHIBITORS
424, 4zogA, 0.7600, 2.59, 0.342, 269, 263, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
425, 4ewhB, 0.7599, 2.81, 0.336, 273, 265, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
426, 4i5cB, 0.7598, 2.37, 0.308, 291, 260, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
427, 5flfB, 0.7597, 2.96, 0.313, 292, 268, DISEASE LINKED MUTATION IN FGFR
428, 2ivsA, 0.7594, 2.73, 0.337, 284, 264, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
429, 4uy9A, 0.7593, 2.77, 0.250, 313, 268, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
430, 3ue4A, 0.7592, 2.85, 0.342, 270, 266, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
431, 4bbeA, 0.7591, 2.53, 0.300, 288, 263, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
432, 2g2hA, 0.7591, 2.79, 0.338, 272, 266, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
433, 1k9aB, 0.7591, 2.35, 0.309, 441, 259, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
434, 4ivdA, 0.7590, 2.33, 0.313, 290, 259, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
435, 4ei4A, 0.7590, 2.27, 0.314, 289, 258, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 20
436, 5xgmA, 0.7588, 3.24, 0.803, 288, 274, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH GO6976
437, 2hziB, 0.7588, 2.30, 0.344, 264, 259, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
438, 4e4nA, 0.7587, 2.41, 0.308, 291, 260, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
439, 5usyA, 0.7580, 2.52, 0.302, 287, 262, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
440, 3dqwA, 0.7579, 3.09, 0.279, 278, 272, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
441, 5cxhA, 0.7577, 3.11, 0.327, 277, 269, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT ORALLY BIOAVAILABLE THIAZOLE INHIBITOR
442, 3eqrA, 0.7577, 2.70, 0.346, 270, 263, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
443, 2qohA, 0.7577, 2.46, 0.331, 271, 260, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
444, 3zc6C, 0.7574, 2.21, 0.309, 275, 256, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH AN INDAZOLE SUBSTITUTED PYRROLOPYRAZINE INHIBITOR
445, 3dk3A, 0.7574, 2.51, 0.342, 266, 260, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
446, 5khxA, 0.7573, 2.13, 0.306, 276, 255, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH PF-4950736
447, 4j96B, 0.7573, 3.06, 0.313, 305, 268, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
448, 3dqwB, 0.7573, 3.04, 0.280, 278, 271, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
449, 3eqpB, 0.7571, 2.61, 0.347, 270, 262, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
450, 6bl8B, 0.7570, 2.75, 0.336, 268, 265, PREDICTING THE CONFORMATIONAL VARIABILITY OF ABL TYROSINE KINASE USING MOLECULAR DYNAMICS SIMULATIONS AND MARKOV STATE MODELS
451, 3zc6A, 0.7570, 2.29, 0.311, 277, 257, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH AN INDAZOLE SUBSTITUTED PYRROLOPYRAZINE INHIBITOR
452, 2g1tD, 0.7566, 2.63, 0.327, 277, 260, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
453, 4gl9C, 0.7565, 2.55, 0.305, 282, 262, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS3 IN COMPLEX WITH JAK2 KINASE DOMAIN AND FRAGMENT OF GP130 INTRACELLULAR DOMAIN
454, 1k9aA, 0.7561, 2.36, 0.313, 439, 259, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
455, 5tr6A, 0.7560, 2.88, 0.340, 272, 265, DISCOVERY OF TAK-659 AN ORALLY AVAILABLE INVESTIGATIONAL INHIBITOR OF SPLEEN TYROSINE KINASE (SYK)
456, 4gfgA, 0.7559, 3.19, 0.332, 277, 271, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R9021
457, 5f20A, 0.7558, 2.21, 0.306, 274, 255, STRUCTURE OF TYK2 WITH INHIBITOR 4: 3-AZANYL-5-(2-METHYLPHENYL)-7-(1- METHYLPYRAZOL-3-YL)-1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
458, 4k6zA, 0.7558, 2.45, 0.308, 279, 260, THE JAK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 37
459, 3eqrB, 0.7558, 2.85, 0.341, 271, 264, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
460, 3dk7A, 0.7558, 2.53, 0.338, 265, 260, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
461, 2hziA, 0.7557, 2.46, 0.341, 268, 261, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
462, 2g1tB, 0.7557, 2.61, 0.331, 273, 260, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
463, 2f4jA, 0.7557, 3.10, 0.323, 287, 269, STRUCTURE OF THE KINASE DOMAIN OF AN IMATINIB-RESISTANT ABL MUTANT IN COMPLEX WITH THE AURORA KINASE INHIBITOR VX-680
464, 4j98B, 0.7556, 2.96, 0.316, 304, 266, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
465, 3l8pA, 0.7556, 2.45, 0.314, 292, 258, CRYSTAL STRUCTURE OF CYTOPLASMIC KINASE DOMAIN OF TIE2 COMPLEXED WITH INHIBITOR CEP11207
466, 4uy9B, 0.7553, 2.84, 0.254, 315, 268, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
467, 5ui0B, 0.7552, 3.02, 0.315, 304, 267, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
468, 5ttuA, 0.7550, 2.27, 0.316, 271, 256, JAK3 WITH COVALENT INHIBITOR 7
469, 1xbcA, 0.7549, 2.75, 0.347, 268, 262, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH STAUROSPORIN
470, 5usyB, 0.7546, 2.59, 0.302, 287, 262, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
471, 3eqpA, 0.7545, 2.61, 0.350, 268, 260, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
472, 5wevA, 0.7544, 2.53, 0.313, 293, 262, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
473, 4cnhB, 0.7544, 3.16, 0.262, 293, 271, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2- METHOXYPHENYL)ETHOXY)-5-(1-METHYL-1H-123-TRIAZOL-5-YL) PYRIDIN-2-AMINE
474, 5bmmB, 0.7543, 2.75, 0.281, 275, 263, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC25B
475, 4twpA, 0.7543, 2.52, 0.331, 266, 260, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
476, 2g1tA, 0.7543, 2.59, 0.332, 271, 259, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
477, 4z16A, 0.7542, 2.42, 0.310, 271, 258, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
478, 3eyhA, 0.7542, 2.39, 0.322, 285, 258, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
479, 5cxzA, 0.7541, 2.94, 0.337, 269, 264, SYK CATALYTIC DOMAIN COMPLEXED WITH NAPHTHYRIDINE INHIBITOR
480, 2x2lA, 0.7540, 2.72, 0.336, 287, 262, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
481, 4at5A, 0.7539, 3.07, 0.277, 294, 267, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH GW2580
482, 3eygA, 0.7539, 2.45, 0.322, 280, 258, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
483, 1fvrB, 0.7539, 3.05, 0.299, 300, 268, TIE2 KINASE DOMAIN
484, 5khwB, 0.7538, 2.29, 0.316, 276, 256, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
485, 4wnmA, 0.7537, 2.93, 0.345, 273, 264, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT TRIAZOLOPYRIDINE INHIBITOR
486, 3kf4A, 0.7536, 3.00, 0.327, 281, 266, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
487, 5bmmA, 0.7535, 2.76, 0.281, 275, 263, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC25B
488, 5y5uA, 0.7533, 2.61, 0.337, 266, 261, CRYSTAL STRUCTURES OF SPLEEN TYROSINE KINASE IN COMPLEX WITH A NOVEL INHIBITOR 
489, 3lxpA, 0.7533, 2.64, 0.307, 285, 261, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
490, 4gl9A, 0.7531, 2.60, 0.305, 282, 262, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS3 IN COMPLEX WITH JAK2 KINASE DOMAIN AND FRAGMENT OF GP130 INTRACELLULAR DOMAIN
491, 2x2mA, 0.7531, 2.89, 0.326, 286, 264, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
492, 6drwA, 0.7529, 2.64, 0.298, 289, 262, JAK2 JH1 IN COMPLEX WITH JNJ-7706621 (CRYSTAL FORM 2) 
493, 2ozoA, 0.7529, 3.03, 0.298, 545, 265, AUTOINHIBITED INTACT HUMAN ZAP-70
494, 5ui0A, 0.7526, 3.05, 0.318, 301, 267, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
495, 5u6bC, 0.7526, 2.71, 0.310, 270, 258, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
496, 2j0lA, 0.7525, 3.10, 0.333, 274, 270, CRYSTAL STRUCTURE OF A THE ACTIVE CONFORMATION OF THE KINASE DOMAIN OF FOCAL ADHESION KINASE WITH A PHOSPHORYLATED ACTIVATION LOOP.
497, 3zc6D, 0.7524, 2.31, 0.309, 267, 256, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH AN INDAZOLE SUBSTITUTED PYRROLOPYRAZINE INHIBITOR
498, 4z16C, 0.7523, 2.46, 0.310, 271, 258, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
499, 2g2fB, 0.7523, 2.56, 0.346, 264, 260, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
500, 5vo6A, 0.7521, 2.12, 0.316, 271, 253, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE INHIBITOR
501, 1xbaA, 0.7521, 2.71, 0.349, 266, 261, CRYSTAL STRUCTURE OF APO SYK TYROSINE KINASE DOMAIN
502, 4twpB, 0.7520, 2.78, 0.322, 271, 264, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
503, 4k33A, 0.7520, 2.97, 0.313, 293, 265, CRYSTAL STRUCTURE OF FGF RECEPTOR 3 (FGFR3) KINASE DOMAIN HARBORING THE K650E MUTATION A GAIN-OF-FUNCTION MUTATION RESPONSIBLE FOR THANATOPHORIC DYSPLASIA TYPE II AND SPERMATOCYTIC SEMINOMA
504, 2hz4B, 0.7518, 2.48, 0.337, 261, 258, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
505, 4fl2A, 0.7517, 2.99, 0.341, 555, 264, STRUCTURAL AND BIOPHYSICAL CHARACTERIZATION OF THE SYK ACTIVATION SWITCH
506, 3vf8A, 0.7516, 2.66, 0.346, 265, 260, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH PYRAZOLYLBENZIMIDAZOLE INHIBITOR 416
507, 4rx7A, 0.7514, 3.09, 0.342, 272, 266, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR
508, 2xa4A, 0.7512, 2.28, 0.298, 276, 255, INHIBITORS OF JAK2 KINASE DOMAIN
509, 1oplB, 0.7509, 2.65, 0.340, 365, 262, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
510, 3zepC, 0.7508, 2.38, 0.319, 276, 257, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
511, 3zepA, 0.7508, 2.48, 0.319, 274, 257, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
512, 3kxxA, 0.7507, 3.23, 0.312, 305, 269, STRUCTURE OF THE MUTANT FIBROBLAST GROWTH FACTOR RECEPTOR 1
513, 4z16D, 0.7506, 2.50, 0.310, 271, 258, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
514, 4k2rA, 0.7506, 3.11, 0.292, 551, 264, STRUCTURAL BASIS FOR ACTIVATION OF ZAP-70 BY PHOSPHORYLATION OF THE SH2-KINASE LINKER
515, 2ivvA, 0.7505, 2.63, 0.338, 282, 260, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR PP1
516, 5u6cA, 0.7503, 2.53, 0.352, 272, 256, CRYSTAL STRUCTURE OF THE MER KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
517, 3zepD, 0.7503, 2.44, 0.312, 272, 256, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
518, 4yhfB, 0.7502, 2.46, 0.300, 269, 257, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
519, 2v7aA, 0.7502, 2.91, 0.328, 269, 265, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
520, 3lcdA, 0.7501, 2.86, 0.285, 290, 263, INHIBITOR BOUND TO A DFG-IN STRUCTURE OF THE KINASE DOMAIN OF CSF-1R
521, 5lmbA, 0.7500, 2.61, 0.335, 264, 260, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
522, 6c7yA, 0.7499, 2.29, 0.310, 273, 255, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS1 IN COMPLEX WITH JAK1 KINASE DOMAIN 
523, 3kxxB, 0.7499, 3.14, 0.317, 305, 268, STRUCTURE OF THE MUTANT FIBROBLAST GROWTH FACTOR RECEPTOR 1
524, 5flfC, 0.7498, 2.99, 0.313, 283, 265, DISEASE LINKED MUTATION IN FGFR
525, 5tt7A, 0.7496, 3.04, 0.332, 274, 265, DISCOVERY OF TAK-659 AN ORALLY AVAILABLE INVESTIGATIONAL INHIBITOR OF SPLEEN TYROSINE KINASE (SYK)
526, 1fvrA, 0.7496, 3.05, 0.300, 299, 267, TIE2 KINASE DOMAIN
527, 5u6bA, 0.7495, 2.83, 0.317, 270, 259, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
528, 4xeyB, 0.7495, 2.63, 0.344, 359, 259, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
529, 2xa4B, 0.7495, 2.23, 0.307, 275, 254, INHIBITORS OF JAK2 KINASE DOMAIN
530, 4xeyA, 0.7493, 2.83, 0.342, 269, 263, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
531, 3mftA, 0.7493, 3.02, 0.198, 302, 268, CASK-4M CAM KINASE DOMAIN MN2+
532, 3dk6A, 0.7493, 2.56, 0.336, 262, 259, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
533, 2pvfA, 0.7493, 2.96, 0.314, 285, 264, CRYSTAL STRUCTURE OF TYROSINE PHOSPHORYLATED ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH ATP ANALOG AND SUBSTRATE PEPTIDE
534, 3aglA, 0.7490, 3.47, 0.167, 338, 276, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
535, 4xg3B, 0.7487, 2.68, 0.342, 267, 260, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
536, 5khwA, 0.7483, 2.40, 0.316, 276, 256, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
537, 5hezC, 0.7482, 2.67, 0.308, 289, 260, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
538, 4j96A, 0.7482, 3.04, 0.320, 302, 266, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
539, 4c61B, 0.7482, 2.19, 0.308, 274, 253, INHIBITORS OF JAK2 KINASE DOMAIN
540, 3dk6B, 0.7480, 2.40, 0.342, 259, 257, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
541, 1u4dB, 0.7480, 2.43, 0.344, 262, 256, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
542, 1pkgA, 0.7480, 2.72, 0.296, 290, 260, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
543, 3zmmB, 0.7477, 2.20, 0.308, 274, 253, INHIBITORS OF JAK2 KINASE DOMAIN
544, 2ckeD, 0.7476, 3.16, 0.170, 300, 270, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
545, 5hezA, 0.7474, 2.71, 0.308, 287, 260, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
546, 4rx8A, 0.7474, 3.03, 0.341, 269, 264, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR2
547, 3c0gB, 0.7474, 3.04, 0.190, 320, 268, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
548, 2ckeA, 0.7473, 3.26, 0.173, 301, 271, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
549, 6fekA, 0.7472, 2.87, 0.332, 294, 262, ONCOGENIC POINT MUTATION OF RET RECEPTOR TYROSINE KINASE
550, 5u6yK, 0.7472, 3.34, 0.154, 459, 273, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
551, 4u5jA, 0.7472, 2.80, 0.285, 267, 263, C-SRC IN COMPLEX WITH RUXOLITINIB
552, 2h8hA, 0.7472, 2.54, 0.284, 444, 257, SRC KINASE IN COMPLEX WITH A QUINAZOLINE INHIBITOR
553, 2ckeC, 0.7471, 3.18, 0.174, 300, 270, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
554, 1qcfA, 0.7471, 2.71, 0.293, 449, 259, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH A SRC FAMILY- SELECTIVE TYROSINE KINASE INHIBITOR
555, 5m0lA, 0.7470, 3.50, 0.181, 338, 276, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH THE METHYLATED FASUDIL-DERIVED FRAGMENT N-METHYLISOQUINOLINE-5- SULFONAMIDE (LIGAND 02) 
556, 4xg3A, 0.7470, 2.55, 0.350, 262, 257, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
557, 2f7eE, 0.7470, 3.53, 0.173, 336, 277, PKA COMPLEXED WITH (S)-2-(1H-INDOL-3-YL)-1-(5-ISOQUINOLIN-6- YL-PYRIDIN-3-YLOXYMETHYL-ETYLAMINE
558, 1k9aE, 0.7470, 2.63, 0.307, 440, 261, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
559, 4aw2A, 0.7469, 3.77, 0.150, 398, 280, CRYSTAL STRUCTURE OF CDC42 BINDING PROTEIN KINASE ALPHA (MRCK ALPHA)
560, 5xp7B, 0.7468, 2.75, 0.284, 267, 261, C-SRC IN COMPLEX WITH ATP-CHCL
561, 4k11A, 0.7468, 2.56, 0.284, 447, 257, THE STRUCTURE OF 1NA IN COMPLEX WITH SRC T338G
562, 2a2aA, 0.7468, 3.15, 0.174, 304, 270, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
563, 4j98A, 0.7467, 3.03, 0.321, 304, 265, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
564, 3srvA, 0.7467, 2.56, 0.337, 262, 258, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITOR
565, 3brbB, 0.7467, 2.60, 0.349, 271, 255, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE- PROTEIN KINASE MER IN COMPLEX WITH ADP
566, 5u6yC, 0.7466, 3.19, 0.154, 459, 272, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
567, 3idcA, 0.7466, 3.54, 0.170, 341, 276, CRYSTAL STRUCTURE OF (102-265)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
568, 2ojfE, 0.7466, 3.61, 0.173, 336, 278, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
569, 3fhiA, 0.7465, 3.46, 0.167, 336, 275, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN THE CATALYTIC AND REGULATORY (RI{ALPHA}) SUBUNITS OF PKA
570, 2ckeB, 0.7464, 3.19, 0.174, 300, 270, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
571, 2oh0E, 0.7463, 3.54, 0.173, 336, 277, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
572, 2a2aD, 0.7463, 3.27, 0.170, 303, 271, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
573, 3mfrA, 0.7462, 2.98, 0.199, 302, 267, CASK-4M CAM KINASE DOMAIN NATIVE
574, 3fqeA, 0.7462, 2.98, 0.338, 269, 263, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH YM193306
575, 3aglB, 0.7462, 3.52, 0.181, 335, 276, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
576, 2uzuE, 0.7462, 3.53, 0.173, 336, 277, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
577, 2f7xE, 0.7462, 3.45, 0.174, 336, 276, PROTEIN KINASE A BOUND TO (S)-2-(1H-INDOL-3-YL)-1-[5-((E)-2- PYRIDIN-4-YL-VINYL)-PYRIDIN-3-YLOXYMETHYL]-ETHYLAMINE
578, 5xp5A, 0.7461, 2.85, 0.285, 267, 263, C-SRC IN COMPLEX WITH ATP-CHF
579, 4rzvB, 0.7461, 2.57, 0.216, 271, 259, CRYSTAL STRUCTURE OF THE BRAF (R509H) KINASE DOMAIN MONOMER BOUND TO VEMURAFENIB
580, 3mvjE, 0.7461, 3.42, 0.178, 334, 275, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
581, 4j97C, 0.7459, 2.89, 0.321, 283, 262, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
582, 3c0gA, 0.7459, 3.02, 0.184, 309, 267, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
583, 2gqgB, 0.7459, 2.66, 0.333, 276, 261, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
584, 2gnfA, 0.7459, 3.52, 0.174, 339, 276, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH Y- 27632
585, 5n3lA, 0.7458, 3.41, 0.172, 337, 274, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-[(1R)-2-AMINO-1-HYDROXYETHYL]BENZENE-1 2-DIOL
586, 2j0jA, 0.7458, 3.06, 0.337, 611, 264, CRYSTAL STRUCTURE OF A FRAGMENT OF FOCAL ADHESION KINASE CONTAINING THE FERM AND KINASE DOMAINS.
587, 1jbpE, 0.7457, 3.52, 0.170, 339, 276, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE COMPLEXED WITH A SUBSTRATE PEPTIDE ADP AND DETERGENT
588, 3qamE, 0.7456, 3.49, 0.174, 348, 276, CRYSTAL STRUCTURE OF GLU208ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
589, 3e8eE, 0.7456, 3.52, 0.163, 341, 276, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
590, 3cc6A, 0.7456, 3.02, 0.311, 269, 264, CRYSTAL STRUCTURE OF KINASE DOMAIN OF PROTEIN TYROSINE KINASE 2 BETA (PTK2B)
591, 2srcA, 0.7456, 2.69, 0.287, 449, 258, CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRC IN COMPLEX WITH AMP-PNP
592, 5m0cA, 0.7455, 3.46, 0.175, 336, 275, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH THE FASUDIL-FRAGMENT ISOQUINOLINE-5-SULFONAMIDE 
593, 3twjC, 0.7455, 3.63, 0.158, 396, 278, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1447
594, 1re8A, 0.7455, 3.46, 0.160, 337, 275, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 2
595, 2a2aC, 0.7454, 3.28, 0.173, 303, 271, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
596, 4x6qC, 0.7453, 3.50, 0.175, 334, 275, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
597, 3b2tA, 0.7453, 3.24, 0.313, 288, 268, STRUCTURE OF PHOSPHOTRANSFERASE
598, 4j99B, 0.7452, 3.11, 0.305, 291, 266, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
599, 4j95B, 0.7452, 3.03, 0.309, 282, 265, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
600, 3c0hA, 0.7452, 3.02, 0.187, 300, 267, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
601, 2a2aB, 0.7452, 3.29, 0.173, 303, 271, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
602, 1bkxA, 0.7452, 3.49, 0.178, 337, 276, A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND ADENOSINE FURTHER DEFINES CONFORMATIONAL FLEXIBILITY
603, 2gngA, 0.7451, 3.52, 0.178, 338, 276, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE
604, 1apmE, 0.7451, 3.53, 0.174, 338, 276, 2.0 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PEPTIDE INHIBITOR AND DETERGENT
605, 5amnA, 0.7450, 2.93, 0.338, 287, 263, THE DISCOVERY OF 2-SUBSTITUTED PHENOL QUINAZOLINES AS POTENT AND SELECTIVE RET KINASE INHIBITORS
606, 4wb6B, 0.7450, 3.34, 0.176, 340, 273, CRYSTAL STRUCTURE OF A L205R MUTANT OF HUMAN CAMP-DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
607, 3d7uC, 0.7450, 2.18, 0.320, 257, 253, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
608, 3d7uA, 0.7450, 2.18, 0.320, 257, 253, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
609, 3c0hB, 0.7450, 3.01, 0.184, 300, 267, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
610, 5c26A, 0.7449, 3.12, 0.336, 272, 265, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 1
611, 3tnpF, 0.7449, 3.42, 0.175, 334, 274, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
612, 3tnpC, 0.7449, 3.42, 0.175, 334, 274, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
613, 3geqB, 0.7449, 3.00, 0.292, 273, 264, STRUCTURAL BASIS FOR THE CHEMICAL RESCUE OF SRC KINASE ACTIVITY
614, 2uzvA, 0.7449, 3.49, 0.174, 336, 276, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
615, 2gniA, 0.7449, 3.55, 0.170, 338, 276, PKA FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR FASUDIL (HA1077)
616, 4i0sA, 0.7448, 2.88, 0.341, 267, 261, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(6- CHLORO-1-METHYL-1H-INDAZOL-3-YL)-5H-PYRROLO[23-B]PYRAZINE-7- CARBOXYLIC ACID ISOPROPYLAMIDE
617, 3ue4B, 0.7448, 2.95, 0.341, 268, 264, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
618, 3e8eL, 0.7448, 3.46, 0.167, 336, 275, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
619, 3e8eB, 0.7448, 3.45, 0.167, 337, 275, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
620, 3c0iA, 0.7448, 3.05, 0.187, 298, 267, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P212121 FORM
621, 2gfcA, 0.7448, 3.55, 0.174, 335, 276, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
622, 5ng0B, 0.7447, 3.01, 0.234, 282, 265, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
623, 3e8eA, 0.7447, 3.46, 0.171, 341, 275, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
624, 5k0kA, 0.7446, 2.33, 0.351, 260, 251, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC2434
625, 5c27A, 0.7446, 3.08, 0.336, 272, 265, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 2
626, 4wihA, 0.7446, 3.39, 0.182, 350, 274, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS
627, 3mfuA, 0.7446, 3.02, 0.195, 302, 267, CASK-4M CAM KINASE DOMAIN AMPPNP-MN2+
628, 3fjqE, 0.7446, 3.49, 0.181, 334, 276, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA IN COMPLEX WITH PEPTIDE INHIBITOR PKI ALPHA (6-25)
629, 5n3gA, 0.7445, 3.49, 0.171, 337, 275, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE (R)-14-OXAZEPAN-6-OL
630, 5ar5A, 0.7445, 2.94, 0.231, 284, 264, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
631, 4pv0A, 0.7445, 2.95, 0.340, 268, 262, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH AN IMIDAZOPYRAZINE INHIBITOR
632, 1z9xB, 0.7445, 3.22, 0.174, 303, 270, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 3 MONOMERS IN THE ASYMMETRIC UNIT
633, 1z9xA, 0.7445, 3.22, 0.174, 303, 270, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 3 MONOMERS IN THE ASYMMETRIC UNIT
634, 1jluE, 0.7445, 3.54, 0.170, 337, 276, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PHOSPHORYLATED SUBSTRATE PEPTIDE AND DETERGENT
635, 1fmoE, 0.7445, 3.47, 0.175, 336, 275, CRYSTAL STRUCTURE OF A POLYHISTIDINE-TAGGED RECOMBINANT CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH THE PEPTIDE INHIBITOR PKI(5-24) AND ADENOSINE
636, 1cdkB, 0.7445, 3.47, 0.178, 342, 275, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
637, 5n1gA, 0.7444, 3.50, 0.167, 337, 275, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-(2-AMINO-13-THIAZOL-4-YL)-1- OXASPIRO[4.5]DECAN-2-ONE
638, 3e8eP, 0.7444, 3.46, 0.167, 341, 275, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
639, 5ar2B, 0.7443, 2.95, 0.223, 285, 264, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
640, 4puzB, 0.7443, 2.82, 0.342, 265, 260, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH GS- 9973
641, 4j97A, 0.7443, 2.83, 0.322, 282, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
642, 4ij9A, 0.7443, 3.55, 0.178, 335, 276, BOVINE PKA C-ALPHA IN COMPLEX WITH 2-[[5-(4-PYRIDYL)-1H-124-TRIAZOL- 3-YL]SULFANYL]-1-(2-THIOPHENYL)ETHANONE
643, 4fyoA, 0.7443, 2.90, 0.345, 267, 261, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH N-{(S)-1- [7-(34-DIMETHOXY-PHENYLAMINO)-THIAZOLO[54-D]PYRIMIDIN-5-YL]- PYRROLIDIN-3-YL}-TEREPHTHALAMIC ACID
644, 2gnjA, 0.7443, 3.54, 0.178, 335, 276, PKA THREE FOLD MUTANT MODEL OF RHO-KINASE WITH Y-27632
645, 2f7zE, 0.7443, 3.48, 0.174, 336, 276, PROTEIN KINASE A BOUND TO (R)-1-(1H-INDOL-3-YLMETHYL)-2-(2- PYRIDIN-4-YL-[17]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE
646, 5n3iA, 0.7442, 3.50, 0.171, 337, 275, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE METHYL (2S)-2-AMINO-3-PHENYLPROPANOATE
647, 2dq7X, 0.7442, 2.60, 0.287, 262, 258, CRYSTAL STRUCTURE OF FYN KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
648, 1q24A, 0.7442, 3.44, 0.172, 335, 274, PKA DOUBLE MUTANT MODEL OF PKB IN COMPLEX WITH MGATP
649, 5n3kA, 0.7441, 3.50, 0.171, 337, 275, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE O-GUANIDINO-L-HOMOSERINE
650, 5hezD, 0.7441, 2.77, 0.303, 289, 261, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
651, 5hezB, 0.7441, 2.77, 0.303, 289, 261, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
652, 4j99C, 0.7441, 3.08, 0.306, 291, 265, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
653, 4i0tA, 0.7441, 2.84, 0.342, 266, 260, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(5678- TETRAHYDRO-IMIDAZO[15-A]PYRIDIN-1-YL)-5H-PYRROLO[23-B]PYRAZINE-7- CARBOXYLIC ACID TERT-BUTYLAMIDE
654, 4hptE, 0.7441, 3.54, 0.174, 335, 276, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE DISPLAYING COMPLETE PHOSPHORYL TRANSFER OF AMP-PNP ONTO A SUBSTRATE PEPTIDE
655, 4c38A, 0.7441, 3.51, 0.167, 334, 275, PKA-S6K1 CHIMERA WITH COMPOUND 21E (CCT239066) BOUND
656, 3zepB, 0.7441, 2.37, 0.311, 268, 254, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
657, 1rekA, 0.7441, 3.53, 0.166, 336, 277, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 8
658, 1ad5B, 0.7441, 2.61, 0.301, 437, 256, SRC FAMILY KINASE HCK-AMP-PNP COMPLEX
659, 5n3rA, 0.7439, 3.49, 0.175, 336, 275, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-(CARBAMOYLAMINO)-4- METHYLSULFANYLBUTANOIC ACID
660, 5n3nA, 0.7439, 3.43, 0.175, 337, 274, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE [(2R)-24-DIHYDROXY-4-OXOBUTYL]- TRIMETHYLAZANIUM
661, 5n3jA, 0.7439, 3.44, 0.179, 337, 274, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-NITROBENZOIC ACID
662, 3vf9A, 0.7439, 2.86, 0.346, 265, 260, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 027
663, 3dneA, 0.7439, 3.54, 0.174, 336, 276, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
664, 2r2pA, 0.7439, 3.39, 0.287, 283, 272, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 5 (EPHA5)
665, 1rejA, 0.7439, 3.48, 0.167, 333, 275, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 1
666, 4xg6A, 0.7438, 3.07, 0.333, 271, 264, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
667, 4u5jB, 0.7438, 2.87, 0.299, 267, 264, C-SRC IN COMPLEX WITH RUXOLITINIB
668, 4gfoA, 0.7438, 2.09, 0.316, 272, 250, TYK2 KINASE (JH1 DOMAIN) WITH 26-DICHLORO-N-(2-OXO-25- DIHYDROPYRIDIN-4-YL)BENZAMIDE
669, 4c33A, 0.7438, 3.51, 0.171, 335, 275, PKA-S6K1 CHIMERA APO
670, 3sxsA, 0.7438, 2.76, 0.284, 264, 261, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEXED WITH PP2
671, 3qfvA, 0.7438, 3.82, 0.143, 395, 279, MRCK BETA IN COMPLEX WITH TPCA-1
672, 3oogA, 0.7438, 3.47, 0.175, 333, 275, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH A SMALL FRAGMENT
673, 3a4pA, 0.7438, 3.06, 0.331, 285, 263, HUMAN C-MET KINASE DOMAIN COMPLEXED WITH 6-BENZYLOXYQUINOLINE INHIBITOR
674, 2xuuA, 0.7438, 3.17, 0.175, 301, 269, CRYSTAL STRUCTURE OF A DAP-KINASE 1 MUTANT
675, 2g2iB, 0.7438, 2.77, 0.323, 265, 260, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
676, 4c36A, 0.7437, 3.51, 0.167, 335, 275, PKA-S6K1 CHIMERA WITH COMPOUND 15E (CCT147581) BOUND
677, 3srvB, 0.7437, 2.57, 0.346, 263, 257, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITOR
678, 3oxtA, 0.7437, 3.47, 0.175, 335, 274, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
679, 3e8cA, 0.7437, 3.48, 0.167, 341, 275, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
680, 5n3tA, 0.7436, 3.44, 0.172, 337, 274, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 5-CHLOROTHIOPHENE-2-SULFONAMIDE
681, 4d1sA, 0.7436, 2.52, 0.306, 280, 258, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
682, 2hz0A, 0.7436, 2.66, 0.327, 265, 260, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AEG082
683, 1kswA, 0.7436, 2.68, 0.283, 449, 258, STRUCTURE OF HUMAN C-SRC TYROSINE KINASE (THR338GLY MUTANT) IN COMPLEX WITH N6-BENZYL ADP
684, 6f3fA, 0.7435, 2.77, 0.282, 448, 259, AUTOINHIBITED SRC KINASE BOUND TO ADP
685, 5oteA, 0.7435, 4.01, 0.134, 407, 283, MRCK BETA IN COMPLEX WITH BDP-00008900
686, 5n3mA, 0.7435, 3.44, 0.172, 337, 274, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE D-ARGININE
687, 4o21A, 0.7435, 3.45, 0.175, 333, 274, PRODUCT COMPLEX OF METAL-FREE PKAC ATP-GAMMA-S AND SP20.
688, 3zmmA, 0.7435, 2.32, 0.296, 273, 253, INHIBITORS OF JAK2 KINASE DOMAIN
689, 3e8cF, 0.7435, 3.48, 0.167, 341, 275, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
690, 2c1aA, 0.7435, 3.54, 0.174, 335, 276, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL)AMIDE
691, 4c37A, 0.7434, 3.52, 0.175, 335, 275, PKA-S6K1 CHIMERA WITH COMPOUND 21A (CCT196539) BOUND
692, 3e8cB, 0.7434, 3.48, 0.167, 344, 275, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
693, 2uw8A, 0.7434, 3.51, 0.178, 334, 275, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-CHLORO- PHENYL)-2-PHENYL-ETHYLAMINE
694, 5n3sA, 0.7433, 3.45, 0.182, 337, 274, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-HYDROXYBENZAMIDE
695, 5n3qA, 0.7433, 3.40, 0.176, 336, 273, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3-AMINOBENZAMIDE
696, 4ib3A, 0.7433, 3.53, 0.178, 336, 275, STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH ADP PHOSPHORYLATED PEPTIDE PSP20 AND NO METAL
697, 3u4wA, 0.7433, 2.85, 0.290, 275, 262, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC4B
698, 3mdyC, 0.7433, 2.88, 0.176, 320, 262, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
699, 3e8cD, 0.7433, 3.48, 0.167, 344, 275, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
700, 2yaaB, 0.7433, 3.18, 0.171, 299, 269, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
701, 2hckB, 0.7433, 2.62, 0.297, 437, 256, SRC FAMILY KINASE HCK-QUERCETIN COMPLEX
702, 1q62A, 0.7433, 3.49, 0.178, 336, 275, PKA DOUBLE MUTANT MODEL OF PKB
703, 5ugxA, 0.7432, 3.11, 0.317, 297, 265, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
704, 5bx7A, 0.7432, 3.55, 0.174, 343, 276, PKA IN COMPLEX WITH A BENZOTHIOPHENE FRAGMENT COMPOUND.
705, 4wb7B, 0.7432, 3.49, 0.185, 402, 275, CRYSTAL STRUCTURE OF A CHIMERIC FUSION OF HUMAN DNAJ (HSP40) AND CAMP- DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
706, 3x2vA, 0.7432, 3.51, 0.171, 331, 275, MICHAELIS-LIKE COMPLEX OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
707, 3qalE, 0.7432, 3.41, 0.161, 339, 274, CRYSTAL STRUCTURE OF ARG280ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
708, 5n3oA, 0.7431, 3.44, 0.172, 335, 274, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3-(13-OXAZOL-5-YL)ANILINE
709, 5n3hA, 0.7431, 3.44, 0.172, 337, 274, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE PYRIDINE-3-CARBOXAMIDE
710, 4iacA, 0.7431, 3.50, 0.171, 333, 275, X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH MG2+ CONCENTRATION AMP-PCP AND PSEUDO-SUBSTRATE PEPTIDE SP20
711, 2yaaA, 0.7431, 3.11, 0.172, 300, 268, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
712, 5u6yI, 0.7430, 3.51, 0.146, 459, 274, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
713, 5n3pA, 0.7430, 3.40, 0.176, 336, 273, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 1H-INDOL-5-OL
714, 5n1hA, 0.7430, 3.40, 0.176, 337, 273, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE METHYL 4-(AMINOMETHYL)BENZOATE
715, 5n1fA, 0.7430, 3.44, 0.179, 337, 274, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-QUINOLIN-5-YLPYRIDINE-3-CARBOXAMIDE
716, 5bx6A, 0.7430, 3.49, 0.175, 343, 275, PKA IN COMPLEX WITH A HALOGENATED PHTHALAZINONE FRAGMENT COMPOUND.
717, 4yxrA, 0.7430, 3.48, 0.178, 334, 275, CRYSTAL STRUCTURE OF PKA IN COMPLEX WITH INHIBITOR.
718, 4uj9A, 0.7430, 3.49, 0.178, 339, 275, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
719, 3zewA, 0.7430, 2.86, 0.295, 269, 264, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
720, 3mfsA, 0.7430, 3.06, 0.195, 303, 267, CASK-4M CAM KINASE DOMAIN AMPPNP
721, 3e8cE, 0.7430, 3.48, 0.167, 336, 275, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
722, 3e8eI, 0.7429, 3.55, 0.167, 345, 276, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
723, 2yabB, 0.7429, 3.20, 0.175, 299, 269, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
724, 1cdkA, 0.7429, 3.44, 0.185, 342, 275, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
725, 5o2cA, 0.7428, 3.12, 0.205, 368, 268, CRYSTAL STRUCTURE OF WNK3 KINASE AND CCT1 DIDOMAIN IN A UNPHOSPHORYLATED STATE
726, 5n33A, 0.7428, 3.47, 0.182, 347, 274, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3-AMINO-5-(TRIFLUOROMETHYL)-1H-PYRIDIN-2- ONE
727, 4xw6A, 0.7428, 3.46, 0.175, 334, 274, X-RAY STRUCTURE OF PKAC WITH ADP FREE PHOSPHATE ION CP20 MAGNESIUM IONS
728, 4xg4A, 0.7428, 2.78, 0.347, 264, 259, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
729, 4ujbA, 0.7428, 3.49, 0.175, 344, 275, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
730, 4uj1A, 0.7428, 3.49, 0.175, 335, 275, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
731, 3e8cC, 0.7428, 3.66, 0.173, 341, 278, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
732, 2uzwE, 0.7428, 3.58, 0.173, 336, 277, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
733, 5zj6A, 0.7427, 2.76, 0.295, 271, 258, CRYSTAL STRUCTURE OF HCK KINASE COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4- PHENOXYPHENYL)-7H-PYRROLO[2;3-D]PYRIMIDIN-4-AMINE 
734, 5j5xA, 0.7427, 3.47, 0.182, 340, 275, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1416
735, 3vs3B, 0.7427, 2.67, 0.297, 431, 256, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)- 7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE
736, 3vqhA, 0.7427, 3.49, 0.175, 344, 275, BROMINE SAD PARTIALLY RESOLVES MULTIPLE BINDING MODES FOR PKA INHIBITOR H-89
737, 3geqA, 0.7427, 3.00, 0.293, 272, 263, STRUCTURAL BASIS FOR THE CHEMICAL RESCUE OF SRC KINASE ACTIVITY
738, 2yabA, 0.7427, 3.18, 0.171, 299, 269, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
739, 2gnhA, 0.7427, 3.56, 0.178, 338, 276, PKA FIVE FOLD MUTANT MODEL OF RHO-KINASE WITH H1152P
740, 1qpjA, 0.7427, 2.79, 0.294, 265, 262, CRYSTAL STRUCTURE OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH STAUROSPORINE.
741, 1l3rE, 0.7427, 3.43, 0.168, 338, 273, CRYSTAL STRUCTURE OF A TRANSITION STATE MIMIC OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
742, 1ad5A, 0.7427, 2.61, 0.301, 437, 256, SRC FAMILY KINASE HCK-AMP-PNP COMPLEX
743, 5zj6B, 0.7426, 2.77, 0.295, 270, 258, CRYSTAL STRUCTURE OF HCK KINASE COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4- PHENOXYPHENYL)-7H-PYRROLO[2;3-D]PYRIMIDIN-4-AMINE 
744, 2qurA, 0.7426, 3.61, 0.170, 338, 277, CRYSTAL STRUCTURE OF F327A/K285P MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
745, 4wb6A, 0.7425, 3.34, 0.176, 336, 272, CRYSTAL STRUCTURE OF A L205R MUTANT OF HUMAN CAMP-DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
746, 4j97B, 0.7425, 2.86, 0.326, 283, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
747, 3mvjA, 0.7425, 3.38, 0.179, 334, 273, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
748, 2jdtA, 0.7425, 3.55, 0.174, 334, 276, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
749, 2hckA, 0.7425, 2.63, 0.297, 437, 256, SRC FAMILY KINASE HCK-QUERCETIN COMPLEX
750, 1atpE, 0.7425, 3.52, 0.181, 334, 276, 2.2 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH MNATP AND A PEPTIDE INHIBITOR
751, 4j99D, 0.7424, 2.97, 0.309, 281, 262, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
752, 1svgA, 0.7424, 3.51, 0.171, 338, 275, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 4
753, 1rdqE, 0.7424, 3.44, 0.175, 340, 274, HYDROLYSIS OF ATP IN THE CRYSTAL OF Y204A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
754, 5n7uA, 0.7423, 3.48, 0.171, 350, 275, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-BROMO-35-DIMETHYL-1H-PYRAZOLE
755, 5jr7A, 0.7423, 3.62, 0.184, 335, 277, CRYSTAL STRUCTURE OF AN ACRDYS HETERODIMER [RIA(92-365):C] OF PKA
756, 4yxsA, 0.7423, 3.57, 0.174, 335, 276, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
757, 4xg9B, 0.7423, 2.78, 0.342, 265, 260, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
758, 4wb7A, 0.7423, 3.47, 0.179, 402, 274, CRYSTAL STRUCTURE OF A CHIMERIC FUSION OF HUMAN DNAJ (HSP40) AND CAMP- DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
759, 4xliB, 0.7422, 2.70, 0.342, 264, 260, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
760, 4dh7A, 0.7422, 3.44, 0.172, 333, 273, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH HIGH MG2+ AMP-PNP AND IP20 
761, 4dfxE, 0.7422, 3.53, 0.171, 347, 275, CRYSTAL STRUCTURE OF MYRISTOYLATED K7C CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE IN COMPLEX WITH SP20 AND AMP-PNP
762, 3x2wA, 0.7422, 3.52, 0.171, 336, 275, MICHAELIS COMPLEX OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
763, 5mjbA, 0.7421, 3.21, 0.301, 276, 269, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
764, 4xliA, 0.7421, 2.67, 0.342, 264, 260, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
765, 4wb8A, 0.7421, 3.44, 0.172, 334, 273, CRYSTAL STRUCTURE OF HUMAN CAMP-DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT) EXON 1 DELETION
766, 5n7pA, 0.7420, 3.49, 0.182, 350, 275, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3-AMINO-5-(PYRROLIDIN-1-YL)-1H-PYRAZOLE- 4-CARBONITRILE
767, 4wo5A, 0.7420, 2.65, 0.217, 266, 258, CRYSTAL STRUCTURE OF A BRAF KINASE DOMAIN MONOMER
768, 4ujaA, 0.7420, 3.50, 0.178, 336, 275, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
769, 4o22A, 0.7420, 3.52, 0.171, 336, 275, BINARY COMPLEX OF METAL-FREE PKAC WITH SP20.
770, 4c62A, 0.7420, 2.36, 0.296, 273, 253, INHIBITORS OF JAK2 KINASE DOMAIN
771, 4bkjB, 0.7420, 2.56, 0.292, 297, 257, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
772, 2uvxA, 0.7420, 3.55, 0.178, 335, 276, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 7-AZAINDOLE
773, 1ydsE, 0.7420, 3.56, 0.170, 334, 276, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H8 PROTEIN KINASE INHIBITOR [N-(2-METHYLAMINO)ETHYL]-5- ISOQUINOLINESULFONAMIDE
774, 4x6rA, 0.7419, 3.36, 0.169, 347, 272, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
775, 4uj2A, 0.7419, 3.50, 0.164, 335, 275, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
776, 4hpuE, 0.7419, 3.54, 0.175, 336, 275, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE DISPLAYING PARTIAL PHOSPHORYL TRANSFER OF AMP-PNP ONTO A SUBSTRATE PEPTIDE
777, 4dinA, 0.7419, 3.60, 0.167, 340, 276, NOVEL LOCALIZATION AND QUATERNARY STRUCTURE OF THE PKA RI BETA HOLOENZYME
778, 3fqsA, 0.7419, 3.04, 0.340, 268, 262, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R406
779, 6aywB, 0.7418, 3.18, 0.157, 293, 268, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
780, 5mhiA, 0.7418, 3.52, 0.167, 348, 275, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE (5-CHLORO-2-METHOXYPHENYL)METHANAMINE
781, 4rx9A, 0.7418, 3.09, 0.338, 268, 263, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT PYRIMIDINE INHIBITOR
782, 4dg2E, 0.7418, 3.54, 0.171, 347, 275, CRYSTAL STRUCTURE OF MYRISTOYLATED WT CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE IN COMPLEX WITH SP20
783, 3vs4B, 0.7418, 2.58, 0.295, 434, 254, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 5-(4-PHENOXYPHENYL)-7-(TETRAHYDRO-2H-PYRAN-4-YL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
784, 3vryA, 0.7418, 2.60, 0.295, 428, 254, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-7-YL- CYCLOPENTANE
785, 2vo7A, 0.7418, 3.49, 0.178, 335, 275, STRUCTURE OF PKA COMPLEXED WITH 4-(4-CHLOROBENZYL)-1-(7H- PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN-4-YLAMINE
786, 2erzE, 0.7418, 3.56, 0.174, 334, 276, CRYSTAL STRUCTURE OF C-AMP DEPENDENT KINASE (PKA) BOUND TO HYDROXYFASUDIL
787, 5uzkA, 0.7417, 3.57, 0.178, 335, 276, CRYSTAL STRUCTURE OF PKA BOUND TO AN PYRROLO PYRIDINE INHIBITOR
788, 3vs4A, 0.7417, 2.65, 0.294, 429, 255, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 5-(4-PHENOXYPHENYL)-7-(TETRAHYDRO-2H-PYRAN-4-YL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
789, 3utoB, 0.7417, 3.54, 0.152, 566, 276, TWITCHIN KINASE REGION FROM C.ELEGANS (FN31-NL-KIN-CRD-IG26)
790, 3twjA, 0.7417, 3.71, 0.158, 396, 279, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1447
791, 3kkvA, 0.7417, 3.52, 0.175, 335, 275, STRUCTURE OF PKA WITH A PROTEIN KINASE B-SELECTIVE INHIBITOR.
792, 6aywA, 0.7416, 3.06, 0.154, 293, 267, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
793, 4ybkA, 0.7416, 2.83, 0.281, 266, 260, C-HELIX-OUT DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
794, 4ib0A, 0.7416, 3.44, 0.172, 334, 273, X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH NA+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
795, 4dg3E, 0.7416, 3.44, 0.168, 335, 273, CRYSTAL STRUCTURE OF R336A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED TURN MOTIF.
796, 4dfzE, 0.7416, 3.53, 0.171, 347, 275, CRYSTAL STRUCTURE OF MYRISTOYLATED K7C CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE IN COMPLEX WITH SP20
797, 5otfA, 0.7415, 4.01, 0.138, 411, 282, MRCK BETA IN COMPLEX WITH BDP-00009066
798, 5ng3A, 0.7415, 2.63, 0.218, 283, 257, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
799, 5jr7C, 0.7415, 3.65, 0.174, 335, 276, CRYSTAL STRUCTURE OF AN ACRDYS HETERODIMER [RIA(92-365):C] OF PKA
800, 4dh3A, 0.7415, 3.45, 0.172, 333, 273, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH HIGH MG2+ ATP AND IP20
801, 4dfnA, 0.7415, 2.97, 0.351, 269, 262, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH AN ADAMANTYLPYRAZINE INHIBITOR
802, 3amaA, 0.7415, 3.57, 0.170, 342, 276, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR JNJ- 7706621
803, 2jdsA, 0.7415, 3.54, 0.175, 334, 275, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A- 443654
804, 1ydrE, 0.7415, 3.56, 0.174, 334, 276, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H7 PROTEIN KINASE INHIBITOR 1-(5- ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE
805, 1q8tA, 0.7415, 3.65, 0.177, 338, 277, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH RHO-KINASE INHIBITOR Y-27632
806, 5izfA, 0.7414, 3.51, 0.188, 336, 276, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1408
807, 3vryB, 0.7414, 2.61, 0.295, 434, 254, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-7-YL- CYCLOPENTANE
808, 1yi6B, 0.7414, 3.20, 0.280, 274, 268, C-TERM TAIL SEGMENT OF HUMAN TYROSINE KINASE (258-533)
809, 2cpkE, 0.7413, 3.45, 0.168, 333, 273, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CYCLIC ADENOSINE MONOPHOSPHATE-DEPENDENT PROTEIN KINASE
810, 2c1bA, 0.7413, 3.57, 0.178, 335, 276, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ( 4R2S)-5 -(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2- YLMETHANESULFONYL)ISOQUINOLINE
811, 5n39A, 0.7412, 3.58, 0.182, 347, 275, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-(23-DIHYDROBENZO[B][14]DIOXIN-6-YL) PYRROLIDINE
812, 4id7A, 0.7412, 2.75, 0.347, 268, 259, ACK1 KINASE IN COMPLEX WITH THE INHIBITOR CIS-3-[8-AMINO-1-(4- PHENOXYPHENYL)IMIDAZO[15-A]PYRAZIN-3-YL]CYCLOBUTANOL
813, 4c62B, 0.7412, 2.25, 0.307, 271, 251, INHIBITORS OF JAK2 KINASE DOMAIN
814, 1oecA, 0.7412, 3.04, 0.326, 280, 264, FGFR2 KINASE DOMAIN
815, 5vloB, 0.7411, 3.01, 0.158, 293, 266, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
816, 4j95C, 0.7411, 3.07, 0.314, 281, 264, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
817, 4dh8A, 0.7411, 3.44, 0.172, 333, 273, ROOM TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH HIGH MG2+ AMP-PNP AND IP20
818, 3idbA, 0.7411, 3.74, 0.189, 341, 280, CRYSTAL STRUCTURE OF (108-268)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
819, 2uztA, 0.7411, 3.70, 0.186, 336, 279, PKA STRUCTURES OF AKT INDAZOLE-PYRIDINE INHIBITORS
820, 1vebA, 0.7411, 3.53, 0.171, 338, 275, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 5
821, 5n1lA, 0.7410, 3.49, 0.182, 347, 274, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 25-DIMETHYL-N-PYRIDIN-4-YLFURAN-3- CARBOXAMIDE
822, 4wb5A, 0.7410, 3.45, 0.176, 335, 273, CRYSTAL STRUCTURE OF HUMAN CAMP-DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
823, 4iafA, 0.7410, 3.55, 0.175, 333, 275, ROOM TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH MG2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
824, 3nynA, 0.7410, 3.97, 0.169, 553, 284, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH SANGIVAMYCIN
825, 2qcsA, 0.7410, 3.44, 0.186, 335, 274, A COMPLEX STRUCTURE BETWEEN THE CATALYTIC AND REGULATORY SUBUNIT OF PROTEIN KINASE A THAT REPRESENTS THE INHIBITED STATE
826, 1q61A, 0.7410, 3.72, 0.183, 335, 279, PKA TRIPLE MUTANT MODEL OF PKB
827, 4ib1A, 0.7409, 3.44, 0.172, 335, 273, STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH K+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
828, 4dh1A, 0.7409, 3.37, 0.173, 333, 272, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH LOW MG2+ ATP AND IP20
829, 3nynB, 0.7409, 3.96, 0.169, 553, 284, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH SANGIVAMYCIN
830, 2xynA, 0.7409, 2.59, 0.345, 264, 258, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
831, 1sveA, 0.7409, 3.49, 0.175, 341, 275, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 1
832, 5lmaA, 0.7408, 2.90, 0.342, 267, 260, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
833, 3fqhA, 0.7408, 2.68, 0.346, 262, 257, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A 2-SUBSTITUTED 7-AZAINDOLE
834, 3zo4A, 0.7407, 3.47, 0.172, 335, 274, THE SYNTHESIS AND EVALUATION OF DIAZASPIROCYCLIC PROTEIN KINASE INHIBITORS
835, 3x2uA, 0.7407, 3.55, 0.171, 336, 275, MICHAELIS-LIKE INITIAL COMPLEX OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT.
836, 3ow3A, 0.7407, 3.47, 0.172, 334, 274, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
837, 2uw4A, 0.7407, 3.55, 0.178, 334, 275, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-(5-METHYL- 1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
838, 5h0eA, 0.7406, 2.99, 0.292, 446, 260, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANAMIDE
839, 4puzA, 0.7406, 2.72, 0.345, 263, 258, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH GS- 9973
840, 4iaiA, 0.7406, 3.52, 0.178, 333, 275, X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH CA2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
841, 4dh5A, 0.7406, 3.55, 0.175, 333, 275, ROOM TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH HIGH MG2+ ADP PHOSPHATE AND IP20
842, 3nx8A, 0.7406, 3.52, 0.175, 333, 275, HUMAN CAMP DEPENDENT PROTEIN KINASE IN COMPLEX WITH PHENOL
843, 1ydtE, 0.7406, 3.58, 0.170, 334, 276, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H89 PROTEIN KINASE INHIBITOR N-[2- (4-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE
844, 1u4dA, 0.7406, 2.40, 0.357, 258, 252, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
845, 4xw4A, 0.7405, 3.53, 0.171, 334, 275, X-RAY STRUCTURE OF PKAC WITH AMPPNP SP20 CALCIUM IONS
846, 4iadA, 0.7405, 3.58, 0.185, 334, 276, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH MG2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
847, 4b4lA, 0.7405, 3.14, 0.175, 299, 268, CRYSTAL STRUCTURE OF AN ARD DAP-KINASE 1 MUTANT
848, 3bwjA, 0.7405, 3.39, 0.183, 338, 273, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR LEAD COMPOUND ARC-1034
849, 5n1nA, 0.7404, 3.48, 0.172, 348, 274, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-CHLORO-9-PROPAN-2-YLPURINE
850, 5d7vC, 0.7404, 2.45, 0.296, 264, 253, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
851, 4px6A, 0.7404, 2.76, 0.349, 262, 258, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT PYRIDOPYRIMIDINONE INHIBITOR
852, 4ie9A, 0.7404, 3.51, 0.175, 335, 275, BOVINE PKA C-ALPHA IN COMPLEX WITH 3-PYRIDYLMETHYL-5-METHYL-1H- PYRAZOLE-3-CARBOXYLATE
853, 4iakA, 0.7404, 3.54, 0.171, 334, 275, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH SR2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
854, 4c61A, 0.7404, 2.33, 0.298, 272, 252, INHIBITORS OF JAK2 KINASE DOMAIN
855, 1u54A, 0.7404, 2.48, 0.350, 262, 254, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
856, 5lcqA, 0.7403, 3.50, 0.178, 350, 275, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH LONG-CHAIN FASUDIL-DERIVATIVE (LIGAND 05)
857, 5ghvB, 0.7403, 2.90, 0.346, 265, 260, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
858, 3agmA, 0.7403, 3.52, 0.175, 337, 275, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-670
859, 1gjoA, 0.7403, 3.05, 0.326, 280, 264, THE FGFR2 TYROSINE KINASE DOMAIN
860, 5n3aA, 0.7402, 3.56, 0.171, 349, 275, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-METHYL-5-(1-METHYLIMIDAZOL-2-YL)-13- THIAZOL-2-AMINE
861, 5n32A, 0.7402, 3.52, 0.182, 345, 274, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-CHLOROBENZYL CARBAMIMIDOTHIOATE
862, 4dg0E, 0.7402, 3.55, 0.175, 338, 275, CRYSTAL STRUCTURE OF MYRISTOYLATED WT CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE IN COMPLEX WITH SP20 AND AMP-PNP
863, 4qpsA, 0.7401, 2.09, 0.321, 270, 249, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
864, 4axaA, 0.7401, 3.43, 0.175, 335, 274, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1S)-2-AMINO-1-( 4-CHLOROPHENYL)-1-(4-(1H-PYRAZOL-4-YL)PHENYL)ETHAN-1-OL
865, 3zo2A, 0.7401, 3.56, 0.178, 340, 275, THE SYNTHESIS AND EVALUATION OF DIAZASPIROCYCLIC PROTEIN KINASE INHIBITORS
866, 2x2mB, 0.7401, 2.76, 0.333, 279, 258, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
867, 1xhaA, 0.7401, 3.57, 0.174, 348, 276, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
868, 1u46B, 0.7401, 2.24, 0.356, 257, 250, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED KINASE DOMAIN OF THE TYROSINE KINASE ACK1
869, 5h09A, 0.7400, 3.00, 0.292, 446, 260, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-ETHYL2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANOATE
870, 3vs6B, 0.7400, 2.64, 0.291, 434, 254, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR TERT-BUTYL {4-[4-AMINO-1-(PROPAN-2-YL)-1H-PYRAZOLO[34- D]PYRIMIDIN-3-YL]-2-METHOXYPHENYL}CARBAMATE
871, 3tv7B, 0.7400, 3.96, 0.145, 397, 283, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1342
872, 3pooA, 0.7400, 3.52, 0.175, 331, 275, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
873, 3dqxB, 0.7400, 3.01, 0.284, 268, 264, CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH ATPGS
874, 2pwlA, 0.7400, 3.27, 0.316, 284, 266, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
875, 4pniA, 0.7399, 3.94, 0.161, 492, 286, BOVINE G PROTEIN-COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH GSK2163632A
876, 4mhaA, 0.7399, 2.17, 0.351, 256, 248, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC1817
877, 3zo3A, 0.7399, 3.56, 0.178, 337, 275, THE SYNTHESIS AND EVALUATION OF DIAZASPIROCYCLIC PROTEIN KINASE INHIBITORS
878, 3owpA, 0.7399, 3.71, 0.194, 334, 279, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
879, 1xh9A, 0.7399, 3.63, 0.174, 336, 276, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
880, 1svhA, 0.7399, 3.59, 0.174, 335, 276, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 8
881, 5n37A, 0.7398, 3.49, 0.172, 347, 274, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-(13-BENZODIOXOL-5-YLMETHYL) CYCLOPENTANAMINE
882, 3pvbA, 0.7398, 3.36, 0.180, 341, 272, CRYSTAL STRUCTURE OF (73-244)RIA:C HOLOENZYME OF CAMP-DEPENDENT PROTEIN KINASE
883, 3dndA, 0.7398, 3.58, 0.174, 334, 276, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
884, 2uw3A, 0.7398, 3.50, 0.175, 334, 274, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 5-METHYL-4- PHENYL-1H-PYRAZOLE
885, 1u54B, 0.7398, 2.48, 0.356, 261, 253, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
886, 1bx6A, 0.7398, 3.53, 0.174, 337, 276, CRYSTAL STRUCTURE OF THE POTENT NATURAL PRODUCT INHIBITOR BALANOL IN COMPLEX WITH THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
887, 5n3eA, 0.7397, 3.50, 0.182, 348, 274, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 6-DIMETHYLAMINOPYRIDINE-3-CARBOXYLIC ACID
888, 4j97D, 0.7397, 2.82, 0.324, 285, 259, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
889, 5d7vB, 0.7396, 2.47, 0.296, 264, 253, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
890, 4wnkA, 0.7396, 3.72, 0.176, 499, 278, CRYSTAL STRUCTURE OF BOVINE G PROTEIN COUPLED-RECEPTOR KINASE 5 IN COMPLEX WITH CCG215022
891, 3kcfD, 0.7396, 2.88, 0.187, 330, 262, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
892, 5n1mA, 0.7395, 3.52, 0.182, 347, 274, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE (5-CHLORO-2-METHOXYPHENYL)METHANAMINE
893, 5ghvA, 0.7395, 2.90, 0.346, 265, 260, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
894, 4z84A, 0.7395, 3.52, 0.178, 335, 275, PKAB3 IN COMPLEX WITH PYRROLIDINE INHIBITOR 34A
895, 4fynA, 0.7395, 3.01, 0.337, 267, 261, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 3-(8-{4- [ETHYL-(2-HYDROXY-ETHYL)-AMINO]-PHENYLAMINO}-IMIDAZO[12-A]PYRAZIN-5- YL)-PHENOL
896, 3qfvB, 0.7395, 3.88, 0.151, 396, 279, MRCK BETA IN COMPLEX WITH TPCA-1
897, 3ovvA, 0.7395, 3.50, 0.175, 335, 274, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
898, 3mdyA, 0.7395, 2.72, 0.174, 320, 259, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
899, 3en4B, 0.7395, 2.92, 0.294, 266, 262, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP121 A MULTITARGETED KINASE INHIBITOR
900, 2uw7A, 0.7395, 3.50, 0.175, 335, 275, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
901, 2gu8A, 0.7395, 3.52, 0.175, 335, 275, DISCOVERY OF 2-PYRIMIDYL-5-AMIDOTHIOPHENES AS NOVEL AND POTENT INHIBITORS FOR AKT: SYNTHESIS AND SAR STUDIES
902, 6babA, 0.7394, 3.08, 0.158, 290, 266, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
903, 3zo1A, 0.7394, 3.56, 0.175, 339, 275, THE SYNTHESIS AND EVALUATION OF DIAZASPIROCYCLIC PROTEIN KINASE INHIBITORS
904, 3kcfA, 0.7394, 2.75, 0.192, 328, 261, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
905, 2w4kA, 0.7394, 3.16, 0.179, 301, 268, X-RAY STRUCTURE OF A DAP-KINASE 2-302
906, 4w7pA, 0.7393, 3.75, 0.147, 388, 279, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO YB-15-QD37
907, 4l00B, 0.7393, 2.78, 0.211, 278, 261, CRYSTAL STRUCTURE OF THE APO JAK1 PSEUDOKINASE DOMAIN
908, 4bkjA, 0.7393, 2.64, 0.292, 295, 257, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
909, 2uw5A, 0.7393, 3.50, 0.179, 333, 274, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (R)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
910, 2gnlA, 0.7393, 3.59, 0.178, 338, 276, PKA THREEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR H- 1152P
911, 1xh5A, 0.7393, 3.59, 0.174, 335, 276, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
912, 5d7vD, 0.7392, 2.46, 0.296, 264, 253, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
913, 3vs6A, 0.7392, 2.65, 0.295, 434, 254, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR TERT-BUTYL {4-[4-AMINO-1-(PROPAN-2-YL)-1H-PYRAZOLO[34- D]PYRIMIDIN-3-YL]-2-METHOXYPHENYL}CARBAMATE
914, 2vz6A, 0.7392, 3.02, 0.143, 291, 265, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
915, 5ng3D, 0.7391, 2.71, 0.221, 278, 258, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
916, 5h0hA, 0.7391, 2.84, 0.295, 446, 258, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-NN4-TRIMETHYLPENTANAMIDE
917, 4y93A, 0.7391, 2.73, 0.296, 429, 260, CRYSTAL STRUCTURE OF THE PH-TH-KINASE CONSTRUCT OF BRUTON S TYROSINE KINASE (BTK)
918, 2wd1A, 0.7391, 3.02, 0.346, 289, 260, HUMAN C-MET KINASE IN COMPLEX WITH AZAINDOLE INHIBITOR
919, 2uvzA, 0.7391, 3.49, 0.179, 334, 274, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH C-PHENYL-C-(4-( 9H-PURIN-6-YL)-PHENYL)-METHYLAMINE
920, 2f2uB, 0.7391, 3.67, 0.151, 383, 278, CRYSTAL STRUCTURE OF THE RHO-KINASE KINASE DOMAIN
921, 5d7vA, 0.7390, 2.57, 0.295, 268, 254, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN
922, 2vnyA, 0.7390, 3.57, 0.175, 334, 275, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)AMINE
923, 2uvyA, 0.7390, 3.56, 0.178, 333, 275, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH METHYL-(4-(9H- PURIN-6-YL)-BENZYL)-AMINE
924, 1xbbA, 0.7390, 3.06, 0.340, 268, 262, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH GLEEVEC
925, 1iasA, 0.7390, 3.06, 0.158, 330, 266, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
926, 5n36A, 0.7389, 3.51, 0.172, 347, 274, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3H-ISOINDOL-2-IUM-1-AMINE
927, 5wfjA, 0.7388, 2.36, 0.313, 265, 252, THE JAK3 KINASE DOMAIN IN COMPLEX WITH A COVALENT INHIBITOR
928, 5n3bA, 0.7388, 3.51, 0.172, 342, 274, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-(PYRIDIN-3-YL)ETHANAMINE
929, 5m0bA, 0.7388, 3.55, 0.185, 350, 276, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A SHORT-CHAINED N-(2-AMINOETHYL)ISOQUINOLINE-5-SULFONAMIDE) FASUDIL-DERIVATIVE (LIGAND 03) 
930, 4mkcA, 0.7388, 3.48, 0.256, 303, 273, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE COMPLEXED WITH LDK378
931, 3p0mA, 0.7388, 3.59, 0.178, 335, 276, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
932, 3ambA, 0.7388, 3.57, 0.174, 340, 276, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR VX- 680
933, 2ofuA, 0.7388, 2.86, 0.294, 272, 262, X-RAY CRYSTAL STRUCTURE OF 2-AMINOPYRIMIDINE CARBAMATE 43 BOUND TO LCK
934, 5n3cA, 0.7387, 3.50, 0.172, 348, 274, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE THIOPHENE-3-CARBOXIMIDAMIDE
935, 5n1eA, 0.7387, 3.56, 0.182, 347, 275, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-(13-BENZODIOXOL-5-YL)-2-PIPERIDIN-1- YLACETAMIDE
936, 4w7pD, 0.7386, 3.74, 0.151, 387, 279, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO YB-15-QD37
937, 4i0rA, 0.7386, 2.92, 0.340, 264, 259, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(345- TRIMETHOXY-PHENYL)-5H-PYRROLO[23-B]PYRAZINE-7-CARBOXYLIC ACID ISOPROPYLAMIDE
938, 3vs3A, 0.7386, 2.64, 0.295, 434, 254, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[TRANS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)- 7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE
939, 2v7aB, 0.7386, 2.98, 0.331, 268, 263, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
940, 2g2iA, 0.7386, 2.76, 0.324, 271, 259, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
941, 1smhA, 0.7386, 3.51, 0.175, 348, 275, PROTEIN KINASE A VARIANT COMPLEX WITH COMPLETELY ORDERED N- TERMINAL HELIX
942, 4fl3A, 0.7385, 2.93, 0.328, 538, 259, STRUCTURAL AND BIOPHYSICAL CHARACTERIZATION OF THE SYK ACTIVATION SWITCH
943, 4dflA, 0.7385, 2.80, 0.349, 263, 258, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A SULFONAMIDOPYRAZINE PIPERIDINE INHIBITOR
944, 3tkuA, 0.7385, 3.79, 0.147, 395, 278, MRCK BETA IN COMPLEX WITH FASUDIL
945, 3kcfC, 0.7385, 2.88, 0.172, 330, 262, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
946, 3brbA, 0.7385, 2.33, 0.353, 260, 249, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE- PROTEIN KINASE MER IN COMPLEX WITH ADP
947, 5h0bA, 0.7384, 2.94, 0.293, 446, 259, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-4-METHYLPENTANOIC ACID
948, 3vs5B, 0.7384, 2.59, 0.292, 427, 253, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-(1-METHYLPIPERIDIN-4-YL)-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
949, 2pvyA, 0.7384, 2.79, 0.326, 288, 258, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
950, 5w86C, 0.7383, 2.43, 0.316, 273, 253, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
951, 5h0gA, 0.7383, 3.01, 0.292, 446, 260, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR (S)-2-(((1R4S)-4-(4-AMINO-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-7-YL)CYCLOHEXYL)AMINO)-N4-DIMETHYLPENTANAMIDE
952, 4z83E, 0.7383, 3.48, 0.179, 335, 274, PKAB3 IN COMPLEX WITH PYRROLIDINE INHIBITOR 47A
953, 4mxzA, 0.7383, 3.03, 0.289, 266, 263, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
954, 4mxyA, 0.7383, 3.03, 0.289, 266, 263, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
955, 4e26A, 0.7383, 2.70, 0.216, 270, 259, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
956, 3v8sD, 0.7383, 3.76, 0.154, 397, 279, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18)
957, 5w86D, 0.7382, 2.35, 0.327, 272, 251, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
958, 5n3dA, 0.7382, 3.54, 0.182, 346, 274, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-(TRIFLUOROMETHYL)BENZENECARBOXIMIDAMIDE
959, 4uakA, 0.7382, 3.83, 0.143, 404, 279, MRCK BETA IN COMPLEX WITH ADP
960, 3zfxA, 0.7382, 2.88, 0.312, 267, 260, CRYSTAL STRUCTURE OF EPHB1
961, 3vrzB, 0.7382, 2.65, 0.295, 430, 254, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-BENZYLUREA
962, 3utoA, 0.7382, 3.61, 0.159, 559, 276, TWITCHIN KINASE REGION FROM C.ELEGANS (FN31-NL-KIN-CRD-IG26)
963, 2gqgA, 0.7382, 2.89, 0.332, 277, 262, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
964, 1xh8A, 0.7382, 3.52, 0.178, 337, 275, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
965, 2jdvA, 0.7381, 3.62, 0.174, 334, 276, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH A-443654
966, 4xw5A, 0.7380, 3.39, 0.173, 334, 272, X-RAY STRUCTURE OF PKAC WITH ATP CP20 CALCIUM IONS
967, 3zfxD, 0.7380, 2.88, 0.312, 265, 260, CRYSTAL STRUCTURE OF EPHB1
968, 3kf4B, 0.7380, 2.75, 0.331, 270, 260, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
969, 2qu5A, 0.7380, 3.13, 0.297, 292, 263, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR
970, 3vs5A, 0.7379, 2.61, 0.296, 429, 253, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-(1-METHYLPIPERIDIN-4-YL)-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE
971, 2vnwA, 0.7379, 3.58, 0.175, 334, 275, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)METHANAMINE
972, 5n1kA, 0.7378, 3.56, 0.172, 341, 274, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-AMINO-1-(4-FLUOROPHENYL)ETHANOL
973, 1xh7A, 0.7378, 3.58, 0.178, 337, 275, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
974, 1xh6A, 0.7378, 3.62, 0.178, 331, 276, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
975, 5uhnA, 0.7377, 3.18, 0.317, 282, 265, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A N549H/E565A DOUBLE GAIN-OF-FUNCTION MUTATION
976, 5h2uC, 0.7377, 2.46, 0.292, 264, 253, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
977, 4iayA, 0.7377, 3.58, 0.175, 333, 275, ROOM TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH SR2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
978, 3kcfE, 0.7377, 3.02, 0.159, 330, 264, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
979, 2a27C, 0.7377, 3.28, 0.175, 303, 269, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
980, 5mjbB, 0.7376, 3.29, 0.301, 278, 269, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
981, 3zfxI, 0.7376, 2.79, 0.313, 263, 259, CRYSTAL STRUCTURE OF EPHB1
982, 3zfxH, 0.7376, 2.91, 0.310, 266, 261, CRYSTAL STRUCTURE OF EPHB1
983, 2vo6A, 0.7376, 3.49, 0.182, 335, 274, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4- CHLOROBENZYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YLAMINE
984, 4cd0A, 0.7375, 3.42, 0.269, 295, 271, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPANE-12-DIOL
985, 3tv7D, 0.7375, 3.81, 0.151, 397, 279, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1342
986, 2ya9A, 0.7375, 3.18, 0.175, 299, 268, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
987, 2a27A, 0.7375, 3.28, 0.175, 304, 269, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
988, 1q8uA, 0.7375, 3.62, 0.188, 341, 277, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR H-1152P
989, 6d20A, 0.7374, 2.97, 0.300, 296, 263, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE RECEPTOR IN COMPLEX WITH 5-(4-FLUOROPHENYL)THIENO[2;3-D]PYRIMIDIN-4(3H)-ONE AND 5-{[2;4- DICHLORO-5-(PYRIDIN-2-YL)BENZENE-1-CARBONYL]AMINO}-N-(2-HYDROXY-2- METHYLPROPYL)-1-PHENYL-1H-PYRAZOLE-3-CARBOXAMIDE INHIBITORS 
990, 5n23A, 0.7374, 3.54, 0.172, 333, 274, PROTEIN KINASE A MUTANTS AS SURROGATE MODEL FOR AURORA B WITH AT9283 INHIBITOR
991, 5eydA, 0.7374, 3.14, 0.347, 289, 262, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH AMG 337
992, 3fzrA, 0.7374, 2.77, 0.318, 261, 258, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-431396
993, 2vo3A, 0.7374, 3.51, 0.175, 334, 274, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
994, 1iasE, 0.7374, 3.13, 0.158, 330, 266, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
995, 1b6cH, 0.7374, 3.05, 0.177, 326, 265, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
996, 5ng2B, 0.7373, 2.88, 0.231, 278, 260, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
997, 4gu6A, 0.7373, 2.94, 0.345, 271, 261, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
998, 3f6xA, 0.7373, 2.77, 0.291, 264, 258, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
999, 2a27E, 0.7373, 3.28, 0.175, 303, 269, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1000, 1xh4A, 0.7373, 3.59, 0.178, 334, 275, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1001, 4iazA, 0.7372, 3.58, 0.175, 334, 275, STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH BA2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
1002, 1stcE, 0.7372, 3.56, 0.174, 334, 276, CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH STAUROSPORINE
1003, 3v8sB, 0.7371, 3.79, 0.154, 397, 279, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18)
1004, 3tkuB, 0.7371, 3.91, 0.147, 395, 279, MRCK BETA IN COMPLEX WITH FASUDIL
1005, 2vo0A, 0.7371, 3.54, 0.178, 340, 275, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
1006, 1iasD, 0.7371, 2.97, 0.159, 330, 264, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
1007, 1iasC, 0.7371, 2.96, 0.159, 330, 264, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
1008, 5vndB, 0.7370, 3.24, 0.331, 295, 266, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
1009, 5tiuA, 0.7370, 3.01, 0.342, 266, 260, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH INHIBITOR
1010, 5t8pB, 0.7370, 3.22, 0.179, 328, 268, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO BENZOXEPIN COMPOUND 2
1011, 4hzrB, 0.7370, 2.52, 0.357, 258, 252, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN
1012, 5m75A, 0.7369, 3.61, 0.188, 350, 277, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A (S)-METHYL SUBSTITUED FASUDIL-DERIVATIVE 
1013, 4tl0A, 0.7369, 3.29, 0.175, 300, 269, CRYSTAL STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 WITH A CRUCIAL PHOSPHOMIMICKING MUTATION
1014, 3l9lA, 0.7369, 3.60, 0.174, 338, 276, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
1015, 1b6cD, 0.7369, 3.04, 0.177, 326, 265, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
1016, 5y5tA, 0.7368, 2.88, 0.341, 263, 258, CRYSTAL STRUCTURES OF SPLEEN TYROSINE KINASE IN COMPLEX WITH A NOVEL INHIBITOR 
1017, 2pvyD, 0.7368, 2.92, 0.317, 283, 259, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
1018, 2gcdB, 0.7368, 3.34, 0.187, 308, 273, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
1019, 4w7pC, 0.7367, 3.69, 0.152, 383, 276, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO YB-15-QD37
1020, 3f6xC, 0.7367, 2.71, 0.296, 265, 257, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1021, 1qpcA, 0.7367, 2.93, 0.286, 270, 262, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
1022, 3lcsA, 0.7366, 3.53, 0.255, 304, 275, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
1023, 3faaE, 0.7366, 3.00, 0.186, 330, 263, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
1024, 5vhbA, 0.7365, 3.61, 0.175, 325, 275, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH THE PKI PEPTIDE AND AMINOBENZOTHIAZOLE BASED INHIBITOR
1025, 5h2uD, 0.7365, 2.48, 0.292, 263, 253, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
1026, 2uw6A, 0.7365, 3.51, 0.179, 334, 274, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (S)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
1027, 2pwlB, 0.7365, 3.30, 0.320, 286, 266, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
1028, 1k2pA, 0.7365, 2.69, 0.289, 258, 256, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
1029, 4uxlA, 0.7364, 3.22, 0.321, 288, 268, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH PF-06463922
1030, 5kksB, 0.7362, 3.81, 0.158, 395, 278, ROCK 1 BOUND TO AZAINDOLE THIOZOLE INHIBITOR
1031, 4fz7A, 0.7362, 2.95, 0.340, 265, 259, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 6-((1R2S)- 2-AMINO-CYCLOHEXYLAMINO)-4-(6-ETHYL-PYRIDIN-2-YLAMINO)-PYRIDAZINE-3- CARBOXYLIC ACID AMIDE
1032, 3tnqB, 0.7362, 3.59, 0.171, 331, 275, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
1033, 3lctA, 0.7362, 3.55, 0.258, 308, 275, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
1034, 2uw0A, 0.7362, 3.52, 0.175, 334, 274, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  6-(4-(4-(4- CHLORO-PHENYL)-PIPERIDIN-4-YL)-PHENYL)-9H-PURINE
1035, 1qpdA, 0.7362, 2.89, 0.294, 270, 262, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
1036, 1koaA, 0.7362, 3.71, 0.159, 447, 277, TWITCHIN KINASE FRAGMENT (C.ELEGANS) AUTOREGULATED PROTEIN KINASE AND IMMUNOGLOBULIN DOMAINS
1037, 4aoiA, 0.7361, 2.84, 0.346, 289, 257, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( 3-((1H- PYRROLO(23-B)PYRIDIN-3-YL)METHYL)-(124)TRIAZOLO( 43-B)(124) TRIAZIN-6-YL)BENZONITRILE
1038, 3zzeA, 0.7361, 2.98, 0.347, 286, 259, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH N - ((3Z)-4-CHLORO-7-METHYL-2-OXO-12-DIHYDRO-3H-INDOL-3- YLIDENE)-2-(4-HYDROXYPHENYL)PROPANOHYDRAZIDE
1039, 3v8sA, 0.7361, 3.81, 0.155, 395, 277, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18)
1040, 3nyoA, 0.7361, 4.03, 0.169, 553, 284, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH AMP
1041, 4z55A, 0.7360, 3.49, 0.261, 294, 272, ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE DERIVATIVE OF LDK378
1042, 4ualA, 0.7360, 4.07, 0.139, 403, 281, MRCK BETA IN COMPLEX WITH BDP00005290
1043, 4rssA, 0.7360, 3.06, 0.340, 269, 262, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE SYK WITH AN INHIBITOR
1044, 3g6hA, 0.7360, 3.01, 0.297, 266, 263, SRC THR338ILE INHIBITED IN THE DFG-ASP-OUT CONFORMATION
1045, 3b2tB, 0.7360, 3.01, 0.318, 287, 261, STRUCTURE OF PHOSPHOTRANSFERASE
1046, 2of4A, 0.7360, 2.93, 0.289, 271, 263, CRYSTAL STRUCTURE OF FURANOPYRIMIDINE 1 BOUND TO LCK
1047, 5xp5B, 0.7359, 3.00, 0.285, 267, 263, C-SRC IN COMPLEX WITH ATP-CHF
1048, 5h2uB, 0.7359, 2.51, 0.292, 263, 253, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
1049, 3kxzA, 0.7359, 2.75, 0.296, 263, 260, THE COMPLEX CRYSTAL STRUCTURE OF LCK WITH A PROBE MOLECULE W259
1050, 4at3A, 0.7358, 3.29, 0.274, 289, 266, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH CPD5N
1051, 3zclA, 0.7358, 2.86, 0.346, 289, 257, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-3-(1-(1H-PYRROLO(23-B)PYRIDIN-3-YL)ETHYL)-N-ISOPROPYL-( 124)TRIAZOLO(43-B)PYRIDAZIN-6-AMINE
1052, 3v8sC, 0.7358, 3.81, 0.155, 395, 277, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18)
1053, 2py3A, 0.7358, 3.29, 0.314, 282, 264, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565G MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
1054, 2g15A, 0.7358, 3.19, 0.344, 301, 262, STRUCTURAL CHARACTERIZATION OF AUTOINHIBITED C-MET KINASE
1055, 5h2uA, 0.7357, 2.49, 0.292, 265, 253, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN COMPLEXED WITH DASATINIB
1056, 3et7A, 0.7357, 2.82, 0.324, 261, 259, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-2318841
1057, 2a27F, 0.7357, 3.33, 0.175, 303, 269, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1058, 3l9lB, 0.7356, 3.57, 0.188, 337, 276, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
1059, 3bymA, 0.7356, 2.91, 0.294, 271, 262, X-RAY CO-CRYSTAL STRUCTURE AMINOBENZIMIDAZOLE TRIAZINE 1 BOUND TO LCK
1060, 2c0iA, 0.7356, 2.63, 0.296, 433, 253, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-420983
1061, 2a27B, 0.7356, 3.31, 0.175, 303, 269, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1062, 1fmkA, 0.7356, 2.45, 0.286, 437, 252, CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRC
1063, 5k0xA, 0.7355, 2.42, 0.349, 258, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC2541
1064, 4yc8A, 0.7355, 2.61, 0.357, 259, 255, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
1065, 3nyoB, 0.7355, 4.02, 0.169, 553, 284, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH AMP
1066, 3ad6A, 0.7355, 2.92, 0.290, 272, 262, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
1067, 2x9fA, 0.7355, 2.87, 0.304, 265, 260, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1068, 6dkiA, 0.7354, 2.87, 0.299, 279, 261, CRYSTAL STRUCTURE OF TRK-A IN COMPLEX WITH THE PAN-TRK KINASE INHIBITOR; COMPOUND 19. 
1069, 5n1oA, 0.7354, 3.56, 0.179, 335, 273, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-CHLORO-4-(CHLOROMETHYL)-5- HYDROXYPHENYL)ETHAN-1-ONE
1070, 4l00A, 0.7354, 2.77, 0.200, 277, 260, CRYSTAL STRUCTURE OF THE APO JAK1 PSEUDOKINASE DOMAIN
1071, 4hzrA, 0.7354, 2.61, 0.343, 261, 254, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN
1072, 4g3cB, 0.7354, 3.23, 0.179, 327, 268, CRYSTAL STRUCTURE OF APO MURINE NF-KAPPAB INDUCING KINASE (NIK)
1073, 4fz6A, 0.7354, 3.02, 0.342, 266, 260, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH [6-((S)-2- METHYL-PYRROLIDIN-1-YL)-PYRIDIN-2-YL]-(6-PHENYL-IMIDAZO[12- B]PYRIDAZIN-8-YL)-AMINE
1074, 5ng2A, 0.7353, 2.70, 0.236, 274, 258, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
1075, 4yzbA, 0.7353, 3.23, 0.178, 466, 270, CDPK1 FROM EIMERIA TENELLA IN COMPLEX WITH INHIBITOR UW1521
1076, 4yuqA, 0.7353, 3.12, 0.177, 462, 266, CDPK1 FROM EIMERIA TENELLA IN COMPLEX WITH INHIBITOR UW1354
1077, 3vs2B, 0.7353, 2.65, 0.296, 433, 253, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[CIS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H- PYRROLO[23-D]PYRIMIDIN-4-AMINE
1078, 3tv7A, 0.7353, 3.76, 0.155, 394, 277, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1342
1079, 2z8cA, 0.7353, 2.97, 0.302, 297, 262, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN-2- YL]AMINO}PHENYL)ACETIC ACID
1080, 2q0nA, 0.7353, 3.31, 0.165, 293, 266, STRUCTURE OF HUMAN P21 ACTIVATING KINASE 4 (PAK4) IN COMPLEX WITH A CONSENSUS PEPTIDE
1081, 6g4yB, 0.7352, 3.25, 0.183, 328, 268, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK) IN COMPLEX WITH COMPOUND 1A 
1082, 4yc8B, 0.7352, 2.88, 0.344, 264, 259, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
1083, 4fzaB, 0.7352, 3.15, 0.234, 281, 265, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX
1084, 2ya9B, 0.7352, 3.16, 0.172, 299, 267, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
1085, 2a27H, 0.7352, 3.29, 0.171, 304, 269, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1086, 4zsaA, 0.7351, 3.12, 0.318, 289, 264, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
1087, 4dehA, 0.7351, 2.99, 0.347, 286, 259, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 3
1088, 2c0oA, 0.7351, 2.64, 0.292, 433, 253, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-770041
1089, 5t8pA, 0.7350, 3.24, 0.179, 327, 268, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO BENZOXEPIN COMPOUND 2
1090, 5ng3B, 0.7350, 2.75, 0.227, 275, 256, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
1091, 3vs2A, 0.7350, 2.65, 0.296, 430, 253, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 7-[CIS-4-(4-METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H- PYRROLO[23-D]PYRIMIDIN-4-AMINE
1092, 1u5qB, 0.7350, 3.37, 0.190, 308, 273, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1093, 5t8qB, 0.7349, 3.26, 0.183, 328, 268, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO ARYL PYRROLE FRAGMENT 17
1094, 5ia0C, 0.7349, 3.09, 0.299, 269, 264, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
1095, 1iasB, 0.7349, 2.90, 0.172, 324, 261, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
1096, 1b6cB, 0.7349, 3.08, 0.177, 326, 265, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
1097, 6c0tA, 0.7348, 3.68, 0.174, 334, 276, CRYSTAL STRUCTURE OF CGMP-DEPENDENT PROTEIN KINASE IALPHA (PKG IALPHA) CATALYTIC DOMAIN BOUND WITH N46 
1098, 5w5oM, 0.7348, 2.86, 0.230, 276, 257, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1099, 5j79A, 0.7348, 3.12, 0.217, 283, 263, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
1100, 2hz4A, 0.7348, 2.72, 0.329, 262, 258, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
1101, 2a27G, 0.7348, 3.30, 0.171, 303, 269, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1102, 2a27D, 0.7348, 3.40, 0.174, 304, 270, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1103, 5eycA, 0.7347, 3.10, 0.346, 288, 260, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH NAPHTHYRIDINONE INHIBITOR 5
1104, 4r1vA, 0.7347, 3.04, 0.351, 289, 259, IDENTIFICATION AND OPTIMIZATION OF PYRIDAZINONES AS POTENT AND SELECTIVE C-MET KINASE INHIBITORS
1105, 3tv7C, 0.7347, 3.87, 0.151, 394, 278, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1342
1106, 3fzoA, 0.7347, 3.02, 0.319, 262, 260, CRYSTAL STRUCTURE OF PYK2-APO PROLINE-RICH TYROSINE KINASE
1107, 3bhhB, 0.7347, 2.98, 0.144, 289, 263, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
1108, 2c0tA, 0.7347, 2.65, 0.296, 427, 253, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-641359
1109, 1kobA, 0.7347, 3.71, 0.152, 352, 276, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
1110, 4mneB, 0.7346, 2.84, 0.212, 270, 259, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1111, 3ppzA, 0.7346, 2.58, 0.243, 264, 255, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
1112, 3lckA, 0.7346, 2.95, 0.286, 270, 262, THE KINASE DOMAIN OF HUMAN LYMPHOCYTE KINASE (LCK) ACTIVATED FORM (AUTO-PHOSPHORYLATED ON TYR394)
1113, 3dqxA, 0.7346, 3.00, 0.293, 267, 263, CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH ATPGS
1114, 3ac1A, 0.7346, 2.94, 0.294, 270, 262, CRYSTAL STRUCTURE OF PYRAZIN DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
1115, 5lcpA, 0.7345, 3.62, 0.191, 350, 277, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH FASUDIL (M77)
1116, 5kktB, 0.7344, 3.79, 0.152, 394, 277, ROCK 1 BOUND TO AZAINDOLE THIOZOLE PIPERAZINE INHIBITOR
1117, 3tcpA, 0.7344, 2.42, 0.347, 256, 248, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC569
1118, 4j99A, 0.7343, 3.09, 0.305, 280, 262, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
1119, 3tv6B, 0.7343, 2.69, 0.226, 276, 257, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A METHOXYPYRAZOLOPYRIDINYL BENZAMIDE INHIBITOR
1120, 4gt4B, 0.7342, 2.55, 0.304, 273, 253, STRUCTURE OF UNLIGANDED INACTIVE ROR2 KINASE DOMAIN
1121, 3ad4A, 0.7342, 2.90, 0.291, 270, 261, CRYSTAL STRUCTURE OF METHOXY BENZOFURAN DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
1122, 3tv4B, 0.7341, 2.77, 0.225, 276, 258, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH AN BROMOPYRIDINE BENZAMIDE INHIBITOR
1123, 3js2A, 0.7341, 3.17, 0.321, 295, 265, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
1124, 3faaA, 0.7341, 2.84, 0.184, 328, 261, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
1125, 5uglA, 0.7340, 3.23, 0.317, 285, 265, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 TYROSINE KINASE DOMAIN HARBORING THE D650V ACTIVATING MUTATION
1126, 5li1A, 0.7340, 3.45, 0.165, 331, 272, STRUCTURE OF A PAR3-INHIBITORY PEPTIDE BOUND TO PKCIOTA CORE KINASE DOMAIN
1127, 5ew8A, 0.7340, 3.15, 0.318, 291, 264, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
1128, 4wbbB, 0.7340, 3.53, 0.179, 334, 274, SINGLE TURNOVER AUTOPHOSPHORYLATION CYCLE OF THE PKA RIIB HOLOENZYME
1129, 4uv0A, 0.7340, 3.32, 0.171, 300, 269, STRUCTURE OF A SEMISYNTHETIC PHOSPHORYLATED DAPK
1130, 4f4pA, 0.7340, 2.84, 0.341, 262, 258, SYK IN COMPLEX WITH LIGAND LASW836
1131, 3zbxA, 0.7340, 2.79, 0.344, 282, 256, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR 6- ((6-(4-FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN- 3-YL)METHYL)QUINOLINE.
1132, 3kxxC, 0.7340, 3.00, 0.326, 286, 261, STRUCTURE OF THE MUTANT FIBROBLAST GROWTH FACTOR RECEPTOR 1
1133, 2etkB, 0.7340, 3.80, 0.148, 398, 277, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO HYDROXYFASUDIL
1134, 4xyfA, 0.7339, 3.04, 0.346, 290, 260, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (S)-5-(8-FLUORO-3-(1-(3-(2- METHOXYETHOXY)QUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43-A]PYRIDIN-6- YL)-3-METHYLISOXAZOLE
1135, 4w7pB, 0.7339, 3.68, 0.156, 387, 275, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO YB-15-QD37
1136, 4g3dA, 0.7339, 3.25, 0.199, 324, 267, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK)
1137, 3kcfB, 0.7339, 3.03, 0.163, 324, 263, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
1138, 3bhhA, 0.7339, 2.98, 0.137, 289, 263, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
1139, 2psqA, 0.7339, 3.41, 0.307, 287, 267, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
1140, 1yi6A, 0.7339, 3.34, 0.294, 274, 269, C-TERM TAIL SEGMENT OF HUMAN TYROSINE KINASE (258-533)
1141, 3zxzA, 0.7338, 2.80, 0.344, 289, 256, X-RAY STRUCTURE OF PF-04217903 BOUND TO THE KINASE DOMAIN OF C-MET
1142, 3skcB, 0.7338, 2.70, 0.226, 276, 257, HUMAN B-RAF KINASE IN COMPLEX WITH AN AMIDE LINKED PYRAZOLOPYRIDINE INHIBITOR
1143, 3ppzB, 0.7338, 2.70, 0.241, 264, 257, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
1144, 3l9pA, 0.7338, 3.55, 0.264, 303, 273, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
1145, 5vloA, 0.7337, 3.07, 0.148, 290, 264, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1146, 4uwcA, 0.7337, 3.10, 0.312, 300, 263, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
1147, 3faaD, 0.7337, 3.04, 0.159, 330, 264, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
1148, 3ac3A, 0.7337, 2.90, 0.291, 270, 261, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
1149, 2c0iB, 0.7337, 2.67, 0.296, 433, 253, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-420983
1150, 3l9mB, 0.7336, 3.79, 0.193, 336, 280, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
1151, 3vs0B, 0.7335, 2.56, 0.298, 433, 252, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR N-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL) PHENYL]BENZAMIDE
1152, 3acjA, 0.7335, 2.91, 0.291, 270, 261, CRYSTAL STRUCTURE OF IMIDAZO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
1153, 3ac4A, 0.7335, 2.91, 0.291, 270, 261, CRYSTAL STRUCTURE OF TRIAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
1154, 2etrB, 0.7335, 3.77, 0.152, 398, 277, CRYSTAL STRUCTURE OF ROCK I BOUND TO Y-27632
1155, 5u6yF, 0.7334, 3.40, 0.157, 459, 268, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
1156, 5lcuA, 0.7334, 3.63, 0.191, 350, 277, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A S-METHYL-PIPERAZINE SUBSTITUTED FASUDIL-DERIVATIVE (LIGAND 01)
1157, 4l01B, 0.7334, 2.77, 0.212, 274, 259, CRYSTAL STRUCTURE OF THE V658F APO JAK1 PSEUDOKINASE DOMAIN
1158, 2xvdA, 0.7334, 2.94, 0.299, 270, 261, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1159, 6eixA, 0.7333, 3.05, 0.174, 312, 264, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE Q207E MUTANT OF ACVR1 (ALK2) IN COMPLEX WITH A 2-AMINOPYRIDINE INHIBITOR K02288
1160, 5m6vA, 0.7333, 3.64, 0.188, 350, 277, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A DOUBLE METHYLATED FASUDIL-DERIVATIVE 
1161, 2zm4A, 0.7333, 2.90, 0.291, 270, 261, CRYSTAL STRUCTURE OF IMIDAZO QUINOXALINE 1 BOUND TO THE KINASE DOMAIN OF HUMAN LCK ACTIVATED FORM (AUTO- PHOSPHORYLATED ON TYR394)
1162, 5bmlB, 0.7332, 3.79, 0.155, 395, 277, ROCK 1 BOUND TO A PYRIDINE THIAZOLE INHIBITOR
1163, 3kmmA, 0.7332, 2.91, 0.291, 270, 261, STRUCTURE OF HUMAN LCK KINASE WITH A SMALL MOLECULE INHIBITOR
1164, 3c4fB, 0.7332, 3.21, 0.321, 290, 265, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
1165, 6g4zB, 0.7331, 3.21, 0.180, 325, 266, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK) IN COMPLEX WITH COMPOUND 2F 
1166, 5w5oO, 0.7331, 2.90, 0.230, 276, 257, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1167, 5vndA, 0.7331, 3.16, 0.322, 302, 264, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
1168, 5t0pA, 0.7331, 2.97, 0.291, 264, 261, C-SRC KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
1169, 3ri1A, 0.7331, 3.41, 0.307, 285, 267, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
1170, 3bprA, 0.7331, 2.66, 0.351, 261, 251, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE- PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR C52
1171, 3ad5A, 0.7331, 2.90, 0.287, 270, 261, CRYSTAL STRUCTURE OF TRIAZOLONE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
1172, 3ac2A, 0.7331, 2.90, 0.287, 270, 261, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
1173, 2vz6B, 0.7331, 3.17, 0.154, 294, 266, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
1174, 2c0oB, 0.7331, 2.67, 0.292, 433, 253, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-770041
1175, 6babD, 0.7330, 3.12, 0.158, 291, 266, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1176, 5n3fA, 0.7330, 3.43, 0.167, 318, 269, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-[3-(AMINOMETHYL)PHENYL]ACETAMIDE
1177, 4l01A, 0.7330, 2.87, 0.211, 274, 261, CRYSTAL STRUCTURE OF THE V658F APO JAK1 PSEUDOKINASE DOMAIN
1178, 4fl1A, 0.7330, 3.16, 0.347, 268, 262, STRUCTURAL AND BIOPHYSICAL CHARACTERIZATION OF THE SYK ACTIVATION SWITCH
1179, 4ec8A, 0.7330, 3.37, 0.148, 325, 271, STRUCTURE OF FULL LENGTH CDK9 IN COMPLEX WITH CYCLINT AND DRB
1180, 3tv6A, 0.7330, 2.74, 0.226, 268, 257, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A METHOXYPYRAZOLOPYRIDINYL BENZAMIDE INHIBITOR
1181, 3faaC, 0.7330, 2.87, 0.188, 330, 261, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
1182, 2j0kB, 0.7330, 2.95, 0.347, 612, 259, CRYSTAL STRUCTURE OF A FRAGMENT OF FOCAL ADHESION KINASE CONTAINING THE FERM AND KINASE DOMAINS.
1183, 5aaaA, 0.7329, 3.33, 0.257, 294, 268, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
1184, 4eheB, 0.7329, 2.72, 0.226, 276, 257, B-RAF KINASE DOMAIN IN COMPLEX WITH AN AMINOTHIENOPYRIMIDINE-BASED INHIBITOR
1185, 2py3B, 0.7329, 3.32, 0.311, 284, 264, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565G MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
1186, 5n1dA, 0.7328, 3.63, 0.185, 348, 276, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-METHYL-1-(5-PYRIDIN-3-YLOXYFURAN-2-YL) METHANAMINE
1187, 3ackA, 0.7328, 2.91, 0.291, 270, 261, CRYSTAL STRUCTURE OF PYRROLO PYRAZINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
1188, 4uwcB, 0.7327, 3.12, 0.319, 301, 263, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
1189, 4idvB, 0.7327, 3.27, 0.201, 335, 268, CRYSTAL STRUCTURE OF NIK WITH COMPOUND 4-{3-[2-AMINO-5-(2- METHOXYETHOXY)PYRIMIDIN-4-YL]-1H-INDOL-5-YL}-2-METHYLBUT-3-YN-2-OL (13V)
1190, 3kxxD, 0.7327, 3.01, 0.323, 288, 260, STRUCTURE OF THE MUTANT FIBROBLAST GROWTH FACTOR RECEPTOR 1
1191, 3faaB, 0.7327, 2.87, 0.173, 324, 260, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
1192, 3c4fA, 0.7327, 3.16, 0.318, 290, 264, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
1193, 2of2A, 0.7327, 2.99, 0.289, 271, 263, CRYSTAL STRUCTURE OF FURANOPYRIMIDINE 8 BOUND TO LCK
1194, 1wmkB, 0.7327, 3.37, 0.175, 314, 269, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
1195, 4yhfA, 0.7326, 2.59, 0.299, 268, 254, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
1196, 3ac5A, 0.7326, 2.96, 0.294, 270, 262, CRYSTAL STRUCTURE OF TRIAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
1197, 6d1zA, 0.7325, 2.86, 0.296, 290, 260, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE RECEPTOR IN COMPLEX WITH 5-(4-FLUOROPHENYL)THIENO[2;3-D]PYRIMIDIN-4(3H)-ONE INHIBITOR 
1198, 5tehB, 0.7325, 2.88, 0.287, 262, 258, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-156
1199, 5t8oB, 0.7325, 3.27, 0.179, 328, 268, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO IMIDAZOBENZOXEPIN COMPOUND 3
1200, 4yvcB, 0.7325, 3.80, 0.152, 392, 277, ROCK 1 BOUND TO THIAZOLE INHIBITOR
1201, 4g3eB, 0.7325, 3.21, 0.184, 325, 266, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO A 6-ALKYNYLINDOLINE (CMP1)
1202, 3q5iA, 0.7325, 3.08, 0.208, 470, 265, CRYSTAL STRUCTURE OF PBANKA_031420
1203, 3l9mA, 0.7325, 3.67, 0.184, 338, 277, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
1204, 2v7oA, 0.7325, 3.25, 0.138, 305, 268, CRYSTAL STRUCTURE OF HUMAN CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE II GAMMA
1205, 2gcdA, 0.7325, 3.46, 0.198, 308, 273, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
1206, 1wmkD, 0.7325, 3.37, 0.175, 314, 269, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
1207, 5x5oA, 0.7324, 3.04, 0.244, 291, 258, CRYSTAL STRUCTURE OF ZAK IN COMPLEX WITH COMPOUND D2829
1208, 5k9iB, 0.7324, 2.93, 0.292, 262, 260, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH A COVALENT LYSINE PROBE
1209, 5j87B, 0.7324, 2.83, 0.307, 274, 257, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
1210, 1kobB, 0.7324, 3.54, 0.146, 352, 274, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
1211, 6fngA, 0.7323, 2.82, 0.302, 277, 258, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH AN ISOMER OF NVP-BHG712 
1212, 5k9iA, 0.7323, 2.73, 0.285, 258, 256, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH A COVALENT LYSINE PROBE
1213, 4yveB, 0.7323, 3.80, 0.152, 393, 277, ROCK 1 BOUND TO METHOXYPHENYL THIAZOLE INHIBITOR
1214, 4v0gB, 0.7323, 2.54, 0.317, 272, 252, JAK3 IN COMPLEX WITH A COVALENT EGFR INHIBITOR
1215, 2y0aA, 0.7323, 3.42, 0.174, 300, 270, STRUCTURE OF DAPK1 CONSTRUCT RESIDUES 1-304
1216, 2oiqA, 0.7323, 2.96, 0.288, 265, 260, CRYSTAL STRUCTURE OF CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH THE CANCER DRUG IMATINIB.
1217, 2esmB, 0.7323, 3.77, 0.155, 398, 277, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO FASUDIL
1218, 1u5rB, 0.7323, 3.47, 0.186, 308, 274, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1219, 4yuqB, 0.7322, 2.98, 0.183, 462, 263, CDPK1 FROM EIMERIA TENELLA IN COMPLEX WITH INHIBITOR UW1354
1220, 4idvD, 0.7322, 3.29, 0.201, 335, 268, CRYSTAL STRUCTURE OF NIK WITH COMPOUND 4-{3-[2-AMINO-5-(2- METHOXYETHOXY)PYRIMIDIN-4-YL]-1H-INDOL-5-YL}-2-METHYLBUT-3-YN-2-OL (13V)
1221, 4deiA, 0.7322, 2.93, 0.346, 287, 257, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 24
1222, 2x7oB, 0.7322, 3.06, 0.163, 330, 264, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
1223, 5u7qB, 0.7321, 3.77, 0.152, 385, 276, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
1224, 5m71A, 0.7321, 3.65, 0.191, 350, 277, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH AN (R)-METHYL SUBSTITUED FASUDIL-DERIVATIVE. 
1225, 4mh7B, 0.7321, 2.28, 0.350, 255, 246, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC1896
1226, 4j95A, 0.7321, 3.13, 0.313, 279, 262, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
1227, 4at4A, 0.7321, 3.32, 0.278, 292, 266, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH EX429
1228, 4ap7A, 0.7321, 2.92, 0.346, 289, 257, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( (6-(4- FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN-3-YL)METHYL) PHENOL
1229, 3l9nA, 0.7321, 3.53, 0.189, 332, 275, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 27
1230, 1wmkH, 0.7321, 3.38, 0.178, 304, 269, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
1231, 1wmkG, 0.7321, 3.38, 0.178, 313, 269, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
1232, 1wmkE, 0.7321, 3.38, 0.178, 313, 269, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
1233, 1wmkC, 0.7321, 3.38, 0.178, 303, 269, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
1234, 1wmkA, 0.7321, 3.38, 0.178, 303, 269, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
1235, 4idvC, 0.7320, 3.28, 0.198, 335, 268, CRYSTAL STRUCTURE OF NIK WITH COMPOUND 4-{3-[2-AMINO-5-(2- METHOXYETHOXY)PYRIMIDIN-4-YL]-1H-INDOL-5-YL}-2-METHYLBUT-3-YN-2-OL (13V)
1236, 3zc5A, 0.7320, 2.83, 0.344, 289, 256, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-6-(1-(6-(1-METHYL-1H-PYRAZOL-4-YL)-(124)TRIAZOLO(43- B)PYRIDAZIN-3-YL)ETHYL)QUINOLINE.
1237, 2c0tB, 0.7320, 2.69, 0.292, 429, 253, SRC FAMILY KINASE HCK WITH BOUND INHIBITOR A-641359
1238, 5u6yB, 0.7319, 3.14, 0.158, 459, 265, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
1239, 5ar3A, 0.7319, 3.00, 0.227, 279, 260, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH AMP-PCP
1240, 4v0gA, 0.7319, 2.55, 0.325, 267, 252, JAK3 IN COMPLEX WITH A COVALENT EGFR INHIBITOR
1241, 3zfxE, 0.7319, 2.89, 0.314, 262, 258, CRYSTAL STRUCTURE OF EPHB1
1242, 3rhkA, 0.7319, 3.01, 0.337, 298, 258, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF C-MET KINASE IN COMPLEX WITH ARQ 197
1243, 1wmkF, 0.7319, 3.38, 0.178, 303, 269, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
1244, 5o0eA, 0.7318, 3.55, 0.193, 349, 275, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUNDS RKP120 AND FASUDIL 
1245, 4degA, 0.7318, 3.00, 0.349, 286, 258, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDAZINE INHIBITOR 2
1246, 3lijA, 0.7318, 3.19, 0.199, 465, 266, CRYSTAL STRUCTURE OF FULL LENGTH CPCDPK3 (CGD5_820) IN COMPLEX WITH CA2+ AND AMPPNP
1247, 3f6xD, 0.7318, 3.13, 0.295, 267, 264, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1248, 2x7oC, 0.7318, 3.07, 0.163, 330, 264, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
1249, 2wgjA, 0.7318, 2.84, 0.344, 289, 256, X-RAY STRUCTURE OF PF-02341066 BOUND TO THE KINASE DOMAIN OF C-MET
1250, 5w5oK, 0.7317, 2.90, 0.230, 275, 257, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1251, 3fqhB, 0.7317, 2.68, 0.346, 258, 254, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A 2-SUBSTITUTED 7-AZAINDOLE
1252, 2oiqB, 0.7317, 3.05, 0.294, 265, 262, CRYSTAL STRUCTURE OF CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH THE CANCER DRUG IMATINIB.
1253, 2j0mB, 0.7317, 2.66, 0.343, 257, 254, CRYSTAL STRUCTURE A TWO-CHAIN COMPLEX BETWEEN THE FERM AND KINASE DOMAINS OF FOCAL ADHESION KINASE.
1254, 1s9iA, 0.7317, 3.59, 0.207, 303, 271, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP
1255, 5u6yL, 0.7316, 3.16, 0.158, 459, 265, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
1256, 5jfsA, 0.7316, 2.80, 0.306, 277, 258, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-00593174
1257, 3byoA, 0.7316, 2.95, 0.291, 270, 261, X-RAY CO-CRYSTAL STRUCTURE OF 2-AMINO-6-PHENYLPYRIMIDO[5  4 :56]PYRIMIDO[12-A]BENZIMIDAZOL-5(6H)-ONE 25 BOUND TO LCK
1258, 2x7oD, 0.7316, 3.07, 0.163, 330, 264, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
1259, 1u5qA, 0.7316, 3.37, 0.199, 308, 272, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1260, 1opjB, 0.7316, 2.99, 0.331, 288, 260, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
1261, 6c0uA, 0.7315, 3.52, 0.181, 338, 271, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE CALPHA SUBUNIT BOUND WITH N46 
1262, 4wboA, 0.7315, 3.94, 0.166, 497, 283, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH AMLEXANOX
1263, 4rwiA, 0.7315, 3.10, 0.327, 305, 263, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
1264, 4idvA, 0.7315, 3.29, 0.201, 335, 268, CRYSTAL STRUCTURE OF NIK WITH COMPOUND 4-{3-[2-AMINO-5-(2- METHOXYETHOXY)PYRIMIDIN-4-YL]-1H-INDOL-5-YL}-2-METHYLBUT-3-YN-2-OL (13V)
1265, 5wngA, 0.7314, 3.86, 0.154, 395, 279, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
1266, 5a46B, 0.7314, 3.17, 0.318, 297, 264, FGFR1 IN COMPLEX WITH DOVITINIB
1267, 4xg7A, 0.7314, 3.09, 0.342, 266, 260, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
1268, 1qpeA, 0.7314, 2.92, 0.291, 270, 261, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
1269, 4ysjB, 0.7313, 3.08, 0.186, 462, 264, CALCIUM-DEPENDENT PROTEIN KINASE FROM EIMERIA TENELLA IN COMPLEX WITH ADP
1270, 4hctA, 0.7313, 2.68, 0.312, 265, 253, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 52
1271, 5w5oB, 0.7312, 2.86, 0.234, 275, 256, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1272, 4c35A, 0.7312, 3.63, 0.178, 337, 275, PKA-S6K1 CHIMERA WITH COMPOUND 1 (NU1085) BOUND
1273, 2x7oE, 0.7312, 3.08, 0.163, 330, 264, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
1274, 2hz4C, 0.7312, 2.56, 0.335, 259, 254, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
1275, 1opjA, 0.7312, 3.00, 0.327, 287, 260, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
1276, 5w5oJ, 0.7311, 2.78, 0.231, 275, 255, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1277, 5u6yD, 0.7311, 3.20, 0.155, 459, 265, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
1278, 5lcrA, 0.7311, 3.65, 0.191, 350, 277, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH OPEN-CHAIN FASUDIL-DERIVATIVE (LIGAND 04)
1279, 5ig1B, 0.7311, 3.44, 0.170, 304, 270, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
1280, 3zosB, 0.7311, 2.93, 0.293, 303, 259, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
1281, 3vs1A, 0.7311, 2.69, 0.292, 424, 253, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-PHENYLUREA
1282, 1mqbB, 0.7311, 3.00, 0.299, 265, 261, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
1283, 5m6yA, 0.7310, 3.66, 0.191, 350, 277, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A METHYLISOQUINOLINE FASUDIL-DERIVATIVE 
1284, 5lmbB, 0.7310, 2.69, 0.335, 261, 254, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
1285, 5j7hA, 0.7310, 3.37, 0.266, 291, 267, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) BOUND BY BRIGATINIB
1286, 5ar5B, 0.7310, 2.93, 0.238, 279, 260, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
1287, 4dc2A, 0.7310, 3.34, 0.160, 328, 268, STRUCTURE OF PKC IN COMPLEX WITH A SUBSTRATE PEPTIDE FROM PAR-3
1288, 2xynC, 0.7310, 2.67, 0.344, 262, 256, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
1289, 2x7oA, 0.7310, 3.08, 0.163, 330, 264, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
1290, 5w5oD, 0.7309, 2.88, 0.234, 275, 256, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1291, 3ac8A, 0.7309, 2.94, 0.291, 270, 261, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
1292, 2zm1A, 0.7309, 2.99, 0.294, 270, 262, CRYSTAL STRUCTURE OF IMIDAZO PYRAZIN 1 BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
1293, 2x4fB, 0.7309, 3.05, 0.177, 288, 265, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
1294, 2x0gA, 0.7309, 3.41, 0.164, 318, 269, X-RAY STRUCTURE OF A DAP-KINASE CALMODULIN COMPLEX
1295, 4rx5A, 0.7308, 2.72, 0.306, 265, 255, BRUTON S TYROSINE KINASE (BTK) WITH PYRIDAZINONE COMPOUND 23
1296, 4mbjB, 0.7308, 2.75, 0.226, 276, 257, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINE-BASED INHIBITOR
1297, 4fobA, 0.7308, 3.58, 0.265, 295, 272, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 1
1298, 3vs0A, 0.7308, 2.61, 0.294, 428, 252, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR N-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL) PHENYL]BENZAMIDE
1299, 6fd3A, 0.7307, 3.31, 0.191, 296, 267, THIOPHOSPHORYLATED PAK3 KINASE DOMAIN
1300, 5hesA, 0.7307, 3.06, 0.256, 287, 258, HUMAN LEUCINE ZIPPER- AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK MLT HCCS-4 MRK AZK MLTK) IN COMPLEX WITH VEMURAFENIB
1301, 4h58A, 0.7307, 2.59, 0.220, 263, 254, BRAF IN COMPLEX WITH COMPOUND 3
1302, 4fvrA, 0.7307, 2.56, 0.209, 274, 254, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN MUTANT V617F (MG- ATP-BOUND FORM)
1303, 4cmoA, 0.7307, 3.38, 0.265, 295, 268, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 2-((1R)-1-((3-AMINO-6-(2- METHOXYPYRIDIN- -YL)PYRAZIN-2-YL)OXY)ETHYL)-4-FLUORO-N-METHYLBENZAMIDE
1304, 4ccbA, 0.7307, 3.38, 0.262, 287, 267, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 3-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)-5-(5-METHYL-1H-PYRAZOL-4-YL)PYRIDIN-2-AMINE
1305, 3vrzA, 0.7307, 2.71, 0.292, 429, 253, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-BENZYLUREA
1306, 3u6iA, 0.7307, 2.99, 0.327, 281, 257, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 58A
1307, 2xynB, 0.7307, 2.83, 0.336, 264, 259, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
1308, 5w5oI, 0.7306, 2.89, 0.230, 275, 256, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1309, 5lctA, 0.7305, 3.67, 0.191, 350, 277, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A R-METHYL-PIPERAZINE SUBSTITUTED FASUDIL-DERIVATIVE (LIGAND 02)
1310, 4yzbB, 0.7305, 3.23, 0.179, 464, 268, CDPK1 FROM EIMERIA TENELLA IN COMPLEX WITH INHIBITOR UW1521
1311, 4mxoA, 0.7305, 3.06, 0.280, 266, 261, HUMAN SRC KINASE BOUND TO KINASE INHIBITOR BOSUTINIB
1312, 4c34A, 0.7305, 3.55, 0.179, 336, 274, PKA-S6K1 CHIMERA WITH STAUROSPORINE BOUND
1313, 5u6yA, 0.7304, 3.12, 0.159, 459, 264, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
1314, 4wotD, 0.7304, 3.77, 0.160, 389, 275, ROCK2 IN COMPLEX WITH 1426382-07-1
1315, 4pp7B, 0.7304, 2.74, 0.227, 274, 256, HIGHLY POTENT AND SELECTIVE 3-N-METHYLQUINAZOLINE-4(3H)-ONE BASED INHIBITORS OF B-RAFV600E KINASE
1316, 3tacA, 0.7304, 3.55, 0.165, 324, 272, CRYSTAL STRUCTURE OF THE LIPRIN-ALPHA/CASK COMPLEX
1317, 1u46A, 0.7304, 2.52, 0.360, 255, 250, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED KINASE DOMAIN OF THE TYROSINE KINASE ACK1
1318, 5w5oA, 0.7303, 2.89, 0.234, 275, 256, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1319, 5w5oL, 0.7302, 2.88, 0.230, 275, 256, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1320, 5ng0A, 0.7302, 2.78, 0.233, 274, 257, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
1321, 5kz0A, 0.7302, 3.33, 0.262, 293, 267, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-[(1R)- 1-{[2-AMINO-5-(13-DIMETHYL-1H-PYRAZOL-4-YL)PYRIDIN-3-YL]OXY}ETHYL]- 4-FLUORO-NN-DIMETHYLBENZAMIDE
1322, 4y95A, 0.7302, 2.64, 0.311, 266, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
1323, 1b6cF, 0.7302, 3.14, 0.174, 326, 265, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
1324, 5w5oF, 0.7301, 2.88, 0.234, 275, 256, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1325, 4wboD, 0.7301, 4.03, 0.173, 491, 283, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH AMLEXANOX
1326, 2zybA, 0.7301, 2.95, 0.291, 270, 261, CRYSTAL STRUCTURE OF PHENYLIMIDAZO PYRAZIN 2 BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
1327, 2q0bA, 0.7301, 3.27, 0.317, 280, 262, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565A MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
1328, 2j0kA, 0.7301, 2.81, 0.344, 598, 256, CRYSTAL STRUCTURE OF A FRAGMENT OF FOCAL ADHESION KINASE CONTAINING THE FERM AND KINASE DOMAINS.
1329, 5ig1A, 0.7300, 3.44, 0.174, 300, 270, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
1330, 4fzfB, 0.7300, 3.23, 0.226, 279, 265, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX WITH DKI
1331, 2pz5A, 0.7300, 3.29, 0.317, 280, 262, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549T MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
1332, 5wneA, 0.7299, 3.84, 0.144, 384, 277, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
1333, 4ysmB, 0.7299, 3.44, 0.183, 475, 273, CALCIUM-DEPENDENT PROTEIN KINASE FROM EIMERIA TENELLA
1334, 2rfsA, 0.7299, 2.49, 0.349, 264, 249, X-RAY STRUCTURE OF SU11274 BOUND TO C-MET
1335, 5w5oE, 0.7298, 2.88, 0.234, 275, 256, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1336, 5nw8A, 0.7298, 3.64, 0.188, 337, 276, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUNDS RKP032 AND FASUDIL 
1337, 5nkhA, 0.7298, 3.55, 0.311, 295, 273, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3E
1338, 5eobA, 0.7298, 3.16, 0.350, 288, 260, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
1339, 5am6A, 0.7298, 3.09, 0.318, 295, 261, NATIVE FGFR1 WITH AN INHIBITOR
1340, 3ocsA, 0.7298, 2.62, 0.304, 264, 253, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI1746
1341, 2pzpA, 0.7298, 3.21, 0.322, 280, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K526E MUTATION RESPONSIBLE FOR CROUZON SYNDROME
1342, 5w5oH, 0.7297, 2.89, 0.238, 275, 256, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1343, 5w5oG, 0.7297, 2.79, 0.231, 275, 255, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1344, 5o49A, 0.7297, 3.17, 0.319, 289, 263, HUMAN FGF IN COMPLEX WITH A COVALENT INHIBITOR
1345, 5m0uA, 0.7297, 3.62, 0.168, 346, 273, APOSTRUCTURE STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) FROM CHO CELLS WITH A PEPTIDIC INHIBITOR FRAGMENT 
1346, 4fnyA, 0.7297, 3.17, 0.245, 273, 261, CRYSTAL STRUCTURE OF THE R1275Q ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
1347, 5ok3A, 0.7296, 3.57, 0.193, 349, 275, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUNDS RKP241 AND FASUDIL 
1348, 5ar2A, 0.7296, 2.85, 0.233, 277, 257, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
1349, 5aabA, 0.7296, 3.41, 0.261, 293, 268, STRUCTURE OF C1156YL1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
1350, 4ysjA, 0.7296, 2.97, 0.183, 459, 262, CALCIUM-DEPENDENT PROTEIN KINASE FROM EIMERIA TENELLA IN COMPLEX WITH ADP
1351, 5aa9A, 0.7295, 3.36, 0.257, 295, 268, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
1352, 4yjoA, 0.7295, 3.13, 0.350, 267, 260, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000222
1353, 3l8vA, 0.7295, 3.36, 0.326, 293, 264, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A BIARYLAMINE BASED INHIBITOR
1354, 2pzpB, 0.7295, 3.31, 0.317, 282, 262, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K526E MUTATION RESPONSIBLE FOR CROUZON SYNDROME
1355, 2pz5B, 0.7295, 3.31, 0.317, 280, 262, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549T MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
1356, 1o6kA, 0.7295, 3.41, 0.163, 317, 270, STRUCTURE OF ACTIVATED FORM OF PKB KINASE DOMAIN S474D WITH GSK3 PEPTIDE AND AMP-PNP
1357, 6dkgA, 0.7294, 2.97, 0.299, 276, 261, CRYSTAL STRUCTURE OF TRK-A IN COMPLEX WITH THE PAN-TRK KINASE INHIBITOR; COMPOUND 13B. 
1358, 5u7rC, 0.7294, 3.71, 0.164, 387, 275, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
1359, 5u6yJ, 0.7294, 3.07, 0.160, 459, 263, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
1360, 5u6yH, 0.7294, 3.07, 0.160, 459, 263, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
1361, 5u6yG, 0.7294, 3.07, 0.160, 459, 263, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
1362, 5u6yE, 0.7294, 3.07, 0.160, 459, 263, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
1363, 4pp7A, 0.7294, 2.77, 0.227, 267, 256, HIGHLY POTENT AND SELECTIVE 3-N-METHYLQUINAZOLINE-4(3H)-ONE BASED INHIBITORS OF B-RAFV600E KINASE
1364, 4cmuA, 0.7294, 3.40, 0.261, 294, 268, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR (10R)-7-AMINO-12-FLUORO-1310 16-TETRAMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(43- H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
1365, 2vd5B, 0.7294, 3.83, 0.149, 380, 276, STRUCTURE OF HUMAN MYOTONIC DYSTROPHY PROTEIN KINASE IN COMPLEX WITH THE BISINDOYLMALEIDE INHIBITOR BIM VIII
1366, 5jfxA, 0.7293, 2.82, 0.306, 277, 258, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-06273340
1367, 5i4nA, 0.7293, 2.55, 0.213, 275, 253, CRYSTAL STRUCTURE OF THE E596A V617F MUTANT JAK2 PSEUDOKINASE DOMAIN BOUND TO MG-ATP
1368, 4tt7A, 0.7293, 3.54, 0.264, 291, 269, CRYSTAL STRUCTURE OF HUMAN ALK WITH A COVALENT MODIFICATION
1369, 3u51A, 0.7293, 2.67, 0.291, 256, 254, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC1
1370, 5wr7A, 0.7292, 2.95, 0.312, 301, 260, CRYSTAL STRUCTURE OF TRK-A COMPLEXED WITH A SELECTIVE INHIBITOR CH7057288
1371, 4e4xB, 0.7292, 2.65, 0.227, 274, 255, CRYSTAL STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH A DIHYDROPYRIDO[23-D]PYRIMIDINONE-BASED INHIBITOR
1372, 4cliA, 0.7292, 3.40, 0.261, 294, 268, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-21016-TRIMETHYL-15 -OXO-10151617-TETRAHYDRO-2H-84-(METHENO)PYRAZOLO(43-H) (2511)BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
1373, 3ndmB, 0.7292, 3.82, 0.155, 396, 277, CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT ISOQUINOLONE DERIVATIVE
1374, 1o6lA, 0.7292, 3.42, 0.163, 316, 270, CRYSTAL STRUCTURE OF AN ACTIVATED AKT/PROTEIN KINASE B (PKB-PIF CHIMERA) TERNARY COMPLEX WITH AMP-PNP AND GSK3 PEPTIDE
1375, 5jfwA, 0.7291, 2.84, 0.306, 277, 258, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05247452
1376, 5ew8B, 0.7291, 3.16, 0.323, 290, 263, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
1377, 4anbA, 0.7291, 3.19, 0.195, 282, 266, CRYSTAL STRUCTURES OF HUMAN MEK1 WITH CARBOXAMIDE-BASED ALLOSTERIC INHIBITOR XL518 (GDC-0973) OR RELATED ANALOGS.
1378, 3vs1B, 0.7291, 2.72, 0.296, 433, 253, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRROLO-PYRIMIDINE INHIBITOR 1-[4-(4-AMINO-7-CYCLOPENTYL-7H-PYRROLO[23-D]PYRIMIDIN-5-YL)PHENYL]- 3-PHENYLUREA
1379, 5vgoA, 0.7290, 2.70, 0.303, 265, 254, BRUTON S TYROSINE KINASE (BTK) WITH COMPOUND G-744
1380, 4ludB, 0.7290, 2.62, 0.295, 409, 251, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
1381, 4e93A, 0.7290, 2.66, 0.287, 361, 254, CRYSTAL STRUCTURE OF HUMAN FELINE SARCOMA VIRAL ONCOGENE HOMOLOGUE (V- FES)IN COMPLEX WITH TAE684
1382, 2q0bB, 0.7290, 3.37, 0.316, 282, 263, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565A MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
1383, 4wboB, 0.7289, 4.03, 0.166, 495, 283, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH AMLEXANOX
1384, 4mxxA, 0.7289, 3.10, 0.294, 266, 262, HUMAN SRC A403T MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
1385, 4l7sA, 0.7289, 2.19, 0.312, 250, 247, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH AN AMINOBENZOTHIAZOLE INHIBITOR
1386, 4g3dB, 0.7289, 3.24, 0.203, 318, 266, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK)
1387, 2vn9B, 0.7289, 3.18, 0.154, 301, 266, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
1388, 2vd5A, 0.7289, 3.86, 0.152, 390, 277, STRUCTURE OF HUMAN MYOTONIC DYSTROPHY PROTEIN KINASE IN COMPLEX WITH THE BISINDOYLMALEIDE INHIBITOR BIM VIII
1389, 5t8qA, 0.7288, 3.25, 0.184, 323, 266, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO ARYL PYRROLE FRAGMENT 17
1390, 4ckrA, 0.7288, 2.78, 0.293, 295, 256, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH DDR1-IN-1
1391, 3pxkB, 0.7288, 2.72, 0.350, 258, 254, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH PYRROLO[23- D]THIAZOLE
1392, 3o7lB, 0.7288, 3.52, 0.165, 326, 272, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
1393, 3k5vB, 0.7288, 2.91, 0.335, 283, 257, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
1394, 5w5oP, 0.7287, 2.90, 0.230, 275, 256, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1395, 5w5oC, 0.7287, 2.91, 0.234, 275, 256, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1396, 5kksA, 0.7287, 3.80, 0.159, 395, 276, ROCK 1 BOUND TO AZAINDOLE THIOZOLE INHIBITOR
1397, 3rhxA, 0.7287, 3.19, 0.319, 289, 263, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
1398, 5vibA, 0.7286, 3.40, 0.181, 308, 271, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH THE PKI PEPTIDE AND AMINOBENZOTHIAZOLE BASED INHIBITORS
1399, 4focA, 0.7286, 3.60, 0.258, 296, 271, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 2
1400, 4an3A, 0.7286, 3.29, 0.195, 280, 267, CRYSTAL STRUCTURES OF HUMAN MEK1 WITH CARBOXAMIDE-BASED ALLOSTERIC INHIBITOR XL518 (GDC-0973) OR RELATED ANALOGS.
1401, 2p2iA, 0.7286, 3.14, 0.304, 289, 260, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NICOTINAMIDE INHIBITOR
1402, 5am7A, 0.7285, 3.07, 0.323, 294, 260, FGFR1 MUTANT WITH AN INHIBITOR
1403, 4xg9A, 0.7285, 2.72, 0.350, 259, 254, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
1404, 2pvyB, 0.7285, 2.93, 0.318, 286, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
1405, 5ng3C, 0.7284, 2.78, 0.221, 272, 253, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
1406, 5j7bB, 0.7284, 2.99, 0.208, 281, 259, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
1407, 3g6gB, 0.7284, 3.00, 0.286, 263, 259, EQUALLY POTENT INHIBITION OF C-SRC AND ABL BY COMPOUNDS THAT RECOGNIZE INACTIVE KINASE CONFORMATIONS
1408, 2vn9A, 0.7284, 3.19, 0.154, 301, 266, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
1409, 5mjaB, 0.7283, 3.40, 0.310, 274, 268, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
1410, 5kupA, 0.7283, 2.72, 0.303, 265, 254, BRUTON S TYROSINE KINASE (BTK) WITH PYRIDAZINONE COMPOUND 9
1411, 4xmoA, 0.7283, 3.03, 0.349, 289, 258, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (R)-5-(8-FLUORO-3-(1- FLUORO-1-(3-METHOXYQUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43- A]PYRIDIN-6-YL)-3-METHYLISOXAZOLE
1412, 2ivsB, 0.7283, 2.77, 0.331, 277, 254, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
1413, 4uwbA, 0.7282, 3.21, 0.322, 299, 264, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
1414, 4idtB, 0.7282, 3.19, 0.212, 335, 264, CRYSTAL STRUCTURE OF NIK WITH 11-BROMO-5678-TETRAHYDROPYRIMIDO[4  5 :34]CYCLOHEPTA[12-B]INDOL-2-AMINE (T28)
1415, 4ccuA, 0.7282, 3.34, 0.263, 292, 266, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPAN-2-OL
1416, 3js2B, 0.7282, 3.12, 0.322, 291, 261, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
1417, 1q8wA, 0.7282, 3.66, 0.188, 334, 276, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR FASUDIL (HA-1077)
1418, 6babC, 0.7281, 2.98, 0.158, 284, 260, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1419, 5wnfA, 0.7280, 3.89, 0.155, 395, 278, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
1420, 4y95D, 0.7280, 2.68, 0.311, 265, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
1421, 4tnbA, 0.7280, 4.06, 0.170, 529, 283, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 5 IN COMPLEX WITH SANGIVAMYCIN
1422, 4rwkA, 0.7280, 3.23, 0.326, 308, 264, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
1423, 4mxzB, 0.7280, 3.05, 0.287, 264, 261, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
1424, 4mxyB, 0.7280, 3.05, 0.287, 264, 261, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
1425, 3ndmD, 0.7280, 3.83, 0.155, 396, 277, CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT ISOQUINOLONE DERIVATIVE
1426, 2pzrA, 0.7280, 3.26, 0.314, 280, 261, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K641R MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
1427, 2i0eA, 0.7280, 3.41, 0.170, 326, 270, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
1428, 4hcuA, 0.7279, 2.69, 0.321, 263, 252, CRYSTAL STRUCTURE OF ITK IN COMPLEXT WITH COMPOUND 40
1429, 4cljA, 0.7279, 3.44, 0.264, 295, 269, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
1430, 3u6hA, 0.7279, 2.91, 0.325, 280, 255, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 26
1431, 2ptkA, 0.7279, 2.38, 0.283, 425, 247, CHICKEN SRC TYROSINE KINASE
1432, 5wnhA, 0.7278, 3.86, 0.152, 394, 277, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
1433, 4y95B, 0.7278, 2.73, 0.310, 266, 255, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
1434, 3iw4A, 0.7278, 3.55, 0.187, 330, 272, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1435, 2pvyC, 0.7278, 2.79, 0.331, 285, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
1436, 2psqB, 0.7278, 3.49, 0.305, 286, 266, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
1437, 5mjaA, 0.7277, 3.14, 0.300, 271, 263, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
1438, 4mbjA, 0.7277, 2.85, 0.226, 269, 257, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINE-BASED INHIBITOR
1439, 4l6qA, 0.7277, 3.84, 0.152, 388, 276, ROCK2 IN COMPLEX WITH BENZOXABOROLE
1440, 3c4wB, 0.7277, 4.11, 0.169, 518, 284, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.7A
1441, 2yjrA, 0.7277, 3.09, 0.262, 278, 260, STRUCTURE OF F1174L MUTANT ANAPLASTIC LYMPHOMA KINASE
1442, 6fu5B, 0.7276, 2.87, 0.217, 286, 258, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE INHIBITOR CSLP18 
1443, 4y95C, 0.7276, 2.73, 0.310, 266, 255, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
1444, 4wotC, 0.7276, 3.75, 0.153, 392, 274, ROCK2 IN COMPLEX WITH 1426382-07-1
1445, 5t68A, 0.7275, 3.20, 0.345, 266, 261, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
1446, 5p9fA, 0.7275, 2.71, 0.306, 266, 255, BTK IN COMPLEX WITH GDC-0834
1447, 4an9A, 0.7275, 3.25, 0.188, 281, 266, CRYSTAL STRUCTURES OF HUMAN MEK1 WITH CARBOXAMIDE-BASED ALLOSTERIC INHIBITOR XL518 (GDC-0973) OR RELATED ANALOGS.
1448, 3d0eB, 0.7275, 3.42, 0.160, 322, 269, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
1449, 5t8oA, 0.7274, 3.26, 0.180, 324, 266, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO IMIDAZOBENZOXEPIN COMPOUND 3
1450, 4qrcA, 0.7274, 3.11, 0.330, 297, 261, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 4 IN COMPLEX WITH PONATINIB
1451, 4gt4A, 0.7274, 2.55, 0.295, 274, 251, STRUCTURE OF UNLIGANDED INACTIVE ROR2 KINASE DOMAIN
1452, 4eheA, 0.7274, 2.84, 0.227, 266, 256, B-RAF KINASE DOMAIN IN COMPLEX WITH AN AMINOTHIENOPYRIMIDINE-BASED INHIBITOR
1453, 4an2A, 0.7274, 3.21, 0.199, 282, 266, CRYSTAL STRUCTURES OF HUMAN MEK1 WITH CARBOXAMIDE-BASED ALLOSTERIC INHIBITOR XL518 (GDC-0973) OR RELATED ANALOGS.
1454, 3e88B, 0.7274, 3.53, 0.159, 319, 271, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1455, 3d0eA, 0.7274, 3.42, 0.160, 322, 269, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
1456, 5o49B, 0.7273, 3.06, 0.323, 286, 260, HUMAN FGF IN COMPLEX WITH A COVALENT INHIBITOR
1457, 5jfvA, 0.7273, 2.88, 0.306, 277, 258, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05206283
1458, 4uwbB, 0.7273, 3.14, 0.324, 299, 262, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
1459, 3e88A, 0.7273, 3.53, 0.159, 319, 271, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1460, 5o5mA, 0.7272, 3.70, 0.188, 336, 276, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUNDS RKP120 AND RKP117 
1461, 2xzsA, 0.7272, 3.54, 0.167, 301, 270, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
1462, 2pzrB, 0.7272, 3.35, 0.305, 282, 262, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K641R MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
1463, 5y5uB, 0.7271, 2.73, 0.344, 257, 253, CRYSTAL STRUCTURES OF SPLEEN TYROSINE KINASE IN COMPLEX WITH A NOVEL INHIBITOR 
1464, 5fd2A, 0.7271, 2.70, 0.228, 264, 254, B-RAF WILD-TYPE KINASE DOMAIN IN COMPLEX WITH A PURINYLPYRIDINYLAMINO- BASED INHIBITOR
1465, 3ppkB, 0.7271, 2.69, 0.228, 264, 254, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
1466, 3ky2A, 0.7271, 3.17, 0.324, 307, 262, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
1467, 3k5vA, 0.7271, 3.02, 0.332, 286, 259, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
1468, 4idtA, 0.7270, 3.19, 0.212, 334, 264, CRYSTAL STRUCTURE OF NIK WITH 11-BROMO-5678-TETRAHYDROPYRIMIDO[4  5 :34]CYCLOHEPTA[12-B]INDOL-2-AMINE (T28)
1469, 3f6xB, 0.7270, 3.12, 0.298, 267, 262, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1470, 4rzvA, 0.7269, 2.48, 0.226, 261, 252, CRYSTAL STRUCTURE OF THE BRAF (R509H) KINASE DOMAIN MONOMER BOUND TO VEMURAFENIB
1471, 3bprD, 0.7269, 2.67, 0.353, 259, 249, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE- PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR C52
1472, 2jdrA, 0.7269, 3.45, 0.163, 316, 270, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH THE INHIBITOR A- 443654
1473, 4l7sB, 0.7268, 2.16, 0.313, 250, 246, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH AN AMINOBENZOTHIAZOLE INHIBITOR
1474, 4ysmA, 0.7267, 3.49, 0.183, 475, 273, CALCIUM-DEPENDENT PROTEIN KINASE FROM EIMERIA TENELLA
1475, 4fvqA, 0.7267, 2.63, 0.206, 274, 253, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN (MG-ATP-BOUND FORM)
1476, 3ppjB, 0.7267, 2.73, 0.220, 264, 255, HUMAN B-RAF KINASE IN COMPLEX WITH A FUROPYRIDINE INHIBITOR
1477, 3pfqA, 0.7267, 3.54, 0.184, 520, 272, CRYSTAL STRUCTURE AND ALLOSTERIC ACTIVATION OF PROTEIN KINASE C BETA II
1478, 3kfaA, 0.7267, 3.14, 0.340, 284, 259, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
1479, 2x4fA, 0.7267, 3.18, 0.169, 289, 266, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
1480, 4xg2A, 0.7266, 3.01, 0.348, 259, 256, CRYSTAL STRUCTURE OF LIGAND-FREE SYK
1481, 4u8zA, 0.7266, 3.39, 0.213, 289, 268, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06447475)
1482, 4l6qB, 0.7266, 3.85, 0.152, 388, 276, ROCK2 IN COMPLEX WITH BENZOXABOROLE
1483, 4iw0A, 0.7266, 3.60, 0.150, 647, 273, CRYSTAL STRUCTURE AND MECHANISM OF ACTIVATION OF TBK1
1484, 4bb4A, 0.7266, 3.06, 0.308, 265, 260, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1485, 3kfaB, 0.7266, 3.15, 0.340, 284, 259, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
1486, 3bprC, 0.7266, 2.70, 0.353, 259, 249, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE- PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR C52
1487, 2wtkB, 0.7266, 3.62, 0.139, 311, 273, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
1488, 6g4yA, 0.7265, 3.24, 0.185, 322, 265, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK) IN COMPLEX WITH COMPOUND 1A 
1489, 5wngD, 0.7265, 3.89, 0.155, 396, 278, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
1490, 4rwlB, 0.7265, 3.12, 0.308, 285, 260, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
1491, 4fodA, 0.7265, 3.61, 0.262, 308, 271, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 36
1492, 3tt0A, 0.7265, 3.22, 0.322, 305, 264, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
1493, 3omvB, 0.7265, 2.71, 0.196, 264, 255, CRYSTAL STRUCTURE OF C-RAF (RAF-1)
1494, 2xb7A, 0.7265, 3.34, 0.269, 286, 264, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH NVP- TAE684
1495, 4wotB, 0.7264, 3.71, 0.146, 394, 274, ROCK2 IN COMPLEX WITH 1426382-07-1
1496, 3thbA, 0.7264, 3.21, 0.215, 287, 265, STRUCTURE OF PLK1 KINASE DOMAIN IN COMPLEX WITH A BENZOLACTAM-DERIVED INHIBITOR
1497, 3en5B, 0.7264, 2.91, 0.288, 261, 257, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP494 A MULTITARGETED KINASE INHIBITOR
1498, 2v55C, 0.7264, 3.90, 0.144, 396, 278, MECHANISM OF MULTI-SITE PHOSPHORYLATION FROM A ROCK-I:RHOE COMPLEX STRUCTURE
1499, 5da3A, 0.7263, 2.69, 0.294, 263, 252, CRYSTAL STRUCTURE OF PTK6 KINASE DOMAIN WITH INHIBITOR
1500, 3vs7A, 0.7263, 2.62, 0.299, 432, 251, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR 1-CYCLOPENTYL-3-(1H-PYRROLO[23-B]PYRIDIN-5-YL)-1H- PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
1501, 3u51B, 0.7263, 2.67, 0.292, 255, 253, SRC IN COMPLEX WITH DNA-TEMPLATED MACROCYCLIC INHIBITOR MC1
1502, 3iw4C, 0.7263, 3.64, 0.187, 332, 273, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1503, 3d4qB, 0.7263, 2.74, 0.220, 264, 255, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
1504, 5winA, 0.7262, 2.65, 0.209, 274, 254, JAK2 PSEUDOKINASE IN COMPLEX WITH JNJ7706621 
1505, 5i9uA, 0.7262, 3.23, 0.314, 281, 264, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
1506, 3d4qA, 0.7262, 2.74, 0.220, 264, 255, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
1507, 3c50A, 0.7262, 4.19, 0.175, 499, 285, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 2.6A
1508, 4z3vA, 0.7261, 2.85, 0.305, 271, 256, FRAGMENT-BASED DISCOVERY OF A SMALL MOLECULE REVERSIBLE INHIBITOR OF BRUTON S TYROSINE KINASE
1509, 3omvA, 0.7261, 2.72, 0.196, 264, 255, CRYSTAL STRUCTURE OF C-RAF (RAF-1)
1510, 5wneD, 0.7260, 3.92, 0.155, 396, 278, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
1511, 5o4aA, 0.7260, 3.26, 0.319, 290, 263, HUMAN FGF IN COMPLEX WITH A COVALENT INHIBITOR
1512, 4qmoA, 0.7260, 3.46, 0.219, 288, 269, MST3 IN COMPLEX WITH IMIDAZOLO-OXINDOLE PKR INHIBITOR C16
1513, 3d9vB, 0.7260, 3.92, 0.144, 398, 278, CRYSTAL STRUCTURE OF ROCK I BOUND TO H-1152P A DI- METHYLATED VARIANT OF FASUDIL
1514, 1t46A, 0.7260, 3.24, 0.286, 297, 262, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C-KIT TYROSINE KINASE
1515, 5wnfD, 0.7259, 3.96, 0.155, 396, 278, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
1516, 5uafA, 0.7259, 2.83, 0.345, 291, 252, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
1517, 5uadA, 0.7259, 2.83, 0.345, 291, 252, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
1518, 5upkB, 0.7258, 3.27, 0.182, 288, 264, CDC42 BINDS PAK4 VIA AN EXTENDED GTPASE-EFFECTOR INTERFACE - 3 PEPTIDE: PAK4CAT PAK4-N45 CDC42
1519, 5t68B, 0.7258, 3.11, 0.344, 264, 259, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
1520, 5j87D, 0.7258, 2.68, 0.308, 263, 253, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
1521, 4knbC, 0.7258, 2.74, 0.347, 271, 251, C-MET IN COMPLEX WITH OSI LIGAND
1522, 4anqA, 0.7258, 3.41, 0.262, 293, 267, STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
1523, 5ugxB, 0.7257, 3.11, 0.314, 282, 258, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
1524, 4xg8A, 0.7257, 2.82, 0.353, 258, 255, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
1525, 4ot6A, 0.7257, 2.69, 0.311, 265, 254, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4- METHANESULFONYL-N-(3-{8-[4-(MORPHOLINE-4-CARBONYL)-PHENYLAMINO]- IMIDAZO[12-A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
1526, 4e4xA, 0.7257, 2.77, 0.227, 267, 255, CRYSTAL STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH A DIHYDROPYRIDO[23-D]PYRIMIDINONE-BASED INHIBITOR
1527, 2v55A, 0.7257, 3.92, 0.144, 393, 278, MECHANISM OF MULTI-SITE PHOSPHORYLATION FROM A ROCK-I:RHOE COMPLEX STRUCTURE
1528, 4wboC, 0.7256, 3.77, 0.178, 481, 276, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH AMLEXANOX
1529, 4aszA, 0.7256, 3.30, 0.280, 289, 264, CRYSTAL STRUCTURE OF APO TRKB KINASE DOMAIN
1530, 3efjA, 0.7256, 2.86, 0.348, 276, 253, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 7
1531, 1k2pB, 0.7256, 2.85, 0.289, 258, 256, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
1532, 5ntjA, 0.7255, 3.62, 0.175, 346, 274, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUND RKP032 
1533, 4nkaB, 0.7255, 3.05, 0.309, 287, 259, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
1534, 3bprB, 0.7255, 2.65, 0.351, 256, 248, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE- PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR C52
1535, 6es0B, 0.7254, 3.24, 0.226, 287, 261, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE ACTIVATION LOOP TARGETING INHIBITOR CS-R35
1536, 5w86A, 0.7254, 2.57, 0.321, 269, 249, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
1537, 5vfiA, 0.7254, 2.84, 0.305, 271, 256, BRUTON S TYROSINE KINASE (BTK) WITH GDC-0853
1538, 5uzjB, 0.7254, 3.85, 0.156, 386, 275, CRYSTAL STRUCTURE OF ROCK1 BOUND TO AN AMINOPYRIDINE INHIBITOR
1539, 2xp2A, 0.7254, 3.41, 0.260, 285, 265, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB (PF-02341066)
1540, 5dg5B, 0.7253, 3.01, 0.341, 297, 258, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP- 4157
1541, 6g4zA, 0.7252, 3.30, 0.184, 322, 266, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK) IN COMPLEX WITH COMPOUND 2F 
1542, 5u7rA, 0.7252, 3.88, 0.156, 387, 276, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
1543, 5p9gA, 0.7252, 2.71, 0.307, 265, 254, STRUCTURE OF BTK WITH RN486
1544, 5bpyA, 0.7252, 2.66, 0.313, 263, 252, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
1545, 4yveA, 0.7252, 3.85, 0.152, 390, 277, ROCK 1 BOUND TO METHOXYPHENYL THIAZOLE INHIBITOR
1546, 3e8nA, 0.7252, 3.30, 0.184, 291, 266, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) COMPLEXED WITH A POTENT INHIBITOR RDEA119 AND MGATP
1547, 3a4oX, 0.7252, 2.73, 0.306, 259, 255, LYN KINASE DOMAIN
1548, 2xzsB, 0.7252, 3.36, 0.169, 293, 267, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
1549, 5t0pB, 0.7251, 3.08, 0.291, 263, 261, C-SRC KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
1550, 4trlA, 0.7251, 3.04, 0.309, 268, 259, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
1551, 4qmpA, 0.7251, 3.45, 0.219, 289, 269, MST3 IN COMPLEX WITH CDK1/2 INHIBITOR III 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
1552, 3pp1A, 0.7251, 3.23, 0.189, 291, 265, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGATP
1553, 5j7bA, 0.7250, 2.83, 0.207, 277, 256, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
1554, 5ftoA, 0.7250, 3.55, 0.259, 298, 270, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH ENTRECTINIB
1555, 4ymjB, 0.7250, 3.13, 0.282, 275, 259, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
1556, 4rwjA, 0.7250, 3.19, 0.323, 307, 263, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
1557, 3eflA, 0.7250, 3.04, 0.297, 286, 256, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH MOTESANIB
1558, 2cdzA, 0.7250, 3.32, 0.175, 289, 263, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH CGP74514A
1559, 5p9kA, 0.7249, 2.80, 0.306, 271, 255, CRYSTAL STRUCTURE OF BTK WITH CNX 774
1560, 5bmlA, 0.7249, 3.78, 0.160, 393, 275, ROCK 1 BOUND TO A PYRIDINE THIAZOLE INHIBITOR
1561, 4hcvA, 0.7249, 2.64, 0.319, 263, 251, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 53
1562, 2h9vA, 0.7249, 3.86, 0.149, 383, 276, STRUCTURAL BASIS FOR INDUCED-FIT BINDING OF RHO-KINASE TO THE INHIBITOR Y27632
1563, 5xvgA, 0.7248, 3.18, 0.195, 292, 261, CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INHIBITOR CZH226
1564, 5xs2A, 0.7248, 3.52, 0.181, 366, 271, CDK8-CYCC IN COMPLEX WITH COMPOUND 17:3-CHLORO-4-(4-PYRIDYL)-1H- PYRROLE-2-CARBOXAMIDE
1565, 5u7rD, 0.7248, 3.74, 0.158, 382, 273, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
1566, 5nkeA, 0.7248, 3.42, 0.321, 292, 268, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3A
1567, 4u7zA, 0.7248, 3.35, 0.184, 291, 266, MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK1) BOUND TO G805
1568, 4o2pB, 0.7248, 3.01, 0.297, 265, 259, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
1569, 3sxrA, 0.7248, 2.92, 0.284, 260, 257, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
1570, 6fnfA, 0.7247, 2.73, 0.298, 267, 255, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH NVP-BHG712 
1571, 5w86B, 0.7247, 2.43, 0.319, 267, 248, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
1572, 4ekkB, 0.7247, 3.58, 0.162, 318, 271, AKT1 WITH AMP-PNP
1573, 3psdB, 0.7247, 2.63, 0.225, 264, 253, NON-OXIME PYRAZOLE BASED INHIBITORS OF B-RAF KINASE
1574, 3iw4B, 0.7247, 3.62, 0.180, 325, 272, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1575, 4u0iA, 0.7246, 3.18, 0.300, 297, 260, CRYSTAL STRUCTURE OF KIT IN COMPLEX WITH PONATINIB
1576, 4ctcA, 0.7246, 3.42, 0.264, 288, 265, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 7-AMINO-3-CYCLOPROPYL-12-FLUORO- 11016-TRIMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(4 3-H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
1577, 3psbB, 0.7246, 2.64, 0.225, 264, 253, FURO[23-C]PYRIDINE-BASED INDANONE OXIMES AS POTENT AND SELECTIVE B- RAF INHIBITORS
1578, 5wnhD, 0.7245, 3.96, 0.155, 397, 278, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
1579, 4zlzA, 0.7245, 2.84, 0.306, 270, 255, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE IN COMPLEX WITH A SUBSTITUTED CINNOLINE
1580, 3qlgB, 0.7245, 2.75, 0.302, 260, 255, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH DASATINIB
1581, 5u7qD, 0.7244, 3.83, 0.149, 383, 275, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
1582, 5ia2A, 0.7244, 3.32, 0.287, 287, 265, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 66
1583, 3vntA, 0.7244, 3.14, 0.305, 301, 259, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
1584, 3ri1B, 0.7244, 3.55, 0.311, 283, 267, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
1585, 5wijA, 0.7243, 2.59, 0.206, 274, 252, JAK2 PSEUDOKINASE IN COMPLEX WITH NU6140 
1586, 5kktA, 0.7243, 3.62, 0.158, 389, 272, ROCK 1 BOUND TO AZAINDOLE THIOZOLE PIPERAZINE INHIBITOR
1587, 4o2pA, 0.7243, 3.22, 0.286, 265, 262, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
1588, 4ansA, 0.7243, 3.44, 0.266, 293, 267, STRUCTURE OF L1196MG1269A DOUBLE MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
1589, 5ar3B, 0.7242, 2.91, 0.227, 276, 256, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH AMP-PCP
1590, 5a46A, 0.7242, 3.30, 0.333, 289, 264, FGFR1 IN COMPLEX WITH DOVITINIB
1591, 4wotA, 0.7242, 3.68, 0.159, 389, 271, ROCK2 IN COMPLEX WITH 1426382-07-1
1592, 2esmA, 0.7242, 3.79, 0.156, 400, 276, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO FASUDIL
1593, 4knbA, 0.7241, 2.77, 0.345, 273, 252, C-MET IN COMPLEX WITH OSI LIGAND
1594, 4f0iB, 0.7241, 3.05, 0.299, 294, 261, CRYSTAL STRUCTURE OF APO TRKA
1595, 4d58B, 0.7241, 3.02, 0.348, 261, 256, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
1596, 3nczA, 0.7241, 3.84, 0.156, 399, 276, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT 2H-ISOQUINOLIN-1-ONE INHIBITOR
1597, 3mblA, 0.7241, 3.21, 0.189, 290, 264, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGADP
1598, 3el8B, 0.7241, 2.83, 0.298, 259, 255, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 5
1599, 2wtkE, 0.7241, 3.92, 0.149, 308, 276, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
1600, 1z9xC, 0.7241, 3.58, 0.177, 303, 271, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 3 MONOMERS IN THE ASYMMETRIC UNIT
1601, 1u5rA, 0.7241, 3.59, 0.186, 308, 274, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1602, 1fgiA, 0.7241, 3.20, 0.322, 283, 261, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
1603, 5p9jA, 0.7240, 2.75, 0.291, 263, 254, BTK1 COCRYSTALLIZED WITH IBRUTINIB
1604, 5jsmB, 0.7239, 2.84, 0.219, 263, 256, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
1605, 5d12A, 0.7239, 2.76, 0.310, 260, 255, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL40
1606, 5a4cB, 0.7239, 3.24, 0.324, 286, 262, FGFR1 LIGAND COMPLEX
1607, 4oliA, 0.7239, 3.11, 0.196, 539, 260, THE PSEUDOKINASE/KINASE PROTEIN FROM JAK-FAMILY MEMBER TYK2
1608, 3uqgA, 0.7239, 3.07, 0.296, 263, 260, C-SRC KINASE DOMAIN IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
1609, 3q4cA, 0.7239, 2.68, 0.224, 264, 254, CRYSTAL STRUCTURE OF WILD TYPE BRAF KINASE DOMAIN IN COMPLEX WITH ORGANOMETALLIC INHIBITOR CNS292
1610, 5wikB, 0.7238, 2.65, 0.202, 274, 253, JAK2 PSEUDOKINASE IN COMPLEX WITH BI-D1870 
1611, 4u43A, 0.7238, 2.90, 0.167, 287, 257, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
1612, 4jdiA, 0.7238, 3.30, 0.182, 289, 264, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
1613, 5a9uA, 0.7237, 3.41, 0.263, 292, 266, STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
1614, 4otfA, 0.7237, 2.69, 0.306, 262, 252, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH GDC0834
1615, 4lmnA, 0.7237, 3.27, 0.185, 292, 265, CRYSTAL STRUCTURE OF MEK1 KINASE BOUND TO GDC0973
1616, 3h3cA, 0.7237, 3.07, 0.324, 263, 259, CRYSTAL STRUCTURE OF PYK2 IN COMPLEX WITH SULFOXIMINE- SUBSTITUTED TRIFLUOROMETHYLPYRIMIDINE ANALOG
1617, 3e8dB, 0.7237, 3.46, 0.160, 317, 269, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1618, 6fnhA, 0.7236, 3.40, 0.303, 277, 267, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH A PYRAZOLO[3;4-D]PYRIMIDINE FRAGMENT OF NVP-BHG712 
1619, 4ymjA, 0.7236, 2.91, 0.290, 270, 255, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
1620, 4tndA, 0.7236, 4.02, 0.167, 529, 281, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 5 IN COMPLEX WITH AMP-PNP
1621, 3e8dA, 0.7236, 3.46, 0.160, 315, 269, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1622, 3bu6A, 0.7236, 3.12, 0.299, 294, 261, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PHOSPHOPEPTIDE
1623, 2yfxA, 0.7236, 3.47, 0.266, 292, 267, STRUCTURE OF L1196M MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
1624, 5imxA, 0.7235, 2.70, 0.273, 266, 253, ANAPLASTIC LYMPHOMA KINASE (ALK) CATALYTIC DOMAIN COMPLEXED WITH NOVEL INHIBITOR 3-SULFONYLPYRAZOL-4-AMINO PYRIMIDINE
1625, 4w8dA, 0.7235, 3.39, 0.217, 289, 267, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06454589).
1626, 4o0xA, 0.7235, 3.39, 0.170, 290, 265, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1627, 4c02A, 0.7235, 3.00, 0.181, 313, 259, CRYSTAL STRUCTURE OF HUMAN ACVR1 (ALK2) IN COMPLEX WITH FKBP12.6 AND DORSOMORPHIN
1628, 4asdA, 0.7235, 3.14, 0.305, 305, 259, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SORAFENIB (BAY 43-9006)
1629, 3f66B, 0.7235, 2.87, 0.344, 269, 253, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
1630, 2etmB, 0.7235, 3.23, 0.342, 263, 260, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
1631, 5hvuA, 0.7234, 3.88, 0.148, 394, 277, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH A PYRIDINE THIAZOLE PIPERIDINE INHIBITOR
1632, 4l53A, 0.7234, 2.93, 0.242, 296, 256, CRYSTAL STRUCTURE OF (1R4R)-4-{4-[7-AMINO-2-(123-BENZOTHIADIAZOL-7- YL)-3-CHLOROFURO[23-C]PYRIDIN-4-YL]-1H-PYRAZOL-1-YL}CYCLOHEXAN-1-OL BOUND TO TAK1-TAB1
1633, 2etkA, 0.7234, 3.87, 0.152, 400, 277, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO HYDROXYFASUDIL
1634, 3efjB, 0.7233, 2.99, 0.328, 275, 253, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 7
1635, 5uplA, 0.7232, 3.37, 0.181, 290, 265, CDC42 BINDS PAK4 VIA AN EXTENDED GTPASE-EFFECTOR INTEFACE - 2 PEPTIDE: PAK4FL CDC42 - UNREFINED
1636, 5u7rB, 0.7232, 3.90, 0.156, 387, 276, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
1637, 3svvA, 0.7232, 3.01, 0.291, 261, 258, CRYSTAL STRUCTURE OF T338C C-SRC COVALENTLY BOUND TO VINYLSULFONAMIDE- PYRAZOLOPYRIMIDINE 9
1638, 3dkfA, 0.7232, 3.25, 0.338, 294, 260, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH INHIBITOR SGX-523
1639, 5iuiA, 0.7231, 3.63, 0.265, 303, 272, CRYSTAL STRUCTURE OF ANAPLASTIC LYPHOMA KINASE (ALK) IN COMPLEX WITH 4
1640, 5aa8A, 0.7231, 3.47, 0.259, 292, 266, STRUCTURE OF C1156YL1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12- FLUORO-21016-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H- 84-(METHENO)PYRAZOLO(43-H)(2511) BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
1641, 4v04B, 0.7231, 3.12, 0.309, 287, 259, FGFR1 IN COMPLEX WITH PONATINIB.
1642, 4v05B, 0.7230, 3.12, 0.308, 286, 260, FGFR1 IN COMPLEX WITH AZD4547.
1643, 4fzdB, 0.7230, 3.32, 0.232, 275, 263, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX WITH WSF MOTIF
1644, 5j87A, 0.7229, 2.70, 0.306, 263, 252, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
1645, 5ftqA, 0.7229, 3.47, 0.262, 293, 267, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH CMPD 17
1646, 5d7aA, 0.7229, 3.14, 0.166, 289, 259, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
1647, 4u3yA, 0.7229, 3.40, 0.211, 295, 266, APO MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4)
1648, 4o0vA, 0.7229, 3.40, 0.181, 290, 265, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1649, 4fvpA, 0.7229, 2.69, 0.206, 274, 253, CRYSTAL STRUCTURE OF THE JAK2 PSEUDOKINASE DOMAIN (APO FORM)
1650, 4ag8A, 0.7229, 3.16, 0.305, 296, 259, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-(3-((E)-2-PYRIDIN-2-YL-VINYL)-1H- INDAZOL-6- YLSULFANYL)-BENZAMIDE)
1651, 3e87B, 0.7229, 3.53, 0.163, 321, 270, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1652, 3e87A, 0.7229, 3.53, 0.163, 321, 270, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1653, 2x39A, 0.7229, 3.41, 0.160, 316, 269, STRUCTURE OF 4-AMINO-N-(4-CHLOROBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE BOUND TO PKB
1654, 2etrA, 0.7229, 3.87, 0.148, 400, 277, CRYSTAL STRUCTURE OF ROCK I BOUND TO Y-27632
1655, 2b4sB, 0.7229, 3.02, 0.297, 294, 259, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
1656, 2acxA, 0.7229, 3.95, 0.160, 495, 281, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 6 BOUND TO AMPPNP
1657, 1zwsD, 0.7229, 3.16, 0.180, 278, 261, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
1658, 6fnhC, 0.7228, 3.34, 0.295, 270, 264, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH A PYRAZOLO[3;4-D]PYRIMIDINE FRAGMENT OF NVP-BHG712 
1659, 5jsmA, 0.7228, 2.59, 0.222, 265, 252, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
1660, 5i0bA, 0.7228, 3.33, 0.163, 288, 264, STRUCTURE OF PAK4
1661, 4otdA, 0.7228, 3.56, 0.181, 334, 271, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN
1662, 3eqgA, 0.7228, 3.52, 0.186, 314, 269, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH PD ADP AND MG2P
1663, 3cquA, 0.7228, 3.44, 0.164, 318, 269, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
1664, 2wkmA, 0.7228, 3.15, 0.345, 286, 258, X-RAY STRUCTURE OF PHA-00665752 BOUND TO THE KINASE DOMAIN OF C-MET
1665, 2f2uA, 0.7228, 3.90, 0.144, 386, 277, CRYSTAL STRUCTURE OF THE RHO-KINASE KINASE DOMAIN
1666, 6c9dA, 0.7227, 3.46, 0.194, 425, 268, CRYSTAL STRUCTURE OF KA1-AUTOINHIBITED MARK1 KINASE 
1667, 5xvaA, 0.7227, 3.28, 0.176, 292, 262, CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INHIBITOR CZH216
1668, 4yhjA, 0.7227, 4.03, 0.163, 501, 282, STRUCTURE AND FUNCTION OF THE HYPERTENSION VARIANT A486V OF G PROTEIN- COUPLED RECEPTOR KINASE 4 (GRK4)
1669, 4h1jA, 0.7227, 3.12, 0.314, 263, 261, CRYSTAL STRUCTURE OF PYK2 WITH THE PYRAZOLE 13A
1670, 4dggA, 0.7227, 2.98, 0.284, 261, 257, C-SRC KINASE DOMAIN IN COMPLEX WITH RM-1-176
1671, 3c4xB, 0.7227, 3.84, 0.176, 475, 278, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.9A
1672, 5w5qA, 0.7226, 3.20, 0.179, 291, 262, MAP4K4 IN COMPLEX WITH INHIBITOR COMPOUND 12 (N3-METHYL-10-(3-METHYL- 3-(5-METHYLOXAZOL-2-YL)BUT-1-YN-1-YL)-6;7-DIHYDRO-5H-5;7- METHANOBENZO[C]IMIDAZO[1;2-A]AZEPINE-2;3-DICARBOXAMIDE) 
1673, 5ut4A, 0.7226, 2.63, 0.209, 273, 253, JAK2 JH2 IN COMPLEX WITH NVP-BSK805
1674, 4arkA, 0.7226, 3.29, 0.185, 291, 265, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN MAP KINASE KINASE 1 (MEK1) IN COMPLEX WITH  A SMALL MOLECULE INHIBITOR AND ADP
1675, 3ik3A, 0.7226, 3.17, 0.333, 280, 258, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
1676, 4o0yA, 0.7225, 3.41, 0.177, 290, 265, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1677, 3dv3A, 0.7225, 3.31, 0.185, 288, 265, MEK1 WITH PF-04622664 BOUND
1678, 5xp7A, 0.7224, 3.15, 0.291, 265, 261, C-SRC IN COMPLEX WITH ATP-CHCL
1679, 4a4oA, 0.7224, 3.26, 0.211, 290, 265, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 2- (2-AMINO-PYRIMIDIN-4-YL)-1567-TETRAHYDRO-PYRROLOPYRIDIN- 4-ONE INHIBITOR
1680, 5wilA, 0.7223, 2.70, 0.206, 274, 253, JAK2 PSEUDOKINASE IN COMPLEX WITH AZD7762 
1681, 4qmmA, 0.7223, 3.48, 0.231, 288, 268, MST3 IN COMPLEX WITH AT-9283 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]- 1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM
1682, 4dggB, 0.7223, 2.86, 0.303, 259, 254, C-SRC KINASE DOMAIN IN COMPLEX WITH RM-1-176
1683, 4d4sB, 0.7223, 3.01, 0.349, 260, 255, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1684, 1zwsH, 0.7223, 3.17, 0.180, 278, 261, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
1685, 5t3qA, 0.7222, 2.91, 0.332, 278, 253, CRYSTAL STRUCTURE OF THE C-MET KINASE DOMAIN IN COMPLEX WITH A PYRAZOLONE INHIBITOR
1686, 5p9iA, 0.7222, 2.85, 0.298, 271, 255, BTK1 SOAKED WITH IBRUTINIB-REV
1687, 4o27B, 0.7222, 3.35, 0.226, 281, 265, CRYSTAL STRUCTURE OF MST3-MO25 COMPLEX WITH WIF MOTIF
1688, 4xbuA, 0.7221, 3.39, 0.174, 292, 264, IN VITRO CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INKA PEPTIDE
1689, 4v05A, 0.7221, 3.19, 0.322, 287, 261, FGFR1 IN COMPLEX WITH AZD4547.
1690, 2jedA, 0.7221, 3.47, 0.167, 324, 269, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
1691, 2i0eB, 0.7221, 3.16, 0.175, 300, 263, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
1692, 1rqqA, 0.7221, 3.22, 0.292, 294, 260, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
1693, 3eqbA, 0.7220, 3.37, 0.184, 289, 266, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
1694, 3beaA, 0.7220, 3.49, 0.295, 310, 264, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH A PYRIMIDINOPYRIDONE INHIBITOR
1695, 5u7qC, 0.7219, 3.86, 0.153, 390, 275, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
1696, 4mxoB, 0.7219, 3.15, 0.287, 264, 261, HUMAN SRC KINASE BOUND TO KINASE INHIBITOR BOSUTINIB
1697, 3oezB, 0.7219, 3.00, 0.284, 261, 257, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH IMATINIB
1698, 5w5oN, 0.7218, 2.80, 0.230, 272, 252, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
1699, 5i9vA, 0.7218, 3.13, 0.314, 279, 261, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH AGS
1700, 4fijA, 0.7218, 3.25, 0.183, 291, 263, CATALYTIC DOMAIN OF HUMAN PAK4
1701, 3slsB, 0.7218, 3.48, 0.195, 294, 267, CRYSTAL STRUCTURE OF HUMAN MEK-1 KINASE IN COMPLEX WITH UCB1353770 AND AMPPNP
1702, 4mxxB, 0.7217, 3.03, 0.287, 260, 258, HUMAN SRC A403T MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
1703, 3ppjA, 0.7217, 2.68, 0.226, 262, 252, HUMAN B-RAF KINASE IN COMPLEX WITH A FUROPYRIDINE INHIBITOR
1704, 3bu3A, 0.7217, 3.18, 0.299, 294, 261, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE
1705, 6fu5A, 0.7216, 3.11, 0.216, 282, 259, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE INHIBITOR CSLP18 
1706, 5xvfA, 0.7216, 3.35, 0.170, 289, 264, CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INHIBITOR CZH062
1707, 5tc0B, 0.7216, 2.22, 0.351, 250, 242, STRUCTURE-BASED OPTIMIZATION OF 1H-IMIDAZOLE-2-CARBOXAMIDES AS AXL KINASE INHIBITORS UTILIZING A MER MUTANT SURROGATE
1708, 5iu2B, 0.7216, 2.98, 0.163, 313, 258, DISCOVERY OF IMIDAZOQUINOLINES AS A NOVEL CLASS OF POTENT SELECTIVE AND IN VIVO EFFICACIOUS COT KINASE INHIBITORS
1709, 4qmqA, 0.7216, 3.52, 0.219, 289, 269, MST3 IN COMPLEX WITH CP-673451
1710, 3vs7B, 0.7216, 2.60, 0.300, 426, 250, CRYSTAL STRUCTURE OF HCK COMPLEXED WITH A PYRAZOLO-PYRIMIDINE INHIBITOR 1-CYCLOPENTYL-3-(1H-PYRROLO[23-B]PYRIDIN-5-YL)-1H- PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
1711, 3v04A, 0.7216, 3.38, 0.184, 289, 266, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
1712, 3el8A, 0.7216, 3.10, 0.296, 263, 260, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 5
1713, 3b8qA, 0.7216, 3.27, 0.296, 292, 260, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
1714, 5vjaC, 0.7215, 2.72, 0.190, 265, 253, CRYSTAL STRUCTURE OF HUMAN ZIPPER-INTERACTING PROTEIN KINASE (ZIPK; ALIAS DAPK3) IN COMPLEX WITH A PYRAZOLO[3;4-D]PYRIMIDINONE LIGAND (HS38) 
1715, 5vjaB, 0.7215, 2.68, 0.189, 266, 254, CRYSTAL STRUCTURE OF HUMAN ZIPPER-INTERACTING PROTEIN KINASE (ZIPK; ALIAS DAPK3) IN COMPLEX WITH A PYRAZOLO[3;4-D]PYRIMIDINONE LIGAND (HS38) 
1716, 5ew3A, 0.7215, 2.89, 0.303, 274, 254, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN IN COMPLEX WITH AAL993
1717, 4rwlA, 0.7215, 3.06, 0.326, 282, 258, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
1718, 4apcB, 0.7215, 2.83, 0.181, 296, 254, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
1719, 5iugA, 0.7214, 3.21, 0.269, 285, 260, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) IN COMPLEX WITH 5A
1720, 4xi2A, 0.7214, 2.98, 0.293, 421, 256, CRYSTAL STRUCTURE OF AN AUTO-INHIBITED FORM OF BRUTON S TRYROSINE KINASE
1721, 4l9iA, 0.7214, 4.23, 0.165, 504, 284, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH PAROXETINE
1722, 4j95D, 0.7214, 2.92, 0.319, 271, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
1723, 4a4lA, 0.7214, 3.28, 0.211, 290, 265, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 5-(2-AMINO-PYRIMIDIN-4-YL)-1H-PYRROLE INHIBITOR
1724, 2uw9A, 0.7214, 3.43, 0.160, 316, 269, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH 4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
1725, 2jkmA, 0.7214, 2.94, 0.342, 260, 257, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
1726, 1s9jA, 0.7214, 3.37, 0.184, 289, 266, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
1727, 5j79B, 0.7213, 2.94, 0.223, 277, 256, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
1728, 4l9iB, 0.7213, 4.00, 0.171, 493, 280, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH PAROXETINE
1729, 4fiiA, 0.7213, 3.26, 0.183, 291, 263, CATALYTIC DOMAIN OF HUMAN PAK4 WITH RPKPLVDP PEPTIDE
1730, 4d55A, 0.7213, 2.97, 0.342, 260, 257, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1731, 3tv4A, 0.7213, 2.87, 0.220, 264, 255, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH AN BROMOPYRIDINE BENZAMIDE INHIBITOR
1732, 3prfB, 0.7213, 2.58, 0.227, 262, 251, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
1733, 3ik3B, 0.7213, 3.30, 0.331, 286, 260, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
1734, 2acxB, 0.7213, 3.85, 0.165, 492, 279, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 6 BOUND TO AMPPNP
1735, 1zwsF, 0.7213, 3.17, 0.180, 278, 261, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
1736, 5jrqA, 0.7212, 2.76, 0.226, 258, 252, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-6-VEM
1737, 5e8uA, 0.7212, 3.05, 0.162, 306, 259, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F)
1738, 4njdA, 0.7212, 3.40, 0.163, 290, 264, STRUCTURE OF P21-ACTIVATED KINASE 4 WITH A NOVEL INHIBITOR KY-04031
1739, 3skcA, 0.7212, 2.53, 0.212, 260, 250, HUMAN B-RAF KINASE IN COMPLEX WITH AN AMIDE LINKED PYRAZOLOPYRIDINE INHIBITOR
1740, 3my1A, 0.7212, 3.41, 0.154, 314, 266, STRUCTURE OF CDK9/CYCLINT1 IN COMPLEX WITH DRB
1741, 3eqcA, 0.7212, 3.52, 0.194, 312, 268, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH COMPOUND 1 ATP-GS AND MG2P
1742, 5p9hA, 0.7211, 2.75, 0.304, 264, 253, BTK1 COCRYSTALLIZED WITH RN983
1743, 5e8tA, 0.7211, 2.97, 0.159, 302, 258, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D)
1744, 4xbrA, 0.7211, 3.40, 0.181, 315, 265, IN CELLULO CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INKA
1745, 4jdjA, 0.7211, 3.31, 0.183, 288, 263, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
1746, 4fieB, 0.7211, 3.49, 0.173, 300, 266, FULL-LENGTH HUMAN PAK4
1747, 4fieA, 0.7211, 3.49, 0.173, 300, 266, FULL-LENGTH HUMAN PAK4
1748, 3nczD, 0.7211, 3.90, 0.159, 397, 277, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT 2H-ISOQUINOLIN-1-ONE INHIBITOR
1749, 5p9mA, 0.7210, 2.96, 0.301, 271, 256, BTK1 BINDS COVALENTLY TO HY-15771 ONO-4059
1750, 3vo3A, 0.7210, 3.19, 0.305, 303, 259, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH IMIDAZO[1 2-B]PYRIDAZINE DERIVATIVE
1751, 1rqqB, 0.7210, 3.19, 0.292, 294, 260, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
1752, 5kmkA, 0.7209, 2.96, 0.298, 304, 258, TRKA JM-KINASE WITH 2-FLUORO-{N}-[2-(4-FLUOROPHENYL)-6-METHYL-3- PYRIDYL]-4-(TRIFLUOROMETHYL)BENZAMIDE
1753, 2i1mA, 0.7209, 3.48, 0.299, 311, 264, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
1754, 1zwsC, 0.7209, 3.02, 0.181, 278, 259, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
1755, 5vefA, 0.7208, 3.27, 0.183, 289, 263, PAK4 KINASE DOMAIN IN COMPLEX WITH FASUDIL
1756, 5iu2A, 0.7208, 2.97, 0.163, 312, 258, DISCOVERY OF IMIDAZOQUINOLINES AS A NOVEL CLASS OF POTENT SELECTIVE AND IN VIVO EFFICACIOUS COT KINASE INHIBITORS
1757, 5fbnD, 0.7208, 2.67, 0.294, 255, 252, BTK KINASE DOMAIN WITH INHIBITOR 1
1758, 4wo5B, 0.7208, 2.36, 0.230, 257, 248, CRYSTAL STRUCTURE OF A BRAF KINASE DOMAIN MONOMER
1759, 4otqA, 0.7208, 2.74, 0.312, 263, 253, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 1-[5-[3-(7-TERT- BUTYL-4-OXO-QUINAZOLIN-3-YL)-2-METHYL-PHENYL]-1-METHYL-2-OXO-3- PYRIDYL]-3-METHYL-UREA
1760, 3c50B, 0.7208, 4.02, 0.171, 496, 281, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 2.6A
1761, 1lufA, 0.7208, 2.93, 0.323, 275, 254, CRYSTAL STRUCTURE OF THE MUSK TYROSINE KINASE: INSIGHTS INTO RECEPTOR AUTOREGULATION
1762, 5vedA, 0.7207, 3.35, 0.182, 289, 264, PAK4 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
1763, 5u9dA, 0.7207, 2.92, 0.301, 271, 256, DISCOVERY OF A POTENT BTK INHIBITOR WITH A NOVEL BINDING MODE USING PARALLEL SELECTIONS WITH A DNA-ENCODED CHEMICAL LIBRARY
1764, 5u7qA, 0.7207, 3.82, 0.150, 388, 274, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
1765, 5ar8B, 0.7207, 2.85, 0.206, 274, 252, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIPHENYLSULFONAMIDE
1766, 4qmvA, 0.7207, 3.44, 0.221, 288, 267, MST3 IN COMPLEX WITH PF-03814735 N-{2-[(1S4R)-6-{[4- (CYCLOBUTYLAMINO)-5-(TRIFLUOROMETHYL)PYRIMIDIN-2-YL]AMINO}-1234- TETRAHYDRO-14-EPIMINONAPHTHALEN-9-YL]-2-OXOETHYL}ACETAMIDE
1767, 4fihA, 0.7207, 3.34, 0.182, 291, 264, CATALYTIC DOMAIN OF HUMAN PAK4 WITH QKFTGLPRQW PEPTIDE
1768, 3qupA, 0.7207, 1.98, 0.385, 241, 239, INHIBITOR BOUND STRUCTURE OF THE KINASE DOMAIN OF THE MURINE RECEPTOR TYROSINE KINASE TYRO3 (SKY)
1769, 3cd8A, 0.7207, 2.88, 0.349, 278, 252, X-RAY STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR.
1770, 3b2wA, 0.7207, 2.66, 0.296, 261, 253, CRYSTAL STRUCTURE OF PYRIMIDINE AMIDE 11 BOUND TO LCK
1771, 1wvyA, 0.7207, 2.87, 0.180, 273, 256, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
1772, 1snxB, 0.7207, 2.19, 0.311, 245, 244, CRYSTAL STRUCTURE OF APO INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1773, 5wimA, 0.7206, 2.62, 0.207, 274, 251, JAK2 PSEUDOKINASE IN COMPLEX WITH AT9283 
1774, 5aacA, 0.7206, 3.45, 0.263, 292, 266, STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
1775, 3v01A, 0.7206, 3.38, 0.184, 289, 266, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
1776, 3slsA, 0.7206, 3.47, 0.192, 292, 266, CRYSTAL STRUCTURE OF HUMAN MEK-1 KINASE IN COMPLEX WITH UCB1353770 AND AMPPNP
1777, 5hvuB, 0.7205, 3.83, 0.158, 394, 273, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH A PYRIDINE THIAZOLE PIPERIDINE INHIBITOR
1778, 3sxrB, 0.7205, 2.90, 0.286, 258, 255, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
1779, 1t45A, 0.7205, 3.34, 0.298, 331, 262, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C- KIT TYROSINE KINASE
1780, 5hlwA, 0.7204, 3.27, 0.328, 284, 259, CRYSTAL STRUCTURE OF C-MET MUTANT Y1230H IN COMPLEX WITH COMPOUND 14
1781, 5bmsA, 0.7204, 3.42, 0.177, 290, 265, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 4 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
1782, 4ekkA, 0.7204, 3.60, 0.163, 318, 270, AKT1 WITH AMP-PNP
1783, 2hy81, 0.7204, 3.40, 0.180, 293, 267, PAK1 COMPLEX WITH ST2001
1784, 5wnhC, 0.7203, 3.94, 0.167, 388, 276, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
1785, 5lihA, 0.7203, 3.37, 0.166, 324, 265, STRUCTURE OF A PEPTIDE-SUBSTRATE BOUND TO PKCIOTA CORE KINASE DOMAIN
1786, 5iuhA, 0.7203, 3.21, 0.274, 285, 259, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE (ALK) IN COMPLEX WITH 5D
1787, 4yhtB, 0.7203, 2.63, 0.215, 258, 251, BRAF COMPLEXED WITH AN INHIBITOR
1788, 4e26B, 0.7203, 2.74, 0.220, 264, 254, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
1789, 3ppkA, 0.7203, 2.70, 0.226, 262, 252, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
1790, 2p55A, 0.7203, 3.32, 0.185, 289, 265, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
1791, 5i9yA, 0.7202, 3.41, 0.293, 287, 266, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DASATINIB
1792, 4l67A, 0.7202, 3.42, 0.174, 289, 264, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF PAK4
1793, 4l52A, 0.7202, 2.82, 0.240, 295, 254, CRYSTAL STRUCTURE OF 1-(4-{4-[7-AMINO-2-(123-BENZOTHIADIAZOL-7-YL) FURO[23-C]PYRIDIN-4-YL]-1H-PYRAZOL-1-YL}PIPERIDIN-1-YL)ETHAN-1-ONE BOUND TO TAK1-TAB1
1794, 4g3gA, 0.7202, 3.27, 0.186, 312, 263, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) V408L BOUND TO A 2-(AMINOTHIAZOLYL)PHENOL (CMP3)
1795, 3socA, 0.7202, 2.97, 0.167, 307, 257, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
1796, 3oezA, 0.7202, 3.07, 0.287, 261, 258, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH IMATINIB
1797, 3f3tB, 0.7202, 2.94, 0.302, 259, 255, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL38 (TYPE III)
1798, 1wvxA, 0.7202, 2.87, 0.180, 275, 256, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
1799, 4otrA, 0.7201, 2.75, 0.312, 263, 253, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6-CYCLOPROPYL-2- [3-[5-[[5-(4-ETHYLPIPERAZIN-1-YL)-2-PYRIDYL]AMINO]-1-METHYL-6-OXO-3- PYRIDYL]-2-(HYDROXYMETHYL)PHENYL]-8-FLUORO-ISOQUINOLIN-1-ONE
1800, 4ogrI, 0.7201, 3.26, 0.151, 318, 265, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
1801, 4fgbA, 0.7201, 2.82, 0.203, 282, 256, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I APO FORM
1802, 3svvB, 0.7201, 2.84, 0.285, 257, 253, CRYSTAL STRUCTURE OF T338C C-SRC COVALENTLY BOUND TO VINYLSULFONAMIDE- PYRAZOLOPYRIMIDINE 9
1803, 4u81A, 0.7200, 3.28, 0.186, 289, 264, MEK1 KINASE BOUND TO SMALL MOLECULE INHIBITOR G659
1804, 4ctbA, 0.7200, 3.47, 0.263, 292, 266, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR (5R)-8-AMINO-3-FLUORO-519-DIMETHYL-20-OXO-5181920- TETRAHYDRO-711-(AZENO)PYRIDO(2 1 :23)IMIDAZO(45-H)(2511) BENZOXADIAZACYCLOTETRADECINE-14-CARBONITRILE
1805, 4crsA, 0.7200, 3.52, 0.175, 331, 268, HUMAN PROTEIN KINASE N2 (PKN2 PRKCL2) IN COMPLEX WITH ATPGAMMAS
1806, 3qlfB, 0.7200, 2.93, 0.278, 258, 255, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE 5
1807, 3gubA, 0.7200, 2.95, 0.179, 278, 257, CRYSTAL STRUCTURE OF DAPKL93G COMPLEXED WITH N6-(2- PHENYLETHYL)ADENOSINE
1808, 3f82A, 0.7200, 2.96, 0.336, 278, 253, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH N- (4-(2-AMINO-3-CHLOROPYRIDIN-4-YLOXY)-3-FLUOROPHENYL)-4- ETHOXY-1-(4-FLUOROPHENYL)-2-OXO-12-DIHYDROPYRIDINE-3- CARBOXAMIDE
1809, 2xirA, 0.7200, 3.18, 0.305, 296, 259, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH PF-00337210 (N2-DIMETHYL-6-(7-(2-MORPHOLINOETHOXY) QUINOLIN-4-YLOXY)BENZOFURAN-3-CARBOXAMIDE)
1810, 1cmkE, 0.7200, 3.74, 0.170, 348, 276, CRYSTAL STRUCTURES OF THE MYRISTYLATED CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE REVEAL OPEN AND CLOSED CONFORMATIONS
1811, 5jsmD, 0.7199, 2.76, 0.221, 259, 253, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
1812, 4zlyA, 0.7199, 2.86, 0.299, 270, 254, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE BOUND TO A CINNOLINE FRAGMENT
1813, 4yo4A, 0.7199, 2.95, 0.179, 280, 257, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT PHTHALAZINE
1814, 4rfyA, 0.7199, 2.76, 0.312, 263, 253, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(MORPHOLINE-4- CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-34- DIHYDROISOQUINOLIN-1-ONE
1815, 4qqjA, 0.7199, 3.19, 0.324, 282, 259, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE DOMAIN HARBORING THE V550L GATE-KEEPER MUTATION
1816, 4pmmA, 0.7199, 2.82, 0.303, 285, 254, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR N-(3-CYCLOPROPYL- 1-PHENYL-1H-PYRAZOL-5-YL)-2-{4-[3-METHOXY-4-(4-METHYL-1H-IMIDAZOL-1- YL)PHENYL]-1H-123-TRIAZOL-1-YL}ACETAMIDE
1817, 4jdkA, 0.7199, 3.24, 0.179, 288, 262, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
1818, 3wzeA, 0.7199, 2.99, 0.309, 298, 256, KDR IN COMPLEX WITH LIGAND SORAFENIB
1819, 3oy3A, 0.7199, 3.14, 0.333, 284, 258, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
1820, 3eqhA, 0.7199, 3.41, 0.195, 314, 266, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH U0126 ADP AND MG2P
1821, 3c4zA, 0.7199, 4.16, 0.170, 493, 283, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 1.84A
1822, 2yacA, 0.7199, 3.31, 0.211, 290, 265, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH NMS-P937
1823, 4qqtA, 0.7198, 3.05, 0.319, 283, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 TYROSINE KINASE DOMAIN
1824, 4g3fA, 0.7198, 3.27, 0.190, 312, 263, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO A 2-(AMINOTHIAZOLY)PHENOL (CMP2)
1825, 3uqfB, 0.7198, 2.52, 0.298, 253, 248, C-SRC KINASE DOMAIN IN COMPLEX WITH BKI RM-1-89
1826, 3qgyB, 0.7198, 2.24, 0.320, 245, 244, CRYSTAL STRUCTURE OF ITK INHIBITOR COMPLEX
1827, 3fc2A, 0.7198, 3.31, 0.211, 293, 265, PLK1 IN COMPLEX WITH BI6727
1828, 1zwsG, 0.7198, 3.20, 0.180, 278, 261, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
1829, 1k9aF, 0.7198, 2.85, 0.305, 436, 256, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
1830, 4j52A, 0.7197, 3.31, 0.208, 293, 265, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A PYRIMIDODIAZEPINONE INHIBITOR
1831, 3efkA, 0.7197, 2.99, 0.332, 276, 253, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 50
1832, 2rfnA, 0.7197, 2.86, 0.344, 268, 250, X-RAY STRUCTURE OF C-MET WITH INHIBITOR.
1833, 5ut2A, 0.7196, 2.72, 0.213, 273, 253, JAK2 JH2 IN COMPLEX WITH PRT062607
1834, 5ta6A, 0.7196, 3.37, 0.203, 294, 266, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR.
1835, 5nk5A, 0.7196, 3.41, 0.320, 287, 266, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1M
1836, 3zh8A, 0.7196, 3.29, 0.163, 318, 264, A NOVEL SMALL MOLECULE APKC INHIBITOR
1837, 2rfnB, 0.7196, 2.86, 0.344, 269, 250, X-RAY STRUCTURE OF C-MET WITH INHIBITOR.
1838, 5dzcA, 0.7195, 3.72, 0.191, 816, 272, CRYSTAL STRUCTURE OF PVX_084705 IN COMPLEX WITH AMP-PNP
1839, 5bq0A, 0.7195, 2.98, 0.294, 265, 255, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
1840, 4ypdA, 0.7195, 2.96, 0.179, 281, 257, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT 4-METHYLPYRIDAZINE
1841, 4yjpA, 0.7195, 3.21, 0.357, 263, 258, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000223
1842, 4kioC, 0.7195, 2.34, 0.312, 251, 247, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
1843, 4fifB, 0.7195, 3.42, 0.181, 292, 265, CATALYTIC DOMAIN OF HUMAN PAK4 WITH RPKPLVDP PEPTIDE
1844, 4fifA, 0.7195, 3.42, 0.181, 293, 265, CATALYTIC DOMAIN OF HUMAN PAK4 WITH RPKPLVDP PEPTIDE
1845, 4d4yB, 0.7195, 3.04, 0.349, 260, 255, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1846, 4aseA, 0.7195, 3.19, 0.305, 305, 259, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH TIVOZANIB (AV-951)
1847, 3zh8B, 0.7195, 3.38, 0.166, 317, 265, A NOVEL SMALL MOLECULE APKC INHIBITOR
1848, 3oy3B, 0.7195, 3.17, 0.333, 284, 258, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
1849, 3d9vA, 0.7195, 3.87, 0.149, 400, 276, CRYSTAL STRUCTURE OF ROCK I BOUND TO H-1152P A DI- METHYLATED VARIANT OF FASUDIL
1850, 2b4sD, 0.7195, 3.13, 0.303, 294, 261, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
1851, 5hu9A, 0.7194, 2.72, 0.331, 266, 251, CRYSTAL STRUCTURE OF ABL1 IN COMPLEX WITH CHMFL-074
1852, 4w8eA, 0.7194, 3.49, 0.225, 290, 267, STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF-06645342)
1853, 4bcgA, 0.7194, 3.35, 0.155, 312, 265, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1854, 3priB, 0.7194, 2.71, 0.225, 264, 253, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
1855, 5wnfC, 0.7193, 3.84, 0.168, 386, 274, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
1856, 5kmnA, 0.7193, 3.15, 0.290, 296, 259, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
1857, 4or5A, 0.7193, 3.51, 0.157, 319, 267, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
1858, 3vhkA, 0.7193, 3.06, 0.307, 297, 257, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BACK POCKET BINDER
1859, 4h1mA, 0.7192, 2.93, 0.340, 256, 256, CRYSTAL STRUCTURE OF PYK2 WITH THE INDOLE 10C
1860, 3q4cB, 0.7192, 2.73, 0.217, 264, 253, CRYSTAL STRUCTURE OF WILD TYPE BRAF KINASE DOMAIN IN COMPLEX WITH ORGANOMETALLIC INHIBITOR CNS292
1861, 3priA, 0.7192, 2.71, 0.225, 264, 253, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
1862, 3emgA, 0.7192, 2.81, 0.357, 255, 252, DISCOVERY AND SAR OF NOVEL 4-THIAZOLYL-2- PHENYLAMINOPYRIMIDINES AS POTENT INHIBITORS OF SPLEEN TYROSINE KINASE (SYK)
1863, 1snxA, 0.7192, 2.23, 0.316, 245, 244, CRYSTAL STRUCTURE OF APO INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1864, 5o26A, 0.7191, 2.95, 0.203, 271, 256, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A DIPHOSPHORYLATED STATE AND IN COMPLEX WITH AMP-PNP/MG2+
1865, 5nk7A, 0.7191, 3.22, 0.294, 284, 262, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2A
1866, 5ar7B, 0.7191, 3.07, 0.222, 278, 257, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
1867, 4yhjB, 0.7191, 4.01, 0.161, 490, 280, STRUCTURE AND FUNCTION OF THE HYPERTENSION VARIANT A486V OF G PROTEIN- COUPLED RECEPTOR KINASE 4 (GRK4)
1868, 4figB, 0.7191, 3.52, 0.184, 292, 266, CATALYTIC DOMAIN OF HUMAN PAK4
1869, 4ehgA, 0.7191, 2.72, 0.221, 262, 253, B-RAF KINASE DOMAIN IN COMPLEX WITH AN AMINOPYRIDIMINE-BASED INHIBITOR
1870, 3zfxB, 0.7191, 2.66, 0.315, 254, 251, CRYSTAL STRUCTURE OF EPHB1
1871, 3rhkB, 0.7191, 3.02, 0.340, 299, 256, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF C-MET KINASE IN COMPLEX WITH ARQ 197
1872, 3a8xA, 0.7191, 3.61, 0.162, 334, 272, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
1873, 6c9dB, 0.7190, 3.52, 0.194, 422, 268, CRYSTAL STRUCTURE OF KA1-AUTOINHIBITED MARK1 KINASE 
1874, 5f9eA, 0.7190, 3.70, 0.180, 334, 272, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
1875, 4lueA, 0.7190, 2.63, 0.304, 422, 247, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH 7-[TRANS-4-(4- METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE (RESULTING FROM DISPLACEMENT OF SKF86002)
1876, 4b9dB, 0.7190, 2.87, 0.181, 295, 254, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
1877, 3psdA, 0.7190, 2.63, 0.227, 262, 251, NON-OXIME PYRAZOLE BASED INHIBITORS OF B-RAF KINASE
1878, 5wngC, 0.7189, 3.88, 0.164, 387, 275, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
1879, 5wneC, 0.7189, 3.84, 0.157, 384, 274, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
1880, 5vjaA, 0.7189, 2.83, 0.184, 266, 255, CRYSTAL STRUCTURE OF HUMAN ZIPPER-INTERACTING PROTEIN KINASE (ZIPK; ALIAS DAPK3) IN COMPLEX WITH A PYRAZOLO[3;4-D]PYRIMIDINONE LIGAND (HS38) 
1881, 5e8wA, 0.7189, 3.07, 0.154, 303, 259, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH STAUROSPORINE
1882, 5ar4B, 0.7189, 3.08, 0.209, 279, 258, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
1883, 4neuA, 0.7189, 3.25, 0.212, 286, 264, X-RAY STRUCTURE OF RECEPTOR INTERACTING PROTEIN 1 (RIP1)KINASE DOMAIN WITH A 1-AMINOISOQUINOLINE INHIBITOR
1884, 3c4xA, 0.7189, 4.02, 0.172, 496, 279, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.9A
1885, 1yrpB, 0.7189, 2.90, 0.187, 275, 256, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
1886, 1yrpA, 0.7189, 2.90, 0.187, 275, 256, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
1887, 5am7B, 0.7188, 3.02, 0.332, 287, 256, FGFR1 MUTANT WITH AN INHIBITOR
1888, 4jdhA, 0.7188, 3.21, 0.183, 289, 262, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
1889, 6fnkA, 0.7187, 3.23, 0.307, 274, 261, CRYSTAL STRUCTURE OF EPHRIN B4 (EPHB4) RECEPTOR PROTEIN KINASE WITH A PYRAZOLO[3;4-D]PYRIMIDINE FRAGMENT OF NVP-BHG712 
1890, 5izjA, 0.7187, 3.67, 0.183, 328, 273, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1411
1891, 5d7aB, 0.7187, 3.03, 0.168, 286, 256, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
1892, 4u80A, 0.7187, 3.27, 0.186, 286, 263, MEK 1 KINASE BOUND TO G799
1893, 4mneC, 0.7187, 2.65, 0.212, 260, 250, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1894, 4figA, 0.7187, 3.52, 0.184, 292, 266, CATALYTIC DOMAIN OF HUMAN PAK4
1895, 4appA, 0.7187, 3.49, 0.189, 291, 265, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH (S)-N-(5-(3-BENZYL-1-METHYLPIPERAZINE-4- CARBONYL)-66-DIMETHYL-1456-TETRAHYDROPYRROLO(34-C) PYRAZOL-3-YL)-3-PHENOXYBENZAMIDE
1896, 4anlA, 0.7187, 3.54, 0.267, 292, 266, STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE
1897, 2j0iA, 0.7187, 3.26, 0.172, 289, 262, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
1898, 5jrsA, 0.7186, 2.52, 0.320, 258, 247, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO -34-DIHYDROQUINAZOLIN-3-YL) PHENYL]-7-(2-HYDROXYPROPAN-2-Y L)-9H-CARBAZOLE-1-CARBOXAMIDE
1899, 5fbnC, 0.7186, 2.79, 0.296, 256, 253, BTK KINASE DOMAIN WITH INHIBITOR 1
1900, 4zsaB, 0.7186, 3.16, 0.322, 282, 258, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
1901, 3zfxG, 0.7186, 2.58, 0.316, 253, 250, CRYSTAL STRUCTURE OF EPHB1
1902, 3prfA, 0.7186, 2.58, 0.236, 262, 250, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
1903, 2jdoA, 0.7186, 3.46, 0.160, 314, 269, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
1904, 1fpuB, 0.7186, 2.87, 0.340, 270, 253, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
1905, 4m13A, 0.7185, 2.80, 0.321, 264, 252, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 8 [4- (CARBAMOYLAMINO)-1-(7-PROPOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE]
1906, 3kb7A, 0.7185, 3.29, 0.216, 289, 264, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
1907, 2yhvA, 0.7185, 3.55, 0.271, 291, 266, STRUCTURE OF L1196M MUTANT ANAPLASTIC LYMPHOMA KINASE
1908, 2xikA, 0.7185, 3.40, 0.242, 288, 265, STRUCTURE OF HUMAN YSK1 (YEAST SPS1-STE20-RELATED KINASE 1)
1909, 6fnhB, 0.7184, 3.31, 0.311, 271, 264, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH A PYRAZOLO[3;4-D]PYRIMIDINE FRAGMENT OF NVP-BHG712 
1910, 6babB, 0.7184, 3.04, 0.154, 285, 259, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1911, 5j5sB, 0.7184, 2.81, 0.289, 258, 253, SRC KINASE IN COMPLEX WITH A SULFONAMIDE INHIBITOR
1912, 5am6B, 0.7184, 3.07, 0.328, 280, 256, NATIVE FGFR1 WITH AN INHIBITOR
1913, 4nwmA, 0.7184, 2.65, 0.312, 261, 250, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-809959 AKA 4-TERT-BUTYL-N-[2-ME THYL-3-(6-{[4- (MORPHOLINE-4-CARBONYL)PHENYL]AMINO}-9H- PURIN-2-YL)PHENYL]BENZAMIDE
1914, 3zfxF, 0.7184, 2.61, 0.316, 254, 250, CRYSTAL STRUCTURE OF EPHB1
1915, 3ocbB, 0.7184, 3.64, 0.162, 319, 271, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
1916, 3mj2A, 0.7184, 2.50, 0.323, 259, 248, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH INHIBITOR BMS-509744
1917, 3gu8A, 0.7184, 2.97, 0.179, 278, 257, CRYSTAL STRUCTURE OF DAPKL93G WITH N6-CYCLOPENTYLADENOSINE
1918, 3gqlA, 0.7184, 3.45, 0.307, 287, 264, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
1919, 6dkwA, 0.7183, 3.03, 0.298, 284, 258, CRYSTAL STRUCTURE OF TRK-A IN COMPLEX WITH THE PAN-TRK KINASE INHIBITOR; COMPOUND 3. 
1920, 5ut5A, 0.7183, 2.71, 0.209, 272, 253, JAK2 JH2 IN COMPLEX WITH GLPG0634
1921, 5d7aC, 0.7183, 2.98, 0.172, 286, 256, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
1922, 4qmyA, 0.7183, 3.60, 0.228, 287, 268, MST3 IN COMPLEX WITH STAUROSPORINE
1923, 4ogrA, 0.7183, 3.30, 0.158, 314, 265, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
1924, 3psbA, 0.7183, 2.65, 0.227, 262, 251, FURO[23-C]PYRIDINE-BASED INDANONE OXIMES AS POTENT AND SELECTIVE B- RAF INHIBITORS
1925, 1zwsB, 0.7183, 3.06, 0.181, 278, 259, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
1926, 5nk1A, 0.7182, 3.23, 0.294, 284, 262, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1K
1927, 5dg5A, 0.7182, 3.14, 0.341, 297, 258, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP- 4157
1928, 4m0zA, 0.7182, 2.81, 0.321, 264, 252, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 5 {4- (CARBAMOYLAMINO)-1-(7-METHOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE}
1929, 4m0yA, 0.7181, 2.87, 0.313, 263, 252, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 1 [4- (CARBAMOYLAMINO)-1-(NAPHTHALEN-1-YL)-1H-PYRAZOLE-3-CARBOXAMIDE]
1930, 4asxB, 0.7181, 3.04, 0.171, 307, 258, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
1931, 3fzpA, 0.7181, 3.01, 0.305, 259, 256, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH ATPGS
1932, 3dgkA, 0.7181, 2.98, 0.179, 278, 257, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN
1933, 2bdfB, 0.7181, 3.06, 0.301, 265, 259, SRC KINASE IN COMPLEX WITH INHIBITOR AP23451
1934, 1pkgB, 0.7181, 2.74, 0.308, 277, 250, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
1935, 5uszA, 0.7180, 2.72, 0.209, 272, 253, JAK2 JH2 IN COMPLEX WITH JNJ-7706621
1936, 5ebzL, 0.7180, 3.64, 0.174, 655, 270, CRYSTAL STRUCTURE OF HUMAN IKK1
1937, 5e90A, 0.7180, 3.01, 0.163, 303, 258, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249F S280T Y282FS287NA350CL352F) IN COMPLEX WITH 3-AMINO-6- [4-(2- HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3-YL]PYRAZINE-2- CARBOXAMIDE
1938, 4mcvA, 0.7180, 3.25, 0.295, 267, 261, STAR 12 BOUND TO ANALOG-SENSITIVE SRC KINASE
1939, 1phkA, 0.7180, 2.94, 0.205, 277, 258, TWO STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHORYLASE KINASE: AN ACTIVE PROTEIN KINASE COMPLEXED WITH NUCLEOTIDE SUBSTRATE-ANALOGUE AND PRODUCT
1940, 4zk5A, 0.7179, 3.09, 0.181, 286, 259, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
1941, 4nwmB, 0.7179, 2.67, 0.308, 261, 250, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-809959 AKA 4-TERT-BUTYL-N-[2-ME THYL-3-(6-{[4- (MORPHOLINE-4-CARBONYL)PHENYL]AMINO}-9H- PURIN-2-YL)PHENYL]BENZAMIDE
1942, 3mv5A, 0.7179, 3.52, 0.164, 315, 269, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
1943, 3g6gA, 0.7179, 3.09, 0.302, 264, 258, EQUALLY POTENT INHIBITION OF C-SRC AND ABL BY COMPOUNDS THAT RECOGNIZE INACTIVE KINASE CONFORMATIONS
1944, 3f3uB, 0.7179, 2.98, 0.290, 259, 255, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL37 (TYPE III)
1945, 5nk2A, 0.7178, 3.42, 0.318, 290, 264, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2B
1946, 4or5F, 0.7178, 3.60, 0.152, 324, 269, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
1947, 4d5hB, 0.7178, 3.08, 0.349, 260, 255, FOCAL ADHESION KINASE CATALYTIC DOMAIN
1948, 4cmtA, 0.7178, 3.46, 0.261, 284, 264, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)-5-(3-(METHYLSULFONYL)PHENYL)PYRIDIN-2-AMINE
1949, 4bcfA, 0.7178, 3.28, 0.160, 307, 263, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1950, 3zlsA, 0.7178, 3.58, 0.186, 315, 269, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 6
1951, 3g5dA, 0.7178, 2.84, 0.304, 256, 253, KINASE DOMAIN OF CSRC IN COMPLEX WITH DASATINIB
1952, 6dkbA, 0.7177, 3.14, 0.300, 272, 260, CRYSTAL STRUCTURE OF TRK-A IN COMPLEX WITH THE PAN-TRK KINASE INHIBITOR; COMPOUND 10B. 
1953, 5ia3A, 0.7177, 3.19, 0.296, 275, 260, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH PD173955
1954, 4rfzA, 0.7177, 2.75, 0.310, 263, 252, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-8-FLUORO-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5- (MORPHOLINE-4-CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3- PYRIDYL]PHENYL]ISOQUINOLIN-1-ONE
1955, 4q9zB, 0.7177, 3.80, 0.164, 308, 274, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
1956, 4itjB, 0.7177, 3.17, 0.219, 276, 256, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-4
1957, 3gu6A, 0.7177, 2.98, 0.179, 280, 257, CRYSTAL STRUCTURE OF DAPKQ23V-ADP
1958, 2yn8B, 0.7177, 2.97, 0.293, 260, 256, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
1959, 2w4jA, 0.7177, 2.98, 0.179, 276, 257, X-RAY STRUCTURE OF A DAP-KINASE 2-277
1960, 2bdjA, 0.7177, 2.59, 0.293, 254, 249, SRC KINASE IN COMPLEX WITH INHIBITOR AP23464
1961, 5uzjA, 0.7176, 3.79, 0.150, 387, 273, CRYSTAL STRUCTURE OF ROCK1 BOUND TO AN AMINOPYRIDINE INHIBITOR
1962, 5ut1A, 0.7176, 2.64, 0.207, 272, 251, JAK2 JH2 IN COMPLEX WITH BI-D1870
1963, 5friA, 0.7176, 2.88, 0.161, 301, 255, ALK5 IN COMPLEX WITHA AN N-(4-ANILINO-2-PYRIDYL)ACETAMIDE INHIBITOR.
1964, 4nttB, 0.7176, 3.67, 0.175, 339, 274, STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE BOUND TO ADP AND ONE MAGNESIUM ION
1965, 4m15A, 0.7176, 2.77, 0.323, 263, 251, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 9 [4- (CARBAMOYLAMINO)-1-[7-(PROPAN-2-YLOXY)NAPHTHALEN-1-YL]-1H-PYRAZOLE-3- CARBOXAMIDE] AND ADP
1966, 3zosA, 0.7176, 2.93, 0.298, 301, 255, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
1967, 6b8yA, 0.7175, 3.12, 0.158, 304, 259, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH N-(3- FLUOROPYRIDIN-4-YL)-2-[6-(TRIFLUOROMETHYL)PYRIDIN-2-YL]-7H-PYRROLO[2 3-D]PYRIMIDIN-4-AMINE
1968, 5wnjA, 0.7175, 2.64, 0.251, 264, 251, CRYSTAL STRUCTURE OF MURINE RECEPTOR-INTERACTING PROTEIN KINASE 4 (RIPK4) D143N IN COMPLEX WITH LESTAURTINIB 
1969, 5veeA, 0.7175, 3.49, 0.174, 289, 265, PAK4 KINASE DOMAIN IN COMPLEX WITH FRAX486
1970, 5cwzA, 0.7175, 3.01, 0.172, 284, 256, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
1971, 4yvcA, 0.7175, 3.64, 0.159, 388, 270, ROCK 1 BOUND TO THIAZOLE INHIBITOR
1972, 3orxA, 0.7175, 3.29, 0.210, 283, 262, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1973, 5nkgA, 0.7174, 3.27, 0.321, 292, 262, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3D
1974, 3orxC, 0.7174, 3.29, 0.210, 283, 262, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1975, 1sm2A, 0.7174, 2.25, 0.311, 245, 244, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
1976, 5nkcA, 0.7173, 3.37, 0.299, 286, 264, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2H
1977, 5l2qB, 0.7173, 3.11, 0.138, 282, 260, SERINE/THREONINE-PROTEIN KINASE 40 (STK40) KINASE HOMOLOGY DOMAIN
1978, 5dh3B, 0.7173, 3.55, 0.225, 283, 267, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
1979, 4ot5A, 0.7173, 2.75, 0.310, 263, 252, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4-TERT-BUTYL-N- (3-{8-[4-(4-METHYL-PIPERAZINE-1-CARBONYL)-PHENYLAMINO]-IMIDAZO[12- A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
1980, 4m12A, 0.7173, 2.82, 0.321, 264, 252, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 7 [4- (CARBAMOYLAMINO)-1-(7-ETHOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE]
1981, 3gu5A, 0.7173, 2.99, 0.179, 280, 257, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP-MG2+
1982, 2rkuA, 0.7173, 3.33, 0.204, 294, 265, STRUCTURE OF PLK1 IN COMPLEX WITH BI2536
1983, 1ql6A, 0.7173, 3.07, 0.201, 281, 259, THE CATALYTIC MECHANISM OF PHOSPHORYLASE KINASE PROBED BY MUTATIONAL STUDIES
1984, 4nk9B, 0.7172, 3.29, 0.308, 282, 260, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
1985, 4ehgB, 0.7172, 2.63, 0.212, 260, 250, B-RAF KINASE DOMAIN IN COMPLEX WITH AN AMINOPYRIDIMINE-BASED INHIBITOR
1986, 4bchA, 0.7172, 3.40, 0.158, 308, 265, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1987, 4yhtA, 0.7171, 2.59, 0.217, 256, 249, BRAF COMPLEXED WITH AN INHIBITOR
1988, 4mneG, 0.7171, 2.47, 0.219, 259, 247, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
1989, 3zh8C, 0.7171, 3.25, 0.168, 312, 262, A NOVEL SMALL MOLECULE APKC INHIBITOR
1990, 3q4uA, 0.7171, 2.77, 0.198, 298, 252, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
1991, 3c51A, 0.7171, 3.91, 0.177, 487, 277, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 3.55A
1992, 3c4wA, 0.7171, 4.02, 0.173, 494, 278, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.7A
1993, 6fnjA, 0.7170, 2.91, 0.310, 262, 255, CRYSTAL STRUCTURE OF EPHRIN B4 (EPHB4) RECEPTOR PROTEIN KINASE WITH AN ISOMER OF NVP-BHG712 
1994, 6d1yA, 0.7170, 3.20, 0.305, 300, 259, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE RECEPTOR IN COMPLEX WITH 2;4-DICHLORO-N-(3-METHYL-1-PHENYL-1H-PYRAZOL-5-YL)BENZAMIDE INHIBITOR 
1995, 5grnA, 0.7170, 3.02, 0.297, 285, 256, CRYSTAL STRUCTURE OF PDGFRA IN COMPLEX WITH WQ-C-159
1996, 4ra5A, 0.7170, 3.72, 0.176, 332, 272, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
1997, 1rw8A, 0.7170, 3.00, 0.160, 301, 257, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH ATP SITE INHIBITOR
1998, 5swhB, 0.7169, 2.97, 0.282, 261, 255, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
1999, 5o4aB, 0.7169, 3.14, 0.310, 291, 258, HUMAN FGF IN COMPLEX WITH A COVALENT INHIBITOR
2000, 4x2fA, 0.7169, 3.03, 0.160, 303, 257, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
2001, 4d5kB, 0.7169, 2.88, 0.349, 256, 252, FOCAL ADHESION KINASE CATALYTIC DOMAIN
2002, 3en4A, 0.7169, 2.95, 0.286, 257, 255, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP121 A MULTITARGETED KINASE INHIBITOR
2003, 2phkA, 0.7169, 2.93, 0.191, 277, 257, THE CRYSTAL STRUCTURE OF A PHOSPHORYLASE KINASE PEPTIDE SUBSTRATE COMPLEX: KINASE SUBSTRATE RECOGNITION
2004, 2owbA, 0.7169, 3.36, 0.215, 294, 265, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
2005, 1r0pA, 0.7169, 3.43, 0.345, 301, 261, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH THE MICROBIAL ALKALOID K-252A
2006, 5htiA, 0.7168, 3.30, 0.340, 290, 259, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH LXM108
2007, 4mcvB, 0.7168, 3.29, 0.287, 265, 261, STAR 12 BOUND TO ANALOG-SENSITIVE SRC KINASE
2008, 4j53A, 0.7168, 3.35, 0.211, 293, 265, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH TAK-960
2009, 4apcA, 0.7168, 2.86, 0.178, 293, 253, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
2010, 6gt1B, 0.7167, 2.83, 0.194, 269, 253, NEK7 BOUND TO PURINE INHIBITOR 
2011, 5wnlA, 0.7166, 2.54, 0.257, 262, 249, CRYSTAL STRUCTURE OF MURINE RECEPTOR-INTERACTING PROTEIN 4 (RIPK4) D143N BOUND TO STAUROSPORINE 
2012, 5i9zA, 0.7166, 3.05, 0.306, 273, 258, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DANUSERTIB (PHA739358)
2013, 4yjuA, 0.7166, 3.04, 0.333, 262, 255, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000249
2014, 3nczC, 0.7166, 3.86, 0.150, 389, 274, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT 2H-ISOQUINOLIN-1-ONE INHIBITOR
2015, 3gu4A, 0.7166, 3.00, 0.179, 280, 257, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP
2016, 3g5dB, 0.7166, 2.90, 0.303, 257, 254, KINASE DOMAIN OF CSRC IN COMPLEX WITH DASATINIB
2017, 2bdwB, 0.7166, 3.48, 0.154, 309, 266, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
2018, 6gi6A, 0.7165, 2.74, 0.183, 298, 252, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH A QUINAZOLINONE BASED ALK2 INHIBITOR WITH A 5-METHYL CORE. 
2019, 5zv2A, 0.7165, 3.22, 0.308, 284, 260, FGFR-1 IN COMPLEX WITH LIGAND LENVATINIB 
2020, 5nk3A, 0.7165, 3.51, 0.303, 281, 267, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1L
2021, 5l1zA, 0.7165, 3.24, 0.160, 310, 262, TAR COMPLEX WITH HIV-1 TAT-AFF4-P-TEFB
2022, 4x2nA, 0.7165, 3.03, 0.160, 303, 257, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
2023, 4x2gA, 0.7165, 3.04, 0.160, 303, 257, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
2024, 3eqiA, 0.7165, 3.62, 0.190, 315, 268, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ADP AND MG2P
2025, 3efkB, 0.7165, 2.86, 0.337, 272, 249, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 50
2026, 2vx1A, 0.7165, 3.20, 0.292, 274, 260, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
2027, 1zwsA, 0.7165, 3.10, 0.181, 278, 259, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2028, 5sysA, 0.7164, 3.03, 0.289, 258, 256, C-SRC V281C BOUND TO N-[3-({6-[(1E)-2-CYANO-3-(METHYLAMINO)-3-OXOPROP- 1-EN-1-YL]-7-(2-METHOXYETHYL)-7H-PYRROLO[23-D]PYRIMIDIN-5- YL}ETHYNYL)-4-METHYLPHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE INHIBITOR
2029, 5j5sA, 0.7164, 2.99, 0.286, 258, 255, SRC KINASE IN COMPLEX WITH A SULFONAMIDE INHIBITOR
2030, 5b7vA, 0.7164, 3.04, 0.328, 282, 256, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
2031, 4ogrE, 0.7164, 3.23, 0.153, 310, 262, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
2032, 4knbB, 0.7164, 2.50, 0.344, 256, 244, C-MET IN COMPLEX WITH OSI LIGAND
2033, 3q53A, 0.7164, 3.36, 0.192, 291, 265, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN IN COMPLEX WITH ATP
2034, 3genA, 0.7164, 2.82, 0.306, 264, 252, THE 1.6 A CRYSTAL STRUCTURE OF HUMAN BRUTON S TYROSINE KINASE BOUND TO A PYRROLOPYRIMIDINE-CONTAINING COMPOUND
2035, 3fy2A, 0.7164, 3.41, 0.303, 285, 264, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION BOUND TO SUBSTRATE KQWDNYEFIW
2036, 3dfcB, 0.7164, 3.02, 0.179, 280, 257, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH AMPPNP
2037, 2evaA, 0.7164, 2.99, 0.240, 295, 254, STRUCTURAL BASIS FOR THE INTERACTION OF TAK1 KINASE WITH ITS ACTIVATING PROTEIN TAB1
2038, 5ebzJ, 0.7163, 3.70, 0.173, 655, 271, CRYSTAL STRUCTURE OF HUMAN IKK1
2039, 4uwyA, 0.7163, 3.07, 0.324, 296, 256, FGFR1 APO STRUCTURE
2040, 4pf4A, 0.7163, 3.01, 0.179, 278, 257, 1.1A X-RAY STRUCTURE OF THE APO CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE 1 AA 1-277
2041, 4m69A, 0.7163, 3.10, 0.191, 284, 256, CRYSTAL STRUCTURE OF THE MOUSE RIP3-MLKL COMPLEX
2042, 3t9tA, 0.7163, 2.79, 0.320, 263, 250, CRYSTAL STRUCTURE OF BTK MUTANT (F435TK596R) COMPLEXED WITH IMIDAZO[15-A]QUINOXALINE
2043, 3eqdA, 0.7163, 3.60, 0.190, 315, 268, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ATP-GS AND MG2P
2044, 2vx0A, 0.7163, 3.18, 0.300, 273, 260, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
2045, 2biyA, 0.7163, 3.47, 0.211, 287, 266, STRUCTURE OF PDK1-S241A MUTANT KINASE DOMAIN
2046, 6fnjB, 0.7162, 2.92, 0.310, 262, 255, CRYSTAL STRUCTURE OF EPHRIN B4 (EPHB4) RECEPTOR PROTEIN KINASE WITH AN ISOMER OF NVP-BHG712 
2047, 5nk4A, 0.7162, 3.35, 0.300, 290, 263, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2C
2048, 5kmjA, 0.7162, 3.14, 0.301, 300, 259, TRKA JM-KINASE WITH {N}-(2-PYRIDYLMETHYL)-2-[2-(2-THIENYL)INDOL-1- YL]ACETAMIDE
2049, 5e8sA, 0.7162, 2.91, 0.161, 301, 255, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (WT)
2050, 5a4cA, 0.7162, 3.24, 0.305, 294, 259, FGFR1 LIGAND COMPLEX
2051, 4q9zA, 0.7162, 3.66, 0.174, 331, 270, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
2052, 4l3pA, 0.7162, 2.85, 0.237, 295, 253, CRYSTAL STRUCTURE OF 2-(1-BENZOTHIOPHEN-7-YL)-4-[1-(PIPERIDIN-4-YL)- 1H-PYRAZOL-4-YL]FURO[23-C]PYRIDIN-7-AMINE BOUND TO TAK1-TAB1
2053, 3orxD, 0.7162, 3.25, 0.207, 282, 261, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2054, 5nkdA, 0.7161, 3.34, 0.300, 287, 263, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2I
2055, 5kmoA, 0.7161, 3.12, 0.295, 291, 258, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(2- PYRIDYL)UREA
2056, 4txcA, 0.7161, 2.98, 0.179, 276, 257, CRYSTAL STRUCTURE OF DAPK1 KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
2057, 3q4uD, 0.7161, 2.71, 0.179, 299, 251, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
2058, 3q4uC, 0.7161, 2.62, 0.180, 296, 250, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
2059, 2zvaA, 0.7161, 3.03, 0.314, 261, 258, LYN TYROSINE KINASE DOMAIN-DASATINIB COMPLEX
2060, 2wqbA, 0.7161, 3.12, 0.304, 289, 257, STRUCTURE OF THE TIE2 KINASE DOMAIN IN COMPLEX WITH A THIAZOLOPYRIMIDINE INHIBITOR
2061, 5usqA, 0.7160, 2.89, 0.161, 299, 255, ALK-5 KINASE INHIBITOR COMPLEX
2062, 5jsmC, 0.7160, 2.61, 0.224, 262, 250, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-3-VEM
2063, 4v01B, 0.7160, 3.06, 0.310, 275, 255, FGFR1 IN COMPLEX WITH PONATINIB (CO-CRYSTALLISATION).
2064, 3eqfA, 0.7160, 3.43, 0.189, 314, 265, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH K252A AND MG2P
2065, 1jklA, 0.7160, 3.01, 0.179, 280, 257, 1.6A X-RAY STRUCTURE OF BINARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE
2066, 4qmsA, 0.7159, 3.72, 0.227, 283, 269, MST3 IN COMPLEX WITH DASATINIB
2067, 4bcjA, 0.7159, 3.44, 0.155, 309, 265, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2068, 2ijmB, 0.7159, 3.16, 0.350, 261, 257, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
2069, 5zv2B, 0.7158, 3.38, 0.318, 282, 261, FGFR-1 IN COMPLEX WITH LIGAND LENVATINIB 
2070, 5ta8A, 0.7158, 3.32, 0.208, 294, 264, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR
2071, 5nk9A, 0.7158, 3.23, 0.295, 285, 261, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2E
2072, 4ithB, 0.7158, 2.85, 0.216, 270, 250, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-1 ANALOG
2073, 3uqgB, 0.7158, 2.91, 0.296, 257, 253, C-SRC KINASE DOMAIN IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
2074, 3i5nA, 0.7158, 3.21, 0.354, 280, 254, CRYSTAL STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR 13
2075, 3gu7A, 0.7158, 3.02, 0.179, 280, 257, CRYSTAL STRUCTURE OF DAPKQ23V-ADP-MG2+
2076, 3ccnA, 0.7158, 2.86, 0.352, 275, 250, X-RAY STRUCTURE OF C-MET WITH TRIAZOLOPYRIDAZINE INHIBITOR.
2077, 2hznA, 0.7158, 2.73, 0.340, 272, 250, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AFG210
2078, 2hk5A, 0.7158, 3.11, 0.302, 269, 258, HCK KINASE IN COMPLEX WITH LCK TARGETTED INHIBITOR PG-1009247
2079, 5ezrA, 0.7157, 3.59, 0.193, 803, 269, CRYSTAL STRUCTURE OF PVX_084705 BOUND TO COMPOUND
2080, 4rg0A, 0.7157, 2.77, 0.310, 263, 252, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-[8-FLUORO-2- [2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(4-METHYLPIPERAZIN-1-YL)-2- PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-1-OXO-34-DIHYDROISOQUINOLIN- 6-YL]-2-METHYL-PROPANENITRILE
2081, 4nk9A, 0.7157, 3.30, 0.308, 281, 260, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
2082, 2fb8A, 0.7157, 2.55, 0.225, 259, 249, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
2083, 1snuA, 0.7157, 2.28, 0.311, 245, 244, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
2084, 6d22A, 0.7156, 3.24, 0.309, 299, 262, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE RECEPTOR 
2085, 5nkfA, 0.7156, 3.31, 0.321, 291, 262, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3B
2086, 5ebzF, 0.7156, 3.72, 0.170, 655, 271, CRYSTAL STRUCTURE OF HUMAN IKK1
2087, 5av0A, 0.7156, 2.97, 0.180, 275, 256, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH 73 4 - TRIHYDROXYISOFLAVONE.
2088, 4g3cA, 0.7156, 3.14, 0.185, 315, 259, CRYSTAL STRUCTURE OF APO MURINE NF-KAPPAB INDUCING KINASE (NIK)
2089, 4fnwA, 0.7156, 3.64, 0.258, 304, 267, CRYSTAL STRUCTURE OF THE APO F1174L ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
2090, 3zbfA, 0.7156, 3.16, 0.324, 281, 259, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH CRIZOTINIB
2091, 3uqfA, 0.7156, 3.06, 0.296, 260, 257, C-SRC KINASE DOMAIN IN COMPLEX WITH BKI RM-1-89
2092, 3tz8B, 0.7156, 3.15, 0.291, 263, 258, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL104
2093, 1snuB, 0.7156, 2.07, 0.317, 241, 240, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
2094, 4zjiA, 0.7155, 2.97, 0.178, 278, 258, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
2095, 3f66A, 0.7155, 3.21, 0.345, 288, 258, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
2096, 5nk6A, 0.7154, 3.24, 0.295, 284, 261, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2D
2097, 5kmlA, 0.7154, 3.25, 0.292, 296, 260, TRKA JM-KINASE WITH 1-(5-METHYL-3-PHENYL-12-OXAZOL-4-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
2098, 5i9xA, 0.7154, 3.36, 0.293, 284, 263, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH BOSUTINIB (SKI-606)
2099, 5hq0A, 0.7154, 3.00, 0.182, 292, 258, TERNARY COMPLEX OF HUMAN PROTEINS CDK1 CYCLIN B AND CKS2 BOUND TO AN INHIBITOR
2100, 5e8zA, 0.7154, 3.06, 0.159, 303, 258, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 3- AMINO-6-[4-(2-HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3- YL]PYRAZINE-2-CARBOXAMIDE
2101, 4y72A, 0.7154, 3.00, 0.182, 292, 258, HUMAN CDK1/CYCLINB1/CKS2 WITH INHIBITOR
2102, 4u45A, 0.7154, 3.14, 0.185, 289, 260, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
2103, 4d4vA, 0.7154, 2.85, 0.353, 256, 252, FOCAL ADHESION KINASE CATALYTIC DOMAIN
2104, 4agcA, 0.7154, 3.25, 0.305, 304, 259, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-( 3-((E)-2-PYRIDIN-2-YL-VINYL)-1H-INDAZOL-6-YLSULFANYL)- BENZAMIDE)
2105, 3h9rA, 0.7154, 2.74, 0.190, 312, 252, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TYPE I ACTIVIN RECEPTOR (ACVR1) IN COMPLEX WITH FKBP12 AND DORSOMORPHIN
2106, 2vwyA, 0.7154, 3.27, 0.299, 274, 261, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
2107, 1j3hB, 0.7154, 3.54, 0.166, 327, 271, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
2108, 4x0mA, 0.7153, 3.05, 0.160, 303, 257, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
2109, 4mnfB, 0.7153, 2.57, 0.226, 257, 248, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
2110, 3oxzA, 0.7153, 2.85, 0.343, 268, 251, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN BOUND WITH A DFG-OUT INHIBITOR AP24534
2111, 5l2qA, 0.7152, 3.10, 0.147, 293, 259, SERINE/THREONINE-PROTEIN KINASE 40 (STK40) KINASE HOMOLOGY DOMAIN
2112, 4gv1A, 0.7152, 3.63, 0.163, 329, 270, PKB ALPHA IN COMPLEX WITH AZD5363
2113, 3vvhB, 0.7152, 3.39, 0.196, 290, 265, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
2114, 2wotA, 0.7152, 3.11, 0.159, 303, 258, ALK5 IN COMPLEX WITH 4-((56-DIMETHYL-2-(2-PYRIDYL)-3- PYRIDYL)OXY)-N-(345-TRIMETHOXYPHENYL)PYRIDIN-2-AMINE
2115, 1ig1A, 0.7152, 3.03, 0.179, 280, 257, 1.8A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MN.
2116, 5kmmA, 0.7151, 3.01, 0.300, 301, 257, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(1- NAPHTHYL)UREA
2117, 4ib5A, 0.7151, 3.13, 0.143, 331, 258, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
2118, 3ehaA, 0.7151, 3.08, 0.179, 279, 257, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH AMPPNP
2119, 5ut0A, 0.7150, 2.63, 0.208, 272, 250, JAK2 JH2 IN COMPLEX WITH AT9283
2120, 3mvhA, 0.7150, 3.57, 0.164, 311, 268, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
2121, 3fxxA, 0.7150, 3.46, 0.302, 288, 265, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION BOUND TO SUBSTRATE KQWDNYE[PTYR]IW
2122, 5j87C, 0.7149, 2.76, 0.308, 261, 250, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
2123, 5isoA, 0.7149, 2.97, 0.195, 453, 256, STRUCTURE OF FULL LENGTH HUMAN AMPK (NON-PHOSPHORYLATED AT T-LOOP) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A BENZIMIDAZOLE DERIVATIVE (991)
2124, 5av1A, 0.7149, 2.98, 0.180, 275, 256, CRYSTAL STRUCTURE OF DAPK1 IN THE PRESENCE OF BROMIDE IONS.
2125, 4zp5A, 0.7149, 3.08, 0.172, 284, 256, MAP4K4 IN COMPLEX WITH INHIBITOR
2126, 4yjtA, 0.7149, 3.24, 0.333, 268, 258, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000233
2127, 4xlvA, 0.7149, 3.23, 0.300, 307, 260, CRYSTAL STRUCTURE OF THE ACTIVATED INSULIN RECEPTOR TYROSINE KINASE DIMER
2128, 4gk4A, 0.7149, 3.31, 0.299, 275, 261, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 90
2129, 3f5gA, 0.7149, 2.98, 0.180, 279, 256, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH ADP AND MG2+
2130, 3eh9A, 0.7149, 2.99, 0.180, 278, 256, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH ADP
2131, 4u40A, 0.7148, 3.21, 0.177, 295, 260, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
2132, 4bggA, 0.7148, 2.66, 0.180, 296, 250, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
2133, 3mi9A, 0.7148, 3.62, 0.160, 328, 269, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB
2134, 3cp9A, 0.7148, 3.23, 0.309, 288, 256, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
2135, 1zwsE, 0.7148, 3.31, 0.180, 278, 261, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2136, 5vjaD, 0.7147, 2.68, 0.187, 261, 251, CRYSTAL STRUCTURE OF HUMAN ZIPPER-INTERACTING PROTEIN KINASE (ZIPK; ALIAS DAPK3) IN COMPLEX WITH A PYRAZOLO[3;4-D]PYRIMIDINONE LIGAND (HS38) 
2137, 5hesB, 0.7147, 2.63, 0.235, 278, 247, HUMAN LEUCINE ZIPPER- AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK MLT HCCS-4 MRK AZK MLTK) IN COMPLEX WITH VEMURAFENIB
2138, 5f0aA, 0.7147, 3.84, 0.191, 811, 272, CRYSTAL STRUCTURE OF PVX_084705 WITH BOUND 1-TERT-BUTYL-3-(3- CHLOROPHENOXY)-1H-PYRAZOLO[34-D]PYRIMIDIN-4-AMINE INHIBITOR
2139, 5ebzE, 0.7147, 3.76, 0.173, 655, 271, CRYSTAL STRUCTURE OF HUMAN IKK1
2140, 5b7vB, 0.7147, 3.16, 0.309, 277, 256, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
2141, 4qmxA, 0.7147, 3.55, 0.228, 287, 267, MST3 IN COMPLEX WITH SARACATINIB
2142, 4bggB, 0.7147, 2.65, 0.180, 293, 250, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
2143, 3zlxA, 0.7147, 3.63, 0.194, 312, 268, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 18
2144, 3v8tB, 0.7147, 2.11, 0.320, 244, 241, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 477
2145, 5ut6A, 0.7146, 2.62, 0.208, 272, 250, JAK2 JH2 IN COMPLEX WITH A DIAMINOPYRIMIDINE
2146, 5u6cB, 0.7146, 2.39, 0.353, 257, 241, CRYSTAL STRUCTURE OF THE MER KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
2147, 4qnaA, 0.7146, 3.67, 0.228, 284, 268, MST3 IN COMPLEX WITH 2-(46-DIAMINO-135-TRIAZIN-2-YL)PHENOL
2148, 4pmpA, 0.7146, 2.93, 0.308, 280, 253, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 1-CYCLOPROPYL-1- [3-(13-THIAZOL-2-YL)BENZYL]-3-[4-(TRIFLUOROMETHOXY)PHENYL]UREA
2149, 4mxcA, 0.7146, 3.21, 0.341, 290, 258, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
2150, 4m14A, 0.7146, 2.78, 0.320, 263, 250, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 9 [4- (CARBAMOYLAMINO)-1-[7-(PROPAN-2-YLOXY)NAPHTHALEN-1-YL]-1H-PYRAZOLE-3- CARBOXAMIDE]
2151, 4gcjA, 0.7146, 3.22, 0.178, 304, 258, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
2152, 4eklA, 0.7146, 3.63, 0.163, 329, 270, AKT1 WITH GDC0068
2153, 4d4vB, 0.7146, 2.87, 0.351, 255, 251, FOCAL ADHESION KINASE CATALYTIC DOMAIN
2154, 3vvhC, 0.7146, 3.20, 0.202, 283, 262, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
2155, 3orxB, 0.7146, 3.19, 0.208, 280, 259, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2156, 3mtfB, 0.7146, 2.82, 0.187, 298, 252, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH A 2- AMINOPYRIDINE INHIBITOR
2157, 2fb8B, 0.7146, 2.67, 0.224, 259, 250, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
2158, 5ut3A, 0.7145, 2.70, 0.207, 272, 251, JAK2 JH2 IN COMPLEX WITH IKK-2 INHIBITOR VI
2159, 5i9wA, 0.7145, 2.81, 0.320, 267, 253, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ANP
2160, 5ebzD, 0.7145, 3.72, 0.170, 655, 271, CRYSTAL STRUCTURE OF HUMAN IKK1
2161, 5cwzB, 0.7145, 2.97, 0.169, 284, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
2162, 4x2kA, 0.7145, 3.07, 0.160, 303, 257, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
2163, 4x2jA, 0.7145, 3.07, 0.160, 303, 257, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
2164, 3fzsA, 0.7145, 2.89, 0.343, 254, 254, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH BIRB796
2165, 1jksA, 0.7145, 3.03, 0.179, 280, 257, 1.5A X-RAY STRUCTURE OF APO FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
2166, 1jkkA, 0.7145, 3.05, 0.179, 277, 257, 2.4A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MG.
2167, 5oxgC, 0.7144, 2.87, 0.198, 301, 253, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
2168, 4nw5A, 0.7144, 3.25, 0.184, 302, 261, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 8
2169, 3zlyA, 0.7144, 3.60, 0.195, 310, 267, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 8
2170, 3cpcA, 0.7144, 3.14, 0.295, 284, 254, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
2171, 3c4cA, 0.7144, 2.55, 0.218, 258, 248, B-RAF KINASE IN COMPLEX WITH PLX4720
2172, 2e2bA, 0.7144, 2.67, 0.341, 270, 249, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH INNO-406
2173, 6cz3A, 0.7143, 2.80, 0.292, 262, 250, STRUCTURE OF THE PTK6 KINASE DOMAIN BOUND TO A TYPE I INHIBITOR (3- FLUORO-4-{[6-METHYL-3-(1H-PYRAZOL-4-YL)IMIDAZO[1;2-A]PYRAZIN-8- YL]AMINO}PHENYL)(MORPHOLIN-4-YL)METHANONE 
2174, 4yneA, 0.7143, 2.92, 0.302, 281, 255, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
2175, 4brxA, 0.7143, 3.13, 0.335, 259, 257, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH A DIARYLAMINO-135-TRIAZINE INHIBITOR
2176, 4b9dA, 0.7143, 2.90, 0.182, 290, 253, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
2177, 3rwqA, 0.7143, 3.34, 0.202, 283, 262, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
2178, 1agwA, 0.7143, 3.13, 0.324, 278, 256, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
2179, 5cenA, 0.7142, 2.88, 0.236, 281, 254, CRYSTAL STRUCTURE OF DLK (KINASE DOMAIN)
2180, 5av3A, 0.7142, 2.99, 0.180, 275, 256, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF IODIDE IONS.
2181, 4ybjB, 0.7142, 2.76, 0.291, 253, 251, TYPE II DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
2182, 3qklA, 0.7142, 3.55, 0.164, 317, 269, SPIROCHROMANE AKT INHIBITORS
2183, 3ndmA, 0.7142, 3.85, 0.165, 383, 272, CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT ISOQUINOLONE DERIVATIVE
2184, 2vwxA, 0.7142, 3.16, 0.293, 274, 259, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
2185, 4c8bA, 0.7141, 2.99, 0.206, 279, 253, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
2186, 3bu5A, 0.7141, 3.19, 0.295, 291, 258, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE AND ATP
2187, 2yakA, 0.7141, 3.02, 0.183, 277, 257, STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 (DAPK1) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OSV)
2188, 2pmlX, 0.7141, 3.91, 0.131, 340, 274, CRYSTAL STRUCTURE OF PFPK7 IN COMPLEX WITH AN ATP ANALOGUE
2189, 5ebzI, 0.7140, 3.77, 0.173, 655, 271, CRYSTAL STRUCTURE OF HUMAN IKK1
2190, 4ks7A, 0.7140, 3.45, 0.186, 286, 263, PAK6 KINASE DOMAIN IN COMPLEX WITH PF-3758309
2191, 3zlwA, 0.7140, 3.65, 0.190, 312, 268, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 3
2192, 3unkA, 0.7140, 3.13, 0.183, 295, 257, CDK2 IN COMPLEX WITH INHIBITOR YL5-083
2193, 3qkmA, 0.7140, 3.55, 0.164, 329, 269, SPIROCYCLIC SULFONAMIDES AS AKT INHIBITORS
2194, 5ebzH, 0.7139, 3.65, 0.167, 655, 270, CRYSTAL STRUCTURE OF HUMAN IKK1
2195, 4h58B, 0.7139, 2.73, 0.227, 262, 251, BRAF IN COMPLEX WITH COMPOUND 3
2196, 4bciA, 0.7139, 3.40, 0.155, 308, 264, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
2197, 3socB, 0.7139, 2.98, 0.185, 309, 254, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
2198, 3qkkA, 0.7139, 3.63, 0.163, 326, 270, SPIROCHROMANE AKT INHIBITORS
2199, 3lq5A, 0.7139, 3.41, 0.155, 307, 264, STRUCTURE OF CDK9/CYCLINT IN COMPLEX WITH S-CR8
2200, 3fztA, 0.7139, 3.02, 0.318, 259, 255, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-4618433
2201, 3aoxA, 0.7139, 3.55, 0.264, 298, 265, X-RAY CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CH5424802
2202, 1fgkA, 0.7139, 3.19, 0.327, 278, 257, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
2203, 6ccyA, 0.7138, 3.76, 0.161, 325, 273, CRYSTAL STRUCTURE OF AKT1 IN COMPLEX WITH A SELECTIVE INHIBITOR 
2204, 2vwzA, 0.7138, 3.29, 0.299, 274, 261, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
2205, 1jktB, 0.7138, 3.11, 0.178, 276, 258, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
2206, 4ntsB, 0.7137, 3.85, 0.167, 341, 276, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
2207, 4dceB, 0.7137, 3.36, 0.249, 284, 261, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH A PIPERIDINE-CARBOXAMIDE INHIBITOR
2208, 4cffC, 0.7137, 2.85, 0.197, 422, 254, STRUCTURE OF FULL LENGTH HUMAN AMPK IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A THIENOPYRIDONE DERIVATIVE (A-769662)
2209, 3g2fA, 0.7137, 2.90, 0.198, 302, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE II (BMPR2) AT 2.35 A RESOLUTION
2210, 2bdfA, 0.7137, 2.99, 0.297, 261, 256, SRC KINASE IN COMPLEX WITH INHIBITOR AP23451
2211, 1yomB, 0.7137, 2.94, 0.272, 261, 254, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH PURVALANOL A
2212, 1gngB, 0.7137, 3.38, 0.179, 355, 262, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
2213, 5nkbA, 0.7136, 3.25, 0.295, 285, 261, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4A
2214, 5hznE, 0.7136, 3.37, 0.309, 296, 259, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2215, 5ebzC, 0.7136, 3.78, 0.173, 655, 271, CRYSTAL STRUCTURE OF HUMAN IKK1
2216, 5bx0A, 0.7136, 3.54, 0.195, 315, 267, AN AUTOMATED MICROSCALE THERMOPHORESIS SCREENING APPROACH FOR FRAGMENT-BASED LEAD DISCOVERY
2217, 4nw6A, 0.7136, 3.26, 0.184, 302, 261, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 27
2218, 4gs6A, 0.7136, 2.92, 0.245, 294, 253, IRREVERSIBLE INHIBITION OF TAK1 KINASE BY 5Z-7-OXOZEAENOL
2219, 4fnxA, 0.7136, 3.59, 0.265, 292, 264, CRYSTAL STRUCTURE OF THE APO R1275Q ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
2220, 3t8oA, 0.7136, 4.12, 0.179, 493, 280, RHODOPSIN KINASE (GRK1) L166K MUTANT AT 2.5A RESOLUTION
2221, 3q4tA, 0.7136, 2.98, 0.169, 305, 255, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
2222, 3of0B, 0.7136, 2.70, 0.294, 251, 248, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN
2223, 3cqwA, 0.7136, 3.58, 0.164, 318, 269, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
2224, 2qu6A, 0.7136, 3.08, 0.308, 283, 253, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
2225, 5t18A, 0.7135, 2.74, 0.309, 261, 249, CRYSTAL STRUCTURE OF BRUTON AGAMMABULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-986142 AKA (2S)-6-FLUORO-5-[3-(8-FLUORO-1-METHYL-24-DIOXO- 1234-TETRAHYDROQUINAZOLIN-3-YL)-2-METHYLPHENYL]-2-(2- HYDROXYPROPAN-2-YL)-2349-TETRAHYDRO-1H-CARBAZOLE-8-CARBOXAMIDE
2226, 5njzA, 0.7135, 3.07, 0.298, 273, 258, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1G
2227, 5auxA, 0.7135, 3.00, 0.180, 275, 256, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH KAEMPFEROL.
2228, 4zhxC, 0.7135, 2.85, 0.197, 452, 254, NOVEL BINDING SITE FOR ALLOSTERIC ACTIVATION OF AMPK
2229, 3miaA, 0.7135, 3.70, 0.148, 324, 270, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH ATP-BOUND HUMAN P-TEFB
2230, 5uabA, 0.7134, 2.88, 0.353, 288, 249, MET TYROSINE KINASE INHIBITION ENHANCES THE ANTITUMOR EFFICACY OF AN HGF ANTIBODY
2231, 4ks8A, 0.7134, 3.32, 0.188, 286, 261, PAK6 KINASE DOMAIN IN COMPLEX WITH SUNITINIB
2232, 4gk3A, 0.7134, 3.29, 0.300, 275, 260, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 87
2233, 4g3eA, 0.7134, 3.23, 0.185, 314, 260, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO A 6-ALKYNYLINDOLINE (CMP1)
2234, 4cfeA, 0.7134, 2.85, 0.197, 425, 254, STRUCTURE OF FULL LENGTH HUMAN AMPK IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A BENZIMIDAZOLE DERIVATIVE (991)
2235, 3qlgA, 0.7134, 3.12, 0.284, 259, 257, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH DASATINIB
2236, 3f5uA, 0.7134, 3.02, 0.180, 279, 256, CRYSTAL STRUCTURE OF THE DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH AMPPNP AND MG2+
2237, 5hznA, 0.7133, 3.37, 0.309, 296, 259, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2238, 5auvA, 0.7133, 3.00, 0.180, 275, 256, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH APIGENIN.
2239, 4yjsA, 0.7133, 2.94, 0.355, 257, 251, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000226
2240, 4aojA, 0.7133, 2.91, 0.312, 260, 253, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
2241, 3rhxB, 0.7133, 3.16, 0.332, 275, 256, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
2242, 3o7lD, 0.7133, 3.81, 0.175, 333, 275, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
2243, 1py5A, 0.7133, 3.12, 0.163, 301, 258, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH INHIBITOR
2244, 6es0A, 0.7132, 3.58, 0.223, 288, 264, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE ACTIVATION LOOP TARGETING INHIBITOR CS-R35
2245, 5av2A, 0.7132, 3.01, 0.180, 275, 256, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF BROMIDE IONS.
2246, 4obpA, 0.7132, 3.19, 0.185, 285, 259, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 29) 6-(2-FLUOROPYRIDIN-4- YL)PYRIDO[32-D]PYRIMIDIN-4-AMINE
2247, 4gg7A, 0.7132, 3.34, 0.353, 278, 258, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
2248, 4dn5A, 0.7132, 3.27, 0.218, 331, 261, CRYSTAL STRUCTURE OF NF-KB-INDUCING KINASE (NIK)
2249, 4dglD, 0.7132, 3.17, 0.147, 328, 258, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
2250, 2pmnX, 0.7132, 3.66, 0.133, 340, 270, CRYSTAL STRUCTURE OF PFPK7 IN COMPLEX WITH AN ATP-SITE INHIBITOR
2251, 1iepB, 0.7132, 2.79, 0.340, 274, 250, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.
2252, 4pp9B, 0.7131, 2.38, 0.306, 247, 245, ITK KINASE DOMAIN WITH COMPOUND 1 (N-[1-(3-CYANOBENZYL)-1H-PYRAZOL-4- YL]-2H-INDAZOLE-3-CARBOXAMIDE)
2253, 3os3A, 0.7131, 3.10, 0.194, 272, 258, MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH CH4858061 AND MGATP
2254, 5ia0A, 0.7130, 3.17, 0.302, 263, 258, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
2255, 5ar4A, 0.7130, 2.93, 0.224, 274, 254, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
2256, 1tkiB, 0.7130, 3.71, 0.130, 321, 270, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
2257, 1tkiA, 0.7130, 3.71, 0.130, 321, 270, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
2258, 5ebzK, 0.7129, 3.79, 0.173, 655, 271, CRYSTAL STRUCTURE OF HUMAN IKK1
2259, 5ebzB, 0.7129, 3.77, 0.173, 655, 271, CRYSTAL STRUCTURE OF HUMAN IKK1
2260, 4rewA, 0.7129, 3.08, 0.206, 411, 257, CRYSTAL STRUCTURE OF THE NON-PHOSPHORYLATED HUMAN ALPHA1 BETA2 GAMMA1 HOLO-AMPK COMPLEX
2261, 4ludA, 0.7129, 2.66, 0.297, 421, 246, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
2262, 4gt5A, 0.7129, 3.19, 0.304, 290, 260, CRYSTAL STRUCTURE OF THE INACTIVE TRKA KINASE DOMAIN
2263, 4d5kA, 0.7129, 2.86, 0.347, 255, 251, FOCAL ADHESION KINASE CATALYTIC DOMAIN
2264, 4d4yA, 0.7129, 2.86, 0.347, 255, 251, FOCAL ADHESION KINASE CATALYTIC DOMAIN
2265, 4cffA, 0.7129, 2.90, 0.204, 424, 255, STRUCTURE OF FULL LENGTH HUMAN AMPK IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A THIENOPYRIDONE DERIVATIVE (A-769662)
2266, 2pmoX, 0.7129, 3.70, 0.137, 340, 271, CRYSTAL STRUCTURE OF PFPK7 IN COMPLEX WITH HYMENIALDISINE
2267, 5di1A, 0.7128, 3.27, 0.167, 285, 258, MAP4K4 IN COMPLEX WITH AN INHIBITOR
2268, 3qhwC, 0.7128, 3.22, 0.165, 297, 260, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
2269, 3ocbA, 0.7128, 3.74, 0.166, 315, 271, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
2270, 6gipA, 0.7127, 2.73, 0.175, 296, 251, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH A QUINAZOLINONE BASED ALK2 INHIBITOR WITH A 2; 5-DIMETHYL CORE. 
2271, 6b1uC, 0.7127, 2.85, 0.197, 459, 254, STRUCTURE OF FULL-LENGTH HUMAN AMPK (A2B1G1) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR SC4 
2272, 5wnkA, 0.7127, 2.73, 0.259, 263, 251, CRYSTAL STRUCTURE OF MURINE RECEPTOR-INTERACTING PROTEIN 4 (RIPK4) D143N BOUND TO TG100-115 
2273, 5j95A, 0.7127, 3.10, 0.172, 284, 256, MAP4K4 IN COMPLEX WITH INHIBITOR
2274, 5hznF, 0.7127, 3.34, 0.302, 296, 258, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2275, 4qmzA, 0.7127, 3.59, 0.228, 286, 267, MST3 IN COMPLEX WITH SUNITINIB
2276, 3dtwA, 0.7127, 3.28, 0.284, 288, 257, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZISOXAZOLE INHIBITOR
2277, 2y4iC, 0.7127, 3.73, 0.190, 313, 269, KSR2-MEK1 HETERODIMER
2278, 2p0cA, 0.7127, 2.43, 0.358, 249, 240, CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER
2279, 2etmA, 0.7127, 3.23, 0.345, 262, 258, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
2280, 5lihB, 0.7126, 3.27, 0.169, 318, 260, STRUCTURE OF A PEPTIDE-SUBSTRATE BOUND TO PKCIOTA CORE KINASE DOMAIN
2281, 5jgbA, 0.7126, 2.92, 0.245, 295, 253, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 10
2282, 5hznB, 0.7126, 3.34, 0.302, 296, 258, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2283, 5auwA, 0.7126, 2.97, 0.184, 274, 255, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH QUERCETIN.
2284, 4gg5A, 0.7126, 3.25, 0.349, 274, 255, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
2285, 4cfeC, 0.7126, 2.90, 0.204, 403, 255, STRUCTURE OF FULL LENGTH HUMAN AMPK IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A BENZIMIDAZOLE DERIVATIVE (991)
2286, 3vn9A, 0.7126, 3.71, 0.190, 291, 268, RIFINED CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED MAP2K6 IN A PUTATIVE AUTO-INHIBITION STATE
2287, 3v5lD, 0.7126, 2.27, 0.305, 246, 243, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
2288, 3qhwA, 0.7126, 3.23, 0.165, 297, 260, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
2289, 5hznG, 0.7125, 3.32, 0.302, 296, 258, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2290, 5hznC, 0.7125, 3.32, 0.302, 296, 258, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2291, 5fg8A, 0.7125, 3.05, 0.163, 269, 257, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
2292, 5auyA, 0.7125, 3.02, 0.180, 275, 256, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH MORIN.
2293, 4zjiB, 0.7125, 2.93, 0.203, 276, 256, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
2294, 4asxA, 0.7125, 3.09, 0.180, 310, 255, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
2295, 3warA, 0.7125, 3.17, 0.143, 334, 258, CRYSTAL STRUCTURE OF HUMAN CK2A
2296, 1agwB, 0.7125, 3.17, 0.332, 272, 256, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
2297, 6cz2A, 0.7124, 2.89, 0.292, 261, 250, STRUCTURE OF THE PTK6 KINASE DOMAIN 
2298, 5uhnB, 0.7124, 3.05, 0.336, 269, 253, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A N549H/E565A DOUBLE GAIN-OF-FUNCTION MUTATION
2299, 4ra5B, 0.7124, 3.55, 0.169, 310, 267, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
2300, 3vvhA, 0.7124, 3.46, 0.186, 287, 264, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
2301, 3gvuA, 0.7124, 2.69, 0.345, 271, 249, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH GLEEVEC
2302, 3a7iA, 0.7124, 3.59, 0.228, 286, 267, HUMAN MST3 KINASE IN COMPLEX WITH ADENINE
2303, 5av4A, 0.7123, 2.98, 0.180, 274, 255, CRYSTAL STRUCTURE OF DAPK1-GENISTEIN COMPLEX IN THE PRESENCE OF BROMIDE IONS.
2304, 4qmnA, 0.7123, 3.69, 0.228, 283, 268, MST3 IN COMPLEX WITH BOSUTINIB
2305, 4c7tA, 0.7123, 3.14, 0.344, 259, 256, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH A DIARYLAMINO-135-TRIAZINE INHIBITOR
2306, 4b6lA, 0.7123, 3.50, 0.169, 281, 266, DISCOVERY OF ORAL POLO-LIKE KINASE (PLK) INHIBITORS WITH ENHANCED SELECTIVITY PROFILE USING RESIDUE TARGETED DRUG DESIGN
2307, 3qruA, 0.7123, 2.98, 0.181, 295, 254, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-12
2308, 2fgiA, 0.7123, 3.09, 0.325, 274, 255, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
2309, 5m56A, 0.7122, 3.15, 0.120, 331, 258, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
2310, 5ia0B, 0.7122, 3.19, 0.308, 266, 260, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
2311, 5ezvC, 0.7122, 2.87, 0.197, 440, 254, X-RAY CRYSTAL STRUCTURE OF AMP-ACTIVATED PROTEIN KINASE ALPHA-2/ALPHA- 1 RIM CHIMAERA (ALPHA-2(1-347)/ALPHA-1(349-401)/ALPHA-2(397-END) BETA-1 GAMMA-1) CO-CRYSTALLIZED WITH C2 (5-(5-HYDROXYL-ISOXAZOL-3- YL)-FURAN-2-PHOSPHONIC ACID)
2312, 5ebzA, 0.7122, 3.79, 0.170, 655, 271, CRYSTAL STRUCTURE OF HUMAN IKK1
2313, 4o0tA, 0.7122, 3.68, 0.187, 292, 268, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
2314, 4mneE, 0.7122, 3.43, 0.186, 286, 263, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
2315, 3ow4B, 0.7122, 3.60, 0.164, 317, 269, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
2316, 3ornA, 0.7122, 3.27, 0.190, 280, 263, MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH CH4987655 AND MGAMP-PNP
2317, 3of0A, 0.7122, 3.00, 0.290, 260, 255, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN
2318, 2yjsA, 0.7122, 3.62, 0.265, 286, 264, STRUCTURE OF C1156Y MUTANT ANAPLASTIC LYMPHOMA KINASE
2319, 5oxgB, 0.7121, 2.70, 0.180, 296, 250, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
2320, 4d58A, 0.7121, 2.83, 0.336, 255, 250, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
2321, 3qtwA, 0.7121, 2.96, 0.177, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR RC-2-13
2322, 3lm0A, 0.7121, 2.95, 0.181, 278, 254, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B)
2323, 2pl0A, 0.7121, 2.72, 0.289, 268, 249, LCK BOUND TO IMATINIB
2324, 4f64A, 0.7120, 3.18, 0.324, 278, 256, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
2325, 4dceA, 0.7120, 3.54, 0.262, 288, 263, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH A PIPERIDINE-CARBOXAMIDE INHIBITOR
2326, 4dawA, 0.7120, 3.39, 0.192, 293, 265, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH THE RUTHENIUM PHTHALIMIDE COMPLEX
2327, 1s9iB, 0.7120, 3.49, 0.216, 291, 264, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP
2328, 5kwhB, 0.7119, 3.18, 0.147, 331, 258, CRYSTAL STRUCTURE OF CK2
2329, 5jgaA, 0.7119, 3.01, 0.260, 296, 254, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 11C
2330, 5ia1A, 0.7119, 2.90, 0.298, 261, 255, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH MLN8054
2331, 5h9bA, 0.7119, 3.02, 0.168, 269, 256, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/AMPPN
2332, 4ueuA, 0.7119, 2.87, 0.337, 256, 252, TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL
2333, 3qtxA, 0.7119, 3.05, 0.180, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR RC-2-35
2334, 3d7tB, 0.7119, 3.28, 0.297, 265, 259, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
2335, 2jkkA, 0.7119, 3.08, 0.341, 258, 255, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
2336, 1sm2B, 0.7119, 2.15, 0.317, 241, 240, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED INTERLEUKIN-2 TYROSINE KINASE CATALYTIC DOMAIN
2337, 6gt1A, 0.7118, 2.90, 0.194, 267, 253, NEK7 BOUND TO PURINE INHIBITOR 
2338, 5ku8B, 0.7118, 3.18, 0.143, 331, 258, CRYSTAL STRUCTURE OF CK2
2339, 5h8eB, 0.7118, 3.18, 0.143, 331, 258, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
2340, 4f63A, 0.7118, 3.23, 0.327, 278, 257, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 1
2341, 3vheA, 0.7118, 3.22, 0.306, 303, 258, CRYSTAL STRUCTURE OF HUMAN VEGFR2 KINASE DOMAIN WITH A NOVEL PYRROLOPYRIMIDINE INHIBITOR.
2342, 3q9xB, 0.7118, 3.18, 0.147, 330, 258, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
2343, 3q4tB, 0.7118, 3.14, 0.172, 308, 256, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
2344, 3py0A, 0.7118, 3.04, 0.188, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR SU9516
2345, 3pxyA, 0.7118, 2.98, 0.181, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR JWS648
2346, 3my0M, 0.7118, 3.08, 0.167, 298, 257, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2347, 2exmA, 0.7118, 3.24, 0.178, 298, 258, HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE
2348, 1fgkB, 0.7118, 3.18, 0.332, 272, 256, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
2349, 5kmiA, 0.7117, 2.97, 0.302, 300, 255, TRKA JM-KINASE WITH 1-(9{H}-FLUOREN-9-YL)-3-(2-METHYL-4-PHENYL- PYRIMIDIN-5-YL)UREA
2350, 5ebzG, 0.7117, 3.69, 0.167, 655, 270, CRYSTAL STRUCTURE OF HUMAN IKK1
2351, 4v01A, 0.7117, 3.09, 0.311, 273, 254, FGFR1 IN COMPLEX WITH PONATINIB (CO-CRYSTALLISATION).
2352, 4dn5B, 0.7117, 3.31, 0.218, 330, 261, CRYSTAL STRUCTURE OF NF-KB-INDUCING KINASE (NIK)
2353, 4agwA, 0.7117, 2.94, 0.287, 258, 254, DISCOVERY OF A SMALL MOLECULE TYPE II INHIBITOR OF WILD- TYPE AND GATEKEEPER MUTANTS OF BCR-ABL PDGFRALPHA KIT AND SRC KINASES
2354, 3qhrC, 0.7117, 3.29, 0.161, 297, 261, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
2355, 3qhrA, 0.7117, 3.29, 0.161, 297, 261, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
2356, 2xh5A, 0.7117, 3.57, 0.160, 316, 269, STRUCTURE OF 4-(4-TERT-BUTYLBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDIN-4-AMINE BOUND TO PKB
2357, 6fnmA, 0.7116, 3.21, 0.297, 270, 259, CRYSTAL STRUCTURE OF EPHRIN B4 (EPHB4) RECEPTOR PROTEIN KINASE WITH DASATINIB 
2358, 5tehA, 0.7116, 2.99, 0.278, 261, 255, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-156
2359, 5isoC, 0.7116, 2.98, 0.203, 429, 256, STRUCTURE OF FULL LENGTH HUMAN AMPK (NON-PHOSPHORYLATED AT T-LOOP) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A BENZIMIDAZOLE DERIVATIVE (991)
2360, 5h8bB, 0.7116, 3.19, 0.147, 331, 258, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
2361, 4ypsA, 0.7116, 2.84, 0.303, 280, 251, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
2362, 4qmuA, 0.7116, 3.56, 0.229, 286, 266, MST3 IN COMPLEX WITH JNJ-7706621 4-({5-AMINO-1-[(26-DIFLUOROPHENYL) CARBONYL]-1H-124-TRIAZOL-3-YL}AMINO)BENZENESULFONAMIDE
2363, 4otgA, 0.7116, 3.79, 0.174, 322, 270, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH LESTAURTINIB
2364, 3r9dA, 0.7116, 3.02, 0.181, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR RC-2-135
2365, 4g9cB, 0.7115, 2.88, 0.218, 264, 252, HUMAN B-RAF KINASE DOMAIN BOUND TO A TYPE II PYRAZOLOPYRIDINE INHIBITOR
2366, 4fx3C, 0.7115, 3.18, 0.165, 298, 260, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
2367, 4fx3A, 0.7115, 3.23, 0.165, 298, 261, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
2368, 3u9cA, 0.7115, 3.19, 0.143, 331, 258, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
2369, 3u6jA, 0.7115, 3.59, 0.303, 308, 264, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLONE INHIBITOR
2370, 3qqkA, 0.7115, 2.95, 0.182, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR L4
2371, 3f3vB, 0.7115, 3.17, 0.292, 262, 257, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
2372, 1pxnA, 0.7115, 2.98, 0.181, 294, 254, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-[4-(4-METHYL-2-METHYLAMINO-THIAZOL-5-YL)- PYRIMIDIN-2-YLAMINO]-PHENOL
2373, 1bygA, 0.7115, 2.30, 0.309, 246, 243, KINASE DOMAIN OF HUMAN C-TERMINAL SRC KINASE (CSK) IN COMPLEX WITH INHIBITOR STAUROSPORINE
2374, 5fm2A, 0.7114, 3.16, 0.333, 273, 255, CRYSTAL STRUCTURE OF HYPER-PHOSPHORYLATED RET KINASE DOMAIN WITH (PROXIMAL) JUXTAMEMBRANE SEGMENT
2375, 5dh3A, 0.7114, 3.48, 0.226, 287, 266, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
2376, 4pmsA, 0.7114, 3.00, 0.303, 283, 254, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 4-NAPHTHALEN-1-YL- 1-[(5-PHENYL-124-OXADIAZOL-3-YL)METHYL]-1H-PYRROLO[32-C]PYRIDINE- 2-CARBOXYLIC ACID
2377, 3vw8A, 0.7114, 3.35, 0.341, 303, 258, CRYSTAL STRUCTURE OF HUMAN C-MET KINASE DOMAIN WITH ITS INHIBITOR
2378, 3rpvA, 0.7114, 3.00, 0.181, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR RC-2-88
2379, 1uvrA, 0.7114, 3.38, 0.202, 284, 262, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-8
2380, 1pf8A, 0.7114, 3.26, 0.178, 298, 258, CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH A NUCLEOSIDE INHIBITOR
2381, 5swhA, 0.7113, 2.92, 0.295, 258, 254, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
2382, 4jnwA, 0.7113, 3.66, 0.126, 320, 269, BACTERIALLY EXPRESSED TITIN KINASE
2383, 4g2fA, 0.7113, 3.28, 0.301, 275, 259, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH COMPOUND 7
2384, 3qtzA, 0.7113, 3.06, 0.176, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR RC-2-36
2385, 3ag9B, 0.7113, 3.41, 0.181, 317, 265, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
2386, 3a7fA, 0.7113, 3.49, 0.223, 283, 265, HUMAN MST3 KINASE
2387, 5izjB, 0.7112, 3.64, 0.181, 325, 270, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1411
2388, 4xv9A, 0.7112, 2.76, 0.229, 261, 249, B-RAF KINASE DOMAIN IN COMPLEX WITH PLX5568
2389, 4md7F, 0.7112, 3.20, 0.147, 332, 258, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
2390, 3qqgA, 0.7112, 3.04, 0.180, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR L2-5
2391, 3hngA, 0.7112, 3.12, 0.327, 288, 254, CRYSTAL STRUCTURE OF VEGFR1 IN COMPLEX WITH N-(4-CHLOROPHENYL)-2- ((PYRIDIN-4-YLMETHYL)AMINO)BENZAMIDE
2392, 3d7uB, 0.7112, 2.99, 0.276, 258, 254, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
2393, 3at3A, 0.7112, 3.14, 0.144, 332, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVATIVE
2394, 1h1wA, 0.7112, 3.22, 0.204, 284, 260, HIGH RESOLUTION CRYSTAL STRUCTURE OF THE HUMAN PDK1 CATALYTIC DOMAIN
2395, 1fvvA, 0.7112, 3.22, 0.157, 298, 261, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
2396, 5h8eA, 0.7111, 3.20, 0.147, 331, 258, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
2397, 4d5hA, 0.7111, 2.89, 0.339, 255, 251, FOCAL ADHESION KINASE CATALYTIC DOMAIN
2398, 2xmyA, 0.7111, 3.06, 0.180, 295, 255, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
2399, 1vjyA, 0.7111, 2.94, 0.157, 299, 254, CRYSTAL STRUCTURE OF A NAPHTHYRIDINE INHIBITOR OF HUMAN TGF- BETA TYPE I RECEPTOR
2400, 5oxgA, 0.7110, 2.73, 0.180, 293, 250, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
2401, 4mnfA, 0.7110, 2.50, 0.232, 257, 246, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
2402, 4md7H, 0.7110, 3.20, 0.147, 330, 258, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
2403, 3wowA, 0.7110, 3.24, 0.151, 334, 259, CRYSTAL STRUCTURE OF HUMAN CK2A WITH AMPPNP
2404, 3g6hB, 0.7110, 3.15, 0.288, 259, 257, SRC THR338ILE INHIBITED IN THE DFG-ASP-OUT CONFORMATION
2405, 1szmA, 0.7110, 3.41, 0.177, 317, 265, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
2406, 4xg8C, 0.7109, 2.81, 0.353, 254, 249, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
2407, 4ubaA, 0.7109, 3.11, 0.144, 333, 257, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
2408, 4ixpA, 0.7109, 3.32, 0.188, 334, 261, CRYSTAL STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK)
2409, 3u9cB, 0.7109, 3.12, 0.148, 331, 257, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
2410, 2xnbA, 0.7109, 3.11, 0.176, 296, 256, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
2411, 6c3eA, 0.7108, 2.64, 0.215, 258, 246, CRYSTAL STRUCTURE OF RIP1 KINASE BOUND TO INHIBITOR
2412, 5ax9C, 0.7108, 2.98, 0.185, 282, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
2413, 5auzA, 0.7108, 3.00, 0.180, 274, 255, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH GENISTEIN.
2414, 4u3yB, 0.7108, 3.58, 0.166, 300, 265, APO MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4)
2415, 4euuA, 0.7108, 3.08, 0.167, 307, 258, STRUCTURE OF BX-795 COMPLEXED WITH HUMAN TBK1 KINASE DOMAIN PHOSPHORYLATED ON SER172
2416, 3unjA, 0.7108, 3.00, 0.185, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR YL1-038-31
2417, 3qtuA, 0.7108, 3.00, 0.181, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR RC-2-132
2418, 2x4zA, 0.7108, 3.52, 0.182, 290, 264, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH PF-03758309
2419, 1xo2B, 0.7108, 3.15, 0.163, 289, 258, CRYSTAL STRUCTURE OF A HUMAN CYCLIN-DEPENDENT KINASE 6 COMPLEX WITH A FLAVONOL INHIBITOR FISETIN
2420, 1h1pC, 0.7108, 3.36, 0.161, 296, 261, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
2421, 3rk5A, 0.7107, 3.01, 0.181, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR RC-2-72
2422, 3my0A, 0.7107, 3.06, 0.168, 296, 256, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2423, 6b1uA, 0.7106, 2.96, 0.204, 441, 255, STRUCTURE OF FULL-LENGTH HUMAN AMPK (A2B1G1) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR SC4 
2424, 5o26B, 0.7106, 3.00, 0.209, 265, 253, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A DIPHOSPHORYLATED STATE AND IN COMPLEX WITH AMP-PNP/MG2+
2425, 4xcuA, 0.7106, 3.42, 0.326, 288, 261, CRYSTAL STRUCTURE OF FGFR4 WITH AN IRREVERSIBLE INHIBITOR
2426, 3uo5A, 0.7106, 3.20, 0.181, 267, 260, AURORA A IN COMPLEX WITH YL1-038-31
2427, 3oomA, 0.7106, 2.91, 0.174, 297, 253, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH THE IMIDAZO[12-B]PYRIDAZINE INHIBITOR K00507
2428, 2wxvA, 0.7106, 3.50, 0.158, 302, 265, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
2429, 5oy6B, 0.7105, 2.76, 0.180, 292, 250, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
2430, 4wsqB, 0.7105, 2.85, 0.143, 310, 251, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2431, 4md7G, 0.7105, 3.20, 0.147, 332, 258, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
2432, 3ow4A, 0.7105, 3.65, 0.167, 317, 270, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
2433, 3at4A, 0.7105, 3.20, 0.147, 331, 258, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVERTIVE
2434, 2ou7A, 0.7105, 3.39, 0.205, 292, 264, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
2435, 5osdA, 0.7104, 3.14, 0.182, 266, 258, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2436, 5lxmA, 0.7104, 3.02, 0.184, 266, 255, CRYSTAL STRUCTURE OF AURORA-A BOUND TO A HYDROCARBON-STAPLED PROTEOMIMETIC OF TPX2
2437, 5jgdA, 0.7104, 3.03, 0.256, 295, 254, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 12
2438, 5h8bA, 0.7104, 3.20, 0.147, 331, 258, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
2439, 5dykA, 0.7104, 3.86, 0.196, 809, 271, CRYSTAL STRUCTURE OF PF3D7_1436600
2440, 5d11B, 0.7104, 2.77, 0.312, 255, 250, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL235
2441, 4r1yA, 0.7104, 2.75, 0.350, 265, 246, IDENTIFICATION AND OPTIMIZATION OF PYRIDAZINONES AS POTENT AND SELECTIVE C-MET KINASE INHIBITOR
2442, 4kwpA, 0.7104, 3.19, 0.147, 329, 258, CRYSTAL STRUCTURE OF HUMAN CK2-ALPHA IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR (K164) AT 1.25 A RESOLUTION
2443, 4euuB, 0.7104, 3.10, 0.171, 307, 258, STRUCTURE OF BX-795 COMPLEXED WITH HUMAN TBK1 KINASE DOMAIN PHOSPHORYLATED ON SER172
2444, 3qu0A, 0.7104, 3.00, 0.181, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR RC-2-38
2445, 3qqhA, 0.7104, 3.07, 0.184, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR L2-2
2446, 3qc9C, 0.7104, 4.03, 0.173, 482, 277, CRYSTAL STRUCTURE OF CROSS-LINKED BOVINE GRK1 T8C/N480C DOUBLE MUTANT COMPLEXED WITH ADP AND MG
2447, 2ijmA, 0.7104, 3.12, 0.352, 260, 256, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
2448, 1uwhA, 0.7104, 2.98, 0.217, 264, 253, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
2449, 1h1pA, 0.7104, 3.33, 0.165, 296, 260, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
2450, 5itaB, 0.7103, 2.38, 0.214, 252, 243, CRYSTAL STRUCTURE OF BRAF KINASE DOMAIN BOUND TO AZ-VEM
2451, 5ceiA, 0.7103, 3.54, 0.185, 345, 265, CRYSTAL STRUCTURE OF CDK8:CYCLIN C COMPLEX WITH COMPOUND 22
2452, 4zhxA, 0.7103, 2.96, 0.204, 408, 255, NOVEL BINDING SITE FOR ALLOSTERIC ACTIVATION OF AMPK
2453, 4wsqA, 0.7103, 2.88, 0.143, 317, 252, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2454, 4v04A, 0.7103, 3.20, 0.309, 290, 256, FGFR1 IN COMPLEX WITH PONATINIB.
2455, 4jnwB, 0.7103, 3.67, 0.126, 321, 269, BACTERIALLY EXPRESSED TITIN KINASE
2456, 3q52A, 0.7103, 3.52, 0.192, 292, 266, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN
2457, 6ginA, 0.7102, 2.86, 0.179, 296, 252, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH AN QUINAZOLINONE BASED ALK2 INHIBITOR WITH A 4-MORPHOLINOPHENYL SOLVENT ACCESSIBLE GROUP. 
2458, 4f64B, 0.7102, 3.21, 0.332, 272, 256, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
2459, 3qa0B, 0.7102, 3.20, 0.147, 330, 258, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
2460, 3g2fB, 0.7102, 2.87, 0.195, 300, 251, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE II (BMPR2) AT 2.35 A RESOLUTION
2461, 3g0fA, 0.7102, 3.35, 0.298, 291, 258, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
2462, 3axwA, 0.7102, 3.18, 0.143, 329, 258, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA COMPLEXED WITH A POTENT INHIBITOR
2463, 1yomA, 0.7102, 2.95, 0.276, 260, 254, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH PURVALANOL A
2464, 1jwhB, 0.7102, 3.21, 0.151, 335, 258, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
2465, 5oxgD, 0.7101, 2.79, 0.195, 293, 251, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
2466, 4u44A, 0.7101, 3.15, 0.182, 286, 258, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
2467, 4qmtA, 0.7101, 3.64, 0.228, 284, 267, MST3 IN COMPLEX WITH HESPERADIN
2468, 4nkaA, 0.7101, 3.14, 0.310, 279, 255, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
2469, 3ti1A, 0.7101, 3.10, 0.184, 294, 255, CDK2 IN COMPLEX WITH SUNITINIB
2470, 2jkqA, 0.7101, 3.10, 0.345, 258, 255, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
2471, 1wvwA, 0.7101, 3.03, 0.176, 275, 256, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
2472, 1ds5A, 0.7101, 3.23, 0.151, 328, 258, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
2473, 5ar7A, 0.7100, 3.19, 0.215, 278, 256, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
2474, 4md7E, 0.7100, 3.21, 0.147, 332, 258, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
2475, 4hvsA, 0.7100, 3.22, 0.300, 326, 257, CRYSTAL STRUCTURE OF KIT KINASE DOMAIN WITH A SMALL MOLECULE INHIBITOR PLX647
2476, 4aojC, 0.7100, 2.92, 0.312, 261, 253, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
2477, 3zewB, 0.7100, 2.73, 0.312, 252, 250, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
2478, 3s00A, 0.7100, 2.99, 0.186, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR L4-14
2479, 3my0U, 0.7100, 3.08, 0.168, 285, 256, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2480, 3my0L, 0.7100, 3.05, 0.168, 296, 256, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2481, 3f3uA, 0.7100, 3.20, 0.291, 261, 258, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL37 (TYPE III)
2482, 1gagA, 0.7100, 3.39, 0.303, 300, 261, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH A BISUBSTRATE INHIBITOR
2483, 6e4tA, 0.7099, 3.03, 0.200, 361, 255, STRUCTURE OF AMPK BOUND TO ACTIVATOR 
2484, 5kwhA, 0.7099, 3.21, 0.143, 331, 258, CRYSTAL STRUCTURE OF CK2
2485, 5ezvA, 0.7099, 3.03, 0.199, 441, 256, X-RAY CRYSTAL STRUCTURE OF AMP-ACTIVATED PROTEIN KINASE ALPHA-2/ALPHA- 1 RIM CHIMAERA (ALPHA-2(1-347)/ALPHA-1(349-401)/ALPHA-2(397-END) BETA-1 GAMMA-1) CO-CRYSTALLIZED WITH C2 (5-(5-HYDROXYL-ISOXAZOL-3- YL)-FURAN-2-PHOSPHONIC ACID)
2486, 3v8wB, 0.7099, 2.10, 0.310, 242, 239, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 469
2487, 3r8vA, 0.7099, 3.00, 0.186, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR RC-1-135
2488, 3qqjA, 0.7099, 3.08, 0.176, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR L2
2489, 3ql8A, 0.7099, 2.98, 0.182, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-260
2490, 2p0cB, 0.7099, 2.42, 0.360, 248, 239, CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER
2491, 1fpuA, 0.7099, 3.01, 0.340, 275, 253, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
2492, 5t1hB, 0.7098, 3.20, 0.143, 331, 258, CRYSTAL STRUCTURE OF CK2
2493, 5o21A, 0.7098, 2.96, 0.194, 272, 252, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED STATE WITH CHLORIDE BOUND IN THE ACTIVE SITE
2494, 5hu3A, 0.7098, 2.96, 0.157, 266, 254, DROSOPHILA CAMKII-D136N IN COMPLEX WITH A PHOSPHORYLATED FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
2495, 5fetA, 0.7098, 3.76, 0.194, 802, 268, CRYSTAL STRUCTURE OF PVX_084705 IN PRESENCE OF COMPOUND 2
2496, 5auuA, 0.7098, 3.02, 0.180, 274, 255, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH LUTEOLIN.
2497, 4ra4A, 0.7098, 3.65, 0.183, 317, 268, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE C ALPHA IN COMPLEX WITH COMPOUND 28 ((R)-6-((3S4S)-13-DIMETHYL-PIPERIDIN-4-YL)-7-(2-FLUORO- PHENYL)-4-METHYL-210-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
2498, 4kabB, 0.7098, 3.11, 0.350, 258, 254, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 3-METHYL-14- DIHYDRO-PYRAZOLO[45-C]PYRAZOLE
2499, 3wilA, 0.7098, 3.15, 0.144, 331, 257, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND3 COMPLEX
2500, 3ngaA, 0.7098, 3.21, 0.143, 331, 258, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
2501, 3my0B, 0.7098, 3.05, 0.168, 295, 256, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2502, 2wouA, 0.7098, 2.92, 0.162, 299, 253, ALK5 IN COMPLEX WITH 4-((4-((26-DIMETHYL-3-PYRIDYL)OXY)-2- PYRIDYL)AMINO)BENZENESULFONAMIDE
2503, 1yhwA, 0.7098, 3.53, 0.188, 293, 266, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH ONE POINT MUTATIONS (K299R)
2504, 1jktA, 0.7098, 3.06, 0.179, 276, 257, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
2505, 4mneF, 0.7097, 2.54, 0.220, 258, 246, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
2506, 3ugcA, 0.7097, 2.65, 0.310, 274, 248, STRUCTURAL BASIS OF JAK2 INHIBITION BY THE TYPE II INHIBTOR NVP-BBT594
2507, 3tn8A, 0.7097, 3.38, 0.145, 304, 262, CDK9/CYCLIN T IN COMPLEX WITH CAN508
2508, 3rk9A, 0.7097, 3.03, 0.181, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR RC-2-74
2509, 3mtfA, 0.7097, 2.87, 0.175, 296, 252, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH A 2- AMINOPYRIDINE INHIBITOR
2510, 3be9A, 0.7097, 3.20, 0.143, 327, 258, STRUCTURE-BASED DESIGN AND SYNTHESIS OF NOVEL MACROCYCLIC PYRAZOLO[15-A] [135]TRIAZINE COMPOUNDS AS POTENT INHIBITORS OF PROTEIN KINASE CK2 AND THEIR ANTICANCER ACTIVITIES
2511, 2hyyB, 0.7097, 2.71, 0.343, 265, 248, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
2512, 5c03B, 0.7096, 2.62, 0.202, 260, 248, CRYSTAL STRUCTURE OF KINASE
2513, 4jajA, 0.7096, 3.11, 0.182, 265, 258, CRYSTAL STRUCTURE OF AURORA KINASE A IN COMPLEX WITH BENZO[C][1 8]NAPHTHYRIDIN-6(5H)-ONE
2514, 4eqcA, 0.7096, 3.48, 0.192, 296, 265, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN IN COMPLEX WITH FRAX597 INHIBITOR
2515, 3wikA, 0.7096, 3.20, 0.143, 334, 258, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND10 COMPLEX
2516, 3v5jB, 0.7096, 2.02, 0.311, 241, 238, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 090
2517, 3uodA, 0.7096, 3.23, 0.181, 266, 260, AURORA A IN COMPLEX WITH RPM1693
2518, 3mb6A, 0.7096, 3.22, 0.151, 329, 258, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (CPA)
2519, 3ckxA, 0.7096, 3.48, 0.228, 276, 263, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24) IN COMPLEX WITH STAUROSPORINE
2520, 5wnmA, 0.7095, 2.72, 0.252, 263, 250, CRYSTAL STRUCTURE OF MURINE RECEPTOR-INTERACTING PROTEIN 4 (RIPK4) D143N BOUND TO TOZASERTIB (VX-680) 
2521, 4qmwA, 0.7095, 3.60, 0.229, 286, 266, MST3 IN COMPLEX WITH PP-121 1-CYCLOPENTYL-3-(1H-PYRROLO[23- B]PYRIDIN-5-YL)-1H-PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
2522, 3r28A, 0.7095, 3.09, 0.169, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-140
2523, 3ngaB, 0.7095, 3.22, 0.143, 331, 258, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
2524, 3my0N, 0.7095, 3.07, 0.168, 300, 256, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2525, 5td2B, 0.7094, 2.25, 0.353, 242, 238, STRUCTURE-BASED OPTIMIZATION OF 1H-IMIDAZOLE-2-CARBOXAMIDES AS AXL KINASE INHIBITORS UTILIZING A MER MUTANT SURROGATE
2526, 5o21B, 0.7094, 2.86, 0.199, 273, 251, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED STATE WITH CHLORIDE BOUND IN THE ACTIVE SITE
2527, 5dylA, 0.7094, 3.69, 0.190, 802, 268, CRYSTAL STRUCTURE OF PVX_084705
2528, 4ybjA, 0.7094, 2.98, 0.289, 255, 253, TYPE II DASATINIB ANALOG CRYSTALLIZED WITH C-SRC KINASE
2529, 4nh1B, 0.7094, 3.20, 0.143, 332, 258, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
2530, 4f63B, 0.7094, 3.18, 0.333, 271, 255, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 1
2531, 3at2A, 0.7094, 3.22, 0.143, 334, 258, CRYSTAL STRUCTURE OF CK2ALPHA
2532, 2i0yA, 0.7094, 3.12, 0.311, 289, 254, CFMS TYROSINE KINASE (FGF KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
2533, 1ds5D, 0.7094, 3.24, 0.151, 328, 258, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
2534, 5tobA, 0.7093, 2.52, 0.336, 245, 244, SELECTIVITY SWITCH BETWEEN FAK AND PYK2: MACROCYCLIZATION OF FAK INHIBITORS IMPROVES PYK2 POTENCY
2535, 5l6wL, 0.7093, 3.46, 0.217, 290, 263, STRUCTURE OF THE LIMK1-ATPGAMMAS-CFL1 COMPLEX
2536, 5kvtA, 0.7093, 3.14, 0.300, 287, 257, THE STRUCTURE OF TRKA KINASE DOMAIN BOUND TO THE INHIBITOR ENTRECTINIB
2537, 3rk7A, 0.7093, 3.04, 0.181, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR RC-2-71
2538, 3rjcA, 0.7093, 3.02, 0.181, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR L4-12
2539, 3qzgA, 0.7093, 3.03, 0.181, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-76
2540, 3q4uB, 0.7093, 2.84, 0.172, 300, 250, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
2541, 3f3wA, 0.7093, 3.18, 0.296, 261, 257, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
2542, 2pvnA, 0.7093, 3.22, 0.147, 327, 258, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
2543, 6ginB, 0.7092, 2.93, 0.178, 296, 253, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH AN QUINAZOLINONE BASED ALK2 INHIBITOR WITH A 4-MORPHOLINOPHENYL SOLVENT ACCESSIBLE GROUP. 
2544, 4nh1A, 0.7092, 3.21, 0.143, 330, 258, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
2545, 4gubA, 0.7092, 3.24, 0.143, 329, 258, CASEIN KINASE II BOUND TO INHIBITOR
2546, 4c8bB, 0.7092, 3.02, 0.206, 281, 253, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
2547, 3zm4A, 0.7092, 3.63, 0.195, 309, 266, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 1
2548, 3b8rA, 0.7092, 3.33, 0.292, 289, 257, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
2549, 2fgiB, 0.7092, 3.23, 0.332, 272, 256, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
2550, 1uu7A, 0.7092, 3.24, 0.208, 280, 259, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-2
2551, 5gjfA, 0.7091, 2.97, 0.258, 298, 252, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 3
2552, 4zjjA, 0.7091, 2.94, 0.176, 280, 255, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
2553, 4md8F, 0.7091, 3.22, 0.147, 332, 258, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
2554, 4fnzA, 0.7091, 3.56, 0.251, 287, 263, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PIPERIDINE-CARBOXAMIDE INHIBITOR 2
2555, 4agdA, 0.7091, 3.49, 0.307, 303, 261, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SUNITINIB (SU11248) (N-2- DIETHYLAMINOETHYL)-5-((Z)-(5-FLUORO-2-OXO-1H-INDOL-3- YLIDENE)METHYL)-24-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE)
2556, 3q9xA, 0.7091, 3.21, 0.143, 330, 258, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
2557, 3cthA, 0.7091, 3.63, 0.326, 295, 264, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A AMINOPYRIDINE BASED INHIBITOR
2558, 5l2qD, 0.7090, 3.31, 0.135, 294, 260, SERINE/THREONINE-PROTEIN KINASE 40 (STK40) KINASE HOMOLOGY DOMAIN
2559, 4iebA, 0.7090, 3.67, 0.175, 472, 269, CRYSTAL STRUCTURE OF A GLY128MET MUTANT OF THE TOXOPLASMA CDPK TGME49_101440
2560, 3u87A, 0.7090, 3.21, 0.147, 329, 258, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
2561, 3s0oA, 0.7090, 3.08, 0.165, 293, 254, CDK2 IN COMPLEX WITH INHIBITOR RC-1-138
2562, 3q9zB, 0.7090, 3.22, 0.147, 332, 258, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
2563, 5xy1A, 0.7089, 2.79, 0.312, 253, 250, CRYSTAL STRUCTURE OF LYN KINASE DOMAIN IN COMPLEX WITH N-(1H-INDAZOL- 6-YL)-8-(PIPERIDIN-4-YLOXY)-6-PROPYLQUINAZOLIN-2-AMINE
2564, 5x02A, 0.7089, 3.21, 0.345, 305, 255, CRYSTAL STRUCTURE OF THE FLT3 KINASE DOMAIN BOUND TO THE INHIBITOR FF- 10101
2565, 5sysB, 0.7089, 3.17, 0.285, 258, 256, C-SRC V281C BOUND TO N-[3-({6-[(1E)-2-CYANO-3-(METHYLAMINO)-3-OXOPROP- 1-EN-1-YL]-7-(2-METHOXYETHYL)-7H-PYRROLO[23-D]PYRIMIDIN-5- YL}ETHYNYL)-4-METHYLPHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE INHIBITOR
2566, 5os5A, 0.7089, 3.17, 0.182, 267, 258, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2567, 5itaA, 0.7089, 2.49, 0.209, 250, 244, CRYSTAL STRUCTURE OF BRAF KINASE DOMAIN BOUND TO AZ-VEM
2568, 5hznH, 0.7089, 3.50, 0.309, 303, 259, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2569, 4nttA, 0.7089, 3.86, 0.161, 339, 274, STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE BOUND TO ADP AND ONE MAGNESIUM ION
2570, 4g9cA, 0.7089, 2.77, 0.216, 265, 250, HUMAN B-RAF KINASE DOMAIN BOUND TO A TYPE II PYRAZOLOPYRIDINE INHIBITOR
2571, 4deeA, 0.7089, 3.16, 0.181, 271, 259, AURORA A IN COMPLEX WITH ADP
2572, 3r8uA, 0.7089, 3.15, 0.173, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR RC-1-132
2573, 3qtiA, 0.7089, 3.37, 0.333, 292, 258, C-MET KINASE IN COMPLEX WITH NVP-BVU972
2574, 3qgyA, 0.7089, 2.44, 0.303, 246, 244, CRYSTAL STRUCTURE OF ITK INHIBITOR COMPLEX
2575, 2zv8A, 0.7089, 2.93, 0.316, 257, 253, LYN TYROSINE KINASE DOMAIN-AMP-PNP COMPLEX
2576, 2f57B, 0.7089, 3.56, 0.174, 299, 264, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
2577, 1ykrA, 0.7089, 3.32, 0.174, 298, 258, CRYSTAL STRUCTURE OF CDK2 WITH AN AMINOIMIDAZO PYRIDINE INHIBITOR
2578, 1ds5C, 0.7089, 3.25, 0.151, 328, 258, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
2579, 4eolC, 0.7088, 3.35, 0.168, 299, 262, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2580, 3s95B, 0.7088, 3.29, 0.224, 290, 259, CRYSTAL STRUCTURE OF THE HUMAN LIMK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
2581, 2yn8A, 0.7088, 2.82, 0.299, 253, 251, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
2582, 1yhvA, 0.7088, 3.54, 0.188, 293, 266, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH TWO POINT MUTATIONS (K299R T423E)
2583, 1pxpA, 0.7088, 3.08, 0.181, 294, 254, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- N N -DIMETHYL-BENZENE-14-DIAMINE
2584, 1ir3A, 0.7088, 3.39, 0.303, 300, 261, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH PEPTIDE SUBSTRATE AND ATP ANALOG
2585, 5fm3A, 0.7087, 3.24, 0.336, 276, 256, CRYSTAL STRUCTURE OF HYPER-PHOSPHORYLATED RET KINASE DOMAIN WITH (PROXIMAL) JUXTAMEMBRANE SEGMENT
2586, 5dfpA, 0.7087, 3.49, 0.192, 292, 265, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND FRAX1036
2587, 5autA, 0.7087, 3.04, 0.180, 274, 255, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH ANS.
2588, 3r8lA, 0.7087, 3.09, 0.181, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR L3-4
2589, 3qc9D, 0.7087, 4.02, 0.174, 486, 276, CRYSTAL STRUCTURE OF CROSS-LINKED BOVINE GRK1 T8C/N480C DOUBLE MUTANT COMPLEXED WITH ADP AND MG
2590, 3qc9B, 0.7087, 4.02, 0.174, 481, 276, CRYSTAL STRUCTURE OF CROSS-LINKED BOVINE GRK1 T8C/N480C DOUBLE MUTANT COMPLEXED WITH ADP AND MG
2591, 3gqlC, 0.7087, 3.23, 0.337, 275, 258, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
2592, 1pxoA, 0.7087, 3.11, 0.176, 294, 255, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2-AMINO-4-METHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YL]-(3-NITRO-PHENYL)-AMINE
2593, 5nxcL, 0.7086, 2.86, 0.197, 274, 249, LIM DOMAIN KINASE 1 (LIMK1) IN COMPLEX WITH PF-00477736
2594, 5hznD, 0.7086, 3.50, 0.309, 304, 259, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2595, 4rwiB, 0.7086, 3.20, 0.332, 280, 256, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
2596, 4rlkA, 0.7086, 3.24, 0.143, 327, 258, CRYSTAL STRUCTURE OF Z. MAYS CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
2597, 4qfsA, 0.7086, 3.05, 0.200, 361, 255, STRUCTURE OF AMPK IN COMPLEX WITH BR2-A769662CORE ACTIVATOR AND STAUROSPORINE INHIBITOR
2598, 4md9H, 0.7086, 3.16, 0.144, 328, 257, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
2599, 4f0iA, 0.7086, 2.88, 0.310, 284, 252, CRYSTAL STRUCTURE OF APO TRKA
2600, 3rm7A, 0.7086, 3.09, 0.181, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-91
2601, 3r8zA, 0.7086, 3.04, 0.182, 290, 253, CDK2 IN COMPLEX WITH INHIBITOR RC-1-136
2602, 3qc9A, 0.7086, 4.02, 0.174, 486, 276, CRYSTAL STRUCTURE OF CROSS-LINKED BOVINE GRK1 T8C/N480C DOUBLE MUTANT COMPLEXED WITH ADP AND MG
2603, 3cs9A, 0.7086, 2.61, 0.344, 264, 247, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
2604, 1yolA, 0.7086, 2.81, 0.280, 256, 250, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH CGP77675
2605, 6e4uA, 0.7085, 3.05, 0.200, 365, 255, STRUCTURE OF AMPK BOUND TO ACTIVATOR 
2606, 5ku8A, 0.7085, 3.23, 0.147, 328, 258, CRYSTAL STRUCTURE OF CK2
2607, 4zjjB, 0.7085, 2.90, 0.197, 277, 254, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
2608, 4qfrA, 0.7085, 3.05, 0.200, 361, 255, STRUCTURE OF AMPK IN COMPLEX WITH CL-A769662 ACTIVATOR AND STAUROSPORINE INHIBITOR
2609, 4mf1A, 0.7085, 2.13, 0.304, 243, 240, ITK KINASE DOMAIN IN COMPLEX WITH BENZOTHIAZOLE INHIBITOR 12B (1S2S)- 2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}-N-[6-(1H-PYRAZOL-4-YL)-13- BENZOTHIAZOL-2-YL]CYCLOPROPANECARBOXAMIDE
2610, 4k8aB, 0.7085, 3.13, 0.345, 258, 255, FRAGMENT-BASED DISCOVERY OF FOCAL ADHESION KINASE INHIBITORS
2611, 4fr4A, 0.7085, 4.08, 0.181, 350, 277, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
2612, 2qi8A, 0.7085, 2.80, 0.320, 255, 250, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN
2613, 5t5tA, 0.7084, 3.10, 0.207, 368, 256, AMPK BOUND TO ALLOSTERIC ACTIVATOR
2614, 5oy4B, 0.7084, 3.45, 0.179, 353, 262, GSK3BETA COMPLEX WITH N-(6-(34-DIHYDROXYPHENYL)-1H-PYRAZOLO[34- B]PYRIDIN-3-YL)ACETAMIDE
2615, 5n9lA, 0.7084, 3.15, 0.148, 329, 257, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE DIBENZOFURAN INHIBITOR TF (4B)
2616, 4u40B, 0.7084, 3.50, 0.174, 299, 264, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
2617, 4md8G, 0.7084, 3.23, 0.147, 332, 258, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
2618, 4jboA, 0.7084, 3.08, 0.183, 266, 257, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
2619, 4imyE, 0.7084, 3.48, 0.151, 313, 265, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
2620, 3r0tA, 0.7084, 3.22, 0.151, 327, 258, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-5279
2621, 3qzfA, 0.7084, 3.00, 0.182, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-52
2622, 3qrtA, 0.7084, 2.99, 0.182, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC2-55
2623, 3qa0A, 0.7084, 3.23, 0.143, 330, 258, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
2624, 3q04A, 0.7084, 3.18, 0.144, 328, 257, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 8.5
2625, 1iepA, 0.7084, 2.83, 0.340, 274, 250, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.
2626, 5e8xA, 0.7083, 3.10, 0.160, 304, 257, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F) IN COMPLEX WITH STAUROSPORINE
2627, 3u87B, 0.7083, 3.22, 0.147, 329, 258, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
2628, 3tiyA, 0.7083, 3.03, 0.178, 293, 253, CDK2 IN COMPLEX WITH NSC 35676
2629, 3rniA, 0.7083, 3.18, 0.173, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR RC-3-86
2630, 5oy6A, 0.7082, 2.80, 0.196, 291, 250, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
2631, 5bpyB, 0.7082, 2.56, 0.314, 247, 245, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
2632, 3tizA, 0.7082, 3.08, 0.185, 293, 254, CDK2 IN COMPLEX WITH NSC 111848
2633, 3qtqA, 0.7082, 3.07, 0.181, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR RC-1-137
2634, 3cpbA, 0.7082, 3.28, 0.298, 285, 255, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BISAMIDE INHIBITOR
2635, 2a0cX, 0.7081, 3.01, 0.182, 294, 253, HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II A NOVEL 269- TRISUBSTITUTED PURINE CYCLIN-DEPENDENT KINASE INHIBITOR
2636, 1lp4A, 0.7081, 3.24, 0.143, 327, 258, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 WITH MG-AMPPNP
2637, 5n9nA, 0.7080, 3.09, 0.145, 329, 256, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF85 (4A)
2638, 5kq5A, 0.7080, 3.05, 0.200, 362, 255, AMPK BOUND TO ALLOSTERIC ACTIVATOR
2639, 4r7hA, 0.7080, 3.24, 0.294, 308, 255, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR PLX3397
2640, 4fk3B, 0.7080, 2.72, 0.237, 257, 249, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX3203
2641, 4eokC, 0.7080, 3.37, 0.164, 299, 262, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
2642, 4dgnA, 0.7080, 3.24, 0.143, 325, 258, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR LUTEOLIN
2643, 3q9wA, 0.7080, 3.25, 0.147, 328, 258, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 8.5
2644, 6e4wA, 0.7079, 3.11, 0.207, 361, 256, STRUCTURE OF AMPK BOUND TO ACTIVATOR 
2645, 5hzeA, 0.7079, 3.55, 0.189, 305, 264, MEK1 ADOPTS DFG-OUT CONFORMATION WHEN BOUND TO AN ANALOG OF E6201.
2646, 5c03A, 0.7079, 2.61, 0.202, 260, 247, CRYSTAL STRUCTURE OF KINASE
2647, 4md8H, 0.7079, 3.23, 0.147, 331, 258, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
2648, 3pe2A, 0.7079, 3.19, 0.144, 327, 257, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR CX-5011
2649, 3a8xB, 0.7079, 3.48, 0.173, 329, 266, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
2650, 5jt2A, 0.7078, 2.90, 0.227, 257, 251, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
2651, 4rqvA, 0.7078, 3.55, 0.197, 288, 264, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS2
2652, 4d4sA, 0.7078, 2.95, 0.347, 255, 251, FOCAL ADHESION KINASE CATALYTIC DOMAIN
2653, 4cfxC, 0.7078, 3.49, 0.163, 298, 263, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2654, 3r7vA, 0.7078, 3.11, 0.181, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-9
2655, 3qqfA, 0.7078, 3.16, 0.176, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR L1
2656, 3pxrA, 0.7078, 3.14, 0.173, 294, 255, APO CDK2 CRYSTALLIZED FROM JEFFAMINE
2657, 3my0E, 0.7078, 3.00, 0.161, 294, 254, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2658, 2wihA, 0.7078, 3.51, 0.162, 302, 265, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
2659, 5cqwB, 0.7077, 3.24, 0.147, 331, 258, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
2660, 3v8wA, 0.7077, 2.23, 0.308, 243, 240, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 469
2661, 3r9hA, 0.7077, 3.01, 0.182, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR RC-2-142
2662, 3r7eA, 0.7077, 3.17, 0.176, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-67
2663, 3krjA, 0.7077, 3.22, 0.303, 304, 254, CFMS TYROSINE KINASE IN COMPLEX WITH 4-CYANO-1H-IMIDAZOLE-2-CARBOXYLIC ACID (2-CYCLOHEX-1-ENYL-4-PIPERIDIN-4-YL-PHENYL)-AMIDE
2664, 2g9xC, 0.7077, 3.25, 0.166, 274, 259, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
2665, 1fgiB, 0.7077, 3.29, 0.328, 272, 256, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
2666, 1dawA, 0.7077, 3.24, 0.143, 327, 258, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-AMPPNP
2667, 5ufuA, 0.7076, 3.11, 0.207, 368, 256, STRUCTURE OF AMPK BOUND TO ACTIVATOR
2668, 5cqwA, 0.7076, 3.25, 0.143, 331, 258, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
2669, 4dgmA, 0.7076, 3.25, 0.143, 326, 258, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR APIGENIN
2670, 4agwB, 0.7076, 3.01, 0.280, 257, 254, DISCOVERY OF A SMALL MOLECULE TYPE II INHIBITOR OF WILD- TYPE AND GATEKEEPER MUTANTS OF BCR-ABL PDGFRALPHA KIT AND SRC KINASES
2671, 4ae9A, 0.7076, 3.62, 0.175, 321, 269, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
2672, 3r1sA, 0.7076, 3.17, 0.173, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-127
2673, 3qxoA, 0.7076, 3.00, 0.186, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-84
2674, 3qgwA, 0.7076, 2.40, 0.309, 244, 243, CRYSTAL STRUCTURE OF ITK KINASE BOUND TO AN INHIBITOR
2675, 3q9zA, 0.7076, 3.16, 0.144, 332, 257, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
2676, 3pe1A, 0.7076, 3.24, 0.147, 327, 258, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-4945
2677, 3gniB, 0.7076, 3.50, 0.136, 304, 264, STRUCTURE OF STRAD AND MO25
2678, 1ds5B, 0.7076, 3.27, 0.151, 328, 258, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
2679, 5os4A, 0.7075, 3.10, 0.180, 264, 256, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2680, 4md8E, 0.7075, 3.24, 0.147, 332, 258, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
2681, 4ebvA, 0.7075, 3.20, 0.337, 262, 255, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH NOVEL ALLOSTERIC INHIBITOR
2682, 2pvhA, 0.7075, 3.25, 0.147, 327, 258, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
2683, 2hyyA, 0.7075, 2.67, 0.344, 263, 247, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
2684, 5t1hA, 0.7074, 3.25, 0.147, 331, 258, CRYSTAL STRUCTURE OF CK2
2685, 3tz7A, 0.7074, 3.18, 0.289, 260, 256, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL103
2686, 3r73A, 0.7074, 3.03, 0.186, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-164
2687, 3pyyB, 0.7074, 2.81, 0.339, 257, 248, DISCOVERY AND CHARACTERIZATION OF A CELL-PERMEABLE SMALL-MOLECULE C- ABL KINASE ACTIVATOR THAT BINDS TO THE MYRISTOYL BINDING SITE
2688, 1okyA, 0.7074, 3.22, 0.209, 281, 258, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
2689, 4xx9A, 0.7073, 3.60, 0.201, 288, 264, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RF4
2690, 4rwkB, 0.7073, 3.31, 0.333, 282, 258, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
2691, 4aw1A, 0.7073, 3.50, 0.203, 283, 261, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS210 BOUND TO THE PIF-POCKET
2692, 3qxpA, 0.7073, 3.01, 0.183, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
2693, 3ofmA, 0.7073, 3.26, 0.124, 325, 259, STRUCTURE OF A HUMAN CK2ALPHA PRIME THE PARALOG ISOFORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM HOMO SAPIENS
2694, 3my0G, 0.7073, 3.05, 0.169, 294, 255, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2695, 3ms9B, 0.7073, 2.67, 0.340, 272, 247, ABL KINASE IN COMPLEX WITH IMATINIB AND A FRAGMENT (FRAG1) IN THE MYRISTATE POCKET
2696, 3c13A, 0.7073, 3.22, 0.144, 328, 257, LOW PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2697, 4tyiA, 0.7072, 3.12, 0.337, 277, 255, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4
2698, 4nksB, 0.7072, 3.22, 0.333, 271, 255, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 3
2699, 3my0R, 0.7072, 3.06, 0.169, 294, 255, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2700, 5orpA, 0.7071, 3.10, 0.180, 264, 256, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2701, 3r6xA, 0.7071, 3.04, 0.186, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-158
2702, 3r1qA, 0.7071, 3.13, 0.173, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-102
2703, 3qzhA, 0.7071, 3.14, 0.169, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-124
2704, 3qx4A, 0.7071, 3.12, 0.181, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-78
2705, 3mb7A, 0.7071, 3.27, 0.147, 330, 258, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (AMR)
2706, 3g0fB, 0.7071, 3.25, 0.297, 293, 256, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
2707, 1dayA, 0.7071, 3.26, 0.140, 327, 258, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-GMPPNP
2708, 5os6A, 0.7070, 3.10, 0.180, 264, 256, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2709, 3royA, 0.7070, 3.14, 0.169, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-154
2710, 3my0F, 0.7070, 3.08, 0.169, 294, 255, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2711, 3lvpC, 0.7070, 3.39, 0.297, 293, 259, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
2712, 3a7jA, 0.7070, 3.69, 0.228, 286, 267, HUMAN MST3 KINASE IN COMPLEX WITH MNADP
2713, 2reiA, 0.7070, 3.26, 0.309, 277, 256, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 7 (EPHA7)
2714, 2cchC, 0.7070, 3.27, 0.170, 296, 259, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
2715, 5ax9A, 0.7069, 3.04, 0.182, 282, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
2716, 3tnhA, 0.7069, 3.34, 0.161, 288, 261, CDK9/CYCLIN T IN COMPLEX WITH CAN508
2717, 3ce3A, 0.7069, 3.61, 0.326, 293, 261, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A PYRROLOPYRIDINEPYRIDONE BASED INHIBITOR
2718, 5osfA, 0.7068, 3.11, 0.180, 264, 256, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2719, 5oseA, 0.7068, 3.11, 0.180, 264, 256, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2720, 5nkaA, 0.7068, 3.17, 0.322, 271, 255, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2G
2721, 5b0xA, 0.7068, 3.23, 0.143, 329, 258, CRYSTAL STRUCTURE OF THE CK2A/BENZOIC ACID DERIVATIVE COMPLEX
2722, 4dgoA, 0.7068, 3.27, 0.143, 325, 258, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH TYRPHOSTIN AG99
2723, 4crlA, 0.7068, 3.52, 0.183, 339, 263, CRYSTAL STRUCTURE OF HUMAN CDK8-CYCLIN C IN COMPLEX WITH CORTISTATIN A
2724, 3soaA, 0.7068, 3.50, 0.148, 436, 264, FULL-LENGTH HUMAN CAMKII
2725, 3my0H, 0.7068, 3.08, 0.173, 294, 255, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2726, 3d5uA, 0.7068, 3.47, 0.193, 288, 264, CRYSTAL STRUCTURE OF A WILDTYPE POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN.
2727, 2pvmA, 0.7068, 3.26, 0.143, 327, 258, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
2728, 2pvkA, 0.7068, 3.25, 0.140, 327, 258, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
2729, 5uglB, 0.7067, 3.20, 0.327, 271, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 TYROSINE KINASE DOMAIN HARBORING THE D650V ACTIVATING MUTATION
2730, 5t31A, 0.7067, 3.43, 0.176, 334, 261, EXPLOITING AN ASP-GLU SWITCH IN GLYCOGEN SYNTHASE KINASE 3 TO DESIGN PARALOG SELECTIVE INHIBITORS FOR USE IN ACUTE MYELOID LEUKEMIA
2731, 5orvA, 0.7067, 3.11, 0.180, 264, 256, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2732, 5motA, 0.7067, 3.24, 0.151, 328, 258, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0627 BOUND
2733, 4pp9A, 0.7067, 2.44, 0.307, 246, 244, ITK KINASE DOMAIN WITH COMPOUND 1 (N-[1-(3-CYANOBENZYL)-1H-PYRAZOL-4- YL]-2H-INDAZOLE-3-CARBOXAMIDE)
2734, 4fk3A, 0.7067, 2.50, 0.213, 251, 244, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX3203
2735, 4deaA, 0.7067, 3.25, 0.181, 266, 260, AURORA A IN COMPLEX WITH YL1-038-18
2736, 3tz9B, 0.7067, 3.11, 0.295, 259, 254, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL130
2737, 3f3vA, 0.7067, 3.22, 0.292, 261, 257, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
2738, 3dkgA, 0.7067, 3.30, 0.339, 281, 254, STRUCTURE OF MUTANT(Y1248L) MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH INHIBITOR SGX-523
2739, 3bqcA, 0.7067, 3.22, 0.144, 328, 257, HIGH PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2740, 1uwhB, 0.7067, 3.03, 0.217, 264, 253, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
2741, 5orzA, 0.7066, 3.10, 0.180, 264, 256, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2742, 5oroA, 0.7066, 3.10, 0.180, 264, 256, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2743, 5mohA, 0.7066, 3.17, 0.148, 326, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0583 BOUND.
2744, 5he0A, 0.7066, 4.04, 0.164, 621, 275, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG215022
2745, 5dr2A, 0.7066, 3.09, 0.180, 264, 256, AURORA A KINASE IN COMPLEX WITH AA30 AND ATP IN SPACE GROUP P6122
2746, 5cquA, 0.7066, 3.22, 0.144, 328, 257, MONOCLINIC COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
2747, 4fbxA, 0.7066, 3.24, 0.151, 333, 258, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT CRYSTALLIZED IN THE PRESENCE OF A BISUBSTRATE INHIBITOR
2748, 4eolA, 0.7066, 3.19, 0.163, 294, 258, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2749, 3qwkA, 0.7066, 3.04, 0.182, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-150
2750, 3my0S, 0.7066, 3.08, 0.173, 294, 255, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2751, 3my0Q, 0.7066, 3.09, 0.169, 294, 255, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2752, 3cp9B, 0.7066, 2.85, 0.306, 269, 248, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
2753, 2i0vA, 0.7066, 3.40, 0.300, 303, 257, C-FMS TYROSINE KINASE IN COMPLEX WITH A QUINOLONE INHIBITOR
2754, 2hiwA, 0.7066, 3.02, 0.336, 274, 253, CRYSTAL STRUCTURE OF INACTIVE CONFORMATION ABL KINASE CATALYTIC DOMAIN COMPLEXED WITH TYPE II INHIBITOR
2755, 2b54A, 0.7066, 3.30, 0.178, 298, 258, HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2)COMPLEXED WITH DIN- 232305
2756, 1lpuA, 0.7066, 3.26, 0.143, 327, 258, LOW TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
2757, 5t31B, 0.7065, 3.47, 0.180, 333, 261, EXPLOITING AN ASP-GLU SWITCH IN GLYCOGEN SYNTHASE KINASE 3 TO DESIGN PARALOG SELECTIVE INHIBITORS FOR USE IN ACUTE MYELOID LEUKEMIA
2758, 5owlB, 0.7065, 3.26, 0.147, 332, 258, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
2759, 5ornA, 0.7065, 3.11, 0.180, 264, 256, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2760, 5oniB, 0.7065, 3.26, 0.147, 334, 258, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
2761, 5li9A, 0.7065, 3.76, 0.160, 329, 269, STRUCTURE OF A NUCLEOTIDE-BOUND FORM OF PKCIOTA CORE KINASE DOMAIN
2762, 4ez3A, 0.7065, 3.09, 0.186, 294, 253, CDK2 IN COMPLEX WITH NSC 134199
2763, 3pxkA, 0.7065, 3.03, 0.349, 256, 252, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH PYRROLO[23- D]THIAZOLE
2764, 3kmwA, 0.7065, 2.97, 0.209, 268, 254, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (MGATP)
2765, 2pvlA, 0.7065, 3.25, 0.147, 327, 258, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
2766, 1vywA, 0.7065, 3.56, 0.162, 302, 265, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
2767, 4yjqA, 0.7064, 3.22, 0.335, 264, 254, SYK KINASE DOMAIN IN COMPLEX WITH INHIBITOR GTC000224
2768, 4wunA, 0.7064, 3.14, 0.307, 282, 254, STRUCTURE OF FGFR1 IN COMPLEX WITH AZD4547 (N-{3-[2-(35- DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) AT 1.65 ANGSTROM
2769, 4rfmA, 0.7064, 2.66, 0.317, 249, 246, ITK KINASE DOMAIN IN COMPLEX WITH COMPOUND 1 N-{1-[(11-DIOXO-1-THIAN- 2-YL)(PHENYL)METHYL]-1H- PYRAZOL-4-YL}-55-DIFLUORO-5A-METHYL-1H4H 4AH5H5AH6H-CYCLOPROPA[F]INDAZOLE-3-CARBOXAMIDE
2770, 3tz8A, 0.7064, 3.26, 0.291, 261, 258, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL104
2771, 3repA, 0.7064, 3.05, 0.208, 268, 255, CRYSTAL STRUCTURE OF THE ILK/ALPHA-PARVIN CORE COMPLEX (MNATP)
2772, 3raiA, 0.7064, 3.13, 0.177, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-160
2773, 5os0A, 0.7063, 3.11, 0.180, 264, 256, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2774, 4rerA, 0.7063, 3.13, 0.203, 458, 256, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED HUMAN ALPHA1 BETA2 GAMMA1 HOLO-AMPK COMPLEX BOUND TO AMP AND CYCLODEXTRIN
2775, 4f7sA, 0.7063, 3.46, 0.179, 339, 262, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN THE DMG-IN CONFORMATION
2776, 4f65A, 0.7063, 3.35, 0.307, 279, 257, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 8
2777, 3g0eA, 0.7063, 3.17, 0.305, 332, 256, KIT KINASE DOMAIN IN COMPLEX WITH SUNITINIB
2778, 3el7A, 0.7063, 2.98, 0.295, 254, 251, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 3
2779, 3a8wB, 0.7063, 3.63, 0.160, 327, 268, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
2780, 2qo9A, 0.7063, 3.45, 0.303, 277, 261, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION PHOSPHORYLATED AMP-PNP BOUND
2781, 1zogA, 0.7063, 3.24, 0.151, 325, 258, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES
2782, 1pxjA, 0.7063, 3.05, 0.182, 294, 253, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINE
2783, 5w7tB, 0.7062, 3.08, 0.198, 276, 252, STRUCTURE OF PHOSPHORYLATED WNK1 
2784, 5n9kA, 0.7062, 3.19, 0.144, 329, 257, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF107 (5)
2785, 5icpA, 0.7062, 3.60, 0.185, 343, 265, CDK8-CYCC IN COMPLEX WITH [(S)-2-(4-CHLORO-PHENYL)-PYRROLIDIN-1-YL]- (5-METHYL-IMIDAZO[51-B][134]THIADIAZOL-2-YL)-METHANONE
2786, 4yjvA, 0.7062, 3.19, 0.341, 263, 252, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000250
2787, 4w9xA, 0.7062, 2.97, 0.143, 300, 252, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH BARICITINIB
2788, 4kd1A, 0.7062, 3.31, 0.174, 298, 259, CDK2 IN COMPLEX WITH DINACICLIB
2789, 3hx4A, 0.7062, 3.53, 0.174, 467, 265, CRYSTAL STRUCTURE OF CDPK1 OF TOXOPLASMA GONDII TGME49_101440 IN PRESENCE OF CALCIUM
2790, 2qq7A, 0.7062, 2.72, 0.316, 251, 247, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN WITH IRREVERSIBLE INHIBITOR
2791, 2qkwB, 0.7062, 3.42, 0.207, 290, 261, STRUCTURAL BASIS FOR ACTIVATION OF PLANT IMMUNITY BY BACTERIAL EFFECTOR PROTEIN AVRPTO
2792, 2p2iB, 0.7062, 2.73, 0.305, 263, 246, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NICOTINAMIDE INHIBITOR
2793, 2nryA, 0.7062, 2.94, 0.216, 286, 250, CRYSTAL STRUCTURE OF IRAK-4
2794, 5vilA, 0.7061, 3.21, 0.203, 271, 256, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 6)
2795, 5os1A, 0.7061, 3.11, 0.180, 264, 256, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2796, 4eojC, 0.7061, 3.32, 0.169, 282, 261, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
2797, 3zfxC, 0.7061, 2.62, 0.317, 248, 246, CRYSTAL STRUCTURE OF EPHB1
2798, 3qwjA, 0.7061, 3.03, 0.182, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-142
2799, 3qlfA, 0.7061, 2.67, 0.285, 249, 246, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE 5
2800, 3owkA, 0.7061, 3.24, 0.148, 330, 257, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
2801, 3kxgA, 0.7061, 3.26, 0.147, 326, 258, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 34567-PENTABROMO-1H-INDAZOLE (K64)
2802, 1yolB, 0.7061, 2.92, 0.279, 253, 251, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH CGP77675
2803, 6b3eC, 0.7060, 3.39, 0.152, 307, 263, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLINK IN COMPLEX WITH AN INHIBITOR
2804, 5vamA, 0.7060, 3.05, 0.217, 269, 254, BRAF IN COMPLEX WITH RAF709
2805, 5oy6C, 0.7060, 2.84, 0.196, 291, 250, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
2806, 5os3A, 0.7060, 3.11, 0.180, 264, 256, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2807, 5anjA, 0.7060, 3.23, 0.164, 291, 256, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH N-(9H-PURIN-6-YL) THIOPHENE-2-CARBOXAMIDE  PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
2808, 4cfhA, 0.7060, 3.15, 0.211, 401, 256, STRUCTURE OF AN ACTIVE FORM OF MAMMALIAN AMPK
2809, 3r1yA, 0.7060, 3.20, 0.176, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-134
2810, 3qziA, 0.7060, 3.16, 0.173, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-126
2811, 3pzhA, 0.7060, 3.28, 0.143, 327, 258, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH EMODIN AT 1.92 A RESOLUTION
2812, 5nk0A, 0.7059, 3.24, 0.319, 273, 257, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1J
2813, 5gjgA, 0.7059, 2.92, 0.251, 289, 251, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 4
2814, 4imyA, 0.7059, 3.52, 0.151, 314, 265, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
2815, 3rkbA, 0.7059, 3.13, 0.182, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR RC-2-73
2816, 3nrmA, 0.7059, 3.11, 0.183, 263, 257, IMIDAZO[12-A]PYRAZINE-BASED AURORA KINASE INHIBITORS
2817, 3lm5A, 0.7059, 3.06, 0.177, 274, 254, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B) IN COMPLEX WITH QUERCETIN
2818, 1oguC, 0.7059, 3.38, 0.165, 272, 261, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
2819, 5orwA, 0.7058, 3.12, 0.180, 264, 256, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2820, 5orrA, 0.7058, 3.11, 0.180, 264, 256, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2821, 5e8yA, 0.7058, 2.95, 0.202, 298, 252, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH STAUROSPORINE
2822, 4md9M, 0.7058, 3.25, 0.147, 331, 258, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
2823, 2qocA, 0.7058, 3.30, 0.309, 283, 259, HUMAN EPHA3 KINASE DOMAIN PHOSPHORYLATED AMP-PNP BOUND STRUCTURE
2824, 2qluA, 0.7058, 3.05, 0.171, 297, 252, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE II KINASE DOMAIN FROM HUMAN
2825, 6b3eA, 0.7057, 3.45, 0.147, 309, 265, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLINK IN COMPLEX WITH AN INHIBITOR
2826, 5p9lA, 0.7057, 2.90, 0.305, 252, 249, BTK1 IN COMPLEX WITH CC 292
2827, 4eonA, 0.7057, 3.53, 0.155, 299, 264, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
2828, 4cnhA, 0.7057, 3.60, 0.268, 285, 261, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2- METHOXYPHENYL)ETHOXY)-5-(1-METHYL-1H-123-TRIAZOL-5-YL) PYRIDIN-2-AMINE
2829, 2ofvA, 0.7057, 2.29, 0.289, 244, 239, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 1 BOUND TO LCK
2830, 1zohA, 0.7057, 3.28, 0.147, 326, 258, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
2831, 1m2qA, 0.7057, 3.27, 0.151, 327, 258, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO-XANTEN-9- ONE/CK2 KINASE COMPLEX
2832, 5v5nA, 0.7056, 3.12, 0.253, 294, 253, CRYSTAL STRUCTURE OF TAKINIB BOUND TO TAK1
2833, 5oryA, 0.7056, 3.12, 0.180, 264, 256, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2834, 5k0xB, 0.7056, 2.49, 0.343, 254, 239, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC2541
2835, 3kxmA, 0.7056, 3.27, 0.147, 326, 258, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR K74
2836, 1hckA, 0.7056, 3.23, 0.180, 294, 255, HUMAN CYCLIN-DEPENDENT KINASE 2
2837, 4onaA, 0.7055, 3.45, 0.198, 465, 263, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1517
2838, 4md9G, 0.7055, 3.21, 0.148, 329, 257, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
2839, 3up2A, 0.7055, 3.26, 0.181, 266, 260, AURORA A IN COMPLEX WITH RPM1686
2840, 3pvgA, 0.7055, 3.28, 0.143, 326, 258, CRYSTAL STRUCTURE OF Z. MAYS CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMO-1-CARBOXYMETHYLBENZIMIDAZOLE (K68)
2841, 3hmmA, 0.7055, 2.87, 0.167, 293, 251, STRUCTURE OF ALK5 + GW855857
2842, 2qobA, 0.7055, 3.44, 0.305, 279, 259, HUMAN EPHA3 KINASE DOMAIN BASE STRUCTURE
2843, 5orxA, 0.7054, 3.13, 0.180, 264, 256, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2844, 5orsA, 0.7054, 3.12, 0.180, 264, 256, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2845, 5ackA, 0.7054, 3.55, 0.198, 286, 263, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND 7 BOUND TO THE PIF-POCKET
2846, 4uxqA, 0.7054, 3.17, 0.314, 286, 255, FGFR4 IN COMPLEX WITH PONATINIB
2847, 4uwyB, 0.7054, 3.15, 0.328, 273, 253, FGFR1 APO STRUCTURE
2848, 4rt7A, 0.7054, 3.21, 0.341, 274, 255, CRYSTAL STRUCTURE OF FLT3 WITH A SMALL MOLECULE INHIBITOR
2849, 4p5qA, 0.7054, 3.34, 0.302, 275, 258, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
2850, 4kikB, 0.7054, 3.58, 0.189, 648, 264, HUMAN IKB KINASE BETA
2851, 4cegA, 0.7054, 3.04, 0.180, 264, 255, CRYSTAL STRUCTURE OF AURORA A 122-403 C290A C393A BOUND TO ADP
2852, 3tudA, 0.7054, 3.06, 0.335, 256, 254, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH N-(4-METHYL-3-(8-METHYL-7- OXO-2-(PHENYLAMINO)-78-DIHYDROPYRIDO[23-D]PYRIMIDIN-6-YL)PHENYL)-3- (TRIFLUOROMETHYL)BENZAMIDE
2853, 3owjA, 0.7054, 3.25, 0.144, 328, 257, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A PYRIDOCARBAZOLE DERIVATIVE INHIBITOR
2854, 3my0I, 0.7054, 3.05, 0.165, 293, 254, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2855, 3ky2B, 0.7054, 3.48, 0.341, 280, 258, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
2856, 2qokA, 0.7054, 3.47, 0.304, 281, 260, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:S768A TRIPLE MUTANT
2857, 2hyyD, 0.7054, 2.73, 0.340, 264, 247, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
2858, 1lr4A, 0.7054, 3.28, 0.143, 327, 258, ROOM TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
2859, 5otiA, 0.7053, 3.25, 0.148, 327, 257, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 27
2860, 4ubaB, 0.7053, 3.26, 0.151, 333, 258, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
2861, 3ddpC, 0.7053, 3.19, 0.171, 298, 258, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
2862, 2v5qB, 0.7053, 3.56, 0.200, 285, 265, CRYSTAL STRUCTURE OF WILD-TYPE PLK-1 KINASE DOMAIN IN COMPLEX WITH A SELECTIVE DARPIN
2863, 1pxiA, 0.7053, 3.16, 0.181, 294, 254, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(25-DICHLORO-THIOPHEN-3-YL)-PYRIMIDIN-2- YLAMINE
2864, 4oh4A, 0.7052, 3.19, 0.184, 299, 255, CRYSTAL STRUCTURE OF BRI1 IN COMPLEX WITH BKI1
2865, 4fkuA, 0.7052, 3.17, 0.177, 293, 254, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
2866, 3tzmA, 0.7052, 2.93, 0.163, 295, 252, TGF-BETA RECEPTOR TYPE 1 IN COMPLEX WITH SB431542
2867, 1k3aA, 0.7052, 3.42, 0.291, 288, 258, STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR KINASE
2868, 4mneA, 0.7051, 3.26, 0.189, 286, 259, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
2869, 4itiB, 0.7051, 2.94, 0.213, 270, 249, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-3 ANALOG
2870, 4eomC, 0.7051, 3.33, 0.165, 275, 261, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
2871, 4eokA, 0.7051, 3.16, 0.160, 293, 257, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
2872, 3tucA, 0.7051, 2.96, 0.333, 257, 252, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH 1-BENZYL-N-(5-(67- DIMETHOXYQUINOLIN-4-YLOXY)PYRIDIN-2-YL)-2-OXO-12-DIHYDROPYRIDINE-3- CARBOXAMIDE
2873, 3my0V, 0.7051, 2.94, 0.171, 282, 252, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2874, 5uuuA, 0.7050, 3.98, 0.170, 414, 276, DESIGN SYNTHESIS AND EVALUATION OF THE FIRST SELECTIVE AND POTENT G- PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2) INHIBITOR FOR THE POTENTIAL TREATMENT OF HEART FAILURE
2875, 5idpA, 0.7050, 3.51, 0.183, 342, 263, CDK8-CYCC IN COMPLEX WITH (3-AMINO-1H-INDAZOL-5-YL)-[(S)-2-(4-FLUORO- PHENYL)-PIPERIDIN-1-YL]-METHANONE
2876, 5cspA, 0.7050, 3.30, 0.151, 327, 258, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
2877, 4rllA, 0.7050, 3.15, 0.145, 329, 256, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
2878, 4ib5C, 0.7050, 3.27, 0.147, 332, 258, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
2879, 1gngA, 0.7050, 3.50, 0.172, 348, 262, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
2880, 5omyA, 0.7049, 3.28, 0.151, 332, 258, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
2881, 5gjdA, 0.7049, 3.15, 0.263, 292, 255, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 2
2882, 5ek7B, 0.7049, 3.35, 0.307, 286, 257, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
2883, 4ygaC, 0.7049, 3.53, 0.194, 449, 263, CDPK1 FROM TOXOPLASMA GONDII BOUND TO INHIBITORY VHH-1B7
2884, 4u42A, 0.7049, 2.93, 0.171, 282, 252, MAP4K4 T181E MUTANT BOUND TO INHIBITOR COMPOUND 1
2885, 3my0C, 0.7049, 3.09, 0.169, 299, 255, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2886, 3f3tA, 0.7049, 3.23, 0.288, 261, 257, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL38 (TYPE III)
2887, 3bhyA, 0.7049, 3.01, 0.202, 268, 253, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH A BETA-CARBOLINE LIGAND
2888, 2oxyA, 0.7049, 3.27, 0.143, 327, 258, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
2889, 2eufB, 0.7049, 3.15, 0.156, 282, 257, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLIN IN COMPLEX WITH THE INHIBITOR PD0332991
2890, 1ctpE, 0.7049, 3.79, 0.191, 332, 272, STRUCTURE OF THE MAMMALIAN CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND AN INHIBITOR PEPTIDE DISPLAYS AN OPEN CONFORMATION
2891, 5oniA, 0.7048, 3.19, 0.148, 334, 257, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
2892, 5mo4A, 0.7048, 3.13, 0.318, 429, 255, ABL1 KINASE (T334I_D382N) IN COMPLEX WITH ASCIMINIB AND NILOTINIB
2893, 5k5xA, 0.7048, 3.56, 0.296, 345, 260, CRYSTAL STRUCTURE OF HUMAN PDGFRA
2894, 5hnbA, 0.7048, 3.50, 0.183, 342, 262, CDK8-CYCC IN COMPLEX WITH [6-HYDROXY-3-(3-METHYL-BENZYL)-1H-INDAZOL-5- YL]-((S)-3-HYDROXY-PYRROLIDIN-1-YL)-METHANONE
2895, 5d12B, 0.7048, 2.85, 0.312, 253, 250, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL40
2896, 5csvA, 0.7048, 3.27, 0.147, 327, 258, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 6 BOUND
2897, 4tyjA, 0.7048, 3.35, 0.329, 278, 255, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
2898, 4mneD, 0.7048, 3.26, 0.189, 285, 259, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
2899, 4md9P, 0.7048, 3.25, 0.151, 328, 258, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
2900, 4ib5B, 0.7048, 3.27, 0.147, 329, 258, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
2901, 4i4fA, 0.7048, 2.91, 0.344, 255, 250, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH AN ALLOSTERIC BINDING PYRAZOLOBENZOTHIAZINE COMPOUND.
2902, 2wtkC, 0.7048, 3.86, 0.147, 285, 272, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
2903, 2qc6A, 0.7048, 3.30, 0.147, 326, 258, PROTEIN KINASE CK2 IN COMPLEX WITH DBC
2904, 2pvjA, 0.7048, 3.28, 0.140, 326, 258, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
2905, 6bfaA, 0.7047, 3.46, 0.198, 464, 263, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1553
2906, 5wniA, 0.7047, 2.81, 0.252, 263, 250, CRYSTAL STRUCTURE OF MURINE RECEPTOR-INTERACTING PROTEIN KINASE 4 (RIPK4) D143N IN COMPLEX WITH ATP 
2907, 5oy6D, 0.7047, 2.85, 0.196, 292, 250, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
2908, 5hlnB, 0.7047, 3.48, 0.172, 346, 262, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
2909, 4rqkA, 0.7047, 3.50, 0.202, 285, 262, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS1
2910, 4mx9A, 0.7047, 3.48, 0.194, 459, 263, CDPK1 FROM NEOSPORA CANINUM IN COMPLEX WITH INHIBITOR UW1294
2911, 4md9E, 0.7047, 3.30, 0.151, 329, 258, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
2912, 3wigA, 0.7047, 3.38, 0.204, 278, 260, HUMAN MEK1 KINASE IN COMPLEX WITH CH5126766 AND MGAMP-PNP
2913, 3fxzA, 0.7047, 3.56, 0.189, 292, 265, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX LAMBDA-FL172
2914, 2helA, 0.7047, 3.03, 0.320, 256, 253, CRYSTAL STRUCTURE OF A MUTANT EPHA4 KINASE DOMAIN (Y742A)
2915, 6ehkA, 0.7046, 3.23, 0.152, 327, 257, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH CAM4712 AND COMPOUND 37
2916, 5vilB, 0.7046, 3.24, 0.203, 271, 256, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 6)
2917, 5uq0A, 0.7046, 3.15, 0.308, 266, 253, FGFR1 KINASE DOMAIN COMPLEX WITH FRAGMENT 22-DIMETHYL-23- DIHYDROBENZOFURAN-7-CARBOXAMIDE
2918, 5owhA, 0.7046, 3.28, 0.151, 334, 258, HIGH SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3-AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
2919, 5n1vB, 0.7046, 3.27, 0.143, 331, 258, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
2920, 5lvlA, 0.7046, 3.50, 0.202, 285, 262, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND PS653 BOUND TO THE ATP-BINDING SITE
2921, 4aojB, 0.7046, 2.96, 0.302, 258, 252, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
2922, 2oxdA, 0.7046, 3.28, 0.151, 325, 258, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE K17 K22 AND K32 INHIBITORS
2923, 1jamA, 0.7046, 3.31, 0.147, 327, 258, CRYSTAL STRUCTURE OF APO-FORM OF Z. MAYS CK2 PROTEIN KINASE ALPHA SUBUNIT
2924, 5lqfA, 0.7045, 2.95, 0.185, 287, 254, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
2925, 5dt3A, 0.7045, 3.05, 0.180, 263, 255, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
2926, 5d11A, 0.7045, 2.88, 0.304, 254, 250, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL235
2927, 5cu6A, 0.7045, 3.31, 0.151, 327, 258, CRYSTAL STRUCTURE OF CK2ALPHA
2928, 4md9F, 0.7045, 3.23, 0.148, 327, 257, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
2929, 4ficA, 0.7045, 2.57, 0.291, 251, 244, KINASE DOMAIN OF CSRC IN COMPLEX WITH A HINGE REGION-BINDING FRAGMENT
2930, 3blrA, 0.7045, 3.48, 0.148, 300, 263, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH FLAVOPIRIDOL
2931, 3b8qB, 0.7045, 2.98, 0.316, 271, 250, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
2932, 2zv9A, 0.7045, 2.94, 0.317, 256, 252, LYN TYROSINE KINASE DOMAIN-PP2 COMPLEX
2933, 2qu6B, 0.7045, 2.86, 0.308, 260, 247, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
2934, 2pvrA, 0.7045, 3.30, 0.147, 328, 258, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 (C- TERMINAL DELETION MUTANT 1-335) IN COMPLEX WITH TWO SULFATE IONS
2935, 2bpmA, 0.7045, 3.59, 0.158, 302, 265, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
2936, 5e91A, 0.7044, 2.95, 0.203, 297, 251, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH 3-AMINO-6-[4-(2- HYDROXYETHYL)PHENYL]-N-[4- (MORPHOLIN-4-YL)PYRIDIN-3-YL] PYRAZINE-2-CARBOXAMIDE
2937, 5c01B, 0.7044, 2.64, 0.206, 260, 247, CRYSTAL STRUCTURE OF KINASE
2938, 4lueB, 0.7044, 2.61, 0.310, 417, 242, CRYSTAL STRUCTURE OF HCK IN COMPLEX WITH 7-[TRANS-4-(4- METHYLPIPERAZIN-1-YL)CYCLOHEXYL]-5-(4-PHENOXYPHENYL)-7H-PYRROLO[23- D]PYRIMIDIN-4-AMINE (RESULTING FROM DISPLACEMENT OF SKF86002)
2939, 1pw2A, 0.7044, 3.18, 0.177, 294, 254, APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2
2940, 5otyA, 0.7043, 3.24, 0.152, 327, 257, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH CAM4712
2941, 5ooiA, 0.7043, 3.19, 0.121, 329, 257, STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
2942, 5if1A, 0.7043, 3.34, 0.157, 298, 261, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
2943, 4i3zC, 0.7043, 3.40, 0.165, 295, 260, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
2944, 4i3zA, 0.7043, 3.40, 0.165, 295, 260, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
2945, 4fr4C, 0.7043, 4.05, 0.178, 344, 276, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
2946, 2oxxA, 0.7043, 3.29, 0.151, 325, 258, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
2947, 2jedB, 0.7043, 3.55, 0.174, 320, 265, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
2948, 5ikwA, 0.7042, 3.00, 0.139, 297, 252, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
2949, 5fboA, 0.7042, 2.89, 0.300, 255, 250, BTK-INHIBITOR CO-STRUCTURE
2950, 5dn3A, 0.7042, 3.14, 0.183, 264, 257, AURORA A IN COMPLEX WITH ATP AND AA35.
2951, 4ae6A, 0.7042, 3.60, 0.176, 319, 267, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
2952, 3e3bX, 0.7042, 3.12, 0.129, 334, 256, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2ALPHA PRIME WITH A POTENT INDAZOLE-DERIVATIVE INHIBITOR
2953, 2v5qA, 0.7042, 3.52, 0.197, 285, 264, CRYSTAL STRUCTURE OF WILD-TYPE PLK-1 KINASE DOMAIN IN COMPLEX WITH A SELECTIVE DARPIN
2954, 2hwoA, 0.7042, 2.79, 0.285, 251, 246, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR
2955, 5orlA, 0.7041, 3.04, 0.180, 264, 255, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2956, 4ii5C, 0.7041, 3.40, 0.165, 295, 260, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
2957, 4ii5A, 0.7041, 3.40, 0.165, 295, 260, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
2958, 3dbeA, 0.7041, 3.39, 0.195, 284, 261, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 557
2959, 3bhuC, 0.7041, 3.31, 0.166, 271, 259, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
2960, 5ts8A, 0.7040, 3.31, 0.155, 332, 258, Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 56-DIBROMOBENZOTRIAZOLE
2961, 5owlA, 0.7040, 3.24, 0.144, 331, 257, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
2962, 5nqcA, 0.7040, 3.40, 0.150, 331, 260, CK2ALPHA IN COMPLEX WITH NMR154
2963, 4mxaA, 0.7040, 3.46, 0.198, 459, 263, CDPK1 FROM NEOSPORA CANINUM IN COMPLEX WITH INHIBITOR RM-1-132
2964, 4m84A, 0.7040, 3.47, 0.198, 464, 263, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1455
2965, 4j1rD, 0.7040, 3.52, 0.188, 345, 261, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
2966, 4j1rB, 0.7040, 3.52, 0.184, 346, 261, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
2967, 4j1rA, 0.7040, 3.52, 0.184, 343, 261, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
2968, 4anmA, 0.7040, 3.29, 0.143, 328, 258, COMPLEX OF CK2 WITH A CDC7 INHIBITOR
2969, 3kxnA, 0.7040, 3.29, 0.147, 327, 258, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR TETRAIODOBENZIMIDAZOLE (K88)
2970, 5vamB, 0.7039, 2.77, 0.226, 260, 248, BRAF IN COMPLEX WITH RAF709
2971, 5oslA, 0.7039, 3.26, 0.148, 328, 257, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 7
2972, 5hngA, 0.7039, 3.25, 0.206, 280, 257, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2973, 4utdA, 0.7039, 3.04, 0.180, 266, 255, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP IN AN ACTIVE CONFORMATION
2974, 4fr4B, 0.7039, 4.17, 0.180, 350, 278, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
2975, 4debA, 0.7039, 3.25, 0.181, 264, 259, AURORA A IN COMPLEX WITH RK2-17-01
2976, 3v5lB, 0.7039, 2.15, 0.324, 241, 238, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
2977, 3tz9A, 0.7039, 3.28, 0.284, 261, 257, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL130
2978, 3rpoA, 0.7039, 3.23, 0.173, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-156
2979, 3qgwB, 0.7039, 2.12, 0.312, 240, 237, CRYSTAL STRUCTURE OF ITK KINASE BOUND TO AN INHIBITOR
2980, 3q9yA, 0.7039, 3.24, 0.148, 327, 257, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 8.5
2981, 3q6uA, 0.7039, 3.40, 0.331, 287, 257, STRUCTURE OF THE APO MET RECEPTOR KINASE IN THE DUALLY-PHOSPHORYLATED ACTIVATED STATE
2982, 3eflB, 0.7039, 2.81, 0.308, 263, 247, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH MOTESANIB
2983, 2c4gA, 0.7039, 3.55, 0.155, 301, 264, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
2984, 1hclA, 0.7039, 3.26, 0.173, 294, 255, HUMAN CYCLIN-DEPENDENT KINASE 2
2985, 5ortA, 0.7038, 3.14, 0.180, 264, 256, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2986, 5ek7A, 0.7038, 3.42, 0.310, 286, 258, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
2987, 4j1rC, 0.7038, 3.53, 0.184, 344, 261, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
2988, 3my0D, 0.7038, 3.07, 0.169, 298, 254, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
2989, 2xbaA, 0.7038, 3.58, 0.269, 283, 260, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PHA-E429
2990, 2uzdA, 0.7038, 3.36, 0.162, 295, 259, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
2991, 2hyyC, 0.7038, 2.77, 0.344, 262, 247, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
2992, 6gt1C, 0.7037, 2.72, 0.185, 257, 248, NEK7 BOUND TO PURINE INHIBITOR 
2993, 6fniA, 0.7037, 3.21, 0.307, 261, 254, CRYSTAL STRUCTURE OF EPHRIN B4 (EPHB4) RECEPTOR PROTEIN KINASE WITH NVP-BHG712 
2994, 5oy4A, 0.7037, 3.52, 0.176, 349, 262, GSK3BETA COMPLEX WITH N-(6-(34-DIHYDROXYPHENYL)-1H-PYRAZOLO[34- B]PYRIDIN-3-YL)ACETAMIDE
2995, 5f94B, 0.7037, 3.55, 0.172, 349, 262, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
2996, 5aneA, 0.7037, 3.10, 0.182, 294, 253, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-METHOXY-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
2997, 4wa9A, 0.7037, 2.64, 0.347, 246, 242, THE CRYSTAL STRUCTURE OF HUMAN ABL1 WILD TYPE KINASE DOMAIN IN COMPLEX WITH AXITINIB
2998, 4qmlA, 0.7037, 3.57, 0.231, 280, 264, MST3 IN COMPLEX WITH AMP-PNP
2999, 4gu9B, 0.7037, 3.25, 0.346, 255, 254, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH (2-FLUORO- PHENYL)-(1H-PYRAZOLO[34-D]PYRIMIDIN-4-YL)-AMINE
3000, 4eonC, 0.7037, 3.42, 0.157, 298, 261, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
3001, 5vioB, 0.7036, 3.28, 0.198, 271, 257, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 13)
3002, 5os8A, 0.7036, 3.23, 0.148, 327, 257, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 11
3003, 5ooiB, 0.7036, 3.29, 0.120, 325, 258, STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
3004, 5m4cA, 0.7036, 3.28, 0.143, 329, 258, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER LOW-SALT CONDITIONS
3005, 5cu0A, 0.7036, 3.26, 0.148, 327, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
3006, 4yjrA, 0.7036, 3.21, 0.341, 263, 252, SYK KINASE DOMAIN IN COMPLEX WITH INHIBITOR GTC000225
3007, 4twoA, 0.7036, 3.40, 0.301, 278, 259, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH COMPOUND 164
3008, 3fwqB, 0.7036, 3.49, 0.149, 334, 261, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
3009, 3a8wA, 0.7036, 3.53, 0.166, 326, 265, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
3010, 5movA, 0.7035, 3.21, 0.148, 325, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0633 BOUND
3011, 4kioD, 0.7035, 2.19, 0.310, 242, 239, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
3012, 4eopA, 0.7035, 3.29, 0.162, 297, 259, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
3013, 4bggC, 0.7035, 2.76, 0.182, 279, 247, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
3014, 3qx2A, 0.7035, 3.24, 0.176, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-190
3015, 2zv7A, 0.7035, 2.95, 0.313, 257, 252, LYN TYROSINE KINASE DOMAIN APO FORM
3016, 5ur1A, 0.7034, 3.23, 0.311, 278, 254, FGFR1 KINASE DOMAIN COMPLEX WITH SN37333 IN REVERSIBLE BINDING MODE
3017, 5i3oA, 0.7034, 3.02, 0.139, 302, 252, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3018, 5hbhA, 0.7034, 3.49, 0.161, 336, 261, CDK8-CYCC IN COMPLEX WITH 5-{5-CHLORO-4-[1-(2-METHOXY-ETHYL)-18- DIAZA-SPIRO[4.5]DEC-8-YL]-PYRIDIN-3-YL}-1-METHYL-13-DIHYDRO- BENZO[C]ISOTHIAZOLE 22-DIOXIDE
3019, 5deyA, 0.7034, 3.79, 0.190, 295, 268, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
3020, 4eoiC, 0.7034, 3.33, 0.166, 296, 259, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
3021, 4cfxA, 0.7034, 3.43, 0.153, 298, 262, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
3022, 3r8pA, 0.7034, 3.09, 0.182, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-6
3023, 1uu8A, 0.7034, 3.27, 0.206, 277, 257, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-1
3024, 1f0qA, 0.7034, 3.30, 0.151, 329, 258, CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT OF PROTEIN KINASE CK2 IN COMPLEX WITH THE NUCLEOTIDE COMPETITIVE INHIBITOR EMODIN
3025, 5vioA, 0.7033, 3.25, 0.203, 271, 256, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 13)
3026, 5nwzA, 0.7033, 3.17, 0.308, 271, 253, FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE DOMAIN (449-753) IN COMPLEX WITH IRREVERSIBLE LIGAND CGA159527
3027, 4fr4F, 0.7033, 4.13, 0.173, 346, 277, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
3028, 3r71A, 0.7033, 3.24, 0.173, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-162
3029, 3og7B, 0.7033, 2.69, 0.231, 254, 247, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX4032
3030, 2qi8B, 0.7033, 2.72, 0.301, 249, 246, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN
3031, 5m4fA, 0.7032, 3.28, 0.143, 330, 258, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER LOW-SALT CONDITIONS
3032, 5hieB, 0.7032, 2.82, 0.217, 259, 249, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
3033, 5e92A, 0.7032, 3.04, 0.202, 298, 252, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH AMPPNP
3034, 4xv2B, 0.7032, 2.54, 0.230, 249, 243, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH DABRAFENIB
3035, 4u44B, 0.7032, 3.61, 0.175, 296, 263, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
3036, 4o0sA, 0.7032, 3.20, 0.183, 265, 257, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
3037, 3ii5A, 0.7032, 2.82, 0.225, 262, 249, THE COMPLEX OF WILD-TYPE B-RAF WITH PYRAZOLO PYRIMIDINE INHIBITOR
3038, 5hbeA, 0.7031, 3.68, 0.181, 344, 265, CDK8-CYCC IN COMPLEX WITH 8-[3-CHLORO-5-(1-METHYL-22-DIOXO-2 3- DIHYDRO-1H-2L6-BENZO[C]ISOTHIAZOL-5-YL)-PYRIDIN- 4-YL]-1-OXA-38- DIAZA-SPIRO[4.5]DECAN-2-ONE
3039, 5cu2A, 0.7031, 3.25, 0.152, 328, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
3040, 4md9K, 0.7031, 3.25, 0.156, 328, 257, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
3041, 4m97A, 0.7031, 3.57, 0.201, 465, 264, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM NEOSPORA CANINUM
3042, 3qtiB, 0.7031, 3.23, 0.336, 280, 253, C-MET KINASE IN COMPLEX WITH NVP-BVU972
3043, 3i79A, 0.7031, 3.57, 0.193, 455, 264, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1)
3044, 3c1xA, 0.7031, 3.52, 0.326, 290, 258, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A PYRROLOTRIAZINE BASED INHIBITOR
3045, 5otrA, 0.7030, 3.30, 0.152, 327, 257, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 14
3046, 5orhB, 0.7030, 3.20, 0.148, 325, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 2
3047, 5dnrA, 0.7030, 3.11, 0.184, 264, 256, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P41212
3048, 5ct7A, 0.7030, 2.78, 0.223, 257, 247, BRAF IN COMPLEX WITH RAF265
3049, 4md9L, 0.7030, 3.32, 0.147, 328, 258, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
3050, 4lfiB, 0.7030, 3.31, 0.147, 371, 258, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
3051, 4lfiA, 0.7030, 3.31, 0.147, 370, 258, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
3052, 4ksqA, 0.7030, 2.81, 0.222, 258, 248, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR 5B
3053, 3o17B, 0.7030, 3.01, 0.193, 357, 254, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
3054, 3bz3A, 0.7030, 3.41, 0.345, 259, 258, CRYSTAL STRUCTURE ANALYSIS OF FOCAL ADHESION KINASE WITH A METHANESULFONAMIDE DIAMINOPYRIMIDINE INHIBITOR
3055, 2e2bB, 0.7030, 2.63, 0.348, 262, 244, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH INNO-406
3056, 6cz4A, 0.7029, 2.91, 0.278, 257, 248, STRUCTURE OF THE PTK6 KINASE DOMAIN BOUND TO A TYPE II INHIBITOR 2- {[(3R;4S)-3-FLUORO-1-{[4-(TRIFLUOROMETHOXY)PHENYL]ACETYL}PIPERIDIN-4- YL]OXY}-5-(1-METHYL-1H-IMIDAZOL-4-YL)PYRIDINE-3-CARBOXAMIDE 
3057, 5os7A, 0.7029, 3.29, 0.148, 326, 257, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 4
3058, 5n1vA, 0.7029, 3.30, 0.147, 331, 258, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
3059, 4hw7A, 0.7029, 3.30, 0.295, 289, 254, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR PLX647-OME
3060, 4g9rA, 0.7029, 2.83, 0.230, 262, 248, B-RAF V600E KINASE DOMAIN BOUND TO A TYPE II DIHYDROQUINAZOLINE INHIBITOR
3061, 4eoqC, 0.7029, 3.39, 0.165, 275, 261, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
3062, 4eopC, 0.7029, 3.39, 0.162, 296, 260, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
3063, 4a06A, 0.7029, 3.28, 0.205, 282, 258, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS114 BOUND TO THE PIF-POCKET
3064, 3rpsA, 0.7029, 3.27, 0.148, 334, 257, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
3065, 2hiwB, 0.7029, 3.07, 0.340, 274, 253, CRYSTAL STRUCTURE OF INACTIVE CONFORMATION ABL KINASE CATALYTIC DOMAIN COMPLEXED WITH TYPE II INHIBITOR
3066, 1h1sC, 0.7029, 3.42, 0.165, 296, 260, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
3067, 6gmdB, 0.7028, 3.29, 0.148, 326, 257, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 3 
3068, 5i3rA, 0.7028, 3.03, 0.139, 302, 252, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3069, 4wg5A, 0.7028, 3.48, 0.191, 464, 262, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1647
3070, 4rwjB, 0.7028, 3.38, 0.319, 282, 257, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
3071, 4rvtB, 0.7028, 3.76, 0.170, 297, 265, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
3072, 4rvtA, 0.7028, 3.07, 0.163, 281, 252, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
3073, 4o0rA, 0.7028, 3.58, 0.196, 293, 265, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
3074, 4l44A, 0.7028, 3.60, 0.175, 321, 263, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM II)
3075, 3twjB, 0.7028, 3.70, 0.152, 395, 263, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1447
3076, 3sc1A, 0.7028, 3.21, 0.211, 278, 256, NOVEL ISOQUINOLONE PDK1 INHIBITORS DISCOVERED THROUGH FRAGMENT-BASED LEAD DISCOVERY
3077, 3r7yA, 0.7028, 3.17, 0.173, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-88
3078, 3ej1A, 0.7028, 3.27, 0.154, 295, 259, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
3079, 2wpaA, 0.7028, 3.45, 0.163, 302, 263, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
3080, 2cchA, 0.7028, 3.33, 0.162, 296, 259, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
3081, 1om1A, 0.7028, 3.31, 0.151, 325, 258, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH IQA
3082, 1m2rA, 0.7028, 3.31, 0.155, 327, 258, CRYSTAL STRUCTURE OF 58-DI-AMINO-14-DI-HYDROXY- ANTHRAQUINONE/CK2 KINASE COMPLEX
3083, 1j91B, 0.7028, 3.38, 0.139, 327, 259, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
3084, 1j91A, 0.7028, 3.31, 0.147, 327, 258, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
3085, 5xqxA, 0.7027, 3.43, 0.185, 340, 260, HUMAN CDK8-CYCC IN COMPLEX WITH COMPOUND 4: N-METHYL-4-(4-PYRIDYL)-1H- PYRROLE-2-CARBOXAMIDE
3086, 5vilC, 0.7027, 3.23, 0.203, 271, 256, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 6)
3087, 5mmrA, 0.7027, 3.28, 0.148, 326, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
3088, 5ct7B, 0.7027, 2.55, 0.221, 254, 244, BRAF IN COMPLEX WITH RAF265
3089, 5csxA, 0.7027, 2.89, 0.229, 261, 249, CRYSTAL STRUCTURE OF B-RAF IN COMPLEX WITH BI 882370
3090, 3rpsB, 0.7027, 3.32, 0.151, 334, 258, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
3091, 3my0T, 0.7027, 3.04, 0.166, 292, 253, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3092, 3krwA, 0.7027, 3.97, 0.182, 618, 274, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (SOAK)
3093, 3gqlB, 0.7027, 3.32, 0.307, 276, 257, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
3094, 3d94A, 0.7027, 3.29, 0.304, 288, 253, CRYSTAL STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE IN COMPLEX WITH PQIP
3095, 2zjwA, 0.7027, 3.25, 0.144, 332, 257, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH ELLAGIC ACID
3096, 1uv5A, 0.7027, 3.52, 0.164, 348, 262, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH 6-BROMOINDIRUBIN-3 -OXIME
3097, 1ol7A, 0.7027, 3.13, 0.180, 261, 255, STRUCTURE OF HUMAN AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288
3098, 1mq4A, 0.7027, 3.10, 0.184, 261, 255, CRYSTAL STRUCTURE OF AURORA-A PROTEIN KINASE
3099, 1m2pA, 0.7027, 3.32, 0.151, 325, 258, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO- ANTHRAQUINONE/CK2 KINASE COMPLEX
3100, 4pteB, 0.7026, 3.57, 0.167, 347, 263, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
3101, 4l46A, 0.7026, 3.78, 0.180, 317, 266, CRYSTAL STRUCTURES OF HUMAN P70S6K1-WT
3102, 4kioA, 0.7026, 2.10, 0.325, 240, 237, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
3103, 3zrmA, 0.7026, 3.53, 0.179, 344, 262, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
3104, 3krxA, 0.7026, 4.06, 0.167, 618, 275, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (CO-CRYSTAL)
3105, 3bhhD, 0.7026, 3.43, 0.147, 286, 259, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
3106, 2qonA, 0.7026, 3.53, 0.306, 281, 258, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:Y742A TRIPLE MUTANT
3107, 2bkzA, 0.7026, 3.54, 0.163, 302, 264, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
3108, 5otzA, 0.7025, 3.25, 0.148, 327, 257, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 1
3109, 5ho8A, 0.7025, 3.15, 0.212, 278, 255, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
3110, 5cu0B, 0.7025, 3.28, 0.144, 325, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
3111, 4qfgA, 0.7025, 3.08, 0.208, 365, 255, STRUCTURE OF AMPK IN COMPLEX WITH STAUROSPORINE INHIBITOR AND IN THE ABSENCE OF A SYNTHETIC ACTIVATOR
3112, 4e3cA, 0.7025, 3.59, 0.170, 624, 264, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
3113, 3v5lC, 0.7025, 2.29, 0.317, 244, 240, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
3114, 3nczB, 0.7025, 3.90, 0.149, 379, 269, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT 2H-ISOQUINOLIN-1-ONE INHIBITOR
3115, 3f3wB, 0.7025, 3.29, 0.292, 260, 257, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
3116, 2y7jA, 0.7025, 3.09, 0.179, 284, 257, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
3117, 2oxyB, 0.7025, 3.32, 0.143, 327, 258, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
3118, 6b2eA, 0.7024, 3.08, 0.204, 442, 255, STRUCTURE OF FULL LENGTH HUMAN AMPK (A2B2G1) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR SC4. 
3119, 5ct0A, 0.7024, 3.29, 0.144, 326, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
3120, 3uo4A, 0.7024, 3.27, 0.178, 266, 259, AURORA A IN COMPLEX WITH RPM1680
3121, 3eocA, 0.7024, 3.26, 0.158, 295, 259, CDK2/CYCLINA COMPLEXED WITH A IMIDAZO TRIAZIN-2-AMINE
3122, 2gsfA, 0.7024, 3.47, 0.301, 281, 259, THE HUMAN EPHA3 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
3123, 6gihA, 0.7023, 3.25, 0.153, 324, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH CAM187 BOUND 
3124, 4w9wA, 0.7023, 3.02, 0.143, 306, 252, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH SMALL MOLECULE AZD-7762
3125, 4bn1A, 0.7023, 3.13, 0.184, 261, 255, CRYSTAL STRUCTURE OF V174M MUTANT OF AURORA-A KINASE
3126, 3sxfA, 0.7023, 3.70, 0.192, 452, 266, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR RM-1-89
3127, 3fl5A, 0.7023, 3.32, 0.143, 324, 258, PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR QUINALIZARIN
3128, 3bhtC, 0.7023, 3.36, 0.166, 270, 259, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
3129, 1pjkA, 0.7023, 3.29, 0.144, 331, 257, CRYSTAL STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
3130, 1na7A, 0.7023, 3.25, 0.140, 326, 257, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2
3131, 5ci7A, 0.7022, 3.01, 0.202, 276, 252, STRUCTURE OF ULK1 BOUND TO A SELECTIVE INHIBITOR
3132, 4yznA, 0.7022, 3.19, 0.239, 269, 255, HUMANIZED ROCO4 BOUND TO COMPOUND 19
3133, 4y85A, 0.7022, 3.25, 0.171, 307, 257, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(5-(1H-INDOL- 3-YL)-1H-PYRROLO[23-B]PYRIDIN-3-YL)-134-OXADIAZOL-2-AMINE
3134, 3v5jA, 0.7022, 2.21, 0.311, 241, 238, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 090
3135, 3pj8A, 0.7022, 3.10, 0.182, 288, 253, STRUCTURE OF CDK2 IN COMPLEX WITH A PYRAZOLO[43-D]PYRIMIDINE BIOISOSTERE OF ROSCOVITINE.
3136, 3h30B, 0.7022, 3.45, 0.150, 333, 260, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
3137, 3fy0A, 0.7022, 3.66, 0.189, 292, 265, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX DW1
3138, 2clqA, 0.7022, 2.74, 0.210, 263, 248, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
3139, 2c4gC, 0.7022, 3.50, 0.160, 300, 263, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
3140, 5ya5A, 0.7021, 2.87, 0.344, 273, 247, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH NOVEL INHIBITOR 
3141, 5h8gA, 0.7021, 3.21, 0.141, 324, 256, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7B
3142, 3kxhA, 0.7021, 3.32, 0.143, 326, 258, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR (2-DYMETHYLAMMINO-4567-TETRABROMOBENZOIMIDAZOL-1YL- ACETIC ACID (K66)
3143, 3bhuA, 0.7021, 3.22, 0.167, 297, 258, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
3144, 5w8rA, 0.7020, 3.46, 0.198, 456, 262, TOXOPLASMA GONDII CDPK1 IN COMPLEX WITH INHIBITOR 3CIB-PPI
3145, 5m4uA, 0.7020, 3.20, 0.121, 332, 256, ORTHORHOMBIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
3146, 4j71A, 0.7020, 3.57, 0.176, 347, 262, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
3147, 4fr4D, 0.7020, 4.15, 0.173, 346, 277, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
3148, 3v5wA, 0.7020, 4.22, 0.173, 623, 277, HUMAN G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH SOLUBLE GBETAGAMMA SUBUNITS AND PAROXETINE
3149, 3u4uA, 0.7020, 3.29, 0.140, 327, 257, CASEIN KINASE 2 IN COMPLEX WITH AZ-INHIBITOR
3150, 3rm6A, 0.7020, 3.23, 0.173, 293, 254, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-80
3151, 3od6X, 0.7020, 3.06, 0.198, 344, 252, CRYSTAL STRUCTURE OF P38ALPHA Y323T ACTIVE MUTANT
3152, 5lqfD, 0.7019, 2.91, 0.183, 285, 252, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
3153, 5i5zA, 0.7019, 3.68, 0.182, 345, 264, CDK8-CYCC IN COMPLEX WITH 8-(1-METHYL-22-DIOXO-23-DIHYDRO-1H-2L6- BENZO[C]ISOTHIAZOL-5-YL)-[16]NAPHTHYRIDINE-2-CARBOXYLIC ACID METHYLAMIDE
3154, 5hvkA, 0.7019, 3.50, 0.207, 297, 261, CRYSTAL STRUCTURE OF LIMK1 MUTANT D460N IN COMPLEX WITH FULL-LENGTH COFILIN-1
3155, 4ptgB, 0.7019, 3.52, 0.176, 332, 262, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
3156, 4gu6B, 0.7019, 3.27, 0.341, 258, 255, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
3157, 3zrkA, 0.7019, 3.55, 0.179, 345, 262, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
3158, 3up7A, 0.7019, 3.27, 0.181, 264, 259, AURORA A IN COMPLEX WITH YL1-038-09
3159, 1h1rC, 0.7019, 3.39, 0.162, 296, 260, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
3160, 6bfnB, 0.7018, 3.22, 0.165, 294, 255, CRYSTAL STRUCTURE OF HUMAN IRAK1
3161, 5cswB, 0.7018, 2.74, 0.228, 252, 246, B-RAF IN COMPLEX WITH DABRAFENIB
3162, 4r7iA, 0.7018, 3.30, 0.295, 290, 254, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR GLEEVEC
3163, 3v5lA, 0.7018, 2.14, 0.325, 240, 237, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 542
3164, 2vwvA, 0.7018, 3.03, 0.304, 255, 250, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3165, 2c6tA, 0.7018, 3.32, 0.167, 295, 258, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3166, 1qmzC, 0.7018, 3.39, 0.166, 296, 259, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
3167, 1finA, 0.7018, 3.43, 0.145, 298, 262, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
3168, 5mo7A, 0.7017, 3.30, 0.148, 327, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
3169, 5cyiA, 0.7017, 3.45, 0.164, 298, 262, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
3170, 4y85B, 0.7017, 3.24, 0.171, 306, 257, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(5-(1H-INDOL- 3-YL)-1H-PYRROLO[23-B]PYRIDIN-3-YL)-134-OXADIAZOL-2-AMINE
3171, 4kspA, 0.7017, 2.74, 0.228, 257, 246, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR TAK-632
3172, 3lokA, 0.7017, 2.67, 0.307, 248, 244, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR PD168393
3173, 1uwjA, 0.7017, 3.02, 0.219, 264, 251, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
3174, 6ehuB, 0.7016, 3.32, 0.152, 327, 257, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
3175, 6cd6C, 0.7016, 3.21, 0.169, 265, 255, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH GSK650394
3176, 4wovA, 0.7016, 2.65, 0.207, 258, 246, CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH BMS-066 AKA 2-METHOXY-N-({6-[3-METHYL-7-(METHYLAMINO)- 35810-TETRAAZATRICYCLO[7.3.0.0 6]DODECA-1(9)2(6)4711-PENTAEN- 11-YL]PYRIDIN-2-YL}METHY L)ACETAMIDE
3177, 4cfuC, 0.7016, 3.44, 0.165, 272, 261, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
3178, 4aw5A, 0.7016, 3.07, 0.306, 261, 252, COMPLEX OF THE EPHB4 KINASE DOMAIN WITH AN OXINDOLE INHIBITOR
3179, 3twjD, 0.7016, 3.98, 0.149, 395, 268, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1447
3180, 3qqlA, 0.7016, 3.22, 0.181, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR L3
3181, 3owlA, 0.7016, 3.26, 0.148, 330, 257, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
3182, 2y7jB, 0.7016, 3.15, 0.187, 281, 256, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
3183, 2clxA, 0.7016, 3.09, 0.183, 293, 252, 4-ARYLAZO-35-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY CRYSTAL STRUCTURE IN COMPLEX WITH CDK2 SELECTIVITY AND CELLULAR EFFECTS
3184, 5mmfA, 0.7015, 3.30, 0.148, 326, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
3185, 5iexA, 0.7015, 3.05, 0.175, 285, 251, CRYSTAL STRUCTURE OF (RS)-S-{4-[(5-BROMO-4-{[(2R3R)-2-HYDROXY-1- METHYLPROPYL]OXY}- PYRIMIDIN-2-YL)AMINO]PHENYL}-S- CYCLOPROPYLSULFOXIMIDE BOUND TO CDK2
3186, 5f94A, 0.7015, 3.56, 0.164, 346, 262, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
3187, 4zp5B, 0.7015, 3.85, 0.165, 300, 266, MAP4K4 IN COMPLEX WITH INHIBITOR
3188, 4kabA, 0.7015, 3.18, 0.337, 255, 252, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 3-METHYL-14- DIHYDRO-PYRAZOLO[45-C]PYRAZOLE
3189, 3v5qB, 0.7015, 3.00, 0.300, 265, 250, DISCOVERY OF A SELECTIVE TRK INHIBITOR WITH EFFICACY IN RODENT CANCER TUMOR MODELS
3190, 3rzfA, 0.7015, 3.57, 0.189, 541, 264, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPAB KINASE BETA (I4122)
3191, 3o2mB, 0.7015, 2.99, 0.182, 358, 253, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
3192, 2c6iA, 0.7015, 3.09, 0.179, 292, 252, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3193, 1zoeA, 0.7015, 3.34, 0.147, 325, 258, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
3194, 1qmzA, 0.7015, 3.39, 0.166, 296, 259, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
3195, 1pyxA, 0.7015, 3.53, 0.164, 343, 262, GSK-3 BETA COMPLEXED WITH AMP-PNP
3196, 5oumA, 0.7014, 3.28, 0.152, 326, 257, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 21
3197, 5m56B, 0.7014, 3.30, 0.120, 328, 258, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
3198, 5hieA, 0.7014, 2.78, 0.198, 258, 248, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
3199, 5cu2B, 0.7014, 3.22, 0.145, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
3200, 4mk0A, 0.7014, 4.09, 0.175, 631, 275, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH A A RATIONALLY DESIGNED PAROXETINE DERIVATIVE
3201, 4kaoB, 0.7014, 3.19, 0.344, 254, 253, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-(5-TERT- BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-(4-PYRIDIN-3- YL-PHENYL)-UREA
3202, 4ez7A, 0.7014, 3.28, 0.163, 302, 258, CDK2 IN COMPLEX WITH STAUROSPORINE AND 2 MOLECULES OF 8-ANILINO-1- NAPHTHALENE SULFONIC ACID
3203, 3f69B, 0.7014, 3.23, 0.145, 282, 256, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
3204, 2og8A, 0.7014, 2.61, 0.295, 246, 244, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 36 BOUND TO LCK
3205, 5modA, 0.7013, 3.30, 0.152, 327, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
3206, 5cx9A, 0.7013, 3.28, 0.152, 328, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
3207, 5cswA, 0.7013, 2.67, 0.216, 254, 245, B-RAF IN COMPLEX WITH DABRAFENIB
3208, 4ptcA, 0.7013, 3.55, 0.168, 342, 262, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
3209, 4nu1A, 0.7013, 3.66, 0.163, 356, 264, CRYSTAL STRUCTURE OF A TRANSITION STATE MIMIC OF THE GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED N-TERMINAL AUTO-INHIBITORY PS9 PEPTIDE
3210, 4j8nC, 0.7013, 3.20, 0.179, 266, 257, AURORA A KINASE APO
3211, 4imyC, 0.7013, 3.46, 0.153, 310, 262, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
3212, 4dymA, 0.7013, 2.91, 0.196, 293, 250, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH THE IMIDAZO[12-B]PYRIDAZINE INHIBITOR K00135
3213, 3pyyA, 0.7013, 2.87, 0.343, 265, 248, DISCOVERY AND CHARACTERIZATION OF A CELL-PERMEABLE SMALL-MOLECULE C- ABL KINASE ACTIVATOR THAT BINDS TO THE MYRISTOYL BINDING SITE
3214, 3mssB, 0.7013, 2.66, 0.348, 264, 244, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
3215, 3ku2A, 0.7013, 3.46, 0.191, 457, 262, CRYSTAL STRUCTURE OF INACTIVATED FORM OF CDPK1 FROM TOXOPLASMA GONDII TGME49.101440
3216, 2xchA, 0.7013, 3.31, 0.206, 278, 257, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
3217, 1y8yA, 0.7013, 3.14, 0.183, 292, 252, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
3218, 1pxmA, 0.7013, 2.99, 0.184, 290, 250, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 3-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL
3219, 5moeA, 0.7012, 3.22, 0.148, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
3220, 4pnkA, 0.7012, 4.21, 0.169, 625, 278, G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GSK180736A
3221, 4j8nB, 0.7012, 3.20, 0.179, 266, 257, AURORA A KINASE APO
3222, 4itiA, 0.7012, 3.18, 0.215, 272, 251, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-3 ANALOG
3223, 3nunA, 0.7012, 3.25, 0.203, 278, 256, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH LEAD COMPOUND
3224, 5ot5B, 0.7011, 3.25, 0.152, 325, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 24
3225, 5os7B, 0.7011, 3.22, 0.152, 325, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 4
3226, 5c01A, 0.7011, 2.66, 0.203, 258, 246, CRYSTAL STRUCTURE OF KINASE
3227, 4mneH, 0.7011, 3.35, 0.189, 275, 259, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3228, 4j8nA, 0.7011, 3.20, 0.179, 266, 257, AURORA A KINASE APO
3229, 4cfwA, 0.7011, 3.44, 0.156, 299, 262, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
3230, 3n51A, 0.7011, 3.66, 0.189, 448, 265, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR RM-1-95
3231, 3lq8A, 0.7011, 3.17, 0.343, 278, 251, STRUCTURE OF THE KINASE DOMAIN OF C-MET BOUND TO XL880 (GSK1363089)
3232, 3bhvC, 0.7011, 3.40, 0.165, 271, 260, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
3233, 2v0dA, 0.7011, 3.14, 0.183, 292, 252, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
3234, 6gmdA, 0.7010, 3.22, 0.152, 325, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 3 
3235, 6b8uA, 0.7010, 2.76, 0.224, 253, 246, CRYSTALS STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINYL BENZAMIDE INHIBITOR
3236, 5orjA, 0.7010, 3.23, 0.148, 325, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 3
3237, 5mpjA, 0.7010, 3.28, 0.148, 326, 257, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
3238, 5kkrC, 0.7010, 3.63, 0.200, 309, 265, KSR2:MEK1 COMPLEX BOUND TO THE SMALL MOLECULE APS-2-79
3239, 5ieyA, 0.7010, 3.13, 0.179, 286, 252, CRYSTAL STRUCTURE OF A CDK INHIBITOR BOUND TO CDK2
3240, 5h3qA, 0.7010, 3.37, 0.295, 302, 258, CRYSTAL STRUCTURE OF TRKA KINASE WITH LIGAND
3241, 4ec9A, 0.7010, 3.54, 0.145, 306, 262, CRYSTAL STRUCTURE OF FULL-LENGTH CDK9 IN COMPLEX WITH CYCLIN T
3242, 3zrlB, 0.7010, 3.50, 0.184, 347, 261, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
3243, 3o2mA, 0.7010, 3.00, 0.194, 358, 253, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
3244, 3mssD, 0.7010, 2.66, 0.348, 264, 244, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
3245, 3lvpD, 0.7010, 3.04, 0.304, 282, 250, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
3246, 3kc3E, 0.7010, 2.83, 0.141, 287, 249, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
3247, 2iw8C, 0.7010, 3.24, 0.172, 265, 256, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
3248, 1k9aD, 0.7010, 3.38, 0.302, 433, 258, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
3249, 5othA, 0.7009, 3.32, 0.152, 326, 257, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 26
3250, 5ot6B, 0.7009, 3.22, 0.156, 326, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 19
3251, 5hvkC, 0.7009, 3.57, 0.198, 291, 262, CRYSTAL STRUCTURE OF LIMK1 MUTANT D460N IN COMPLEX WITH FULL-LENGTH COFILIN-1
3252, 5cyiC, 0.7009, 3.42, 0.162, 296, 260, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
3253, 4ptcB, 0.7009, 3.50, 0.168, 347, 262, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
3254, 4erwA, 0.7009, 3.12, 0.183, 292, 252, CDK2 IN COMPLEX WITH STAUROSPORINE
3255, 3d5wA, 0.7009, 3.54, 0.183, 284, 263, CRYSTAL STRUCTURE OF A PHOSPHORYLATED POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH ADP.
3256, 3b8rB, 0.7009, 2.86, 0.300, 267, 247, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
3257, 2c6kA, 0.7009, 3.15, 0.179, 292, 252, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3258, 1oi9C, 0.7009, 3.44, 0.162, 296, 260, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
3259, 5vioC, 0.7008, 3.27, 0.207, 271, 256, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 13)
3260, 5ho7A, 0.7008, 3.22, 0.211, 280, 256, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
3261, 5clpB, 0.7008, 3.30, 0.152, 327, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
3262, 3zrmB, 0.7008, 3.49, 0.180, 347, 261, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
3263, 3w8lB, 0.7008, 3.27, 0.148, 326, 257, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
3264, 3mssA, 0.7008, 2.63, 0.348, 264, 244, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
3265, 3ms9A, 0.7008, 2.63, 0.348, 265, 244, ABL KINASE IN COMPLEX WITH IMATINIB AND A FRAGMENT (FRAG1) IN THE MYRISTATE POCKET
3266, 2wmbC, 0.7008, 3.29, 0.167, 266, 258, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
3267, 2iw8A, 0.7008, 3.26, 0.167, 297, 257, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
3268, 5w5qB, 0.7007, 3.75, 0.174, 297, 264, MAP4K4 IN COMPLEX WITH INHIBITOR COMPOUND 12 (N3-METHYL-10-(3-METHYL- 3-(5-METHYLOXAZOL-2-YL)BUT-1-YN-1-YL)-6;7-DIHYDRO-5H-5;7- METHANOBENZO[C]IMIDAZO[1;2-A]AZEPINE-2;3-DICARBOXAMIDE) 
3269, 5mo8A, 0.7007, 3.30, 0.152, 325, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
3270, 5lvoA, 0.7007, 3.55, 0.198, 285, 262, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PSE10 BOUND TO THE PIF-POCKET
3271, 4eosC, 0.7007, 3.38, 0.166, 296, 259, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
3272, 4bggD, 0.7007, 2.93, 0.180, 286, 250, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
3273, 3my0O, 0.7007, 3.07, 0.166, 297, 253, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3274, 2r7iB, 0.7007, 3.20, 0.154, 322, 254, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
3275, 1fq1B, 0.7007, 3.29, 0.174, 295, 258, CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) IN COMPLEX WITH PHOSPHO-CDK2
3276, 5oulA, 0.7006, 3.29, 0.148, 327, 257, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 9
3277, 5otlB, 0.7006, 3.32, 0.152, 326, 257, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 29
3278, 5nkiA, 0.7006, 3.04, 0.304, 268, 253, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4B
3279, 5mo7B, 0.7006, 3.15, 0.149, 325, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
3280, 5mo5A, 0.7006, 3.23, 0.152, 326, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
3281, 5lvnA, 0.7006, 3.47, 0.196, 283, 260, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENOSINE BOUND TO THE ATP- BINDING SITE
3282, 5ctpB, 0.7006, 3.32, 0.148, 327, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
3283, 4j71B, 0.7006, 3.58, 0.179, 347, 262, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
3284, 4ebwA, 0.7006, 3.32, 0.329, 259, 255, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH NOVEL ALLOSTERIC INHIBITOR
3285, 4e3cD, 0.7006, 3.54, 0.171, 624, 263, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
3286, 3zrkB, 0.7006, 3.63, 0.175, 348, 263, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
3287, 3pwdA, 0.7006, 3.34, 0.151, 327, 258, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH NBC (Z1)
3288, 3my0P, 0.7006, 3.08, 0.166, 290, 253, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3289, 3bhtA, 0.7006, 3.24, 0.167, 297, 258, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
3290, 2bujA, 0.7006, 3.42, 0.190, 291, 258, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
3291, 5oueA, 0.7005, 3.32, 0.148, 328, 257, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 20
3292, 4bcoA, 0.7005, 3.38, 0.154, 298, 260, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3293, 3t3uA, 0.7005, 3.63, 0.196, 452, 265, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR RM-1-130
3294, 3r8mA, 0.7005, 3.01, 0.195, 286, 251, CDK2 IN COMPLEX WITH INHIBITOR L3-3
3295, 3db6A, 0.7005, 3.57, 0.189, 287, 264, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 902
3296, 3d14A, 0.7005, 3.19, 0.180, 262, 255, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-{5-[2-(THIENO[32-D]PYRIMIDIN-4-YLAMINO)- ETHYL]- THIAZOL-2-YL}-3-(3-TRIFLUOROMETHYL-PHENYL)-UREA
3297, 5ot6A, 0.7004, 3.29, 0.152, 327, 257, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 19
3298, 5orhA, 0.7004, 3.24, 0.148, 324, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 2
3299, 5cvhA, 0.7004, 3.31, 0.144, 327, 257, CRYSTAL STRUCTURE OF CK2ALPHA
3300, 4mf1B, 0.7004, 2.48, 0.303, 246, 244, ITK KINASE DOMAIN IN COMPLEX WITH BENZOTHIAZOLE INHIBITOR 12B (1S2S)- 2-{4-[(DIMETHYLAMINO)METHYL]PHENYL}-N-[6-(1H-PYRAZOL-4-YL)-13- BENZOTHIAZOL-2-YL]CYCLOPROPANECARBOXAMIDE
3301, 4dedA, 0.7004, 3.36, 0.181, 265, 260, AURORA A IN COMPLEX WITH YL1-038-21
3302, 3zrlA, 0.7004, 3.57, 0.179, 345, 262, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
3303, 3rcjA, 0.7004, 3.32, 0.209, 281, 258, RAPID PREPARATION OF TRIAZOLYL SUBSTITUTED NH-HETEROCYCLIC KINASE INHIBITORS VIA ONE-POT SONOGASHIRA COUPLING TMS-DEPROTECTION CUAAC SEQUENCE
3304, 3p08A, 0.7004, 2.94, 0.306, 252, 245, CRYSTAL STRUCTURE OF THE HUMAN BTK KINASE DOMAIN
3305, 3fbvD, 0.7004, 3.29, 0.187, 422, 257, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
3306, 2y7jC, 0.7004, 3.13, 0.175, 284, 257, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
3307, 5f95B, 0.7003, 3.54, 0.172, 338, 262, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
3308, 5ct0B, 0.7003, 3.25, 0.148, 326, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
3309, 4wnpC, 0.7003, 3.02, 0.202, 271, 252, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
3310, 4o91A, 0.7003, 2.99, 0.267, 293, 251, CRYSTAL STRUCTURE OF TYPE II INHIBITOR NG25 BOUND TO TAK1-TAB1
3311, 4eqmE, 0.7003, 2.81, 0.165, 268, 248, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
3312, 3qcqA, 0.7003, 3.21, 0.204, 276, 255, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-(3- AMINO-1H-INDAZOL-6-YL)-N4-ETHYL-24-PYRIMIDINEDIAMINE
3313, 3py1A, 0.7003, 3.38, 0.171, 302, 258, CDK2 TERNARY COMPLEX WITH SU9516 AND ANS
3314, 3ewhA, 0.7003, 3.69, 0.305, 300, 262, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDYL-PYRIMIDINE BENZIMIDAZOLE INHIBITOR
3315, 2iw9C, 0.7003, 3.29, 0.167, 268, 257, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
3316, 1pxlA, 0.7003, 2.98, 0.185, 290, 249, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- (4-TRIFLUOROMETHYL-PHENYL)-AMINE
3317, 5w80A, 0.7002, 3.55, 0.191, 453, 262, TOXOPLASMA GONDII CDPK1 IN COMPLEX WITH INHIBITOR GXJ-237
3318, 5w7tA, 0.7002, 3.09, 0.219, 276, 251, STRUCTURE OF PHOSPHORYLATED WNK1 
3319, 5othB, 0.7002, 3.17, 0.153, 324, 255, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 26
3320, 5orjB, 0.7002, 3.24, 0.145, 324, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 3
3321, 4f1mA, 0.7002, 3.40, 0.213, 278, 258, CRYSTAL STRUCTURE OF THE G1179S ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM.
3322, 3hrfA, 0.7002, 3.42, 0.208, 284, 259, CRYSTAL STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN ALLOSTERIC ACTIVATOR BOUND TO THE PIF-POCKET
3323, 3a7gA, 0.7002, 3.74, 0.222, 289, 266, HUMAN MST3 KINASE
3324, 1r1wA, 0.7002, 3.39, 0.343, 287, 254, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET
3325, 5jt2C, 0.7001, 2.81, 0.227, 251, 247, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
3326, 5ia5A, 0.7001, 3.33, 0.324, 273, 256, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH GOLVATINIB (E7050)
3327, 5ew3B, 0.7001, 2.95, 0.312, 266, 247, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN IN COMPLEX WITH AAL993
3328, 4mwhA, 0.7001, 3.31, 0.148, 371, 257, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
3329, 3mssC, 0.7001, 2.65, 0.348, 264, 244, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
3330, 2r7iD, 0.7001, 3.21, 0.154, 322, 254, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
3331, 4wnoA, 0.7000, 3.13, 0.197, 272, 254, STRUCTURE OF ULK1 BOUND TO AN INHIBITOR
3332, 4ow8A, 0.7000, 3.35, 0.191, 276, 257, CRYSTAL STRUCTURE OF KINASE DOMAIN OF PKNA FROM MTB
3333, 4ntsA, 0.7000, 4.02, 0.157, 341, 274, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
3334, 4fi1A, 0.7000, 3.31, 0.148, 371, 257, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
3335, 4eqmF, 0.7000, 2.82, 0.169, 268, 248, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
3336, 4eooC, 0.7000, 3.43, 0.165, 297, 260, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
3337, 3tt0B, 0.7000, 3.20, 0.332, 272, 253, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
3338, 3rwpA, 0.7000, 3.37, 0.202, 277, 257, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
3339, 3r83A, 0.7000, 3.30, 0.176, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-92
3340, 3m1sA, 0.7000, 3.57, 0.168, 348, 262, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
3341, 3hgkA, 0.7000, 3.39, 0.214, 286, 257, CRYSTAL STRUCTURE OF EFFECT PROTEIN AVRPTOB COMPLEXED WITH KINASE PTO
3342, 3fbvM, 0.7000, 3.30, 0.187, 415, 257, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
3343, 1unlB, 0.7000, 3.18, 0.145, 292, 255, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
3344, 5mo6A, 0.6999, 3.25, 0.148, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
3345, 5mmfB, 0.6999, 3.25, 0.148, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
3346, 5cu4A, 0.6999, 3.28, 0.152, 327, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
3347, 4itjA, 0.6999, 3.10, 0.217, 261, 249, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-4
3348, 4bcoC, 0.6999, 3.31, 0.167, 269, 258, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3349, 3m1sB, 0.6999, 3.52, 0.169, 349, 261, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
3350, 3juhB, 0.6999, 3.49, 0.146, 334, 260, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
3351, 3juhA, 0.6999, 3.49, 0.154, 334, 260, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
3352, 3fbvK, 0.6999, 3.30, 0.187, 422, 257, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
3353, 3fbvE, 0.6999, 3.30, 0.187, 415, 257, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
3354, 3cpcB, 0.6999, 2.75, 0.311, 262, 244, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
3355, 3bhhC, 0.6999, 3.50, 0.151, 285, 259, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
3356, 2h96B, 0.6999, 2.99, 0.202, 357, 252, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
3357, 6cd6D, 0.6998, 3.27, 0.169, 267, 255, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH GSK650394
3358, 5cx9B, 0.6998, 3.25, 0.145, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
3359, 4ifgA, 0.6998, 3.38, 0.200, 452, 260, CRYSTAL STRUCTURE OF TGCDPK1 WITH INHIBITOR BOUND
3360, 4eqmD, 0.6998, 2.83, 0.169, 268, 248, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
3361, 4eosA, 0.6998, 3.25, 0.159, 296, 258, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
3362, 4cfnC, 0.6998, 3.45, 0.161, 296, 261, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
3363, 3h9oA, 0.6998, 3.18, 0.209, 275, 254, PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK-1) IN COMPLEX WITH COMPOUND 9
3364, 3fbvN, 0.6998, 3.30, 0.187, 415, 257, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
3365, 3fbvH, 0.6998, 3.30, 0.187, 415, 257, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
3366, 1oiuA, 0.6998, 3.29, 0.159, 296, 258, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
3367, 5os2A, 0.6997, 3.09, 0.182, 261, 253, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3368, 4wnpA, 0.6997, 3.05, 0.202, 273, 253, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
3369, 3my0W, 0.6997, 2.99, 0.171, 281, 251, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3370, 3fbvL, 0.6997, 3.30, 0.187, 415, 257, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
3371, 3fbvG, 0.6997, 3.30, 0.187, 415, 257, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
3372, 3fbvF, 0.6997, 3.31, 0.187, 415, 257, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
3373, 3fbvA, 0.6997, 3.30, 0.187, 415, 257, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
3374, 1jstC, 0.6997, 3.48, 0.153, 297, 261, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
3375, 5mo8B, 0.6996, 3.25, 0.152, 324, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
3376, 5dewA, 0.6996, 3.89, 0.190, 295, 268, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
3377, 4lynA, 0.6996, 3.06, 0.179, 287, 251, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH (2S)-N-(5-(((5-TERT-BUTYL-13-OXAZOL-2-YL)METHYL)SULFANYL)-13- THIAZOL-2-YL)-2-PHENYLPROPANAMIDE
3378, 4cxaA, 0.6996, 3.83, 0.144, 329, 270, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
3379, 3zonA, 0.6996, 2.71, 0.203, 261, 246, HUMAN TYK2 PSEUDOKINASE DOMAIN BOUND TO A KINASE INHIBITOR
3380, 3sdmG, 0.6996, 3.30, 0.187, 415, 257, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
3381, 3sdmF, 0.6996, 3.30, 0.187, 415, 257, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
3382, 3sdmE, 0.6996, 3.30, 0.187, 415, 257, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
3383, 3sdmD, 0.6996, 3.30, 0.187, 415, 257, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
3384, 3sdmC, 0.6996, 3.30, 0.187, 415, 257, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
3385, 3sdmB, 0.6996, 3.30, 0.187, 415, 257, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
3386, 3sdmA, 0.6996, 3.30, 0.187, 415, 257, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
3387, 3sayA, 0.6996, 3.57, 0.176, 347, 261, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
3388, 3qcsA, 0.6996, 3.22, 0.204, 276, 255, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-[2- AMINO-6-(4-MORPHOLINYL)-4-PYRIMIDINYL]-1H-INDAZOL-3-AMINE
3389, 3fbvB, 0.6996, 3.30, 0.187, 415, 257, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
3390, 2b53A, 0.6996, 3.23, 0.165, 294, 254, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN- 234325
3391, 1uwjB, 0.6996, 3.02, 0.223, 263, 251, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
3392, 1h8fB, 0.6996, 3.57, 0.172, 350, 261, GLYCOGEN SYNTHASE KINASE 3 BETA.
3393, 1h8fA, 0.6996, 3.57, 0.172, 352, 261, GLYCOGEN SYNTHASE KINASE 3 BETA.
3394, 5oumB, 0.6995, 3.25, 0.148, 326, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 21
3395, 5mowA, 0.6995, 3.26, 0.145, 328, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
3396, 5hieC, 0.6995, 2.59, 0.213, 253, 244, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
3397, 5he2A, 0.6995, 4.08, 0.171, 628, 275, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224406
3398, 4fc0A, 0.6995, 2.73, 0.228, 254, 246, CRYSTAL STRUCTURE OF HUMAN KINASE DOMAIN OF B-RAF WITH A DFG-OUT INHIBITOR
3399, 3nusA, 0.6995, 3.30, 0.207, 276, 256, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT8
3400, 3lcoA, 0.6995, 3.23, 0.298, 293, 252, INHIBITOR BOUND TO A DFG-OUT STRUCTURE OF THE KINASE DOMAIN OF CSF-1R
3401, 3hgkB, 0.6995, 3.45, 0.213, 286, 258, CRYSTAL STRUCTURE OF EFFECT PROTEIN AVRPTOB COMPLEXED WITH KINASE PTO
3402, 3fbvC, 0.6995, 3.30, 0.187, 415, 257, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
3403, 3f7zB, 0.6995, 3.49, 0.173, 339, 260, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
3404, 1q3wA, 0.6995, 3.59, 0.164, 344, 262, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
3405, 5uklA, 0.6994, 4.26, 0.173, 630, 277, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG222886 (14BD)
3406, 5mpjB, 0.6994, 3.25, 0.148, 324, 256, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
3407, 5hlnA, 0.6994, 3.59, 0.168, 346, 262, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
3408, 5cvhB, 0.6994, 3.25, 0.145, 324, 256, CRYSTAL STRUCTURE OF CK2ALPHA
3409, 4ptgA, 0.6994, 3.64, 0.175, 333, 263, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
3410, 4bcpA, 0.6994, 3.35, 0.166, 298, 259, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3411, 3pwyA, 0.6994, 3.42, 0.208, 281, 259, CRYSTAL STRUCTURE OF AN EXTENDER (SPD28345)-MODIFIED HUMAN PDK1 COMPLEX 2
3412, 2zm3B, 0.6994, 3.58, 0.292, 296, 260, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
3413, 2y6oA, 0.6994, 3.21, 0.305, 263, 256, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN IN COMPLEX WITH DASATINIB.
3414, 4ihpA, 0.6993, 3.52, 0.198, 454, 262, CRYSTAL STRUCTURE OF TGCDPK1 WITH INHIBITOR BOUND
3415, 2w1hA, 0.6993, 3.05, 0.180, 283, 250, FRAGMENT-BASED DISCOVERY OF THE PYRAZOL-4-YL UREA (AT9283) A MULTI-TARGETED KINASE INHIBITOR WITH POTENT AURORA KINASE ACTIVITY
3416, 2o5kA, 0.6993, 3.54, 0.172, 350, 262, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A BENZOIMIDAZOL INHIBITOR
3417, 2iw6C, 0.6993, 3.35, 0.167, 295, 258, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
3418, 1p4fA, 0.6993, 2.97, 0.180, 269, 250, DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH BOUND INHIBITOR FRAGMENT
3419, 5hbjA, 0.6992, 3.60, 0.183, 342, 262, CDK8-CYCC IN COMPLEX WITH 8-[2-AMINO-3-CHLORO-5-(1-METHYL-1H-INDAZOL- 5-YL)-PYRIDIN-4-YL]-28-DIAZA-SPIRO[4.5]DECAN-1-ONE
3420, 4kioB, 0.6992, 2.13, 0.326, 239, 236, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
3421, 3uliA, 0.6992, 3.16, 0.179, 286, 252, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) BOUND TO AZABENZIMIDAZOLE DERIVATIVE
3422, 3lvpB, 0.6992, 3.55, 0.291, 295, 261, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
3423, 3gb2A, 0.6992, 3.59, 0.168, 340, 262, GSK3BETA INHIBITOR COMPLEX
3424, 2uzlA, 0.6992, 3.43, 0.158, 295, 259, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
3425, 1okzA, 0.6992, 3.22, 0.212, 276, 255, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH UCN-01
3426, 5ot5A, 0.6991, 3.33, 0.152, 326, 257, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 24
3427, 5oquA, 0.6991, 3.25, 0.148, 324, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 5
3428, 4p2kA, 0.6991, 3.24, 0.316, 259, 253, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
3429, 4fr4E, 0.6991, 4.15, 0.174, 342, 276, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
3430, 4e3cC, 0.6991, 3.72, 0.166, 624, 265, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
3431, 3qd3A, 0.6991, 3.36, 0.202, 278, 257, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL {(3R6S)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-6-METHYL-3-PIPERIDINYL}CARBAMATE
3432, 3miyA, 0.6991, 2.09, 0.314, 239, 236, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH SUNITINIB
3433, 3ddpA, 0.6991, 3.46, 0.162, 297, 260, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
3434, 2dwbA, 0.6991, 3.08, 0.182, 259, 253, AURORA-A KINASE COMPLEXED WITH AMPPNP
3435, 2c69A, 0.6991, 3.11, 0.175, 292, 251, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3436, 5orkA, 0.6990, 3.27, 0.148, 324, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 6
3437, 5j95B, 0.6990, 3.70, 0.168, 300, 262, MAP4K4 IN COMPLEX WITH INHIBITOR
3438, 5hlpA, 0.6990, 3.62, 0.176, 337, 262, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
3439, 5f95A, 0.6990, 3.59, 0.168, 345, 262, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
3440, 5cshA, 0.6990, 3.27, 0.148, 324, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
3441, 4cfvA, 0.6990, 3.42, 0.165, 300, 261, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
3442, 3v5tA, 0.6990, 3.47, 0.203, 460, 261, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1299
3443, 3h30A, 0.6990, 3.48, 0.150, 333, 260, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
3444, 2g9xA, 0.6990, 3.33, 0.167, 298, 258, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
3445, 1pyxB, 0.6990, 3.55, 0.164, 338, 262, GSK-3 BETA COMPLEXED WITH AMP-PNP
3446, 1j1bB, 0.6990, 3.64, 0.175, 364, 263, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
3447, 5jt2B, 0.6989, 2.48, 0.227, 251, 242, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-BISAMIDE
3448, 5f9eB, 0.6989, 3.45, 0.172, 293, 262, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
3449, 5cvgA, 0.6989, 3.24, 0.153, 326, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH A NOVEL CLOSED CONFORMATION OF THE AD LOOP
3450, 4j8nD, 0.6989, 3.19, 0.180, 265, 256, AURORA A KINASE APO
3451, 3i7bA, 0.6989, 3.55, 0.186, 459, 263, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR NM-PP1
3452, 1q41A, 0.6989, 3.62, 0.179, 339, 262, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
3453, 1h1qC, 0.6989, 3.41, 0.162, 296, 259, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
3454, 5mmrB, 0.6988, 3.24, 0.152, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
3455, 4u43B, 0.6988, 3.79, 0.171, 302, 263, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
3456, 4u3zA, 0.6988, 3.26, 0.176, 282, 255, APO MAP4K4 T181E PHOSPHOMIMETIC MUTANT
3457, 3zdiA, 0.6988, 3.57, 0.176, 348, 261, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE AND INHIBITOR 7D
3458, 3a7gB, 0.6988, 3.75, 0.225, 290, 267, HUMAN MST3 KINASE
3459, 2x7fB, 0.6988, 3.39, 0.182, 288, 258, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
3460, 1uu9A, 0.6988, 3.25, 0.215, 276, 256, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-3
3461, 1q5kB, 0.6988, 3.63, 0.167, 344, 263, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
3462, 1oguA, 0.6988, 3.29, 0.159, 296, 258, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
3463, 1fvvC, 0.6988, 3.50, 0.149, 298, 262, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
3464, 6c4dD, 0.6987, 3.18, 0.215, 266, 251, STRUCTURE BASED DESIGN OF RIP1 KINASE INHIBITORS
3465, 4u41B, 0.6987, 3.64, 0.176, 297, 262, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
3466, 4cfwC, 0.6987, 3.52, 0.161, 297, 261, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
3467, 4cfuA, 0.6987, 3.37, 0.162, 299, 260, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
3468, 3qcxA, 0.6987, 3.23, 0.204, 276, 255, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-{2- AMINO-6-[(3R)-3-METHYL-4-MORPHOLINYL]-4-PYRIMIDINYL}-1H-INDAZOL-3- AMINE
3469, 3og7A, 0.6987, 2.47, 0.224, 247, 241, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX4032
3470, 5vilD, 0.6986, 3.23, 0.204, 271, 255, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 6)
3471, 5ukkA, 0.6986, 4.33, 0.172, 613, 279, HUMAN GRK2 IN COMPLEX WITH HUMAN G-BETA-GAMMA SUBUNITS AND CCG211998 (14AK)
3472, 5cvfA, 0.6986, 3.26, 0.145, 325, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
3473, 4xv2A, 0.6986, 2.32, 0.229, 247, 240, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH DABRAFENIB
3474, 4oboB, 0.6986, 3.65, 0.176, 297, 262, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 22) 6-(3-CHLOROPHENYL) QUINAZOLIN-4-AMINE
3475, 4f65B, 0.6986, 3.40, 0.312, 279, 256, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 8
3476, 3nuyA, 0.6986, 3.31, 0.207, 276, 256, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT17
3477, 3nuuA, 0.6986, 3.30, 0.207, 276, 256, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT11
3478, 3hgkD, 0.6986, 3.31, 0.216, 286, 255, CRYSTAL STRUCTURE OF EFFECT PROTEIN AVRPTOB COMPLEXED WITH KINASE PTO
3479, 3gxlA, 0.6986, 2.82, 0.165, 285, 248, ALK-5 KINASE COMPLEX WITH GW857175
3480, 3byuA, 0.6986, 2.83, 0.294, 256, 248, CO-CRYSTAL STRUCTURE OF LCK AND AMINOPYRIMIDINE REVERSE AMIDE 23
3481, 2hz0B, 0.6986, 2.32, 0.359, 243, 237, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AEG082
3482, 6bfnA, 0.6985, 3.35, 0.169, 301, 255, CRYSTAL STRUCTURE OF HUMAN IRAK1
3483, 5vioD, 0.6985, 3.34, 0.202, 271, 257, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 13)
3484, 5moeB, 0.6985, 3.21, 0.145, 323, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
3485, 4ygaG, 0.6985, 3.64, 0.195, 447, 261, CDPK1 FROM TOXOPLASMA GONDII BOUND TO INHIBITORY VHH-1B7
3486, 4rrvA, 0.6985, 3.54, 0.203, 283, 261, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND PIFTIDE
3487, 4bcnA, 0.6985, 3.40, 0.158, 296, 260, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3488, 3c4yB, 0.6985, 3.91, 0.170, 466, 270, CRYSTAL STRUCTURE OF APO FORM OF G PROTEIN COUPLED RECEPTOR KINASE 1 AT 7.51A
3489, 2pe0A, 0.6985, 3.35, 0.207, 275, 256, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 5-HYDROXY-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-13-DIHYDRO- INDOL-2-ONE COMPLEX
3490, 1w8cA, 0.6985, 3.15, 0.183, 290, 251, CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY-8-ISOPROPYL-9H- PURIN-2-YLAMINE AND MONOMERIC CDK2
3491, 6fnlA, 0.6984, 3.20, 0.312, 262, 253, CRYSTAL STRUCTURE OF EPHRIN B4 (EPHB4) RECEPTOR PROTEIN KINASE 
3492, 5kkrB, 0.6984, 2.84, 0.215, 272, 247, KSR2:MEK1 COMPLEX BOUND TO THE SMALL MOLECULE APS-2-79
3493, 5di1B, 0.6984, 3.74, 0.163, 300, 263, MAP4K4 IN COMPLEX WITH AN INHIBITOR
3494, 4oboA, 0.6984, 3.18, 0.171, 275, 252, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 22) 6-(3-CHLOROPHENYL) QUINAZOLIN-4-AMINE
3495, 1oiyC, 0.6984, 3.48, 0.165, 296, 260, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
3496, 6cd6B, 0.6983, 3.29, 0.169, 266, 255, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH GSK650394
3497, 6bqpA, 0.6983, 3.12, 0.175, 263, 252, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CRENOLANIB
3498, 5valB, 0.6983, 2.92, 0.219, 254, 247, BRAF IN COMPLEX WITH N-(3-(TERT-BUTYL)PHENYL)-4-METHYL-3-(6- MORPHOLINOPYRIMIDIN-4-YL)BENZAMIDE
3499, 4gu9A, 0.6983, 3.02, 0.347, 252, 248, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH (2-FLUORO- PHENYL)-(1H-PYRAZOLO[34-D]PYRIMIDIN-4-YL)-AMINE
3500, 4g3dD, 0.6983, 2.85, 0.214, 290, 248, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK)
3501, 4eoiA, 0.6983, 3.27, 0.163, 294, 257, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
3502, 3tz7B, 0.6983, 3.24, 0.294, 260, 255, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL103
3503, 2uzoA, 0.6983, 3.07, 0.184, 290, 250, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
3504, 6cd6A, 0.6982, 3.21, 0.169, 264, 254, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH GSK650394
3505, 5ouuB, 0.6982, 3.18, 0.153, 325, 255, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 22
3506, 5osjA, 0.6982, 3.19, 0.174, 292, 253, CDK2(WT) WITH COVALENT ADDUCT AT C177
3507, 4g6lA, 0.6982, 3.59, 0.188, 336, 261, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN THE DMG-IN CONFORMATION
3508, 4ct1A, 0.6982, 3.50, 0.200, 283, 260, HUMAN PDK1-PKCZETA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS315 BOUND TO THE PIF-POCKET
3509, 1h26C, 0.6982, 3.35, 0.167, 267, 257, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
3510, 1gy3A, 0.6982, 3.51, 0.154, 295, 260, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
3511, 6eiiA, 0.6981, 3.20, 0.153, 326, 255, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 18
3512, 6ehuA, 0.6981, 3.40, 0.156, 327, 257, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
3513, 5oueB, 0.6981, 3.27, 0.152, 326, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 20
3514, 5mo6B, 0.6981, 3.27, 0.148, 324, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
3515, 4ztlD, 0.6981, 3.02, 0.209, 285, 249, IRAK4-INHIBITOR CO-STRUCTURE
3516, 4f1tA, 0.6981, 3.26, 0.220, 269, 255, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO THE ROCK INHIBITOR H1152
3517, 3sqqA, 0.6981, 2.94, 0.185, 288, 248, CDK2 IN COMPLEX WITH INHIBITOR RC-3-96
3518, 3gokK, 0.6981, 2.89, 0.149, 290, 249, BINDING SITE MAPPING OF PROTEIN LIGANDS
3519, 3dtwB, 0.6981, 2.97, 0.310, 269, 248, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZISOXAZOLE INHIBITOR
3520, 2uzlC, 0.6981, 3.36, 0.159, 295, 258, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
3521, 1q5kA, 0.6981, 3.64, 0.167, 345, 263, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
3522, 1gy3C, 0.6981, 3.44, 0.158, 295, 259, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
3523, 4wg3A, 0.6980, 3.42, 0.200, 460, 260, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1610
3524, 4nusA, 0.6980, 3.57, 0.194, 301, 263, RSK2 N-TERMINAL KINASE IN COMPLEX WITH LJH685
3525, 3t3vA, 0.6980, 3.55, 0.192, 453, 261, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR RM-1-87
3526, 3is5F, 0.6980, 3.12, 0.195, 266, 251, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
3527, 3du8A, 0.6980, 3.59, 0.172, 336, 262, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
3528, 5w91A, 0.6979, 3.40, 0.201, 451, 259, TOXOPLASMA GONDII CDPK1 IN COMPLEX WITH INHIBITOR LZH118
3529, 5ievA, 0.6979, 3.05, 0.180, 284, 250, CRYSTAL STRUCTURE OF BAY 1000394 (RONICICLIB) BOUND TO CDK2
3530, 5cu3B, 0.6979, 3.20, 0.157, 324, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
3531, 4yjnA, 0.6979, 3.43, 0.200, 460, 260, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1639
3532, 4bcmA, 0.6979, 3.30, 0.167, 295, 258, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3533, 3zzwB, 0.6979, 2.83, 0.297, 265, 246, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF ROR2
3534, 3p86A, 0.6979, 2.52, 0.235, 250, 243, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN MUTANT D676N IN COMPLEX WITH STAUROSPORINE
3535, 3dogA, 0.6979, 3.35, 0.167, 297, 258, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
3536, 1pxkA, 0.6979, 3.03, 0.185, 290, 249, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)PYRIMIDIN-2-YL]- N -HYDROXYIMINOFORMAMIDE
3537, 1oiuC, 0.6979, 3.30, 0.172, 265, 256, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
3538, 1i09A, 0.6979, 3.53, 0.177, 338, 260, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
3539, 5te0A, 0.6978, 3.08, 0.143, 316, 252, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH BIBF 1120
3540, 5otdA, 0.6978, 3.36, 0.152, 327, 257, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 25
3541, 5mp8A, 0.6978, 3.28, 0.148, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
3542, 4wnpD, 0.6978, 3.12, 0.202, 272, 253, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
3543, 4jbvA, 0.6978, 3.52, 0.192, 458, 261, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1268
3544, 3p08B, 0.6978, 2.87, 0.305, 258, 243, CRYSTAL STRUCTURE OF THE HUMAN BTK KINASE DOMAIN
3545, 4tzrA, 0.6977, 3.43, 0.196, 461, 260, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1561
3546, 4qo9B, 0.6977, 3.72, 0.238, 285, 265, MST3 IN COMPLEX WITH DANUSERTIB
3547, 4mwiA, 0.6977, 2.82, 0.176, 266, 250, CRYSTAL STRUCTURE OF THE HUMAN MLKL PSEUDOKINASE DOMAIN
3548, 3sayB, 0.6977, 3.59, 0.169, 347, 261, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
3549, 3i4bA, 0.6977, 3.63, 0.167, 359, 263, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
3550, 2zm3A, 0.6977, 3.63, 0.292, 300, 260, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
3551, 2jldA, 0.6977, 3.57, 0.169, 349, 261, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
3552, 1e1xA, 0.6977, 3.12, 0.184, 290, 250, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027
3553, 5w9rA, 0.6976, 3.52, 0.199, 445, 261, TOXOPLASMA GONDII CDPK1 IN COMPLEX WITH INHIBITOR LJQ138
3554, 5imeA, 0.6976, 3.39, 0.191, 280, 256, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
3555, 5i8aA, 0.6976, 2.74, 0.299, 269, 244, TRKA WITH (6~{R})-3-METHYLSULFANYL-6-PHENYL-1-(1~{H}-PYRAZOL-3-YL)-6 7-DIHYDRO-5~{H}-THIENO[34-C]PYRIDIN-4-ONE
3556, 5he3A, 0.6976, 4.03, 0.176, 623, 273, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224411
3557, 4u6rA, 0.6976, 3.44, 0.174, 403, 258, CRYSTAL STRUCTURE OF HUMAN IRE1 CYTOPLASMIC DOMAINS IN COMPLEX WITH A SULFONAMIDE INHIBITOR.
3558, 4bcnC, 0.6976, 3.43, 0.166, 295, 259, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3559, 3sdjC, 0.6976, 3.33, 0.187, 415, 257, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
3560, 3sdjA, 0.6976, 3.33, 0.187, 415, 257, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
3561, 3qa8E, 0.6976, 3.66, 0.170, 622, 264, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
3562, 3gokE, 0.6976, 2.91, 0.149, 290, 249, BINDING SITE MAPPING OF PROTEIN LIGANDS
3563, 3c4cB, 0.6976, 2.83, 0.211, 257, 247, B-RAF KINASE IN COMPLEX WITH PLX4720
3564, 2c5nA, 0.6976, 3.42, 0.154, 296, 260, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
3565, 1h1rA, 0.6976, 3.34, 0.163, 296, 258, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
3566, 5mowB, 0.6975, 3.27, 0.148, 324, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
3567, 5l6oA, 0.6975, 2.93, 0.323, 267, 248, EPHB3 KINASE DOMAIN COVALENTLY BOUND TO AN IRREVERSIBLE INHIBITOR (COMPOUND 3)
3568, 4btmB, 0.6975, 3.63, 0.160, 293, 263, TTBK1 IN COMPLEX WITH INHIBITOR
3569, 3sdjD, 0.6975, 3.34, 0.187, 422, 257, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
3570, 3sdjB, 0.6975, 3.33, 0.187, 415, 257, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
3571, 3gokH, 0.6975, 2.91, 0.149, 290, 249, BINDING SITE MAPPING OF PROTEIN LIGANDS
3572, 3dogC, 0.6975, 3.31, 0.172, 267, 256, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
3573, 3a7hA, 0.6975, 3.74, 0.215, 289, 265, HUMAN MST3 KINASE IN COMPLEX WITH ATP
3574, 2zm3D, 0.6975, 3.59, 0.293, 293, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
3575, 2y7jD, 0.6975, 3.19, 0.184, 281, 256, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
3576, 2r7iA, 0.6975, 3.17, 0.150, 322, 253, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
3577, 5otoB, 0.6974, 3.30, 0.148, 324, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 30
3578, 5airB, 0.6974, 3.61, 0.164, 361, 262, STRUCTURAL ANALYSIS OF MOUSE GSK3BETA FUSED WITH LRP6 PEPTIDE.
3579, 4nm0A, 0.6974, 3.53, 0.169, 356, 261, CRYSTAL STRUCTURE OF PEPTIDE INHIBITOR-FREE GSK-3/AXIN COMPLEX
3580, 4e3cB, 0.6974, 3.67, 0.167, 632, 264, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
3581, 3sdjK, 0.6974, 3.34, 0.187, 422, 257, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
3582, 3sdjH, 0.6974, 3.34, 0.187, 415, 257, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
3583, 3iopA, 0.6974, 3.05, 0.214, 275, 252, PDK-1 IN COMPLEX WITH THE INHIBITOR COMPOUND-8I
3584, 3gokB, 0.6974, 2.90, 0.145, 290, 249, BINDING SITE MAPPING OF PROTEIN LIGANDS
3585, 3a7hB, 0.6974, 3.67, 0.230, 290, 265, HUMAN MST3 KINASE IN COMPLEX WITH ATP
3586, 2g01B, 0.6974, 3.11, 0.193, 356, 254, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
3587, 2c6oA, 0.6974, 3.13, 0.183, 290, 251, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3588, 1h1sA, 0.6974, 3.46, 0.165, 296, 260, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
3589, 5otdB, 0.6973, 3.29, 0.152, 324, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 25
3590, 5ceoA, 0.6973, 2.84, 0.239, 269, 247, DLK IN COMPLEX WITH INHIBITOR 2-((6-(33-DIFLUOROPYRROLIDIN-1-YL)-4- (1-(OXETAN-3-YL)PIPERIDIN-4-YL)PYRIDIN-2-YL)AMINO)ISONICOTINONITRILE
3591, 4usdA, 0.6973, 3.01, 0.180, 268, 250, HUMAN STK10 (LOK) WITH SB-633825
3592, 4rz7A, 0.6973, 3.58, 0.202, 801, 263, CRYSTAL STRUCTURE OF PVX_084705 WITH BOUND PCI32765
3593, 3sdjG, 0.6973, 3.36, 0.187, 415, 257, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
3594, 3qa8C, 0.6973, 3.66, 0.167, 622, 264, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
3595, 3mpmA, 0.6973, 2.94, 0.277, 257, 249, LCK COMPLEXED WITH A PYRAZOLOPYRIMIDINE
3596, 3i4bB, 0.6973, 3.62, 0.167, 347, 263, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
3597, 3du8B, 0.6973, 3.62, 0.172, 339, 262, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
3598, 3c4yA, 0.6973, 4.16, 0.162, 478, 278, CRYSTAL STRUCTURE OF APO FORM OF G PROTEIN COUPLED RECEPTOR KINASE 1 AT 7.51A
3599, 2yiyA, 0.6973, 3.04, 0.271, 293, 251, CRYSTAL STRUCTURE OF COMPOUND 8 BOUND TO TAK1-TAB
3600, 1h0vA, 0.6973, 3.07, 0.184, 288, 250, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[(R)-PYRROLIDINO-5 -YL]METHOXYPURINE
3601, 1b39A, 0.6973, 3.03, 0.185, 290, 249, HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160
3602, 6eiiB, 0.6972, 3.20, 0.153, 326, 255, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 18
3603, 5w9eA, 0.6972, 3.50, 0.203, 451, 261, TOXOPLASMA GONDII CDPK1 IN COMPLEX WITH INHIBITOR GXJ-186
3604, 5vi9A, 0.6972, 3.46, 0.176, 306, 262, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH THE PKI PEPTIDE AND AMINOBENZOTHIAZOLE BASED INHIBITORS
3605, 5otoA, 0.6972, 3.38, 0.152, 327, 257, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 30
3606, 5oquB, 0.6972, 3.29, 0.148, 324, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 5
3607, 5mo5B, 0.6972, 3.28, 0.148, 325, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
3608, 5cu3A, 0.6972, 3.20, 0.153, 325, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
3609, 4fkoA, 0.6972, 3.02, 0.189, 291, 249, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
3610, 3zzwA, 0.6972, 3.02, 0.288, 269, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF ROR2
3611, 3v5qA, 0.6972, 2.97, 0.298, 263, 248, DISCOVERY OF A SELECTIVE TRK INHIBITOR WITH EFFICACY IN RODENT CANCER TUMOR MODELS
3612, 3sdjM, 0.6972, 3.35, 0.187, 415, 257, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
3613, 3sdjF, 0.6972, 3.34, 0.187, 415, 257, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
3614, 3sdjE, 0.6972, 3.34, 0.187, 415, 257, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
3615, 3qa8D, 0.6972, 3.67, 0.170, 622, 264, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
3616, 3fbvJ, 0.6972, 3.24, 0.180, 413, 255, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
3617, 3fbvI, 0.6972, 3.24, 0.180, 413, 255, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
3618, 5kpmA, 0.6971, 3.63, 0.180, 344, 261, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD3731
3619, 5hlpB, 0.6971, 3.64, 0.176, 335, 262, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
3620, 3sdjN, 0.6971, 3.35, 0.187, 415, 257, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
3621, 3sdjL, 0.6971, 3.35, 0.187, 415, 257, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
3622, 2uzeA, 0.6971, 3.45, 0.158, 295, 259, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
3623, 2c6lA, 0.6971, 3.08, 0.180, 291, 250, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3624, 4f1oA, 0.6970, 3.44, 0.226, 276, 257, CRYSTAL STRUCTURE OF THE L1180T MUTANT ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO APPCP
3625, 2y4iB, 0.6970, 2.92, 0.219, 265, 247, KSR2-MEK1 HETERODIMER
3626, 2uzeC, 0.6970, 3.40, 0.154, 295, 259, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
3627, 1j1cB, 0.6970, 3.66, 0.171, 364, 263, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
3628, 5uvcA, 0.6969, 4.10, 0.174, 457, 276, DESIGN SYNTHESIS AND EVALUATION OF THE FIRST SELECTIVE AND POTENT G- PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2) INHIBITOR FOR THE POTENTIAL TREATMENT OF HEART FAILURE
3629, 4ih8A, 0.6969, 3.52, 0.196, 433, 260, CRYSTAL STRUCTURE OF TGCDPK1 WITH INHIBITOR BOUND
3630, 4dbnA, 0.6969, 2.88, 0.223, 257, 247, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN B-RAF WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
3631, 4aw0A, 0.6969, 3.55, 0.200, 283, 260, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS182 BOUND TO THE PIF-POCKET
3632, 3iecD, 0.6969, 3.25, 0.215, 311, 256, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
3633, 3hgkC, 0.6969, 3.28, 0.217, 284, 254, CRYSTAL STRUCTURE OF EFFECT PROTEIN AVRPTOB COMPLEXED WITH KINASE PTO
3634, 2w1cA, 0.6969, 3.21, 0.180, 261, 255, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3635, 2jldB, 0.6969, 3.60, 0.164, 349, 262, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
3636, 1q3wB, 0.6969, 3.61, 0.160, 341, 262, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
3637, 1i09B, 0.6969, 3.57, 0.169, 341, 261, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
3638, 1gz8A, 0.6969, 3.17, 0.183, 290, 251, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-AMINO-6-(3 -METHYL-2 -OXO)BUTOXYPURINE
3639, 5jmsA, 0.6968, 3.39, 0.201, 447, 259, CRYSTAL STRUCTURE OF TGCDPK1 BOUND TO CGP060476
3640, 5cs6A, 0.6968, 3.37, 0.152, 327, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
3641, 4k8aA, 0.6968, 3.02, 0.355, 251, 248, FRAGMENT-BASED DISCOVERY OF FOCAL ADHESION KINASE INHIBITORS
3642, 4ct2A, 0.6968, 3.25, 0.201, 277, 254, HUMAN PDK1-PKCZETA KINASE CHIMERA
3643, 4acgA, 0.6968, 3.61, 0.160, 350, 262, GSK3B IN COMPLEX WITH INHIBITOR
3644, 3upxA, 0.6968, 3.41, 0.201, 445, 259, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1300
3645, 3gokG, 0.6968, 2.80, 0.146, 286, 247, BINDING SITE MAPPING OF PROTEIN LIGANDS
3646, 3dy7A, 0.6968, 2.96, 0.195, 260, 251, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
3647, 2wxvC, 0.6968, 3.55, 0.148, 299, 263, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
3648, 2auhA, 0.6968, 3.51, 0.293, 297, 259, CRYSTAL STRUCTURE OF THE GRB14 BPS REGION IN COMPLEX WITH THE INSULIN RECEPTOR TYROSINE KINASE
3649, 1ol1C, 0.6968, 3.40, 0.158, 296, 259, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
3650, 4y85C, 0.6967, 3.16, 0.165, 303, 255, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(5-(1H-INDOL- 3-YL)-1H-PYRROLO[23-B]PYRIDIN-3-YL)-134-OXADIAZOL-2-AMINE
3651, 3ionA, 0.6967, 3.01, 0.215, 274, 251, PDK1 IN COMPLEX WITH COMPOUND 8H
3652, 3iecB, 0.6967, 3.39, 0.216, 313, 259, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
3653, 3gokJ, 0.6967, 2.80, 0.146, 283, 247, BINDING SITE MAPPING OF PROTEIN LIGANDS
3654, 2fumA, 0.6967, 2.84, 0.161, 263, 248, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
3655, 2cciC, 0.6967, 3.50, 0.162, 296, 260, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
3656, 6cmjB, 0.6966, 3.37, 0.180, 284, 256, HUMAN CAMKK2 WITH GSK650393
3657, 6c4dA, 0.6966, 3.12, 0.220, 267, 250, STRUCTURE BASED DESIGN OF RIP1 KINASE INHIBITORS
3658, 5ukmA, 0.6966, 4.32, 0.173, 621, 278, BOVINE GRK2 IN COMPLEX WITH HUMAN GBETAGAMMA SUBUNITS AND CCG258208 (14AS)
3659, 5kplB, 0.6966, 3.63, 0.180, 339, 261, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD0705
3660, 5ctpA, 0.6966, 3.30, 0.152, 324, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
3661, 4zy4A, 0.6966, 3.53, 0.195, 288, 261, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
3662, 4obqB, 0.6966, 3.61, 0.173, 293, 260, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 31) N-[3-(4- AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
3663, 4i92A, 0.6966, 3.29, 0.155, 289, 252, STRUCTURE OF THE BSK8 KINASE DOMAIN
3664, 4eevA, 0.6966, 3.39, 0.341, 283, 255, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH LY2801653
3665, 4c3fA, 0.6966, 2.95, 0.281, 257, 249, STRUCTURE OF LCK IN COMPLEX WITH A COMPOUND DISCOVERED BY VIRTUAL FRAGMENT LINKING
3666, 3q3bA, 0.6966, 3.65, 0.167, 344, 263, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
3667, 6b8jA, 0.6965, 3.53, 0.173, 344, 260, CO-STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE BETA WITH A SELECTIVE (5-IMIDAZOL-2-YL-4-PHENYLPYRIMIDIN-2-YL)[2-(2-PYRIDYLAMINO) ETHYL]AMINE INHIBITOR
3668, 4grbA, 0.6965, 3.38, 0.144, 327, 257, CASEIN KINASE 2 (CK2) BOUND TO INHIBITOR
3669, 4achA, 0.6965, 3.58, 0.169, 350, 261, GSK3B IN COMPLEX WITH INHIBITOR
3670, 3lfnA, 0.6965, 3.04, 0.189, 285, 249, CRYSTAL STRUCTURE OF CDK2 WITH SAR57 AN AMINOINDAZOLE TYPE INHIBITOR
3671, 3f7zA, 0.6965, 3.65, 0.179, 339, 262, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
3672, 1j1bA, 0.6965, 3.64, 0.164, 354, 262, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
3673, 5kbqA, 0.6964, 3.62, 0.193, 289, 264, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
3674, 5jn2A, 0.6964, 3.39, 0.201, 450, 259, CRYSTAL STRUCTURE OF TGCDPK1 BOUND TO NVPACU106
3675, 5ceqA, 0.6964, 2.86, 0.239, 269, 247, DLK IN COMPLEX WITH INHIBITOR 2-((1-CYCLOPENTYL-5-(1-(OXETAN-3-YL) PIPERIDIN-4-YL)-1H-PYRAZOL-3-YL)AMINO)ISONICOTINONITRILE
3676, 4e7wA, 0.6964, 3.58, 0.181, 359, 260, STRUCTURE OF GSK3 FROM USTILAGO MAYDIS
3677, 3sx9A, 0.6964, 3.37, 0.201, 457, 259, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR RM-1-132
3678, 3f88A, 0.6964, 3.62, 0.179, 340, 262, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
3679, 2bcjA, 0.6964, 4.08, 0.172, 624, 274, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GALPHA-Q AND GBETAGAMMA SUBUNITS
3680, 1q41B, 0.6964, 3.61, 0.172, 343, 262, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
3681, 1jpaA, 0.6964, 3.28, 0.303, 273, 254, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED EPHB2 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
3682, 6cmjA, 0.6963, 3.38, 0.180, 285, 256, HUMAN CAMKK2 WITH GSK650393
3683, 5modB, 0.6963, 3.29, 0.152, 324, 256, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
3684, 3o17A, 0.6963, 3.07, 0.206, 357, 253, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
3685, 3gokD, 0.6963, 2.81, 0.146, 283, 247, BINDING SITE MAPPING OF PROTEIN LIGANDS
3686, 3gokA, 0.6963, 2.81, 0.146, 285, 247, BINDING SITE MAPPING OF PROTEIN LIGANDS
3687, 3bhvA, 0.6963, 3.36, 0.158, 297, 259, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
3688, 2fysA, 0.6963, 3.23, 0.168, 348, 256, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
3689, 1xjdA, 0.6963, 3.10, 0.178, 280, 253, CRYSTAL STRUCTURE OF PKC-THETA COMPLEXED WITH STAUROSPORINE AT 2A RESOLUTION
3690, 1h1qA, 0.6963, 3.46, 0.158, 296, 259, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
3691, 6gt1D, 0.6962, 2.84, 0.178, 260, 247, NEK7 BOUND TO PURINE INHIBITOR 
3692, 5ia4A, 0.6962, 3.24, 0.320, 269, 253, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH FORETINIB (XL880)
3693, 4zk5B, 0.6962, 3.60, 0.173, 294, 260, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
3694, 4pqnA, 0.6962, 2.33, 0.324, 240, 238, ITK KINASE DOMAIN WITH COMPOUND GNE-9822
3695, 4h58C, 0.6962, 2.94, 0.218, 272, 248, BRAF IN COMPLEX WITH COMPOUND 3
3696, 4fkqA, 0.6962, 3.04, 0.181, 283, 249, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
3697, 4bbmA, 0.6962, 3.69, 0.207, 314, 261, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312
3698, 3sd0B, 0.6962, 3.61, 0.168, 349, 262, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
3699, 3qa8B, 0.6962, 3.69, 0.167, 622, 264, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
3700, 3l1sA, 0.6962, 3.62, 0.172, 336, 262, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
3701, 3iecC, 0.6962, 3.30, 0.210, 311, 257, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
3702, 3f88B, 0.6962, 3.60, 0.169, 340, 261, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
3703, 2y6mA, 0.6962, 3.22, 0.306, 262, 255, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN
3704, 1h28C, 0.6962, 3.44, 0.166, 296, 259, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
3705, 5kpmB, 0.6961, 3.63, 0.176, 345, 262, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD3731
3706, 4cfnA, 0.6961, 3.40, 0.158, 296, 259, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
3707, 2c5vC, 0.6961, 3.45, 0.154, 296, 260, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
3708, 6bleA, 0.6960, 3.17, 0.175, 265, 252, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CP673451
3709, 5vo2A, 0.6960, 2.85, 0.239, 269, 247, DLK IN COMPLEX WITH INHIBITOR 5-(1-ISOPROPYL-5-(1-(OXETAN-3-YL) PIPERIDIN-4-YL)-1H-PYRAZOL-3-YL)-3-(TRIFLUOROMETHYL)PYRIDIN-2-AMINE (COMPOUND 7)
3710, 5bvkA, 0.6960, 2.95, 0.305, 278, 249, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
3711, 5bnjA, 0.6960, 3.70, 0.159, 343, 264, CDK8/CYCC IN COMPLEX WITH 8-{3-CHLORO-5-[4-(1-METHYL-1H-PYRAZOL-4-YL)- PHENYL]-PYRIDIN- 4-YL}-28-DIAZA-SPIRO[4.5]DECAN-1-ONE
3712, 4u41A, 0.6960, 3.22, 0.171, 275, 252, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
3713, 3ggfA, 0.6960, 3.40, 0.236, 275, 258, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE MST4 IN COMPLEX WITH AN QUINAZOLIN
3714, 3ddqC, 0.6960, 3.33, 0.172, 266, 256, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
3715, 1z5mA, 0.6960, 3.22, 0.213, 275, 254, CRYSTAL STRUCTURE OF N1-[3-[[5-BROMO-2-[[3-[(1-PYRROLIDINYLCARBONYL) AMINO]PHENYL]AMINO]-4-PYRIMIDINYL]AMINO]PROPYL]-22- DIMETHYLPROPANEDIAMIDE COMPLEXED WITH HUMAN PDK1
3716, 1q4lA, 0.6960, 3.60, 0.169, 342, 261, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
3717, 1k9aC, 0.6960, 3.41, 0.305, 438, 256, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
3718, 5lmkC, 0.6959, 3.30, 0.172, 265, 256, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
3719, 5hieD, 0.6959, 2.66, 0.201, 253, 244, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
3720, 4wg4A, 0.6959, 3.45, 0.196, 454, 260, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1613
3721, 4btjB, 0.6959, 3.66, 0.160, 293, 263, TTBK1 IN COMPLEX WITH ATP
3722, 3rzbA, 0.6959, 2.97, 0.181, 282, 248, CDK2 IN COMPLEX WITH INHIBITOR RC-2-23
3723, 3iggA, 0.6959, 3.15, 0.184, 290, 250, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFQ WITH CDK-2
3724, 3ddqA, 0.6959, 3.41, 0.159, 296, 258, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
3725, 5oyfA, 0.6958, 3.38, 0.152, 327, 257, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 31
3726, 5lqeA, 0.6958, 3.48, 0.162, 295, 259, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
3727, 5lmkA, 0.6958, 3.33, 0.163, 296, 257, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
3728, 4zy5B, 0.6958, 3.71, 0.163, 287, 264, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
3729, 4u45B, 0.6958, 3.67, 0.172, 295, 261, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
3730, 4csvA, 0.6958, 2.59, 0.335, 244, 242, TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL BOUND TO GLEEVEC
3731, 3r9oA, 0.6958, 2.97, 0.185, 282, 248, CDK2 IN COMPLEX WITH INHIBITOR RC-2-143
3732, 3kc3B, 0.6958, 2.81, 0.158, 290, 247, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
3733, 3f5xC, 0.6958, 3.54, 0.149, 298, 262, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
3734, 3blhA, 0.6958, 3.26, 0.160, 291, 256, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1
3735, 2zm3C, 0.6958, 3.56, 0.293, 296, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
3736, 2c5vA, 0.6958, 3.45, 0.158, 296, 260, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
3737, 1urcC, 0.6958, 3.41, 0.158, 296, 259, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
3738, 1oi9A, 0.6958, 3.39, 0.163, 295, 258, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
3739, 5vo1A, 0.6957, 2.85, 0.243, 269, 247, DLK IN COMPLEX WITH COMPOUND 10 (5-(1-ISOPROPYL-5-(3-(OXETAN-3-YL)-3- AZABICYCLO[3.1.0]HEXAN-6-YL)-1H-PYRAZOL-3-YL)-3-(TRIFLUOROMETHYL) PYRIDIN-2-AMINE)
3740, 5kpkA, 0.6957, 3.61, 0.169, 346, 261, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD0209
3741, 5airA, 0.6957, 3.60, 0.169, 353, 261, STRUCTURAL ANALYSIS OF MOUSE GSK3BETA FUSED WITH LRP6 PEPTIDE.
3742, 4yfiC, 0.6957, 2.81, 0.193, 269, 243, TNNI3K COMPLEXED WITH INHIBITOR 1
3743, 3qa8G, 0.6957, 3.70, 0.167, 541, 264, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
3744, 3qa8F, 0.6957, 3.69, 0.167, 622, 264, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
3745, 3eknA, 0.6957, 3.37, 0.298, 297, 258, INSULIN RECEPTOR KINASE COMPLEXED WITH AN INHIBITOR
3746, 3bysA, 0.6957, 2.76, 0.293, 255, 246, CO-CRYSTAL STRUCTURE OF LCK AND AMINOPYRIMIDINE AMIDE 10B
3747, 2gmxB, 0.6957, 3.18, 0.200, 357, 255, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
3748, 2c6mA, 0.6957, 3.11, 0.180, 290, 250, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3749, 5lvmA, 0.6956, 3.54, 0.196, 283, 260, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENINE BOUND TO THE ATP- BINDING SITE
3750, 5kplA, 0.6956, 3.58, 0.173, 339, 260, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD0705
3751, 5he1A, 0.6956, 4.07, 0.176, 618, 273, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224062
3752, 4nm3A, 0.6956, 3.55, 0.161, 357, 261, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED N- TERMINAL AUTO-INHIBITORY PS9 PEPTIDE
3753, 4l45A, 0.6956, 3.67, 0.176, 317, 262, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389E
3754, 4e3cE, 0.6956, 3.64, 0.167, 624, 263, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
3755, 3l1sB, 0.6956, 3.59, 0.153, 330, 262, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
3756, 2wipA, 0.6956, 3.58, 0.165, 297, 261, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
3757, 2qoqA, 0.6956, 3.57, 0.305, 284, 256, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION BASE AMP-PNP BOUND STRUCTURE
3758, 2ofvB, 0.6956, 2.25, 0.275, 244, 236, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 1 BOUND TO LCK
3759, 2g01A, 0.6956, 3.17, 0.185, 355, 254, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
3760, 2b52A, 0.6956, 2.92, 0.186, 283, 247, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH- 042562
3761, 5uyjA, 0.6955, 3.40, 0.180, 281, 256, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
3762, 5o23B, 0.6955, 3.16, 0.195, 278, 251, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE
3763, 5kx7B, 0.6955, 3.06, 0.217, 286, 249, IRAK4-INHIBITOR CO-STRUCTURE
3764, 5i3oB, 0.6955, 3.15, 0.139, 302, 252, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3765, 4yzmB, 0.6955, 2.82, 0.247, 262, 247, HUMANIZED ROCO4 BOUND TO LRRK2-IN1
3766, 4pteA, 0.6955, 3.59, 0.169, 341, 261, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
3767, 4g9rB, 0.6955, 2.93, 0.222, 261, 248, B-RAF V600E KINASE DOMAIN BOUND TO A TYPE II DIHYDROQUINAZOLINE INHIBITOR
3768, 3qa8H, 0.6955, 3.70, 0.170, 541, 264, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
3769, 2rl5A, 0.6955, 3.68, 0.304, 294, 260, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A 23-DIHYDRO-14-BENZOXAZINE INHIBITOR
3770, 1p5eC, 0.6955, 3.47, 0.166, 296, 259, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
3771, 1jwhA, 0.6955, 3.40, 0.147, 336, 258, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
3772, 5l2wA, 0.6954, 3.18, 0.165, 297, 254, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK2/CYCLINE AND DINACICLIB.
3773, 5jrsB, 0.6954, 2.48, 0.326, 240, 239, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO -34-DIHYDROQUINAZOLIN-3-YL) PHENYL]-7-(2-HYDROXYPROPAN-2-Y L)-9H-CARBAZOLE-1-CARBOXAMIDE
3774, 5hkmA, 0.6954, 2.98, 0.212, 272, 250, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
3775, 4nstA, 0.6954, 3.86, 0.152, 322, 269, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
3776, 4acdB, 0.6954, 3.64, 0.164, 350, 262, GSK3B IN COMPLEX WITH INHIBITOR
3777, 3qa8A, 0.6954, 3.68, 0.167, 622, 264, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
3778, 3en7A, 0.6954, 2.62, 0.290, 247, 241, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH S1 A MULTITARGETED KINASE INHIBITOR
3779, 2xyuA, 0.6954, 3.21, 0.307, 260, 254, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN IN COMPLEX WITH VUF 12058
3780, 2uzbA, 0.6954, 3.46, 0.151, 295, 259, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
3781, 2pe1A, 0.6954, 3.37, 0.211, 275, 256, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) {2-OXO-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-23-DIHYDRO-1H- INDOL-5-YL}-UREA {BX-517} COMPLEX
3782, 2fumB, 0.6954, 2.79, 0.154, 262, 247, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
3783, 1oiyA, 0.6954, 3.28, 0.164, 293, 256, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
3784, 6gn1B, 0.6953, 3.61, 0.176, 339, 261, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3B) IN COMPLEX WITH PIK-75 
3785, 5kpkB, 0.6953, 3.64, 0.172, 344, 261, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD0209
3786, 4l43A, 0.6953, 3.61, 0.176, 316, 261, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM I)
3787, 3sd0A, 0.6953, 3.57, 0.172, 350, 261, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
3788, 3my5C, 0.6953, 3.38, 0.171, 266, 257, CDK2/CYCLINA IN COMPLEX WITH DRB
3789, 3kc3F, 0.6953, 2.93, 0.141, 293, 249, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
3790, 3j4rE, 0.6953, 3.76, 0.157, 325, 267, PSEUDO-ATOMIC MODEL OF THE AKAP18-PKA COMPLEX IN A LINEAR CONFORMATION DERIVED FROM ELECTRON MICROSCOPY
3791, 3j4rD, 0.6953, 3.76, 0.157, 325, 267, PSEUDO-ATOMIC MODEL OF THE AKAP18-PKA COMPLEX IN A LINEAR CONFORMATION DERIVED FROM ELECTRON MICROSCOPY
3792, 3j4qE, 0.6953, 3.76, 0.157, 325, 267, PSEUDO-ATOMIC MODEL OF THE AKAP18-PKA COMPLEX IN A BENT CONFORMATION DERIVED FROM ELECTRON MICROSCOPY
3793, 3j4qD, 0.6953, 3.76, 0.157, 325, 267, PSEUDO-ATOMIC MODEL OF THE AKAP18-PKA COMPLEX IN A BENT CONFORMATION DERIVED FROM ELECTRON MICROSCOPY
3794, 2r3rA, 0.6953, 3.10, 0.181, 290, 249, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3795, 2r3pA, 0.6953, 3.06, 0.185, 289, 249, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3796, 2r3oA, 0.6953, 3.07, 0.185, 289, 249, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3797, 2c68A, 0.6953, 3.12, 0.184, 290, 250, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3798, 2bkzC, 0.6953, 3.56, 0.153, 298, 262, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
3799, 1ol5A, 0.6953, 3.26, 0.185, 263, 254, STRUCTURE OF AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288 AND BOUND TO TPX2 1-43
3800, 5wg4A, 0.6952, 4.32, 0.173, 621, 278, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG257284
3801, 5to8A, 0.6952, 2.97, 0.328, 250, 247, SELECTIVITY SWITCH BETWEEN FAK AND PYK2: MACROCYCLIZATION OF FAK INHIBITORS IMPROVES PYK2 POTENCY
3802, 5e8vA, 0.6952, 3.08, 0.192, 296, 250, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A)
3803, 4wovB, 0.6952, 2.65, 0.209, 256, 244, CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH BMS-066 AKA 2-METHOXY-N-({6-[3-METHYL-7-(METHYLAMINO)- 35810-TETRAAZATRICYCLO[7.3.0.0 6]DODECA-1(9)2(6)4711-PENTAEN- 11-YL]PYRIDIN-2-YL}METHY L)ACETAMIDE
3804, 4iq6B, 0.6952, 3.66, 0.164, 332, 262, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
3805, 3fwqA, 0.6952, 3.49, 0.151, 334, 259, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
3806, 2r3iA, 0.6952, 3.10, 0.181, 289, 249, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3807, 2nryB, 0.6952, 3.19, 0.211, 286, 251, CRYSTAL STRUCTURE OF IRAK-4
3808, 5nevA, 0.6951, 3.45, 0.166, 295, 259, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
3809, 4achB, 0.6951, 3.63, 0.164, 350, 262, GSK3B IN COMPLEX WITH INHIBITOR
3810, 3v5pA, 0.6951, 3.41, 0.201, 450, 259, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1288
3811, 3tcpB, 0.6951, 2.31, 0.342, 250, 234, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC569
3812, 3sdjI, 0.6951, 3.28, 0.180, 413, 255, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
3813, 3dlsA, 0.6951, 3.55, 0.158, 285, 259, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3814, 2og8B, 0.6951, 2.84, 0.289, 249, 246, CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 36 BOUND TO LCK
3815, 5nhjA, 0.6950, 3.31, 0.168, 345, 256, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
3816, 4ub7A, 0.6950, 3.34, 0.148, 334, 256, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26) SHOWING AN EXTREME DISTORTION OF THE ATP-BINDING LOOP COMBINED WITH A PI-HALOGEN BOND
3817, 4pmtA, 0.6950, 2.91, 0.301, 273, 246, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR N~4~-(4-MORPHOLIN- 4-YLPHENYL)-N~6~-(PYRIDIN-3-YLMETHYL)PYRIDO[32-D]PYRIMIDINE-46- DIAMINE
3818, 4gk2A, 0.6950, 3.20, 0.303, 265, 251, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 66
3819, 4cqeA, 0.6950, 2.56, 0.227, 250, 242, B-RAF KINASE V600E MUTANT IN COMPLEX WITH  A DIARYLTHIAZOLE B-RAF INHIBITOR
3820, 4acdA, 0.6950, 3.64, 0.164, 350, 262, GSK3B IN COMPLEX WITH INHIBITOR
3821, 2qlqA, 0.6950, 2.54, 0.287, 245, 240, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN WITH COVALENT INHIBITOR RL3
3822, 2bujB, 0.6950, 3.41, 0.187, 286, 257, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
3823, 1wccA, 0.6950, 3.00, 0.181, 283, 248, SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY
3824, 1b38A, 0.6950, 3.08, 0.185, 290, 249, HUMAN CYCLIN-DEPENDENT KINASE 2
3825, 6gn1A, 0.6949, 3.61, 0.176, 339, 261, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3B) IN COMPLEX WITH PIK-75 
3826, 5xfjA, 0.6949, 3.10, 0.324, 266, 250, CRYSTAL STRUCTURE OF LY2874455 IN COMPLEX OF FGFR4 GATEKEEPER MUTATION (V550M) 
3827, 5v24B, 0.6949, 2.98, 0.205, 263, 249, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
3828, 4tygA, 0.6949, 3.56, 0.322, 293, 258, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
3829, 4eojA, 0.6949, 3.32, 0.163, 295, 257, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
3830, 3sdjJ, 0.6949, 3.29, 0.184, 413, 255, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
3831, 2vtmA, 0.6949, 3.07, 0.185, 290, 249, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3832, 6c2yA, 0.6948, 4.01, 0.176, 617, 272, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG257142 
3833, 5drdA, 0.6948, 3.04, 0.183, 259, 251, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
3834, 4p5zA, 0.6948, 3.23, 0.294, 267, 252, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
3835, 3v51A, 0.6948, 3.47, 0.192, 459, 260, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR RM-1-176
3836, 3pupB, 0.6948, 3.65, 0.164, 347, 262, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
3837, 3cikA, 0.6948, 4.12, 0.182, 619, 274, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
3838, 5uy6A, 0.6947, 3.37, 0.180, 282, 255, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
3839, 4ksqB, 0.6947, 2.86, 0.224, 255, 245, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR 5B
3840, 4f0fA, 0.6947, 3.27, 0.227, 276, 255, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM
3841, 2zoqB, 0.6947, 3.20, 0.150, 351, 253, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
3842, 2vtrA, 0.6947, 3.06, 0.185, 290, 249, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3843, 2r3fA, 0.6947, 3.22, 0.179, 290, 251, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3844, 1jpaB, 0.6947, 3.18, 0.311, 269, 251, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED EPHB2 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
3845, 1h28A, 0.6947, 3.31, 0.160, 296, 257, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
3846, 5uq2A, 0.6946, 3.53, 0.149, 296, 261, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
3847, 5orkB, 0.6946, 3.27, 0.149, 323, 255, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 6
3848, 4ygaA, 0.6946, 3.67, 0.192, 448, 261, CDPK1 FROM TOXOPLASMA GONDII BOUND TO INHIBITORY VHH-1B7
3849, 4e3cF, 0.6946, 3.58, 0.172, 624, 262, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
3850, 4cfmA, 0.6946, 3.41, 0.171, 296, 258, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
3851, 3wblA, 0.6946, 3.02, 0.181, 283, 248, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR
3852, 2wevA, 0.6946, 3.46, 0.158, 296, 260, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
3853, 2jbpA, 0.6946, 2.82, 0.146, 283, 247, PROTEIN KINASE MK2 IN COMPLEX WITH AN INHIBITOR (CRYSTAL FORM-2 CO-CRYSTALLIZATION)
3854, 2hwpA, 0.6946, 2.73, 0.281, 245, 242, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR PD168393
3855, 5uoxA, 0.6945, 2.98, 0.201, 263, 249, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3856, 5g1xA, 0.6945, 3.16, 0.182, 262, 253, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH N-MYC
3857, 5cepA, 0.6945, 2.88, 0.243, 269, 247, DLK IN COMPLEX WITH INHIBITOR N-(1-ISOPROPYL-5-(PIPERIDIN-4-YL)-1H- PYRAZOL-3-YL)-4-(TRIFLUOROMETHYL)PYRIDIN-2-AMINE
3858, 4ztmD, 0.6945, 2.96, 0.211, 282, 246, IRAK4-INHIBITOR CO-STRUCTURE
3859, 4a07A, 0.6945, 3.42, 0.205, 282, 258, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS171 BOUND TO THE PIF-POCKET
3860, 3qtrA, 0.6945, 3.00, 0.185, 282, 248, CDK2 IN COMPLEX WITH INHIBITOR RC-1-148
3861, 2pe2A, 0.6945, 3.32, 0.208, 275, 255, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 3-{5-[2-OXO-5-UREIDO-12-DIHYDRO-INDOL-(3Z)-YLIDENEMETHYL]-1H- PYRROL-3-YL}-N-(2-PIPERIDIN-1-YL-ETHYL)-BENZAMIDE COMPLEX
3862, 2iw6A, 0.6945, 3.37, 0.163, 292, 257, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
3863, 1e1vA, 0.6945, 3.08, 0.181, 290, 249, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058
3864, 5lpvA, 0.6944, 3.10, 0.188, 282, 250, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH AMPPNP AND MN FROM ARABIDOPSIS THALIANA
3865, 4xv1B, 0.6944, 2.60, 0.231, 249, 242, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX7904
3866, 4nksA, 0.6944, 3.24, 0.311, 265, 251, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 3
3867, 4eorC, 0.6944, 3.42, 0.167, 270, 257, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
3868, 3tniA, 0.6944, 3.25, 0.165, 297, 255, STRUCTURE OF CDK9/CYCLIN T F241L
3869, 3kc3L, 0.6944, 2.83, 0.158, 291, 247, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
3870, 2henD, 0.6944, 3.16, 0.311, 259, 251, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
3871, 2c5xC, 0.6944, 3.44, 0.158, 296, 259, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
3872, 2c5oC, 0.6944, 3.51, 0.154, 296, 260, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
3873, 1zrzA, 0.6944, 3.48, 0.162, 310, 260, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF ATYPICAL PROTEIN KINASE C-IOTA
3874, 5jrqB, 0.6943, 2.61, 0.232, 246, 241, BRAFV600E KINASE DOMAIN IN COMPLEX WITH CHEMICALLY LINKED VEMURAFENIB INHIBITOR VEM-6-VEM
3875, 5ax9B, 0.6943, 3.30, 0.178, 274, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
3876, 3pupA, 0.6943, 3.66, 0.164, 346, 262, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
3877, 2vtlA, 0.6943, 3.08, 0.185, 290, 249, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3878, 2uzbC, 0.6943, 3.34, 0.156, 292, 257, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
3879, 2i40A, 0.6943, 3.20, 0.161, 291, 255, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
3880, 2henB, 0.6943, 3.16, 0.311, 259, 251, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
3881, 1ol2C, 0.6943, 3.47, 0.158, 296, 259, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
3882, 1o9uA, 0.6943, 3.57, 0.169, 349, 260, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE
3883, 5de2A, 0.6942, 3.18, 0.183, 267, 252, STRUCTURAL MECHANISM OF NEK7 ACTIVATION BY NEK9-INDUCED DIMERISATION
3884, 5ajqA, 0.6942, 3.33, 0.173, 280, 255, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
3885, 4nstC, 0.6942, 3.80, 0.149, 317, 268, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
3886, 4accB, 0.6942, 3.66, 0.164, 350, 262, GSK3B IN COMPLEX WITH INHIBITOR
3887, 3eidA, 0.6942, 3.32, 0.152, 292, 257, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
3888, 3dtcA, 0.6942, 1.96, 0.310, 245, 232, CRYSTAL STRUCTURE OF MIXED-LINEAGE KINASE MLK1 COMPLEXED WITH COMPOUND 16
3889, 2r7iC, 0.6942, 3.21, 0.155, 321, 252, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
3890, 2jboA, 0.6942, 2.95, 0.149, 295, 249, PROTEIN KINASE MK2 IN COMPLEX WITH AN INHIBITOR (CRYSTAL FORM-1 SOAKING)
3891, 1h0wA, 0.6942, 2.96, 0.182, 283, 247, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[CYCLOHEX-3-ENYL]METHOXYPURINE
3892, 1di8A, 0.6942, 3.08, 0.185, 283, 249, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[3-HYDROXYANILINO]-67-DIMETHOXYQUINAZOLINE
3893, 5wg3A, 0.6941, 4.22, 0.170, 618, 276, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG258748
3894, 4acgB, 0.6941, 3.63, 0.160, 350, 262, GSK3B IN COMPLEX WITH INHIBITOR
3895, 3upzA, 0.6941, 3.53, 0.196, 458, 260, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
3896, 3pvuA, 0.6941, 4.07, 0.172, 609, 274, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD101)
3897, 2v22C, 0.6941, 3.40, 0.163, 296, 258, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
3898, 2h96A, 0.6941, 3.20, 0.188, 358, 255, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
3899, 5v19B, 0.6940, 2.78, 0.207, 260, 246, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
3900, 4zy5A, 0.6940, 3.57, 0.188, 283, 260, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
3901, 4xs2A, 0.6940, 3.09, 0.213, 283, 249, IRAK4-INHIBITOR CO-STRUCTURE
3902, 4nm7A, 0.6940, 3.56, 0.153, 355, 261, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 E-MOTIF
3903, 4jqeA, 0.6940, 3.59, 0.138, 369, 261, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH AMPPN
3904, 4iq6A, 0.6940, 3.58, 0.169, 324, 260, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
3905, 4bicA, 0.6940, 2.71, 0.212, 260, 245, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3906, 3qtsA, 0.6940, 2.97, 0.190, 282, 247, CDK2 IN COMPLEX WITH INHIBITOR RC-2-12
3907, 3my5A, 0.6940, 3.31, 0.163, 296, 257, CDK2/CYCLINA IN COMPLEX WITH DRB
3908, 2c5oA, 0.6940, 3.50, 0.154, 296, 260, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
3909, 1j1cA, 0.6940, 3.69, 0.167, 354, 263, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
3910, 5i3rB, 0.6939, 3.17, 0.139, 302, 252, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3911, 4cqeB, 0.6939, 2.56, 0.224, 248, 241, B-RAF KINASE V600E MUTANT IN COMPLEX WITH  A DIARYLTHIAZOLE B-RAF INHIBITOR
3912, 4afjA, 0.6939, 3.55, 0.181, 342, 259, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
3913, 4accA, 0.6939, 3.64, 0.164, 350, 262, GSK3B IN COMPLEX WITH INHIBITOR
3914, 3rprA, 0.6939, 2.99, 0.190, 282, 247, CDK2 IN COMPLEX WITH INHIBITOR RC-2-49
3915, 3r9nA, 0.6939, 2.98, 0.190, 282, 247, CDK2 IN COMPLEX WITH INHIBITOR RC-2-21
3916, 3q96A, 0.6939, 2.85, 0.224, 253, 246, B-RAF KINASE DOMAIN IN COMPLEX WITH A TETRAHYDRONAPHTHALENE INHIBITOR
3917, 3dlsD, 0.6939, 3.48, 0.152, 284, 257, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3918, 2wihC, 0.6939, 3.61, 0.152, 299, 263, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
3919, 5kziA, 0.6938, 3.18, 0.167, 273, 252, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN IMIDAZOPYRIDAZINE INHIBITOR.
3920, 4eomA, 0.6938, 3.37, 0.167, 296, 258, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
3921, 3s95A, 0.6938, 3.54, 0.224, 290, 259, CRYSTAL STRUCTURE OF THE HUMAN LIMK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
3922, 3f5xA, 0.6938, 3.53, 0.149, 297, 261, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
3923, 4yfiA, 0.6937, 2.80, 0.194, 268, 242, TNNI3K COMPLEXED WITH INHIBITOR 1
3924, 3orzB, 0.6937, 3.34, 0.204, 278, 255, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
3925, 2wpaC, 0.6937, 3.63, 0.156, 299, 263, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
3926, 2r7bA, 0.6937, 3.07, 0.215, 274, 251, CRYSTAL STRUCTURE OF THE PHOSPHOINOSITIDE-DEPENDENT KINASE- 1 (PDK-1)CATALYTIC DOMAIN BOUND TO A DIBENZONAPHTHYRIDINE INHIBITOR
3927, 6b16A, 0.6936, 3.56, 0.196, 285, 260, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
3928, 5mrdA, 0.6936, 3.51, 0.205, 283, 259, HUMAN PDK1-PKCIOTA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS267 BOUND TO THE PIF-POCKET
3929, 4dbnB, 0.6936, 2.90, 0.220, 263, 246, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN B-RAF WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
3930, 2jbpB, 0.6936, 2.99, 0.149, 290, 249, PROTEIN KINASE MK2 IN COMPLEX WITH AN INHIBITOR (CRYSTAL FORM-2 CO-CRYSTALLIZATION)
3931, 1vywC, 0.6936, 3.61, 0.148, 299, 263, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
3932, 1r0eB, 0.6936, 3.62, 0.169, 344, 261, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
3933, 5objA, 0.6935, 3.09, 0.183, 260, 252, AURORA A KINASE IN COMPLEX WITH 2-(3-FLUOROPHENYL)QUINOLINE-4- CARBOXYLIC ACID AND ATP
3934, 4kspB, 0.6935, 2.85, 0.216, 256, 245, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR TAK-632
3935, 3pvwA, 0.6935, 4.03, 0.168, 613, 273, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD103A)
3936, 3orzD, 0.6935, 3.37, 0.195, 278, 256, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
3937, 3kc3A, 0.6935, 2.86, 0.146, 288, 247, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
3938, 2wevC, 0.6935, 3.47, 0.158, 296, 259, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
3939, 2r3hA, 0.6935, 3.05, 0.185, 289, 248, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3940, 2jbpD, 0.6935, 2.78, 0.146, 286, 246, PROTEIN KINASE MK2 IN COMPLEX WITH AN INHIBITOR (CRYSTAL FORM-2 CO-CRYSTALLIZATION)
3941, 2iw9A, 0.6935, 3.24, 0.161, 293, 255, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
3942, 2c5yA, 0.6935, 3.15, 0.176, 290, 250, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
3943, 1q4lB, 0.6935, 3.60, 0.161, 337, 261, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
3944, 3rahA, 0.6934, 3.00, 0.190, 282, 247, CDK2 IN COMPLEX WITH INHIBITOR RC-2-22
3945, 3qcyA, 0.6934, 3.34, 0.208, 275, 255, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 4-[2- AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-N-PHENYL-2- MORPHOLINECARBOXAMIDE
3946, 3hrcA, 0.6934, 3.54, 0.197, 279, 259, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ATP
3947, 2cciA, 0.6934, 3.42, 0.171, 296, 258, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
3948, 1y91A, 0.6934, 3.06, 0.185, 286, 248, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
3949, 1r0eA, 0.6934, 3.62, 0.169, 344, 261, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
3950, 1pkdC, 0.6934, 3.47, 0.158, 296, 259, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
3951, 5m4iA, 0.6933, 3.37, 0.148, 331, 256, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
3952, 5kx8C, 0.6933, 3.13, 0.216, 287, 250, IRAK4-INHIBITOR CO-STRUCTURE
3953, 4nm5A, 0.6933, 3.60, 0.161, 361, 261, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 C-MOTIF
3954, 4nifB, 0.6933, 3.21, 0.169, 349, 254, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
3955, 4neuB, 0.6933, 2.97, 0.232, 268, 250, X-RAY STRUCTURE OF RECEPTOR INTERACTING PROTEIN 1 (RIP1)KINASE DOMAIN WITH A 1-AMINOISOQUINOLINE INHIBITOR
3956, 4lgdB, 0.6933, 3.66, 0.206, 350, 267, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3957, 4iwqA, 0.6933, 3.82, 0.143, 626, 265, CRYSTAL STRUCTURE AND MECHANISM OF ACTIVATION OF TBK1
3958, 4fkvA, 0.6933, 3.02, 0.185, 282, 248, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
3959, 3be2A, 0.6933, 3.63, 0.314, 290, 258, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZAMIDE INHIBITOR
3960, 1mqbA, 0.6933, 3.25, 0.311, 263, 254, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
3961, 1ke8A, 0.6933, 2.99, 0.186, 282, 247, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO- 12-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(13- THIAZOL-2-YL)BENZENESULFONAMIDE
3962, 5deyB, 0.6932, 3.60, 0.173, 281, 260, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
3963, 4ygaE, 0.6932, 3.65, 0.192, 442, 260, CDPK1 FROM TOXOPLASMA GONDII BOUND TO INHIBITORY VHH-1B7
3964, 4xufB, 0.6932, 3.23, 0.341, 274, 252, CRYSTAL STRUCTURE OF THE FLT3 KINASE DOMAIN BOUND TO THE INHIBITOR QUIZARTINIB (AC220)
3965, 4wunB, 0.6932, 3.31, 0.310, 268, 252, STRUCTURE OF FGFR1 IN COMPLEX WITH AZD4547 (N-{3-[2-(35- DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) AT 1.65 ANGSTROM
3966, 4nifE, 0.6932, 3.21, 0.169, 348, 254, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
3967, 4aotA, 0.6932, 3.04, 0.185, 278, 249, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
3968, 2xckA, 0.6932, 3.10, 0.210, 275, 252, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
3969, 2jbpI, 0.6932, 2.88, 0.146, 289, 247, PROTEIN KINASE MK2 IN COMPLEX WITH AN INHIBITOR (CRYSTAL FORM-2 CO-CRYSTALLIZATION)
3970, 1e9hC, 0.6932, 3.48, 0.162, 296, 259, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
3971, 5xzwB, 0.6931, 2.67, 0.202, 379, 242, CRYSTAL STRUCTURE OF RAD53 1-466
3972, 4bcmC, 0.6931, 3.50, 0.162, 294, 259, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3973, 4b7tA, 0.6931, 3.53, 0.169, 350, 260, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE AND LEUCETTINE L4
3974, 3qd4A, 0.6931, 3.29, 0.205, 276, 254, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL{(3R5R)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-5-METHYL-3-PIPERIDINYL}CARBAMATE
3975, 6c4dB, 0.6930, 3.20, 0.217, 266, 249, STRUCTURE BASED DESIGN OF RIP1 KINASE INHIBITORS
3976, 5d9lA, 0.6930, 3.56, 0.187, 299, 262, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BIS-PHENOL PYRAZOLE
3977, 3iecA, 0.6930, 3.31, 0.215, 311, 256, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
3978, 3dj7A, 0.6930, 3.15, 0.183, 257, 252, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 130.
3979, 2p2hA, 0.6930, 3.46, 0.316, 292, 256, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDINYL-TRIAZINE INHIBITOR
3980, 2ow3A, 0.6930, 3.61, 0.185, 346, 260, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
3981, 2c5xA, 0.6930, 3.50, 0.154, 296, 260, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
3982, 5v62A, 0.6929, 3.16, 0.154, 349, 253, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP3
3983, 5ouuA, 0.6929, 3.31, 0.154, 324, 254, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 22
3984, 2x7fC, 0.6929, 3.31, 0.180, 285, 255, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
3985, 2qvsE, 0.6929, 3.75, 0.158, 323, 266, CRYSTAL STRUCTURE OF TYPE IIA HOLOENZYME OF CAMP-DEPENDENT PROTEIN KINASE
3986, 1w98A, 0.6929, 3.30, 0.153, 297, 255, THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E
3987, 4bcpC, 0.6928, 3.33, 0.165, 267, 255, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
3988, 3q3bB, 0.6928, 3.67, 0.164, 341, 262, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
3989, 3ns9A, 0.6928, 3.09, 0.177, 289, 249, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR BS-194
3990, 2ow3B, 0.6928, 3.60, 0.185, 351, 260, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
3991, 5valA, 0.6927, 2.81, 0.220, 254, 245, BRAF IN COMPLEX WITH N-(3-(TERT-BUTYL)PHENYL)-4-METHYL-3-(6- MORPHOLINOPYRIMIDIN-4-YL)BENZAMIDE
3992, 5acbC, 0.6927, 3.83, 0.148, 324, 270, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
3993, 4usdB, 0.6927, 3.07, 0.185, 267, 249, HUMAN STK10 (LOK) WITH SB-633825
3994, 3tnwA, 0.6927, 3.41, 0.154, 295, 259, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
3995, 2oibA, 0.6927, 2.91, 0.217, 280, 244, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
3996, 2ogvA, 0.6927, 3.55, 0.293, 317, 256, CRYSTAL STRUCTURE OF THE AUTOINHIBITED HUMAN C-FMS KINASE DOMAIN
3997, 4ztmA, 0.6926, 3.19, 0.211, 287, 251, IRAK4-INHIBITOR CO-STRUCTURE
3998, 4lgdD, 0.6926, 3.59, 0.207, 338, 266, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3999, 3pxfA, 0.6926, 3.45, 0.163, 302, 258, CDK2 IN COMPLEX WITH TWO MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
4000, 2c5nC, 0.6926, 3.48, 0.158, 296, 259, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
4001, 1ke9A, 0.6926, 3.09, 0.185, 281, 248, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4- ({[AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2- OXO-23-DIHYDRO-1H-INDOLE
4002, 5oszA, 0.6925, 3.44, 0.152, 327, 257, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 23
4003, 5mp8B, 0.6925, 3.28, 0.150, 323, 254, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
4004, 2x6dA, 0.6925, 2.97, 0.188, 255, 250, AURORA-A BOUND TO AN INHIBITOR
4005, 2wmbA, 0.6925, 3.42, 0.167, 296, 258, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
4006, 1mruB, 0.6925, 3.11, 0.159, 271, 251, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
4007, 6cpeA, 0.6924, 3.06, 0.184, 256, 250, STRUCTURE OF APO; DEPHOSPHORYLATED AURORA A (122-403) IN AN ACTIVE CONFORMATION 
4008, 6c3eB, 0.6924, 2.91, 0.216, 259, 245, CRYSTAL STRUCTURE OF RIP1 KINASE BOUND TO INHIBITOR
4009, 5dt4A, 0.6924, 3.08, 0.183, 259, 251, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
4010, 5cshB, 0.6924, 3.28, 0.150, 323, 253, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
4011, 4yc3A, 0.6924, 3.37, 0.174, 295, 258, CDK1/CYCLINB1/CKS2 APO
4012, 4fkrA, 0.6924, 3.05, 0.185, 282, 248, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4013, 2qo2A, 0.6924, 3.43, 0.303, 282, 254, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION DEPHOSPHORYLATED APO STRUCTURE
4014, 2jbpG, 0.6924, 2.84, 0.146, 287, 246, PROTEIN KINASE MK2 IN COMPLEX WITH AN INHIBITOR (CRYSTAL FORM-2 CO-CRYSTALLIZATION)
4015, 1urcA, 0.6924, 3.50, 0.154, 296, 260, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
4016, 1ke5A, 0.6924, 2.99, 0.186, 281, 247, CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO-12-DIHYDRO-3H- INDOL-3-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
4017, 5uq1C, 0.6923, 3.24, 0.169, 289, 255, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
4018, 3kc3I, 0.6923, 2.90, 0.141, 295, 248, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4019, 1uu3A, 0.6923, 3.31, 0.212, 276, 255, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH LY333531
4020, 5v61A, 0.6922, 3.13, 0.151, 348, 252, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP2
4021, 4qo9A, 0.6922, 3.68, 0.237, 280, 262, MST3 IN COMPLEX WITH DANUSERTIB
4022, 4nfnA, 0.6922, 3.74, 0.163, 293, 264, HUMAN TAU TUBULIN KINASE 1 (TTBK1) COMPLEXED WITH 3-({5-[(4-AMINO-4- METHYLPIPERIDIN-1-YL)METHYL]PYRROLO[21-F][124]TRIAZIN-4-YL}AMINO)- 5-BROMOPHENOL
4023, 4fkwA, 0.6921, 2.90, 0.167, 280, 246, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4024, 4c0tA, 0.6921, 3.59, 0.169, 290, 261, CANDIDA ALBICANS PKH KINASE DOMAIN
4025, 3r7iA, 0.6921, 3.01, 0.186, 282, 247, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-74
4026, 3dzqA, 0.6921, 3.33, 0.300, 268, 253, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH INHIBITOR AWL-II- 38.3
4027, 2y9qA, 0.6921, 3.28, 0.169, 349, 255, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
4028, 2w06A, 0.6921, 3.03, 0.186, 282, 247, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5C
4029, 2f57A, 0.6921, 3.54, 0.178, 297, 259, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
4030, 1fvtA, 0.6921, 3.01, 0.186, 282, 247, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH AN OXINDOLE INHIBITOR
4031, 6ccfB, 0.6920, 3.14, 0.171, 262, 251, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH HESPERADIN
4032, 5nevC, 0.6920, 3.43, 0.167, 296, 258, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
4033, 4fklA, 0.6920, 3.13, 0.177, 290, 249, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
4034, 3ii5B, 0.6920, 2.88, 0.228, 257, 246, THE COMPLEX OF WILD-TYPE B-RAF WITH PYRAZOLO PYRIMIDINE INHIBITOR
4035, 5otqA, 0.6919, 3.48, 0.152, 327, 257, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 33
4036, 4dhfA, 0.6919, 3.17, 0.183, 258, 252, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
4037, 3pxzA, 0.6919, 3.47, 0.163, 302, 258, CDK2 TERNARY COMPLEX WITH JWS648 AND ANS
4038, 3naxA, 0.6919, 3.29, 0.184, 278, 255, PDK1 IN COMPLEX WITH INHIBITOR MP7
4039, 2bpmC, 0.6919, 3.61, 0.149, 299, 262, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
4040, 5nudA, 0.6918, 3.41, 0.320, 267, 253, FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE DOMAIN (449-753) IN COMPLEX WITH IRREVERSIBLE LIGAND CGA159527
4041, 5nk8A, 0.6918, 3.15, 0.320, 266, 250, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2F
4042, 4zy4B, 0.6918, 3.74, 0.175, 292, 263, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
4043, 4zs0A, 0.6918, 3.17, 0.183, 257, 252, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO SB-6-OH
4044, 4yo6D, 0.6918, 3.11, 0.213, 285, 249, IRAK4-INHIBITOR CO-STRUCTURE
4045, 4uyaA, 0.6918, 2.73, 0.270, 274, 241, STRUCTURE OF MLK4 KINASE DOMAIN WITH ATPGAMMAS
4046, 4m3qB, 0.6918, 1.94, 0.362, 236, 229, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC1917
4047, 3pixA, 0.6918, 3.27, 0.303, 268, 251, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-ISOPROPYL-7- (4-METHYL-PIPERAZIN-1-YL)-4-(5-METHYL-2H-PYRAZOL-3-YLAMINO)-2H- PHTHALAZIN-1-ONE
4048, 3fz1A, 0.6918, 3.11, 0.185, 284, 248, CRYSTAL STRUCTURE OF A BENZTHIOPHENE INHIBITOR BOUND TO HUMAN CYCLIN-DEPENDENT KINASE-2 (CDK-2)
4049, 1okwC, 0.6918, 3.49, 0.154, 296, 259, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
4050, 1j3hA, 0.6918, 3.87, 0.169, 329, 267, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
4051, 1h08A, 0.6918, 3.11, 0.185, 283, 248, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
4052, 5wg5A, 0.6917, 4.20, 0.172, 617, 274, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224061
4053, 5jkgA, 0.6917, 3.14, 0.320, 266, 250, THE CRYSTAL STRUCTURE OF FGFR4 KINASE DOMAIN IN COMPLEX WITH LY2874455
4054, 4iwoA, 0.6917, 3.66, 0.149, 629, 262, CRYSTAL STRUCTURE AND MECHANISM OF ACTIVATION OF TBK1
4055, 1rjbA, 0.6917, 3.20, 0.339, 298, 248, CRYSTAL STRUCTURE OF FLT3
4056, 5c9cA, 0.6916, 2.85, 0.224, 254, 245, CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND
4057, 4q2aA, 0.6916, 3.26, 0.223, 271, 251, WNK1: A CHLORIDE SENSOR VIA AUTOPHOSPHORYLATION
4058, 4pdoB, 0.6916, 2.93, 0.302, 261, 245, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
4059, 4f99A, 0.6916, 3.28, 0.138, 312, 253, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND NUCLEOTIDE
4060, 3e5aA, 0.6916, 3.42, 0.187, 264, 256, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH VX-680 AND TPX2
4061, 3blqA, 0.6916, 3.56, 0.165, 295, 260, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH ATP
4062, 2whbC, 0.6916, 3.59, 0.146, 296, 261, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
4063, 2uueC, 0.6916, 3.42, 0.151, 296, 258, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
4064, 1ym7D, 0.6916, 4.12, 0.179, 599, 273, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
4065, 6g97A, 0.6915, 3.26, 0.154, 344, 254, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
4066, 5nhhA, 0.6915, 3.32, 0.153, 348, 255, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
4067, 4twnA, 0.6915, 3.51, 0.316, 276, 256, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH BIRB796
4068, 4mtaA, 0.6915, 3.22, 0.171, 273, 252, CRYSTAL STRUCTURE OF PIM-1 KINASE DOMAIN IN COMPLEX WITH 2-METHYL-5- PHENYLFURAN-3-CARBOXYLIC ACID
4069, 4mh7A, 0.6915, 2.45, 0.346, 248, 234, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC1896
4070, 4eorA, 0.6915, 3.21, 0.165, 293, 254, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
4071, 3qd0A, 0.6915, 3.33, 0.205, 274, 254, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH (2R5S)- 1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-6-METHYL-N- PHENYL-3-PIPERIDINECARBOXAMIDE
4072, 3orzC, 0.6915, 3.33, 0.205, 276, 254, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
4073, 3orzA, 0.6915, 3.33, 0.205, 276, 254, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
4074, 3is5B, 0.6915, 3.13, 0.194, 260, 248, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4075, 3hztA, 0.6915, 3.69, 0.215, 421, 261, CRYSTAL STRUCTURE OF TOXOPLASMA GONDII CDPK3 TGME49_105860
4076, 3ctjA, 0.6915, 3.61, 0.323, 289, 257, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A AMINOPYRIDINE BASED INHIBITOR
4077, 1ym7A, 0.6915, 4.12, 0.179, 608, 273, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
4078, 5n4vA, 0.6914, 3.12, 0.171, 273, 251, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE 2-CYCLOPROPYL-45- DIMETHYLTHIENO[54-D]PYRIMIDINE-6-CARBOXYLIC ACID
4079, 5k4jA, 0.6914, 3.03, 0.186, 282, 247, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH COMPOUND 22
4080, 5dewB, 0.6914, 3.70, 0.161, 281, 261, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
4081, 4pdoA, 0.6914, 2.93, 0.302, 261, 245, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
4082, 4nzwB, 0.6914, 3.18, 0.260, 266, 250, CRYSTAL STRUCTURE OF STK25-MO25 COMPLEX
4083, 4dhfB, 0.6914, 3.16, 0.183, 258, 252, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
4084, 3gokC, 0.6914, 2.80, 0.147, 285, 245, BINDING SITE MAPPING OF PROTEIN LIGANDS
4085, 2vv9A, 0.6914, 2.81, 0.184, 279, 244, CDK2 IN COMPLEX WITH AN IMIDAZOLE PIPERAZINE
4086, 1v0bA, 0.6914, 3.09, 0.156, 286, 250, CRYSTAL STRUCTURE OF THE T198A MUTANT OF PFPK5
4087, 1h27C, 0.6914, 3.45, 0.167, 291, 258, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
4088, 6b8uB, 0.6913, 2.66, 0.223, 248, 242, CRYSTALS STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINYL BENZAMIDE INHIBITOR
4089, 5j8iA, 0.6913, 3.07, 0.235, 288, 247, CRYSTAL STRUCTURE OF TL11-113 BOUND TO TAK1-TAB1
4090, 4k0yA, 0.6913, 3.27, 0.174, 274, 253, STRUCTURE OF PIM-1 KINASE BOUND TO N-(4-FLUOROPHENYL)-7-HYDROXY-5- (PIPERIDIN-4-YL)PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
4091, 4fc0B, 0.6913, 2.94, 0.215, 263, 246, CRYSTAL STRUCTURE OF HUMAN KINASE DOMAIN OF B-RAF WITH A DFG-OUT INHIBITOR
4092, 4f9bA, 0.6913, 3.27, 0.134, 318, 253, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND PHA767491
4093, 3r7uA, 0.6913, 3.03, 0.182, 282, 247, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-75
4094, 3lvpA, 0.6913, 3.43, 0.294, 289, 255, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
4095, 3f5pT, 0.6913, 3.71, 0.292, 295, 260, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4096, 3f5pM, 0.6913, 3.73, 0.293, 295, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4097, 2ds1A, 0.6913, 3.18, 0.176, 290, 250, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
4098, 5wngB, 0.6912, 3.74, 0.176, 365, 262, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
4099, 5ur1B, 0.6912, 3.37, 0.312, 265, 253, FGFR1 KINASE DOMAIN COMPLEX WITH SN37333 IN REVERSIBLE BINDING MODE
4100, 5t6iA, 0.6912, 3.53, 0.198, 427, 258, CRYSTAL STRUCTURE OF TGCDPK1 FROM TOXOPLASMA GONDII COMPLEXED WITH 5GB
4101, 5jh6A, 0.6912, 3.06, 0.251, 288, 247, CRYSTAL STRUCTURE OF TL10-92 BOUND TO TAK1-TAB1
4102, 5hidB, 0.6912, 2.99, 0.218, 269, 248, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH AZ628
4103, 5efqA, 0.6912, 3.89, 0.145, 321, 269, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
4104, 5dgzA, 0.6912, 3.22, 0.171, 273, 252, DISCOVERY OF 35-SUBSTITUTED 6-AZAINDAZOLES AS POTENT PAN-PIM INHIBITORS
4105, 4jr7A, 0.6912, 3.30, 0.146, 367, 253, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
4106, 4iwpA, 0.6912, 3.86, 0.143, 628, 265, CRYSTAL STRUCTURE AND MECHANISM OF ACTIVATION OF TBK1
4107, 4fmqA, 0.6912, 3.28, 0.173, 350, 255, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
4108, 3f2aA, 0.6912, 3.45, 0.173, 276, 255, CRYSTAL STRUCTURE OF HUMAN PIM-1 IN COMPLEX WITH DAPPA
4109, 2x1nC, 0.6912, 3.46, 0.151, 296, 259, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
4110, 2wmaA, 0.6912, 3.46, 0.151, 296, 259, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
4111, 2nruA, 0.6912, 3.23, 0.206, 293, 252, CRYSTAL STRUCTURE OF IRAK-4
4112, 2jbpH, 0.6912, 2.83, 0.150, 282, 246, PROTEIN KINASE MK2 IN COMPLEX WITH AN INHIBITOR (CRYSTAL FORM-2 CO-CRYSTALLIZATION)
4113, 5lqeC, 0.6911, 3.50, 0.162, 296, 259, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
4114, 4ek5A, 0.6911, 3.05, 0.186, 289, 247, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
4115, 2qodA, 0.6911, 3.46, 0.291, 274, 254, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y602F MUTANT
4116, 2qo7A, 0.6911, 3.52, 0.307, 278, 254, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION DEPHOSPHORYLATED AMP-PNP BOUND
4117, 2no3A, 0.6911, 3.32, 0.184, 357, 255, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
4118, 5y9mA, 0.6910, 3.32, 0.118, 320, 254, CRYSTAL STRUCTURE OF CK2A2 FORM 3 
4119, 5otlA, 0.6910, 3.22, 0.155, 320, 252, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 29
4120, 5k0kB, 0.6910, 2.33, 0.352, 248, 233, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC2434
4121, 4ty1A, 0.6910, 3.22, 0.167, 273, 252, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AMINOOXADIAZOLE-INDOLE INHIBITOR.
4122, 4ix6B, 0.6910, 3.87, 0.106, 350, 264, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE SOAKED WITH ATP
4123, 2w9zB, 0.6910, 3.04, 0.178, 287, 247, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
4124, 2qoiA, 0.6910, 3.46, 0.291, 274, 254, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F DOUBLE MUTANT
4125, 1h26A, 0.6910, 3.47, 0.167, 296, 258, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
4126, 6c4dC, 0.6909, 3.00, 0.216, 258, 245, STRUCTURE BASED DESIGN OF RIP1 KINASE INHIBITORS
4127, 5nhoA, 0.6909, 3.33, 0.165, 343, 255, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
4128, 5diaA, 0.6909, 3.22, 0.167, 273, 252, PIM1 IN COMPLEX WITH CPD36 ((1S3S)-N1-(6-(5-(PYRIDIN-3-YL)-1H- PYRAZOLO[34-C]PYRIDIN-3-YL)PYRIDIN-2-YL)CYCLOHEXANE-13-DIAMINE)
4129, 4ix4B, 0.6909, 3.90, 0.102, 350, 265, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE IN COMPLEX WITH ADP
4130, 3lfsA, 0.6909, 3.15, 0.181, 290, 249, CRYSTAL STRUCTURE OF CDK2 WITH SAR37 AN AMINOINDAZOLE TYPE INHIBITOR
4131, 2oi4X, 0.6909, 3.23, 0.174, 275, 253, CRYSTAL STRUCTURE OF HUMAN PIM1 IN COMPLEX WITH FLUORINATED RUTHENIUM PYRIDOCARBAZOLE
4132, 2jbpF, 0.6909, 2.86, 0.150, 287, 246, PROTEIN KINASE MK2 IN COMPLEX WITH AN INHIBITOR (CRYSTAL FORM-2 CO-CRYSTALLIZATION)
4133, 1xqzA, 0.6909, 3.34, 0.173, 277, 254, CRYSTAL STRUCTURE OF HPIM-1 KINASE AT 2.1 A RESOLUTION
4134, 4ix3B, 0.6908, 3.92, 0.102, 350, 265, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE
4135, 4fv7A, 0.6908, 3.22, 0.146, 342, 253, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E94
4136, 3pscA, 0.6908, 4.11, 0.172, 614, 273, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
4137, 2whbA, 0.6908, 3.55, 0.150, 296, 260, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
4138, 5v60A, 0.6907, 3.14, 0.151, 347, 252, PHOSPHO-ERK2 BOUND TO AMP-PCP
4139, 5bvwA, 0.6907, 3.11, 0.312, 274, 250, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
4140, 4wnpB, 0.6907, 3.23, 0.197, 272, 254, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
4141, 4obpB, 0.6907, 3.68, 0.170, 290, 259, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 29) 6-(2-FLUOROPYRIDIN-4- YL)PYRIDO[32-D]PYRIMIDIN-4-AMINE
4142, 4ix5B, 0.6907, 3.88, 0.106, 350, 264, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE IN COMPLEX WITH AMP-PNP
4143, 3sw7A, 0.6907, 2.84, 0.180, 278, 244, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
4144, 3idpA, 0.6907, 2.92, 0.224, 255, 246, B-RAF V600E KINASE DOMAIN IN COMPLEX WITH AN AMINOISOQUINOLINE INHIBITOR
4145, 2oh4A, 0.6907, 3.46, 0.310, 297, 255, CRYSTAL STRUCTURE OF VEGFR2 WITH A BENZIMIDAZOLE-UREA INHIBITOR
4146, 2jgzA, 0.6907, 3.26, 0.157, 288, 254, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B
4147, 5ztnB, 0.6906, 3.10, 0.184, 395, 250, THE CRYSTAL STRUCTURE OF HUMAN DYRK2 IN COMPLEX WITH CURCUMIN 
4148, 5ztnA, 0.6906, 3.10, 0.184, 395, 250, THE CRYSTAL STRUCTURE OF HUMAN DYRK2 IN COMPLEX WITH CURCUMIN 
4149, 4n70A, 0.6906, 3.23, 0.167, 274, 252, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
4150, 4lghB, 0.6906, 2.79, 0.283, 247, 244, CRYSTAL STRUCTURE OF 1NM-PP1 BOUND TO ANALOG-SENSITIVE SRC KINASE
4151, 4knbD, 0.6906, 3.01, 0.351, 247, 242, C-MET IN COMPLEX WITH OSI LIGAND
4152, 3dlsC, 0.6906, 3.60, 0.160, 281, 257, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
4153, 1ym7B, 0.6906, 4.15, 0.179, 608, 273, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
4154, 1finC, 0.6906, 3.57, 0.157, 298, 261, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
4155, 6b16B, 0.6905, 3.55, 0.174, 281, 258, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
4156, 5xvuB, 0.6905, 3.49, 0.148, 321, 257, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
4157, 5uorB, 0.6905, 3.00, 0.206, 262, 248, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
4158, 4tyeA, 0.6905, 3.79, 0.314, 292, 261, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
4159, 4afjB, 0.6905, 3.64, 0.178, 346, 259, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
4160, 3d15A, 0.6905, 3.13, 0.183, 256, 251, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-(3-CHLORO-PHENYL)-3-{5-[2-(THIENO[32- D]PYRIMIDIN-4-YLAMINO)- ETHYL]-THIAZOL-2-YL}-UREA [SNS-314]
4161, 2v22A, 0.6905, 3.54, 0.150, 296, 260, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
4162, 2nruB, 0.6905, 3.27, 0.206, 294, 253, CRYSTAL STRUCTURE OF IRAK-4
4163, 1ke7A, 0.6905, 2.98, 0.187, 281, 246, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(22- DIOXIDO-13-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5- (13-OXAZOL-5-YL)-13-DIHYDRO-2H-INDOL-2-ONE
4164, 4qteA, 0.6904, 3.38, 0.164, 348, 256, STRUCTURE OF ERK2 IN COMPLEX WITH VTX-11E 4-{2-[(2-CHLORO-4- FLUOROPHENYL)AMINO]-5-METHYLPYRIMIDIN-4-YL}-N-[(1S)-1-(3- CHLOROPHENYL)-2-HYDROXYETHYL]-1H-PYRROLE-2-CARBOXAMIDE
4165, 1q3dA, 0.6904, 3.66, 0.169, 339, 261, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
4166, 6g33B, 0.6903, 3.21, 0.183, 337, 252, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH 5-IODOTUBERCIDIN 
4167, 6bskA, 0.6903, 3.13, 0.167, 273, 251, HUMAN PIM1 KINASE IN COMPLEX WITH COMPOUND 12B
4168, 5u6iA, 0.6903, 3.28, 0.154, 339, 254, DISCOVERY OF MLI-2 AN ORALLY AVAILABLE AND SELECTIVE LRRK2 INHIBITOR THAT REDUCES BRAIN KINASE ACTIVITY
4169, 5osmA, 0.6903, 3.29, 0.175, 292, 251, CDK2(F80C C177A) WITH COVALENT ADDUCT AT C80
4170, 4eooA, 0.6903, 3.41, 0.156, 294, 257, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
4171, 2wfyC, 0.6903, 3.50, 0.158, 296, 259, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
4172, 1w0xC, 0.6903, 2.94, 0.184, 280, 245, CRYSTAL STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR OLOMOUCINE.
4173, 6ccfA, 0.6902, 3.08, 0.173, 260, 249, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH HESPERADIN
4174, 5v82A, 0.6902, 3.16, 0.179, 273, 251, PIM1 KINASE IN COMPLEX WITH CPD17 (1-(6-(44-DIFLUOROPIPERIDIN-3-YL) PYRIDIN-2-YL)-6-(6-METHYLPYRAZIN-2-YL)-1H-PYRAZOLO[43-C]PYRIDINE)
4175, 5kx8D, 0.6902, 3.05, 0.206, 283, 247, IRAK4-INHIBITOR CO-STRUCTURE
4176, 4y73C, 0.6902, 3.19, 0.219, 290, 251, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
4177, 4wrsA, 0.6902, 3.28, 0.166, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AZASPIRO PYRAZINYL-INDAZOLE INHIBITOR.
4178, 4mblA, 0.6902, 3.28, 0.170, 274, 253, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
4179, 4aotB, 0.6902, 3.35, 0.178, 279, 253, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
4180, 3w8lA, 0.6902, 3.39, 0.145, 326, 256, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
4181, 2qlqB, 0.6902, 2.76, 0.305, 248, 243, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN WITH COVALENT INHIBITOR RL3
4182, 2no3B, 0.6902, 3.24, 0.185, 357, 254, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
4183, 2c6tC, 0.6902, 3.49, 0.163, 295, 258, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
4184, 1ym7C, 0.6902, 4.09, 0.176, 607, 272, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
4185, 1blxA, 0.6902, 3.18, 0.167, 305, 251, P19INK4D/CDK6 COMPLEX
4186, 5t6aA, 0.6901, 3.56, 0.197, 431, 259, CRYSTAL STRUCTURE OF TGCDPK1 FROM TOXOPLASMA GONDII COMPLEXED WITH 5GA
4187, 4im2A, 0.6901, 3.55, 0.144, 618, 257, STRUCTURE OF TANK-BINDING KINASE 1
4188, 3qc4A, 0.6901, 3.56, 0.171, 276, 257, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
4189, 3nszA, 0.6901, 3.47, 0.148, 327, 257, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH AMPPN
4190, 3nayB, 0.6901, 3.23, 0.209, 278, 253, PDK1 IN COMPLEX WITH INHIBITOR MP6
4191, 3ha6A, 0.6901, 3.38, 0.184, 263, 255, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH TPX2 AND COMPOUND 10
4192, 2x1nA, 0.6901, 3.58, 0.154, 296, 260, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
4193, 2qofA, 0.6901, 3.51, 0.291, 280, 254, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F MUTANT
4194, 1pkdA, 0.6901, 3.60, 0.150, 296, 260, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
4195, 5l6pA, 0.6900, 3.33, 0.316, 274, 253, EPHB3 KINASE DOMAIN COVALENTLY BOUND TO AN IRREVERSIBLE INHIBITOR (COMPOUND 6)
4196, 5dosA, 0.6900, 3.11, 0.183, 259, 251, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
4197, 4u3zB, 0.6900, 3.63, 0.174, 294, 259, APO MAP4K4 T181E PHOSPHOMIMETIC MUTANT
4198, 4ditA, 0.6900, 3.53, 0.167, 328, 257, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A IMIDAZOPYRIDINE INHIBITOR
4199, 2x7fA, 0.6900, 3.30, 0.182, 276, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
4200, 2nruD, 0.6900, 3.31, 0.225, 293, 253, CRYSTAL STRUCTURE OF IRAK-4
4201, 1q3dB, 0.6900, 3.64, 0.173, 339, 260, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
4202, 1okvC, 0.6900, 3.47, 0.167, 296, 258, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
4203, 5y9mX, 0.6899, 3.33, 0.119, 319, 253, CRYSTAL STRUCTURE OF CK2A2 FORM 3 
4204, 5drbA, 0.6899, 3.34, 0.226, 273, 252, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH WNK463
4205, 4ficB, 0.6899, 2.80, 0.289, 245, 242, KINASE DOMAIN OF CSRC IN COMPLEX WITH A HINGE REGION-BINDING FRAGMENT
4206, 4eoqA, 0.6899, 3.45, 0.147, 295, 258, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
4207, 3vuhA, 0.6899, 3.21, 0.210, 355, 252, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M3 IN MAP KINASE JNK1
4208, 1yxtA, 0.6899, 3.37, 0.169, 274, 254, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMPPNP
4209, 5ipjA, 0.6898, 3.22, 0.167, 273, 252, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A QUINAZOLINONE-PYRROLOPYRROLONE INHIBITOR.
4210, 5if1C, 0.6898, 3.54, 0.150, 296, 260, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
4211, 5hvjA, 0.6898, 3.51, 0.210, 283, 257, CRYSTAL STRUCTURE OF LIMK1 D460N MUTANT IN COMPLEX WITH AMP-PNP
4212, 4fkiA, 0.6898, 3.13, 0.185, 287, 248, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
4213, 4f9bC, 0.6898, 3.34, 0.134, 316, 253, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND PHA767491
4214, 4alvA, 0.6898, 3.23, 0.171, 274, 252, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
4215, 3vugA, 0.6898, 3.21, 0.210, 356, 252, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
4216, 3rmfA, 0.6898, 2.85, 0.189, 278, 244, CDK2 IN COMPLEX WITH INHIBITOR RC-2-33
4217, 2xj0A, 0.6898, 3.17, 0.171, 274, 251, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-4 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
4218, 2qooA, 0.6898, 3.48, 0.291, 273, 254, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:Y742F TRIPLE MUTANT
4219, 1ckjB, 0.6898, 3.67, 0.145, 293, 262, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
4220, 5dhjA, 0.6897, 3.22, 0.171, 273, 252, PIM1 IN COMPLEX WITH CPD4 (3-METHYL-5-(PYRIDIN-3-YL)-1H-PYRAZOLO[34- C]PYRIDINE)
4221, 4jx7A, 0.6897, 3.30, 0.170, 274, 253, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR 2-[(TRANS- 4-AMINOCYCLOHEXYL)AMINO]-4-{[3-(TRIFLUOROMETHYL) PHENYL]AMINO}PYRIDO[43-D]PYRIMIDIN-5(6H)-ONE
4222, 4f9aC, 0.6897, 3.33, 0.134, 317, 253, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND NUCLEOTIDE
4223, 3cjgA, 0.6897, 3.34, 0.317, 280, 252, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 345-TRIMETHOXY ANILINE CONTAINING PYRIMIDINE
4224, 3cjfA, 0.6897, 3.33, 0.310, 276, 252, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 345-TRIMETHOXY ANILINE CONTAINING PYRIMIDINE
4225, 2w17A, 0.6897, 2.89, 0.188, 278, 245, CDK2 IN COMPLEX WITH THE IMIDAZOLE PYRIMIDINE AMIDE COMPOUND (S)-8B
4226, 2uzdC, 0.6897, 3.43, 0.171, 295, 257, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
4227, 6eqiC, 0.6896, 3.65, 0.157, 392, 261, STRUCTURE OF PINK1 BOUND TO UBIQUITIN
4228, 6dkwB, 0.6896, 3.40, 0.302, 269, 255, CRYSTAL STRUCTURE OF TRK-A IN COMPLEX WITH THE PAN-TRK KINASE INHIBITOR; COMPOUND 3. 
4229, 5j9lA, 0.6896, 3.00, 0.253, 286, 245, CRYSTAL STRUCTURE OF CPT1691 BOUND TO TAK1-TAB1
4230, 4ztnA, 0.6896, 3.20, 0.212, 286, 250, IRAK4-INHIBITOR CO-STRUCTURE
4231, 6bkuA, 0.6895, 3.21, 0.187, 267, 251, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B BOUND TO GSK650394
4232, 5k5nB, 0.6895, 3.53, 0.180, 334, 256, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
4233, 4wt6A, 0.6895, 3.34, 0.170, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIADIAZOLAMINE-INDOLE INHIBITOR.
4234, 4krcA, 0.6895, 3.43, 0.156, 297, 256, CRYSTAL STRUCTURE OF PHO85-PCL10-ATP-GAMMA-S COMPLEX
4235, 2vwwA, 0.6895, 3.14, 0.297, 253, 249, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4236, 5x8iA, 0.6894, 3.26, 0.170, 328, 253, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH COMPOUND 25
4237, 3kvwA, 0.6894, 3.09, 0.165, 403, 249, CRYSTAL STRUCTURE OF DUAL-SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 2 (DYRK2) IN COMPLEX WITH AN INDIRUBIN LIGAND
4238, 3c4eD, 0.6894, 3.31, 0.166, 273, 253, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
4239, 2jbpE, 0.6894, 2.90, 0.146, 282, 246, PROTEIN KINASE MK2 IN COMPLEX WITH AN INHIBITOR (CRYSTAL FORM-2 CO-CRYSTALLIZATION)
4240, 2i40C, 0.6894, 3.52, 0.151, 296, 259, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
4241, 1ckiB, 0.6894, 3.68, 0.145, 286, 262, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
4242, 5vcyA, 0.6893, 3.67, 0.165, 296, 261, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB
4243, 5eolA, 0.6893, 3.24, 0.167, 273, 252, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A MACROCYCLIC QUINOXALINE-PYRROLODIHYDROPIPERIDINONE INHIBITOR
4244, 4ztlC, 0.6893, 3.08, 0.215, 282, 247, IRAK4-INHIBITOR CO-STRUCTURE
4245, 4o0tB, 0.6893, 3.54, 0.163, 280, 258, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
4246, 4k18A, 0.6893, 3.34, 0.177, 277, 254, STRUCTURE OF PIM-1 KINASE BOUND TO 5-(4-CYANOBENZYL)-N-(4- FLUOROPHENYL)-7-HYDROXYPYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
4247, 4im0A, 0.6893, 3.56, 0.140, 619, 257, STRUCTURE OF TANK-BINDING KINASE 1
4248, 4dtkA, 0.6893, 3.23, 0.175, 273, 252, NOVEL AND SELECTIVE PAN-PIM KINASE INHIBITOR
4249, 3vc4A, 0.6893, 3.28, 0.170, 274, 253, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
4250, 3cpbB, 0.6893, 2.92, 0.316, 263, 244, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BISAMIDE INHIBITOR
4251, 2xj2A, 0.6893, 3.10, 0.172, 273, 250, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4252, 2vtiA, 0.6893, 2.96, 0.188, 280, 245, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4253, 1ke6A, 0.6893, 2.95, 0.184, 280, 245, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4- [2-(7-OXO-67-DIHYDRO-8H-[13]THIAZOLO[54-E]INDOL-8- YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE
4254, 6cpfA, 0.6892, 3.12, 0.184, 259, 250, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP IN AN ACTIVE CONFORMATION 
4255, 5idnA, 0.6892, 3.50, 0.187, 336, 257, CDK8-CYCC IN COMPLEX WITH [(S)-2-(4-CHLORO-PHENYL)-PYRROLIDIN-1-YL]- (3-METHYL-1H-PYRAZOLO[34-B]PYRIDIN-5-YL)-METHANONE
4256, 5dvrA, 0.6892, 3.55, 0.198, 386, 257, CRYSTAL STRUCTURE OF TGCDPK1 FROM TOXOPLASMA GONDII COMPLEXED WITH GW780159X
4257, 4y73A, 0.6892, 3.24, 0.223, 289, 251, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
4258, 3vuiA, 0.6892, 3.23, 0.210, 355, 252, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
4259, 3v8tA, 0.6892, 2.22, 0.308, 238, 234, CRYSTAL STRUCTURE OF INTERLEUKIN-2 INDUCIBLE T-CELL KINASE ITK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 477
4260, 3r00A, 0.6892, 3.21, 0.175, 274, 252, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
4261, 3qf9A, 0.6892, 3.19, 0.171, 274, 252, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A FURAN- THIAZOLIDINEDIONE LIGAND
4262, 3miyB, 0.6892, 2.38, 0.315, 240, 238, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH SUNITINIB
4263, 2oibD, 0.6892, 3.11, 0.201, 288, 249, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
4264, 1sykA, 0.6892, 4.00, 0.152, 348, 270, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
4265, 5vczA, 0.6891, 3.53, 0.162, 294, 259, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB ISOMER
4266, 4i94B, 0.6891, 3.50, 0.158, 297, 253, STRUCTURE OF BSK8 IN COMPLEX WITH AMP-PNP
4267, 3piyA, 0.6891, 3.07, 0.312, 262, 247, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH R406
4268, 3f5pI, 0.6891, 3.77, 0.292, 294, 260, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4269, 2wmaC, 0.6891, 3.43, 0.172, 265, 256, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
4270, 2gmxA, 0.6891, 3.26, 0.206, 357, 253, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
4271, 1ol1A, 0.6891, 3.55, 0.158, 296, 260, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
4272, 5x8iB, 0.6890, 3.27, 0.170, 327, 253, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH COMPOUND 25
4273, 5k7gD, 0.6890, 2.95, 0.212, 283, 245, IRAK4 IN COMPLEX WITH AZ3862
4274, 5dwrA, 0.6890, 3.21, 0.167, 273, 251, IDENTIFICATION OF N-(4-((1R3S5S)-3-AMINO-5-METHYLCYCLOHEXYL)PYRIDIN- 3-YL)-6-(26-DIFLUOROPHENYL)-5-FLUOROPICOLINAMIDE (PIM447) A POTENT AND SELECTIVE PROVIRAL INSERTION SITE OF MOLONEY MURINE LEUKEMIA (PIM) 12 AND 3 KINASE INHIBITOR IN CLINICAL TRIALS FOR HEMATOLOGICAL MALIGNANCIES
4275, 3rpyA, 0.6890, 2.81, 0.189, 277, 243, CDK2 IN COMPLEX WITH INHIBITOR RC-2-40
4276, 3eocC, 0.6890, 3.44, 0.151, 293, 258, CDK2/CYCLINA COMPLEXED WITH A IMIDAZO TRIAZIN-2-AMINE
4277, 3cs9B, 0.6890, 2.71, 0.342, 247, 243, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
4278, 3bgzA, 0.6890, 3.11, 0.168, 267, 250, HUMAN PIM-1 KINASE IN COMPLEX WITH DIPHENYL INDOLE INHIBITOR VX3
4279, 2vtoA, 0.6890, 3.09, 0.190, 283, 247, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4280, 2uueA, 0.6890, 3.57, 0.154, 296, 260, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
4281, 2o64A, 0.6890, 3.39, 0.173, 274, 254, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETAGETIN
4282, 2jkoA, 0.6890, 3.29, 0.355, 256, 251, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4283, 2clqB, 0.6890, 2.79, 0.213, 259, 244, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
4284, 2bzhB, 0.6890, 3.25, 0.174, 275, 253, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
4285, 5v80A, 0.6889, 3.23, 0.175, 273, 252, PIM1 KINASE IN COMPLEX WITH CPD1 (1-METHYL-4-(3-(6-(PIPERAZIN-1-YL) PYRIDIN-2-YL)-1H-PYRAZOLO[3;4-C]PYRIDIN-5-YL)PIPERAZIN-2-ONE) 
4286, 4yo6A, 0.6889, 3.20, 0.216, 286, 250, IRAK4-INHIBITOR CO-STRUCTURE
4287, 4i4eA, 0.6889, 3.20, 0.340, 254, 250, STRUCTURE OF FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH HINGE BINDING PYRAZOLOBENZOTHIAZINE COMPOUND.
4288, 4f9aA, 0.6889, 3.32, 0.138, 315, 253, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND NUCLEOTIDE
4289, 4au8B, 0.6889, 2.89, 0.158, 277, 247, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
4290, 3pxqA, 0.6889, 3.31, 0.158, 298, 253, CDK2 IN COMPLEX WITH 3 MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
4291, 3cxwA, 0.6889, 3.21, 0.175, 272, 252, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A BETA CARBOLINE LIGAND I
4292, 1h25C, 0.6889, 3.39, 0.169, 278, 255, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
4293, 5maiA, 0.6888, 3.02, 0.167, 312, 246, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
4294, 5efqC, 0.6888, 3.89, 0.146, 325, 268, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
4295, 4qp8B, 0.6888, 3.08, 0.164, 337, 250, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
4296, 4alwA, 0.6888, 3.26, 0.167, 273, 252, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
4297, 3wzdA, 0.6888, 3.19, 0.301, 278, 249, KDR IN COMPLEX WITH LIGAND LENVATINIB
4298, 3vudA, 0.6888, 3.28, 0.198, 355, 253, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
4299, 3uimA, 0.6888, 3.04, 0.184, 291, 245, STRUCTURAL BASIS FOR THE IMPACT OF PHOSPHORYLATION ON PLANT RECEPTOR- LIKE KINASE BAK1 ACTIVATION
4300, 3kc3H, 0.6888, 2.95, 0.146, 290, 247, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4301, 2vwuA, 0.6888, 3.17, 0.297, 253, 249, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4302, 2pzyC, 0.6888, 3.04, 0.145, 307, 248, STRUCTURE OF MK2 COMPLEXED WITH COMPOUND 76
4303, 1ol2A, 0.6888, 3.55, 0.154, 296, 260, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
4304, 5m44A, 0.6887, 3.42, 0.156, 329, 256, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
4305, 5iisA, 0.6887, 3.39, 0.170, 273, 253, DESIGN SYNTHESIS AND STRUCTURE ACTIVITY RELATIONSHIP OF POTENT PAN- PIM KINASE INHIBITORS DERIVED FROM THE PYRIDYL-AMIDE SCAFFOLD
4306, 4zy6A, 0.6887, 3.65, 0.189, 284, 259, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
4307, 4ztnD, 0.6887, 3.14, 0.213, 285, 249, IRAK4-INHIBITOR CO-STRUCTURE
4308, 4ux9D, 0.6887, 3.05, 0.189, 344, 249, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
4309, 5xvuC, 0.6886, 3.48, 0.152, 321, 256, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
4310, 5ke0A, 0.6886, 3.35, 0.153, 340, 255, DISCOVERY OF 1-1H-PYRAZOLO 43-C PYRIDINE-6-YL UREA INHIBITORS OF EXTRACELLULAR SIGNAL REGULATED KINASE ERK FOR THE TREATMENT OF CANCERS
4311, 4xhkB, 0.6886, 3.16, 0.171, 269, 251, PIM1 KINASE IN COMPLEX WITH COMPOUND 1S
4312, 3sw4A, 0.6886, 2.98, 0.184, 279, 245, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
4313, 3gokL, 0.6886, 2.80, 0.148, 284, 244, BINDING SITE MAPPING OF PROTEIN LIGANDS
4314, 3gokF, 0.6886, 2.80, 0.148, 284, 244, BINDING SITE MAPPING OF PROTEIN LIGANDS
4315, 3f5pG, 0.6886, 3.77, 0.292, 299, 260, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4316, 3dlsE, 0.6886, 3.64, 0.152, 282, 257, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
4317, 3dkoA, 0.6886, 3.43, 0.312, 275, 253, COMPLEX BETWEEN THE KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 7 (EPHA7) AND INHIBITOR ALW-II-49-7
4318, 2objA, 0.6886, 3.23, 0.167, 272, 251, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH INHIBITOR
4319, 5lxdA, 0.6885, 3.07, 0.169, 385, 249, CRYSTAL STRUCTURE OF DYRK2 IN COMPLEX WITH EHT 1610 (COMPOUND 2)
4320, 5dt0A, 0.6885, 3.13, 0.183, 259, 251, AURORA A KINASE IN COMPLEX WITH JNJ-7706621 IN SPACE GROUP P6122
4321, 4wsyA, 0.6885, 3.25, 0.167, 273, 252, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIAZOLAMINE-INDAZOLE INHIBITOR.
4322, 3f5pD, 0.6885, 3.77, 0.292, 297, 260, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4323, 1yxuD, 0.6885, 3.32, 0.174, 273, 253, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
4324, 4n6zA, 0.6884, 3.07, 0.165, 272, 249, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
4325, 4maoA, 0.6884, 2.82, 0.193, 298, 244, RSK2 T493M C-TERMINAL KINASE DOMAIN IN COMPLEX WITH RMM58
4326, 4azfA, 0.6884, 3.13, 0.184, 404, 250, HUMAN DYRK2 IN COMPLEX WITH LEUCETTINE L41
4327, 3f5pS, 0.6884, 3.78, 0.292, 295, 260, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4328, 3f5pC, 0.6884, 3.77, 0.292, 301, 260, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4329, 3d5xA, 0.6884, 3.51, 0.182, 279, 258, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH WORTMANNIN.
4330, 2chlA, 0.6884, 3.88, 0.127, 298, 267, STRUCTURE OF CASEIN KINASE 1 GAMMA 3
4331, 3vbqA, 0.6883, 3.13, 0.172, 271, 250, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
4332, 3is5A, 0.6883, 3.13, 0.206, 260, 248, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4333, 3gokI, 0.6883, 2.81, 0.148, 284, 244, BINDING SITE MAPPING OF PROTEIN LIGANDS
4334, 3cy2A, 0.6883, 3.26, 0.171, 271, 252, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A BETA CARBOLINE LIGAND II
4335, 3a2cF, 0.6883, 3.03, 0.158, 287, 247, CRYSTAL STRUCTURE OF A PYRAZOLOPYRIMIDINE INHIBITOR COMPLEX BOUND TO MAPKAP KINASE-2 (MK2)
4336, 5w5jB, 0.6882, 2.42, 0.212, 257, 236, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES
4337, 5t6kA, 0.6882, 3.46, 0.202, 432, 257, CRYSTAL STRUCTURE OF TGCDPK1 FROM TOXOPLASMA GONDII COMPLEXED WITH GW780159X
4338, 5lxdB, 0.6882, 3.07, 0.169, 385, 249, CRYSTAL STRUCTURE OF DYRK2 IN COMPLEX WITH EHT 1610 (COMPOUND 2)
4339, 5kgdA, 0.6882, 3.24, 0.171, 273, 252, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-PYRIDIN-3-YL-1~{H}- BENZIMIDAZOLE
4340, 4twcA, 0.6882, 3.86, 0.140, 293, 265, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
4341, 3lw0B, 0.6882, 3.28, 0.308, 292, 250, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
4342, 3f5pA, 0.6882, 3.77, 0.292, 299, 260, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4343, 3dpkA, 0.6882, 3.35, 0.308, 279, 250, CFMS TYROSINE KINASE IN COMPLEX WITH A PYRIDOPYRIMIDINONE INHIBITOR
4344, 5oo0A, 0.6881, 3.20, 0.177, 288, 249, CDK2(WT) COVALENT ADDUCT WITH D28 AT C177
4345, 5d10B, 0.6881, 2.91, 0.305, 247, 243, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL236
4346, 4r5yB, 0.6881, 2.85, 0.229, 254, 245, THE COMPLEX STRUCTURE OF BRAF V600E KINASE DOMAIN WITH A NOVEL BRAF INHIBITOR
4347, 4l3lA, 0.6881, 3.57, 0.181, 291, 259, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN (ZINC ANOMALOUS)
4348, 4ix6A, 0.6881, 3.87, 0.106, 346, 263, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE SOAKED WITH ATP
4349, 3ncgA, 0.6881, 3.56, 0.178, 426, 259, ACTIVATED CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM CRYPTOSPORIDIUM PARVUM (CPCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR NM-PP1
4350, 3mwuA, 0.6881, 3.56, 0.174, 447, 259, ACTIVATED CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM CRYPTOSPORIDIUM PARVUM (CPCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR RM-1-95
4351, 3kc3K, 0.6881, 2.87, 0.147, 280, 245, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4352, 5lpzA, 0.6880, 3.28, 0.175, 283, 251, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1196) IN COMPLEX WITH ADP FROM ARABIDOPSIS THALIANA
4353, 5ko1A, 0.6880, 2.93, 0.177, 265, 249, PSEUDOKINASE DOMAIN OF MLKL BOUND TO COMPOUND 4.
4354, 4y5qA, 0.6880, 3.52, 0.174, 449, 258, ACTIVATED CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM CRYPTOSPORIDIUM PARVUM (CPCDPK1) IN COMPLEX WITH AMP
4355, 4xv3A, 0.6880, 2.38, 0.207, 244, 237, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX7922
4356, 4fkgA, 0.6880, 3.11, 0.186, 286, 247, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
4357, 4aluA, 0.6880, 3.31, 0.166, 274, 253, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
4358, 3jpvA, 0.6880, 3.15, 0.171, 273, 251, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A PYRROLO[23- A]CARBAZOLE LIGAND
4359, 3dlsF, 0.6880, 3.54, 0.148, 281, 256, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
4360, 2xj1A, 0.6880, 3.23, 0.167, 273, 251, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INIBITOR
4361, 5n4rA, 0.6879, 3.16, 0.171, 273, 251, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 2-(AZEPAN-1-YL)-1-(1H-INDOL-3-YL) PROPAN-1-ONE
4362, 5lpwA, 0.6879, 3.23, 0.185, 280, 249, CRYSTAL STRUCTURE OF THE APO-BRI1 KINASE DOMAIN (865-1160)
4363, 4jvgB, 0.6879, 3.12, 0.225, 259, 249, B-RAF KINASE IN COMPLEX WITH BIRB796
4364, 3f5pH, 0.6879, 3.78, 0.292, 299, 260, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4365, 2vtpA, 0.6879, 3.07, 0.191, 281, 246, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4366, 5yf9X, 0.6878, 3.36, 0.123, 319, 253, CRYSTAL STRUCTURE OF CK2A2 FORM-2 
4367, 5vd3A, 0.6878, 3.53, 0.171, 293, 258, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN (DE-PHOSPHORYLATED) IN COMPLEX WITH SARACATINIB
4368, 4m8tA, 0.6878, 2.84, 0.189, 303, 244, RSK2 T493M C-TERMINAL KINASE DOMAIN IN COMPLEX WITH 3-(3-(1H-PYRAZOL- 4-YL)PHENYL)-2-CYANOACRYLAMIDE
4369, 4ix3A, 0.6878, 3.75, 0.107, 346, 261, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE
4370, 4h3qA, 0.6878, 3.31, 0.169, 352, 255, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
4371, 4cfmC, 0.6878, 3.34, 0.177, 266, 254, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
4372, 3lw0A, 0.6878, 3.34, 0.311, 292, 251, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
4373, 3f5pB, 0.6878, 3.77, 0.292, 298, 260, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4374, 3cs9D, 0.6878, 3.00, 0.341, 263, 246, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
4375, 5xvuA, 0.6877, 3.53, 0.152, 321, 257, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
4376, 5t1sA, 0.6877, 3.18, 0.217, 280, 249, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4377, 5mhqA, 0.6877, 3.10, 0.182, 291, 247, CCT068127 IN COMPLEX WITH CDK2
4378, 5kx8A, 0.6877, 3.19, 0.213, 285, 249, IRAK4-INHIBITOR CO-STRUCTURE
4379, 4n6yA, 0.6877, 3.26, 0.171, 273, 252, PIM1 COMPLEXED WITH A PHENYLCARBOXAMIDE
4380, 4jg7A, 0.6877, 3.22, 0.186, 307, 247, STRUCTURE OF RSK2 CTD BOUND TO 3-(3-(1H-PYRROLO[23-B]PYRIDINE-3- CARBONYL)PHENYL)-2-CYANOACRYLAMIDE
4381, 4ix5A, 0.6877, 3.88, 0.106, 346, 263, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE IN COMPLEX WITH AMP-PNP
4382, 3vukA, 0.6877, 3.30, 0.202, 355, 253, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M5 IN MAP KINASE JNK1
4383, 3q4zA, 0.6877, 3.63, 0.198, 282, 258, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
4384, 3lw0D, 0.6877, 3.35, 0.311, 292, 251, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
4385, 3lw0C, 0.6877, 3.35, 0.311, 292, 251, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
4386, 2zoqA, 0.6877, 3.40, 0.169, 351, 255, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
4387, 5m5aA, 0.6876, 2.97, 0.190, 315, 247, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
4388, 5lpbA, 0.6876, 3.16, 0.190, 280, 248, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH ADP FROM ARABIDOPSIS THALIANA
4389, 5j1vA, 0.6876, 3.42, 0.173, 338, 254, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW29 (COMPOUND 13)
4390, 4iz5D, 0.6876, 3.25, 0.165, 347, 254, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
4391, 3ralA, 0.6876, 2.85, 0.189, 277, 243, CDK2 IN COMPLEX WITH INHIBITOR RC-2-34
4392, 3q96B, 0.6876, 2.94, 0.224, 262, 245, B-RAF KINASE DOMAIN IN COMPLEX WITH A TETRAHYDRONAPHTHALENE INHIBITOR
4393, 3nayA, 0.6876, 3.31, 0.202, 278, 253, PDK1 IN COMPLEX WITH INHIBITOR MP6
4394, 3k2lA, 0.6876, 3.25, 0.163, 402, 251, CRYSTAL STRUCTURE OF DUAL-SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 2 (DYRK2)
4395, 3f5pR, 0.6876, 3.81, 0.292, 294, 260, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4396, 3f5pL, 0.6876, 3.74, 0.295, 293, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4397, 3f5pK, 0.6876, 3.75, 0.293, 293, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4398, 2oibC, 0.6876, 2.94, 0.213, 278, 244, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN APO FORM
4399, 2nruC, 0.6876, 3.49, 0.227, 293, 255, CRYSTAL STRUCTURE OF IRAK-4
4400, 5lvpD, 0.6875, 3.56, 0.209, 276, 258, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN HM-PEPTIDE BOUND TO THE PIF-POCKET
4401, 4iz5C, 0.6875, 3.25, 0.165, 347, 254, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
4402, 4iz5B, 0.6875, 3.25, 0.165, 347, 254, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
4403, 4iz5A, 0.6875, 3.25, 0.165, 347, 254, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
4404, 4d9uA, 0.6875, 3.22, 0.181, 307, 248, RSK2 C-TERMINAL KINASE DOMAIN (E)-TERT-BUTYL 3-(4-AMINO-7-(3- HYDROXYPROPYL)-5-P-TOLYL-7H-PYRROLO[23-D]PYRIMIDIN-6-YL)-2- CYANOACRYLATE
4405, 4bznA, 0.6875, 3.32, 0.167, 272, 252, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO(12-A) PYRAZINONE INHIBITOR
4406, 4au8A, 0.6875, 2.86, 0.159, 276, 246, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
4407, 3tnwC, 0.6875, 3.51, 0.156, 291, 257, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
4408, 3s1hA, 0.6875, 2.85, 0.189, 277, 243, CDK2 IN COMPLEX WITH INHIBITOR RC-2-39
4409, 2w99B, 0.6875, 3.09, 0.178, 291, 247, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
4410, 2r3jA, 0.6875, 2.92, 0.189, 278, 244, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4411, 1yxxA, 0.6875, 3.38, 0.165, 274, 254, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH (3E)-3-[(4- HYDROXYPHENYL)IMINO]-1H-INDOL-2(3H)-ONE
4412, 1giiA, 0.6875, 3.00, 0.184, 279, 245, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
4413, 4obqA, 0.6874, 3.14, 0.165, 275, 248, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 31) N-[3-(4- AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
4414, 3ej1C, 0.6874, 3.43, 0.147, 294, 258, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
4415, 5k7gC, 0.6873, 3.17, 0.215, 283, 247, IRAK4 IN COMPLEX WITH AZ3862
4416, 4as0A, 0.6873, 3.16, 0.171, 273, 251, CYCLOMETALATED PHTHALIMIDES AS PROTEIN KINASE INHIBITORS
4417, 3i7cA, 0.6873, 3.56, 0.198, 449, 258, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR NA-PP2
4418, 3d2iA, 0.6873, 3.14, 0.180, 255, 250, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240- >ARG MET302->LEU) IN COMPLEX WITH 1-{5-[2-(1-METHYL-1H- PYRAZOLO[43-D]PYRIMIDIN-7-YLAMINO)-ETHYL]-THIAZOL-2-YL}-3- (3-TRIFLUOROMETHYL-PHENYL)-UREA
4419, 5yf9B, 0.6872, 3.35, 0.130, 319, 253, CRYSTAL STRUCTURE OF CK2A2 FORM-2 
4420, 5u94A, 0.6872, 3.09, 0.169, 263, 249, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PASTA KINASE PKNB IN COMPLEX WITH THE POTENTIAL THERAPUTIC KINASE INHIBITOR GSK690693.
4421, 5mahA, 0.6872, 3.01, 0.186, 316, 247, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
4422, 5ih5A, 0.6872, 3.78, 0.148, 286, 263, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A
4423, 5clpA, 0.6872, 3.30, 0.155, 322, 252, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
4424, 4yomB, 0.6872, 3.00, 0.194, 322, 248, STRUCTURE OF SAD KINASE
4425, 4qnyA, 0.6872, 3.27, 0.169, 333, 255, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
4426, 4ix4A, 0.6872, 3.80, 0.107, 346, 262, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE IN COMPLEX WITH ADP
4427, 4i94A, 0.6872, 3.52, 0.158, 297, 253, STRUCTURE OF BSK8 IN COMPLEX WITH AMP-PNP
4428, 3ggfB, 0.6872, 3.49, 0.249, 270, 257, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE MST4 IN COMPLEX WITH AN QUINAZOLIN
4429, 1ckiA, 0.6872, 3.61, 0.153, 292, 261, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
4430, 5o23A, 0.6871, 2.95, 0.195, 269, 246, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE
4431, 4qq5A, 0.6871, 3.46, 0.325, 275, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE HARBORING THE V550L GATE-KEEPER MUTATION IN COMPLEX WITH FIIN-2 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
4432, 4k1bA, 0.6871, 3.26, 0.171, 273, 252, STRUCTURE OF PIM-1 KINASE BOUND TO N-(5-(2-FLUOROPHENYL)-1H-PYRROLO[2 3-B]PYRIDIN-3-YL)-5-((((3R4R)-3-FLUOROPIPERIDIN-4-YL)METHYL)AMINO) PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
4433, 4jvgD, 0.6871, 3.14, 0.225, 262, 249, B-RAF KINASE IN COMPLEX WITH BIRB796
4434, 4gw8A, 0.6871, 3.17, 0.171, 273, 251, HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND LEUCETTINE L41
4435, 3vidA, 0.6871, 3.39, 0.298, 299, 252, CRYSTAL STRUCTURE OF HUMAN VEGFR2 KINASE DOMAIN WITH COMPOUND A.
4436, 3qriA, 0.6871, 2.99, 0.341, 275, 246, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DCC- 2036
4437, 3lfqA, 0.6871, 3.19, 0.177, 289, 249, CRYSTAL STRUCTURE OF CDK2 WITH SAR60 AN AMINOINDAZOLE TYPE INHIBITOR
4438, 3dlsB, 0.6871, 3.70, 0.156, 280, 257, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
4439, 2r64A, 0.6871, 2.95, 0.189, 279, 244, CRYSTAL STRUCTURE OF A 3-AMINOINDAZOLE COMPOUND WITH CDK2
4440, 2oicD, 0.6871, 3.18, 0.218, 284, 248, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
4441, 6fyvA, 0.6870, 3.30, 0.177, 329, 254, X-RAY STRUCTURE OF CLK4-KD(146-480)/CX-4945 AT 2.46A 
4442, 5c9cB, 0.6870, 2.90, 0.225, 251, 244, CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND
4443, 4yp8C, 0.6870, 3.21, 0.212, 287, 250, IRAK4-INHIBITOR CO-STRUCTURE
4444, 4jg8A, 0.6870, 2.96, 0.188, 300, 245, STRUCTURE OF RSK2 T493M CTD MUTANT BOUND TO 2-CYANO-N-(1-HYDROXY-2- METHYLPROPAN-2-YL)-3-(3-(345-TRIMETHOXYPHENYL)-1H-INDAZOL-5-YL) ACRYLAMIDE
4445, 4j7bA, 0.6870, 3.53, 0.209, 284, 258, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
4446, 4bhnA, 0.6870, 2.67, 0.207, 256, 242, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4447, 3rakA, 0.6870, 2.83, 0.185, 277, 243, CDK2 IN COMPLEX WITH INHIBITOR RC-2-32
4448, 2welA, 0.6870, 3.32, 0.157, 304, 254, CRYSTAL STRUCTURE OF SU6656-BOUND CALCIUM/CALMODULIN- DEPENDENT PROTEIN KINASE II DELTA IN COMPLEX WITH CALMODULIN
4449, 2r3mA, 0.6870, 2.93, 0.189, 278, 244, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4450, 1h07A, 0.6870, 3.01, 0.183, 285, 246, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
4451, 4xufA, 0.6869, 3.19, 0.341, 270, 249, CRYSTAL STRUCTURE OF THE FLT3 KINASE DOMAIN BOUND TO THE INHIBITOR QUIZARTINIB (AC220)
4452, 4tw9A, 0.6869, 3.93, 0.143, 290, 266, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
4453, 4l3jA, 0.6869, 3.59, 0.174, 291, 258, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN
4454, 4jx3A, 0.6869, 3.38, 0.173, 274, 254, CRYSTAL STRUCTURE OF PIM1 KINASE
4455, 4jvgC, 0.6869, 3.01, 0.227, 258, 247, B-RAF KINASE IN COMPLEX WITH BIRB796
4456, 3r01A, 0.6869, 3.32, 0.166, 274, 253, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
4457, 2pzyB, 0.6869, 2.88, 0.147, 283, 245, STRUCTURE OF MK2 COMPLEXED WITH COMPOUND 76
4458, 2j2iB, 0.6869, 3.16, 0.171, 273, 251, CRYSTAL STRUCTURE OF THE HUMAB PIM1 IN COMPLEX WITH LY333531
4459, 1p5eA, 0.6869, 3.56, 0.151, 296, 259, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
4460, 5vuaB, 0.6868, 3.25, 0.163, 270, 251, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
4461, 5nwzB, 0.6868, 3.46, 0.310, 268, 252, FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE DOMAIN (449-753) IN COMPLEX WITH IRREVERSIBLE LIGAND CGA159527
4462, 4yffB, 0.6868, 2.98, 0.198, 264, 243, TNNI3K COMPLEXED WITH INHIBITOR 2
4463, 4m67A, 0.6868, 2.91, 0.177, 264, 248, CRYSTAL STRUCTURE OF THE HUMAN MLKL KINASE-LIKE DOMAIN
4464, 4acmA, 0.6868, 2.90, 0.189, 277, 244, CDK2 IN COMPLEX WITH 3-AMINO-6-(4-{[2-(DIMETHYLAMINO)ETHYL] SULFAMOYL}-PHENYL)-N-PYRIDIN-3-YLPYRAZINE-2-CARBOXAMIDE
4465, 3f5pF, 0.6868, 3.80, 0.292, 299, 260, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4466, 1okwA, 0.6868, 3.56, 0.154, 296, 259, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
4467, 4yffA, 0.6867, 2.89, 0.202, 264, 242, TNNI3K COMPLEXED WITH INHIBITOR 2
4468, 4xh6A, 0.6867, 3.27, 0.171, 273, 252, CRYSTAL STRUCTURE OF PROTO-ONCOGENE KINASE PIM1 BOUND TO HISPIDULIN
4469, 4jvgA, 0.6867, 3.15, 0.225, 262, 249, B-RAF KINASE IN COMPLEX WITH BIRB796
4470, 4c57A, 0.6867, 3.73, 0.134, 310, 262, STRUCTURE OF GAK KINASE IN COMPLEX WITH A NANOBODY
4471, 4btmA, 0.6867, 3.76, 0.160, 292, 262, TTBK1 IN COMPLEX WITH INHIBITOR
4472, 2xizA, 0.6867, 3.25, 0.167, 273, 251, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-3 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
4473, 5uitB, 0.6866, 3.07, 0.215, 283, 246, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 14
4474, 4f6uA, 0.6866, 3.42, 0.187, 334, 256, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 5 (1-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-3-[3-(MORPHOLIN-4-YL) PROPYL]UREA)
4475, 2r3qA, 0.6866, 3.07, 0.187, 286, 246, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4476, 2pzyA, 0.6866, 2.98, 0.146, 291, 246, STRUCTURE OF MK2 COMPLEXED WITH COMPOUND 76
4477, 2f2cB, 0.6866, 3.16, 0.159, 280, 251, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLINWITH THE INHIBITOR AMINOPURVALANOL
4478, 1eh4A, 0.6866, 3.87, 0.151, 293, 265, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
4479, 5lpyA, 0.6865, 3.21, 0.185, 282, 248, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH ATP FROM ARABIDOPSIS THALIANA
4480, 5kgeA, 0.6865, 3.28, 0.167, 273, 252, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 5-(34-DICHLOROPHENYL)- 1~{H}-PYRAZOL-3-AMINE
4481, 5fp6A, 0.6865, 2.96, 0.176, 278, 245, STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH SMALL-MOLECULE LIGAND 3-(47-DICHLORO-1H-INDOL-3-YL)PROP-2-YN-1-OL (AT17833) IN AN ALTERNATE BINDING SITE.
4482, 4i6fA, 0.6865, 3.89, 0.140, 285, 265, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
4483, 4enxA, 0.6865, 3.20, 0.164, 266, 250, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH INHIBITOR (2E5Z)-2- (2-CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-NITROBENZYLIDENE)THIAZOLIDIN-4- ONE
4484, 4bzdA, 0.6865, 2.86, 0.177, 277, 243, STRUCTURE OF CDK2 IN COMPLEX WITH A BENZIMIDAZOPYRIMIDINE
4485, 4btjA, 0.6865, 3.72, 0.156, 292, 262, TTBK1 IN COMPLEX WITH ATP
4486, 2vtsA, 0.6865, 3.11, 0.187, 282, 246, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4487, 2r3kA, 0.6865, 2.85, 0.189, 277, 243, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4488, 1vzoA, 0.6865, 3.30, 0.209, 319, 253, THE STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF MSK1 REVEALS A NOVEL AUTOINHIBITORY CONFORMATION FOR A DUAL KINASE PROTEIN
4489, 5vd1A, 0.6864, 3.54, 0.171, 295, 258, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH PHA- 848125
4490, 4p4cA, 0.6864, 3.26, 0.296, 266, 250, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
4491, 4ithA, 0.6864, 2.57, 0.225, 247, 236, CRYSTAL STRUCTURE OF RIP1 KINASE IN COMPLEX WITH NECROSTATIN-1 ANALOG
4492, 4ek4A, 0.6864, 3.15, 0.186, 287, 247, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
4493, 3jxwA, 0.6864, 3.35, 0.166, 274, 253, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
4494, 2bilB, 0.6864, 3.27, 0.171, 274, 252, THE HUMAN PROTEIN KINASE PIM1 IN COMPLEX WITH ITS CONSENSUS PEPTIDE PIMTIDE
4495, 2a1aB, 0.6864, 3.05, 0.160, 269, 244, PKR KINASE DOMAIN-EIF2ALPHA COMPLEX
4496, 1jstA, 0.6864, 3.64, 0.153, 297, 261, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
4497, 5up3A, 0.6863, 2.79, 0.209, 258, 244, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
4498, 4qtbB, 0.6863, 3.43, 0.165, 348, 255, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
4499, 4cfvC, 0.6863, 3.38, 0.169, 264, 254, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
4500, 4aaaA, 0.6863, 3.40, 0.207, 295, 251, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN
4501, 3orxG, 0.6863, 3.42, 0.197, 274, 254, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
4502, 3bgpA, 0.6863, 3.26, 0.167, 272, 251, HUMAN PIM-1 COMPLEXED WITH A BENZOISOXAZOLE INHIBITOR VX1
4503, 2r3gA, 0.6863, 3.08, 0.187, 287, 246, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4504, 4krdA, 0.6862, 3.48, 0.156, 294, 256, CRYSTAL STRUCTURE OF PHO85-PCL10 COMPLEX
4505, 4f9cA, 0.6862, 3.38, 0.142, 306, 253, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND XL413
4506, 3bgqA, 0.6862, 3.16, 0.168, 272, 250, HUMAN PIM-1 KINASE IN COMPLEX WITH AN TRIAZOLO PYRIDAZINE INHIBITOR VX2
4507, 1jsvA, 0.6862, 3.05, 0.184, 287, 245, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[(6-AMINO-4-PYRIMIDINYL) AMINO]BENZENESULFONAMIDE
4508, 5kgiA, 0.6861, 3.18, 0.175, 273, 251, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR 2-[34-BIS(CHLORANYL) PHENOXY]ETHANAMINE
4509, 5hx6A, 0.6861, 3.24, 0.218, 259, 248, CRYSTAL STRUCTURE OF RIP1 KINASE WITH A BENZO[B][14]OXAZEPIN-4-ONE
4510, 4qp7A, 0.6861, 3.12, 0.164, 337, 250, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
4511, 4l42A, 0.6861, 3.50, 0.173, 299, 255, CRYSTAL STRUCTURES OF HUMAN P70S6K1-PIF
4512, 4ek8A, 0.6861, 3.06, 0.192, 280, 245, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
4513, 3orxE, 0.6861, 3.42, 0.193, 274, 254, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
4514, 5n4uA, 0.6860, 3.19, 0.171, 272, 251, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE 5-(2-AMINO-13-THIAZOL-4- YL)-13-DIHYDROBENZIMIDAZOL-2-ONE
4515, 4nfmA, 0.6860, 3.82, 0.155, 293, 264, HUMAN TAU TUBULIN KINASE 1 (TTBK1)
4516, 4i6bA, 0.6860, 3.89, 0.140, 285, 265, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
4517, 2wfyA, 0.6860, 3.57, 0.158, 295, 259, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
4518, 2o3pA, 0.6860, 3.47, 0.173, 274, 255, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETIN
4519, 1ob3A, 0.6860, 2.99, 0.159, 277, 246, STRUCTURE OF P. FALCIPARUM PFPK5
4520, 1h24C, 0.6860, 3.58, 0.159, 293, 258, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
4521, 5vd0A, 0.6859, 3.63, 0.166, 293, 259, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH MK1775
4522, 5k5nA, 0.6859, 3.50, 0.176, 331, 255, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
4523, 5jq5A, 0.6859, 3.07, 0.175, 287, 246, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0942
4524, 5j1wA, 0.6859, 3.30, 0.183, 338, 252, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW31 (COMPOUND 14)
4525, 4yc6E, 0.6859, 3.23, 0.181, 285, 249, CDK1/CKS1
4526, 4x3fB, 0.6859, 3.25, 0.191, 278, 251, CRYSTAL STRUCTURE OF THE INTRACELLULAR DOMAIN OF THE M. TUBERCULOSIS SER/THR KINASE PKNA
4527, 4qnyB, 0.6859, 3.34, 0.172, 339, 256, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
4528, 4i5pA, 0.6859, 3.89, 0.140, 284, 265, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
4529, 4eqmB, 0.6859, 3.22, 0.168, 269, 250, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4530, 3r02A, 0.6859, 3.22, 0.171, 271, 251, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
4531, 3igoA, 0.6859, 3.61, 0.166, 446, 259, CRYSTAL STRUCTURE OF CRYPTOSPORIDIUM PARVUM CDPK1 CGD3_920
4532, 3e3pA, 0.6859, 3.37, 0.179, 337, 252, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
4533, 5ndtA, 0.6858, 3.19, 0.171, 273, 251, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE (E)-3-(2-(THIOPHEN-2-YL)VINYL)-3; 4-DIHYDROQUINOXALIN-2(1H)-ONE 
4534, 5j1wC, 0.6858, 3.41, 0.176, 316, 255, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW31 (COMPOUND 14)
4535, 4fkpA, 0.6858, 2.98, 0.189, 279, 244, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4536, 4ek3A, 0.6858, 3.21, 0.177, 287, 248, CRYSTAL STRUCTURE OF APO CDK2
4537, 4bzoA, 0.6858, 3.26, 0.175, 272, 251, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO- PYRAZINONE INHIBITOR
4538, 3zduA, 0.6858, 3.21, 0.181, 297, 248, CRYSTAL STRUCTURE OF THE HUMAN CDKL3 KINASE DOMAIN
4539, 3idpB, 0.6858, 3.04, 0.215, 256, 246, B-RAF V600E KINASE DOMAIN IN COMPLEX WITH AN AMINOISOQUINOLINE INHIBITOR
4540, 3ezvA, 0.6858, 2.82, 0.182, 277, 242, CDK-2 WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
4541, 2uznA, 0.6858, 2.98, 0.193, 279, 244, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
4542, 5t1tC, 0.6857, 3.20, 0.209, 286, 249, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4543, 5n4xA, 0.6857, 3.27, 0.171, 272, 252, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE 45-DIBROMOTHIOPHENE-2- CARBOHYDRAZIDE
4544, 4i6hA, 0.6857, 3.91, 0.140, 285, 265, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE ALPHA-SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
4545, 4g17A, 0.6857, 3.99, 0.131, 302, 268, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-TERT-BUTYLPHENYL)AMINO]-1H- BENZIMIDAZOLE-6-CARBONITRILE
4546, 3otuA, 0.6857, 3.27, 0.210, 276, 252, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR JS30
4547, 3hdmA, 0.6857, 3.42, 0.173, 285, 255, CRYSTAL STRUCTURE OF SERUM AND GLUCOCORTICOID-REGULATED KINASE 1 IN COMPLEX WITH COMPOUND 1
4548, 3f5pE, 0.6857, 3.81, 0.292, 299, 260, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4549, 1yi3A, 0.6857, 3.22, 0.168, 267, 250, CRYSTAL STRUCTURE OF PIM-1 BOUND TO LY294002
4550, 5xzvB, 0.6856, 2.58, 0.197, 371, 238, CRYSTAL STRUCTURE OF RAD53 1-466 IN COMPLEX WITH AMP-PNP
4551, 5hidA, 0.6856, 2.90, 0.220, 257, 245, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH AZ628
4552, 4y73D, 0.6856, 3.40, 0.222, 288, 252, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
4553, 4rj3A, 0.6856, 3.19, 0.178, 287, 247, CDK2 WITH EGFR INHIBITOR COMPOUND 8
4554, 4oh4B, 0.6856, 3.14, 0.191, 289, 246, CRYSTAL STRUCTURE OF BRI1 IN COMPLEX WITH BKI1
4555, 3wi6E, 0.6856, 2.87, 0.156, 283, 244, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4556, 3wi6C, 0.6856, 2.87, 0.156, 283, 244, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4557, 3ulzA, 0.6856, 3.10, 0.180, 291, 245, CRYSTAL STRUCTURE OF APO BAK1
4558, 3kc3J, 0.6856, 2.93, 0.147, 288, 245, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4559, 1omwA, 0.6856, 4.16, 0.176, 614, 273, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN G PROTEIN-COUPLED RECEPTOR KINASE 2 AND HETEROTRIMERIC G PROTEIN BETA 1 AND GAMMA 2 SUBUNITS
4560, 4qqcA, 0.6855, 3.52, 0.321, 273, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE DOMAIN IN COMPLEX WITH FIIN-2 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
4561, 4f7nA, 0.6855, 3.56, 0.183, 334, 257, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 11 (1- [3-TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-3-(5- HYDROXYPENTYL)UREA)
4562, 4eqmC, 0.6855, 3.24, 0.168, 269, 250, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4563, 3wi6F, 0.6855, 2.88, 0.156, 283, 244, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4564, 5tvtA, 0.6854, 3.21, 0.187, 321, 251, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
4565, 5l2qC, 0.6854, 3.14, 0.137, 282, 248, SERINE/THREONINE-PROTEIN KINASE 40 (STK40) KINASE HOMOLOGY DOMAIN
4566, 5aniA, 0.6854, 3.08, 0.179, 280, 246, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-CHLORO-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
4567, 4mbiA, 0.6854, 3.40, 0.169, 274, 254, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
4568, 4dglC, 0.6854, 3.59, 0.143, 334, 258, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
4569, 3umwA, 0.6854, 3.07, 0.165, 264, 248, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR (Z)-2-[(1H- INDAZOL-3-YL)METHYLENE]-6-METHOXY-7-(PIPERAZIN-1-YLMETHYL)BENZOFURAN- 3(2H)-ONE
4570, 3s2pA, 0.6854, 2.97, 0.189, 279, 244, CRYSTAL STRUCTURE OF CDK2 WITH A 2-AMINOPYRIMIDINE COMPOUND
4571, 3bwfA, 0.6854, 3.20, 0.175, 273, 251, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH AN OSMIUM COMPOUND
4572, 2bzjA, 0.6854, 3.19, 0.171, 273, 251, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU3
4573, 1yxvA, 0.6854, 3.30, 0.167, 274, 252, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH 34-DIHYDROXY-1- METHYLQUINOLIN-2(1H)-ONE
4574, 6b2qB, 0.6853, 3.29, 0.198, 266, 253, DUAL INHIBITION OF THE ESSENTIAL PROTEIN KINASES A AND B IN MYCOBACTERIUM TUBERCULOSIS
4575, 5uiuB, 0.6853, 3.11, 0.211, 287, 247, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 30
4576, 5ih6A, 0.6853, 3.83, 0.148, 286, 263, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A DERIVATIVE
4577, 5d10A, 0.6853, 3.00, 0.286, 248, 245, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL236
4578, 4zy6B, 0.6853, 3.66, 0.171, 280, 258, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
4579, 4twcB, 0.6853, 3.89, 0.147, 292, 265, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
4580, 4izaA, 0.6853, 3.29, 0.173, 346, 254, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
4581, 4eqmA, 0.6853, 3.24, 0.168, 269, 250, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4582, 3wi6B, 0.6853, 2.88, 0.156, 283, 244, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4583, 3r04A, 0.6853, 3.22, 0.167, 271, 251, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
4584, 3dcvA, 0.6853, 3.28, 0.179, 273, 251, CRYSTAL STRUCTURE OF HUMAN PIM1 KINASE COMPLEXED WITH 4-(4- HYDROXY-3-METHYL-PHENYL)-6-PHENYLPYRIMIDIN-2(1H)-ONE
4585, 2erkA, 0.6853, 3.23, 0.151, 351, 252, PHOSPHORYLATED MAP KINASE ERK2
4586, 1h27A, 0.6853, 3.52, 0.159, 296, 258, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
4587, 1ckpA, 0.6853, 2.98, 0.189, 279, 244, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR PURVALANOL B
4588, 5kggA, 0.6852, 3.30, 0.171, 273, 252, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-(5-CHLORANYL-1~{H}-INDOL- 3-YL)ETHANAMINE
4589, 4qp4A, 0.6852, 3.13, 0.164, 337, 250, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
4590, 4bghA, 0.6852, 2.78, 0.187, 275, 241, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PAN-CDK INHIBITOR
4591, 3qrjB, 0.6852, 2.84, 0.348, 265, 244, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN T315I MUTANT IN COMPLEX WITH DCC-2036
4592, 3orxH, 0.6852, 3.44, 0.197, 274, 254, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
4593, 2nryD, 0.6852, 3.03, 0.208, 282, 245, CRYSTAL STRUCTURE OF IRAK-4
4594, 2j9mA, 0.6852, 2.75, 0.183, 275, 240, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH MACROCYCLIC AMINOPYRIMIDINE
4595, 1yxuA, 0.6852, 3.43, 0.165, 273, 254, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
4596, 6ft9C, 0.6851, 3.43, 0.176, 337, 255, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH INHIBITOR 16 
4597, 5telA, 0.6851, 3.37, 0.178, 273, 253, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
4598, 5lvpC, 0.6851, 3.42, 0.216, 275, 255, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN HM-PEPTIDE BOUND TO THE PIF-POCKET
4599, 4yffD, 0.6851, 2.87, 0.221, 257, 240, TNNI3K COMPLEXED WITH INHIBITOR 2
4600, 4yc6A, 0.6851, 3.21, 0.177, 285, 249, CDK1/CKS1
4601, 4lv8A, 0.6851, 3.60, 0.114, 360, 263, MURINE IRGA6 BOUND TO TOXOPLASMA ROP5C A PSEUDOKINASE GDI
4602, 4g16A, 0.6851, 3.98, 0.131, 302, 268, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-{[3-(TRIFLUOROMETHYL)PYRIDIN2- YL]OXY}PHENYL)AMINO]-1H-BENZIMIDAZOLE-6-CARBONITRILE
4603, 3vbvA, 0.6851, 3.33, 0.163, 268, 252, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
4604, 3d7uD, 0.6851, 2.88, 0.291, 248, 244, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
4605, 6fyoA, 0.6850, 3.28, 0.179, 331, 252, X-RAY STRUCTURE OF CLK1-KD(148-484)/CPD-2 AT 2.32A 
4606, 6f3dB, 0.6850, 3.09, 0.215, 283, 246, IRAK4 IN COMPLEX WITH INHIBITOR 
4607, 6b5jB, 0.6850, 3.00, 0.198, 264, 243, TNNI3K COMPLEXED WITH A 46-DIAMINOPYRIMIDINE
4608, 5n50A, 0.6850, 3.20, 0.171, 273, 251, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 2-(4-CHLOROPHENYL) SULFANYLACETOHYDRAZIDE
4609, 5n4yA, 0.6850, 3.19, 0.171, 273, 251, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 25-DIHYDRO-1H-ISOTHIOCHROMENO[3 4-D]PYRAZOL-3-ONE
4610, 4yzmA, 0.6850, 3.23, 0.220, 260, 250, HUMANIZED ROCO4 BOUND TO LRRK2-IN1
4611, 4ll5A, 0.6850, 3.21, 0.171, 268, 251, CRYSTAL STRUCTURE OF PIM-1 IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
4612, 3cy3A, 0.6850, 3.16, 0.172, 270, 250, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND THE JNK INHIBITOR V
4613, 1h25A, 0.6850, 3.55, 0.160, 293, 257, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
4614, 1ckjA, 0.6850, 3.64, 0.149, 296, 261, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
4615, 5n5lA, 0.6849, 3.16, 0.172, 271, 250, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND [2-OXO-2-(1H-PYRROL-2-YL)ETHYL] 5-BROMO-1H- INDOLE-3-CARBOXYLATE
4616, 5hgiA, 0.6849, 3.35, 0.182, 395, 253, CRYSTAL STRUCTURE OF APO HUMAN IRE1 ALPHA
4617, 4yfiB, 0.6849, 3.10, 0.217, 262, 244, TNNI3K COMPLEXED WITH INHIBITOR 1
4618, 4rzwB, 0.6849, 2.94, 0.229, 252, 245, CRYSTAL STRUCTURE OF BRAF (R509H) KINASE DOMAIN BOUND TO AZ628
4619, 5t1tD, 0.6848, 3.12, 0.215, 283, 247, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4620, 5nhpA, 0.6848, 3.44, 0.165, 338, 255, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
4621, 3qriB, 0.6848, 2.82, 0.346, 262, 243, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DCC- 2036
4622, 3ndmC, 0.6848, 3.86, 0.169, 371, 260, CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT ISOQUINOLONE DERIVATIVE
4623, 3is5C, 0.6848, 3.09, 0.199, 259, 246, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4624, 2vtaA, 0.6848, 2.94, 0.189, 278, 243, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4625, 2nryC, 0.6848, 3.04, 0.217, 280, 244, CRYSTAL STRUCTURE OF IRAK-4
4626, 2jbpC, 0.6848, 2.87, 0.143, 284, 244, PROTEIN KINASE MK2 IN COMPLEX WITH AN INHIBITOR (CRYSTAL FORM-2 CO-CRYSTALLIZATION)
4627, 2c47D, 0.6848, 3.80, 0.137, 290, 263, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
4628, 2bdwA, 0.6848, 3.78, 0.153, 309, 262, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
4629, 6g33A, 0.6847, 3.22, 0.184, 335, 250, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH 5-IODOTUBERCIDIN 
4630, 5nhlA, 0.6847, 3.43, 0.165, 345, 255, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
4631, 5imeB, 0.6847, 3.36, 0.170, 280, 253, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
4632, 4z7hA, 0.6847, 3.42, 0.186, 385, 253, CRYSTAL STRUCTURE OF HUMAN IRE1 CYTOPLASMIC KINASE-RNASE REGION - COMPLEX WITH IMIDAZOPYRIDINE COMPOUND 3
4633, 4yc6C, 0.6847, 3.22, 0.177, 285, 249, CDK1/CKS1
4634, 4qp9A, 0.6847, 3.13, 0.168, 335, 250, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-PROPYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
4635, 4a7cA, 0.6847, 3.33, 0.171, 273, 252, CRYSTAL STRUCTURE OF PIM1 KINASE WITH ETP46546
4636, 3ig7A, 0.6847, 2.96, 0.189, 278, 243, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFP WITH CDK-2
4637, 2qq7B, 0.6847, 2.71, 0.308, 244, 240, CRYSTAL STRUCTURE OF DRUG RESISTANT SRC KINASE DOMAIN WITH IRREVERSIBLE INHIBITOR
4638, 5n4zA, 0.6846, 3.21, 0.171, 272, 251, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE (E)-4-(4-HYDROXYPHENYL)BUT-3-EN-2- ONE
4639, 4ztlA, 0.6846, 2.93, 0.210, 280, 243, IRAK4-INHIBITOR CO-STRUCTURE
4640, 4mygB, 0.6846, 3.35, 0.209, 335, 254, MAPK13 ACTIVE FORM
4641, 3e3pB, 0.6846, 3.32, 0.179, 337, 251, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
4642, 2weiA, 0.6846, 3.46, 0.202, 278, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE IN COMPLEX WITH 3- MB-PP1
4643, 2b9iA, 0.6846, 3.17, 0.159, 338, 251, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM MSG5
4644, 6ft9A, 0.6845, 3.31, 0.179, 336, 252, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH INHIBITOR 16 
4645, 6cadB, 0.6845, 2.74, 0.224, 248, 241, CRYSTAL STRUCTURE OF RAF KINASE DOMAIN BOUND TO THE INHIBITOR 2A
4646, 5lvpB, 0.6845, 3.66, 0.202, 276, 258, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN HM-PEPTIDE BOUND TO THE PIF-POCKET
4647, 5l4qA, 0.6845, 2.93, 0.152, 293, 243, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE 1 (AAK1) IN COMPLEX WITH LKB1 (AAK1 DUAL INHIBITOR)
4648, 4o0wA, 0.6845, 3.21, 0.183, 259, 251, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
4649, 4hgsA, 0.6845, 3.96, 0.134, 302, 268, CRYSTAL STRUCTURE OF CK1GS WITH COMPOUND 13
4650, 3zu7A, 0.6845, 3.26, 0.162, 344, 253, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE MAP KINASE ERK2
4651, 3r22A, 0.6845, 3.15, 0.189, 255, 249, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
4652, 3orxF, 0.6845, 3.45, 0.197, 274, 254, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
4653, 2cjmC, 0.6845, 3.51, 0.163, 294, 257, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
4654, 6bwkA, 0.6844, 2.91, 0.181, 263, 248, CRYSTAL STRUCTURE OF THE HUMAN MLKL PSEUDOKINASE DOMAIN T357E/S358E MUTANT 
4655, 5uiqC, 0.6844, 3.07, 0.207, 280, 246, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 9
4656, 5ih4A, 0.6844, 3.82, 0.148, 286, 263, HUMAN CASEIN KINASE 1 ISOFORM DELTA APO (KINASE DOMAIN)
4657, 4rpvA, 0.6844, 3.29, 0.171, 273, 252, CO-CRYSTAL STRUCTURE OF PIM1 WITH COMPOUND 3
4658, 3f5pJ, 0.6844, 3.80, 0.293, 293, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4659, 1yxuC, 0.6844, 3.36, 0.162, 272, 253, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
4660, 1yxuB, 0.6844, 3.41, 0.165, 273, 254, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
4661, 5l4qB, 0.6843, 2.82, 0.149, 287, 242, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE 1 (AAK1) IN COMPLEX WITH LKB1 (AAK1 DUAL INHIBITOR)
4662, 5dpvA, 0.6843, 3.15, 0.184, 257, 250, AURORA A KINASE IN COMPLEX WITH AA35 AND JNJ-7706621 IN SPACE GROUP P6122
4663, 4yp8D, 0.6843, 3.30, 0.220, 285, 250, IRAK4-INHIBITOR CO-STRUCTURE
4664, 4hnfB, 0.6843, 3.76, 0.149, 290, 262, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
4665, 4bieA, 0.6843, 2.73, 0.219, 257, 242, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4666, 3jyaA, 0.6843, 3.37, 0.174, 274, 253, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
4667, 2xiyA, 0.6843, 3.28, 0.171, 273, 251, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-2 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
4668, 2iztA, 0.6843, 3.89, 0.120, 296, 266, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
4669, 1vr2A, 0.6843, 3.41, 0.298, 275, 252, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN
4670, 1h00A, 0.6843, 3.03, 0.193, 278, 244, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
4671, 5l8lA, 0.6842, 3.38, 0.180, 263, 256, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 1)
4672, 4rc4A, 0.6842, 3.27, 0.167, 272, 251, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
4673, 4bckA, 0.6842, 3.67, 0.158, 298, 260, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
4674, 5vubB, 0.6841, 3.24, 0.164, 269, 250, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
4675, 4ztnC, 0.6841, 3.14, 0.211, 284, 247, IRAK4-INHIBITOR CO-STRUCTURE
4676, 4un0C, 0.6841, 3.70, 0.152, 308, 263, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
4677, 4r5yA, 0.6841, 2.78, 0.240, 253, 242, THE COMPLEX STRUCTURE OF BRAF V600E KINASE DOMAIN WITH A NOVEL BRAF INHIBITOR
4678, 4c57B, 0.6841, 3.73, 0.130, 308, 261, STRUCTURE OF GAK KINASE IN COMPLEX WITH A NANOBODY
4679, 3vbtA, 0.6841, 3.34, 0.163, 267, 252, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
4680, 5vcxA, 0.6840, 3.54, 0.176, 287, 255, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN (UNTREATED) IN COMPLEX WITH SARACATINIB
4681, 3zuvC, 0.6840, 3.22, 0.155, 357, 251, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
4682, 3octA, 0.6840, 2.73, 0.310, 244, 242, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE MUTANT V555R IN COMPLEX WITH DASATINIB
4683, 3nyvA, 0.6840, 3.47, 0.195, 445, 256, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH NON-SPECIFIC INHIBITOR WHI-P180
4684, 1xr1A, 0.6840, 3.53, 0.173, 277, 255, CRYSTAL STRUCTURE OF HPIM-1 KINASE IN COMPLEX WITH AMP-PNP AT 2.1 A RESOLUTION
4685, 1e9hA, 0.6840, 3.63, 0.158, 295, 259, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
4686, 6bqqA, 0.6839, 3.45, 0.181, 271, 254, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH BI2526
4687, 5opbA, 0.6839, 3.25, 0.157, 262, 249, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH INDAZOLE LRRK2 INHIBITOR
4688, 2np8A, 0.6839, 3.07, 0.181, 256, 248, STRUCTURAL BASIS FOR THE INHIBITION OF AURORA A KINASE BY A NOVEL CLASS OF HIGH AFFINITY DISUBSTITUTED PYRIMIDINE INHIBITORS
4689, 5vcwA, 0.6838, 3.52, 0.176, 285, 255, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH PELITINIB
4690, 5kgkA, 0.6838, 3.30, 0.171, 273, 252, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 3-(4-METHOXYPHENYL)-1~{H}- PYRAZOL-5-AMINE
4691, 5k00A, 0.6838, 3.12, 0.185, 311, 248, MELK IN COMPLEX WITH NVS-MELK5
4692, 5j1vB, 0.6838, 3.33, 0.183, 337, 252, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW29 (COMPOUND 13)
4693, 5aadA, 0.6838, 2.97, 0.187, 252, 246, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (7A)
4694, 4hglA, 0.6838, 3.99, 0.134, 302, 268, CRYSTAL STRUCTURE OF CK1G3 WITH COMPOUND 1
4695, 3vbxA, 0.6838, 3.34, 0.167, 268, 252, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
4696, 6b2qC, 0.6837, 3.23, 0.195, 264, 251, DUAL INHIBITION OF THE ESSENTIAL PROTEIN KINASES A AND B IN MYCOBACTERIUM TUBERCULOSIS
4697, 5kcxA, 0.6837, 3.35, 0.167, 272, 252, PIM-1 KINASE IN COMPLEX WITH A SELECTIVE N-SUBSTITUTED 7-AZAINDOLE INHIBITOR
4698, 4j7bD, 0.6837, 3.50, 0.199, 281, 256, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
4699, 3wi6D, 0.6837, 2.86, 0.156, 282, 243, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4700, 2r3lA, 0.6837, 2.84, 0.186, 275, 242, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4701, 2henA, 0.6837, 3.31, 0.312, 259, 250, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
4702, 1gihA, 0.6837, 2.85, 0.190, 276, 242, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
4703, 5vucB, 0.6836, 3.09, 0.161, 269, 248, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
4704, 5op2A, 0.6836, 3.19, 0.153, 263, 248, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
4705, 5c1qB, 0.6836, 3.21, 0.167, 273, 251, SERINE/THREONINE-PROTEIN KINASE PIM-1
4706, 4ztmC, 0.6836, 3.12, 0.215, 282, 246, IRAK4-INHIBITOR CO-STRUCTURE
4707, 4yfiD, 0.6836, 3.07, 0.218, 261, 243, TNNI3K COMPLEXED WITH INHIBITOR 1
4708, 2wqnA, 0.6836, 3.04, 0.183, 259, 246, STRUCTURE OF ADP-BOUND HUMAN NEK7
4709, 1buhA, 0.6836, 3.27, 0.173, 287, 249, CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITH CELL CYCLE-REGULATORY PROTEIN CKSHS1
4710, 5n4nA, 0.6835, 3.21, 0.171, 273, 251, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 34-DIMETHYL-5-(1H-124-TRIAZOL- 3-YL)THIOPHENE-2-CARBONITRILE
4711, 5es1A, 0.6835, 3.20, 0.196, 304, 250, CRYSTAL STRUCTURE OF MICROTUBULE AFFINITY-REGULATING KINASE 4 CATALYTIC DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
4712, 4lgdA, 0.6835, 3.84, 0.204, 350, 265, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4713, 4jbpA, 0.6835, 3.04, 0.190, 255, 247, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
4714, 4i41A, 0.6835, 3.28, 0.167, 272, 251, CRYSTAL STRUCTURE OF HUMAN SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE
4715, 4d9tA, 0.6835, 3.03, 0.180, 299, 245, RSK2 C-TERMINAL KINASE DOMAIN WITH INHIBITOR (E)-METHYL 3-(4-AMINO-7- (3-HYDROXYPROPYL)-5-P-TOLYL-7H-PYRROLO[23-D]PYRIMIDIN-6-YL)-2- CYANOACRYLATE
4716, 3zuvA, 0.6835, 3.26, 0.151, 357, 252, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
4717, 2r3nA, 0.6835, 2.80, 0.183, 275, 241, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
4718, 5turA, 0.6834, 3.42, 0.174, 270, 253, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
4719, 5nhvA, 0.6834, 3.52, 0.168, 345, 256, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
4720, 3qrjA, 0.6834, 2.59, 0.351, 258, 239, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN T315I MUTANT IN COMPLEX WITH DCC-2036
4721, 4fkjA, 0.6833, 2.90, 0.194, 278, 242, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
4722, 3py3A, 0.6833, 3.62, 0.171, 355, 257, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38ALPHA MAP KINASE
4723, 3kc3C, 0.6833, 2.85, 0.149, 281, 242, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4724, 6gwrA, 0.6832, 3.70, 0.294, 300, 255, STRUCTURE OF THE KINASE DOMAIN OF HUMAN DDR1 IN COMPLEX WITH A POTENT AND SELECTIVE INHIBITOR OF DDR1 AND DDR2 
4725, 5t1tA, 0.6832, 3.12, 0.215, 283, 246, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4726, 5buiA, 0.6832, 3.16, 0.165, 338, 248, ERK2 COMPLEXED WITH 2-PYRIDIYL TETRAHYDROAZAINDAZOLE
4727, 2henC, 0.6832, 3.31, 0.312, 259, 250, CRYSTAL STRUCTURE OF THE EPHB2 RECEPTOR KINASE DOMAIN IN COMPLEX WITH ADP
4728, 1yhsA, 0.6832, 3.23, 0.168, 267, 250, CRYSTAL STRUCTURE OF PIM-1 BOUND TO STAUROSPORINE
4729, 1vyzA, 0.6832, 3.06, 0.189, 279, 244, STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227
4730, 5uv4A, 0.6831, 3.40, 0.180, 290, 250, CRYSTAL STRUCTURE OF MAIZE SIRK1 (SUCROSE-INDUCED RECEPTOR KINASE 1) KINASE DOMAIN BOUND TO AMP-PNP
4731, 5tx5A, 0.6831, 3.27, 0.219, 259, 247, RIP1 KINASE ( FLAG 1-294 C34A C127A C233A C240A) WITH GSK772
4732, 5t1sB, 0.6831, 3.06, 0.213, 282, 244, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4733, 5oktA, 0.6831, 3.80, 0.145, 285, 262, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH IWP-2 
4734, 5n5mA, 0.6831, 3.19, 0.172, 272, 250, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND (R)-3-(2-((ISOQUINOLIN-5-YLMETHYL)(METHYL) CARBAMOYL)PHENYL)PYRROLIDIN-1-IUM
4735, 5dr9A, 0.6831, 3.12, 0.185, 257, 249, AURORA A KINASE IN COMPLEX WITH AA29 AND JNJ-7706621 IN SPACE GROUP P6122
4736, 2vthA, 0.6831, 2.97, 0.185, 278, 243, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN
4737, 2qolA, 0.6831, 3.52, 0.291, 271, 251, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596:Y602:S768G TRIPLE MUTANT
4738, 5d9kB, 0.6830, 3.23, 0.195, 280, 251, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
4739, 4mhaB, 0.6830, 2.36, 0.346, 246, 231, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE PROTO-ONCOGENE TYROSINE-PROTEIN KINASE MER IN COMPLEX WITH INHIBITOR UNC1817
4740, 4lmuA, 0.6830, 3.23, 0.164, 265, 250, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH THE INHIBITOR QUERCETIN (RESULTING FROM DISPLACEMENT OF SKF86002)
4741, 4kbkB, 0.6830, 3.78, 0.149, 289, 262, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
4742, 3wi6A, 0.6830, 2.87, 0.156, 282, 243, CRYSTAL STRUCTURE OF MAPKAP KINASE-2 (MK2) IN COMPLEX WITH NON- SELECTIVE INHIBITOR
4743, 2vtjA, 0.6830, 2.81, 0.187, 276, 241, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4744, 1v0pA, 0.6830, 3.03, 0.159, 277, 246, STRUCTURE OF P. FALCIPARUM PFPK5-PURVALANOL B LIGAND COMPLEX
4745, 3kc3G, 0.6829, 2.85, 0.152, 276, 243, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4746, 6gttA, 0.6828, 3.34, 0.183, 282, 252, HUMAN STK10 BOUND TO BIRB-796 
4747, 3uzpA, 0.6828, 3.92, 0.148, 292, 264, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P21 CRYSTAL FORM
4748, 2gphA, 0.6828, 3.39, 0.153, 345, 255, DOCKING MOTIF INTERACTIONS IN THE MAP KINASE ERK2
4749, 1xwsA, 0.6828, 3.37, 0.166, 273, 253, CRYSTAL STRUCTURE OF THE HUMAN PIM1 KINASE DOMAIN
4750, 5m57A, 0.6827, 3.07, 0.163, 261, 245, NEK2 BOUND TO ARYLAMINOPURINE 6
4751, 5horA, 0.6827, 2.90, 0.346, 247, 237, CRYSTAL STRUCTURE OF C-MET-M1250T IN COMPLEX WITH SAR125844.
4752, 4qtbA, 0.6827, 3.48, 0.165, 351, 255, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
4753, 4lg4C, 0.6827, 3.65, 0.222, 288, 261, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4754, 3fdnA, 0.6827, 3.13, 0.189, 261, 249, STRUCTURE-BASED DRUG DESIGN OF NOVEL AURORA KINASE A INHIBITORS: STRUCTURE BASIS FOR POTENCY AND SPECIFICITY
4755, 5de2B, 0.6826, 3.03, 0.182, 262, 247, STRUCTURAL MECHANISM OF NEK7 ACTIVATION BY NEK9-INDUCED DIMERISATION
4756, 4yp8A, 0.6826, 3.17, 0.219, 284, 247, IRAK4-INHIBITOR CO-STRUCTURE
4757, 4qoxA, 0.6826, 3.62, 0.195, 462, 257, CRYSTAL STRUCTURE OF CDPK4 FROM PLASMODIUM FALCIPARUM PF3D7_0717500
4758, 2b55A, 0.6826, 2.82, 0.183, 276, 241, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH INDENOPYRAXOLE DIN-101312
4759, 1v1kA, 0.6826, 2.93, 0.189, 277, 243, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
4760, 4yo6C, 0.6825, 3.24, 0.205, 286, 249, IRAK4-INHIBITOR CO-STRUCTURE
4761, 4bicB, 0.6825, 2.88, 0.217, 259, 244, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4762, 2xixA, 0.6825, 3.28, 0.172, 272, 250, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-1 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
4763, 5mqvC, 0.6824, 3.80, 0.149, 288, 262, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
4764, 4xv1A, 0.6824, 2.41, 0.217, 239, 235, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX7904
4765, 4rmzA, 0.6824, 3.22, 0.218, 284, 248, CRYSTAL STRUCTURE OF IRAK-4
4766, 4r6vA, 0.6824, 3.53, 0.327, 273, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE HARBORING THE V550L GATE-KEEPER MUTATION IN COMPLEX WITH FIIN-3 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
4767, 4bibA, 0.6824, 2.65, 0.212, 254, 240, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4768, 2w05A, 0.6824, 2.83, 0.183, 276, 241, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5B
4769, 2o63A, 0.6824, 3.53, 0.173, 274, 255, CRYSTAL STRUCTURE OF PIM1 WITH MYRICETIN
4770, 1mp8A, 0.6824, 3.29, 0.341, 252, 249, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE (FAK)
4771, 1gzkA, 0.6824, 3.09, 0.171, 271, 245, MOLECULAR MECHANISM FOR THE REGULATION OF PROTEIN KINASE B/ AKT BY HYDROPHOBIC MOTIF PHOSPHORYLATION
4772, 6g93A, 0.6823, 3.44, 0.165, 343, 254, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
4773, 5t1sC, 0.6823, 3.17, 0.206, 284, 247, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4774, 5mafA, 0.6823, 3.07, 0.183, 315, 246, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
4775, 4y73B, 0.6823, 3.27, 0.221, 289, 249, CRYSTAL STRUCTURE OF IRAK4 KINASE DOMAIN WITH INHIBITOR
4776, 4rc2A, 0.6823, 3.28, 0.171, 272, 251, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
4777, 4nifA, 0.6823, 2.93, 0.160, 313, 243, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
4778, 3uysC, 0.6823, 3.83, 0.145, 286, 262, CRYSTAL STRUCTURE OF APO HUMAN CK1D
4779, 3pj2A, 0.6823, 2.99, 0.291, 248, 244, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-[4-(2- DIETHYLAMINO-ETHOXY)-PHENYLAMINO]-6-(4-FLUORO-PHENOXY)-8-METHYL-8H- PYRIDO[23-D]PYRIMIDIN-7-ONE
4780, 2pzyD, 0.6823, 3.01, 0.143, 288, 245, STRUCTURE OF MK2 COMPLEXED WITH COMPOUND 76
4781, 5wnhB, 0.6822, 3.98, 0.172, 365, 262, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
4782, 5jznA, 0.6822, 3.18, 0.168, 268, 250, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
4783, 4yffC, 0.6822, 2.86, 0.222, 258, 239, TNNI3K COMPLEXED WITH INHIBITOR 2
4784, 4lggB, 0.6822, 2.98, 0.280, 245, 243, STRUCTURE OF 3MB-PP1 BOUND TO ANALOG-SENSITIVE SRC KINASE
4785, 3vbyA, 0.6822, 3.36, 0.163, 267, 252, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
4786, 3qd2B, 0.6822, 3.21, 0.181, 271, 248, CRSYTAL STRUCTURE OF MOUSE PERK KINASE DOMAIN
4787, 5oq8A, 0.6821, 3.19, 0.154, 261, 247, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
4788, 4xs2B, 0.6821, 3.01, 0.215, 278, 242, IRAK4-INHIBITOR CO-STRUCTURE
4789, 4x3fA, 0.6821, 3.40, 0.187, 274, 252, CRYSTAL STRUCTURE OF THE INTRACELLULAR DOMAIN OF THE M. TUBERCULOSIS SER/THR KINASE PKNA
4790, 4prjA, 0.6821, 3.06, 0.187, 251, 246, AURORA A KINASE DOMAIN WITH COMPOUND 2 (N-[1-(3-CYANOBENZYL)-1H- PYRAZOL-4-YL]-6-(1H-PYRAZOL-4-YL)-1H-INDAZOLE-3-CARBOXAMIDE)
4791, 4lghA, 0.6821, 2.67, 0.282, 243, 238, CRYSTAL STRUCTURE OF 1NM-PP1 BOUND TO ANALOG-SENSITIVE SRC KINASE
4792, 3we4A, 0.6821, 3.61, 0.175, 286, 257, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRIMIDINE DERIVATIVE PF-4708671 2-{[4-(5-ETHYLPYRIMIDIN-4-YL)PIPERAZIN-1- YL]METHYL}-5-(TRIFLUOROMETHYL)-1H-BENZIMIDAZOLE
4793, 3vw6A, 0.6821, 2.71, 0.207, 255, 241, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
4794, 3qc4B, 0.6821, 3.15, 0.169, 278, 248, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
4795, 5toeA, 0.6820, 3.44, 0.174, 272, 253, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
4796, 5dr6A, 0.6820, 3.14, 0.185, 257, 249, AURORA A KINASE IN COMPLEX WITH AA30 AND JNJ-7706621 IN SPACE GROUP P6122
4797, 5ar8A, 0.6820, 2.82, 0.215, 255, 237, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIPHENYLSULFONAMIDE
4798, 4ztmB, 0.6820, 2.91, 0.212, 280, 241, IRAK4-INHIBITOR CO-STRUCTURE
4799, 4k9yA, 0.6820, 3.46, 0.335, 271, 251, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-[4-(6-AMINO- PURIN-9-YL)-PHENYL]-3-(5-TERT-BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-UREA
4800, 4jjrB, 0.6820, 3.71, 0.151, 283, 259, A P21 CRYSTAL FORM OF MAMMALIAN CASEIN KINASE 1 DELTA
4801, 4enyA, 0.6820, 3.08, 0.166, 261, 247, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH (2E5Z)-2-(2- CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-METHOXYBENZYLIDENE)THIAZOLIDIN-4- ONE
4802, 3krlA, 0.6820, 3.38, 0.309, 281, 249, CFMS TYROSINE KINASE IN COMPLEX WITH 5-CYANO-FURAN-2-CARBOXYLIC ACID [4-(4-METHYL-PIPERAZIN-1-YL)-2-PIPERIDIN-1-YL-PHENYL]-AMIDE
4803, 1eh4B, 0.6820, 3.88, 0.148, 293, 264, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
4804, 6g9aA, 0.6819, 3.43, 0.165, 341, 254, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
4805, 6b5jC, 0.6819, 2.93, 0.217, 260, 240, TNNI3K COMPLEXED WITH A 46-DIAMINOPYRIMIDINE
4806, 5d9kA, 0.6819, 3.33, 0.194, 280, 252, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
4807, 4yc6G, 0.6819, 3.28, 0.177, 285, 249, CDK1/CKS1
4808, 4m66A, 0.6819, 2.99, 0.204, 268, 245, CRYSTAL STRUCTURE OF THE MOUSE RIP3 KINASE DOMAIN
4809, 3uytC, 0.6819, 3.91, 0.144, 286, 264, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
4810, 3jy0A, 0.6819, 3.38, 0.167, 275, 252, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
4811, 3cqeA, 0.6819, 3.08, 0.161, 258, 248, WEE1 KINASE COMPLEX WITH INHIBITOR PD074291
4812, 3c4eC, 0.6819, 3.39, 0.166, 272, 253, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
4813, 2wipC, 0.6819, 3.52, 0.160, 292, 256, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
4814, 2bziB, 0.6819, 3.21, 0.172, 272, 250, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU2
4815, 1ywvA, 0.6819, 3.48, 0.165, 274, 254, CRYSTAL STRUCTURES OF PROTO-ONCOGENE KINASE PIM1: A TARGET OF ABERRANT SOMATIC HYPERMUTATIONS IN DIFFUSE LARGE CELL LYMPHOMA
4816, 1gzoA, 0.6819, 3.10, 0.171, 271, 245, STRUCTURE OF PROTEIN KINASE B UNPHOSPHORYLATED
4817, 6brcA, 0.6818, 3.38, 0.187, 265, 252, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
4818, 3f3zA, 0.6818, 3.31, 0.161, 271, 254, CRYSTAL STRUCTURE OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840 IN PRESENCE OF INDIRUBIN E804
4819, 5y86A, 0.6817, 3.23, 0.177, 391, 249, CRYSTAL STRUCTURE OF KINASE 
4820, 5anoA, 0.6817, 2.93, 0.190, 277, 242, CRYSTAL STRUCTURE OF CDK2 PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
4821, 3mvjB, 0.6817, 3.82, 0.174, 320, 264, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
4822, 3c4eA, 0.6817, 3.48, 0.161, 273, 254, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
4823, 1okvA, 0.6817, 3.67, 0.154, 295, 260, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
4824, 4nj3A, 0.6816, 3.00, 0.189, 277, 243, MODULATING THE INTERACTION BETWEEN CDK2 AND CYCLIN A WITH A QUINOLINE- BASED INHIBITOR
4825, 4nifD, 0.6816, 2.95, 0.160, 313, 243, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
4826, 4fktA, 0.6816, 3.12, 0.193, 278, 244, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4827, 3eb0A, 0.6816, 3.10, 0.181, 311, 249, CRYSTAL STRUCTURE OF CGD4_240 FROM CRYPTOSPORIDIUM PARVUM IN COMPLEX WITH INDIRUBIN E804
4828, 3c4eB, 0.6816, 3.42, 0.166, 273, 253, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
4829, 1irkA, 0.6816, 3.44, 0.307, 303, 254, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HUMAN INSULIN RECEPTOR
4830, 6g33C, 0.6815, 3.50, 0.176, 336, 255, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH 5-IODOTUBERCIDIN 
4831, 5uq1A, 0.6815, 3.32, 0.163, 288, 252, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
4832, 5jq8A, 0.6815, 3.09, 0.176, 278, 244, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0943
4833, 5fgkA, 0.6815, 3.60, 0.163, 331, 258, CDK8-CYCC IN COMPLEX WITH 8-[3-(3-AMINO-1H-INDAZOL-6-YL)-5-CHLORO- PYRIDINE-4-YL]-28-DIAZA-SPIRO[4.5]DECAN-1-ONE
4834, 4x3fC, 0.6815, 3.26, 0.188, 273, 250, CRYSTAL STRUCTURE OF THE INTRACELLULAR DOMAIN OF THE M. TUBERCULOSIS SER/THR KINASE PKNA
4835, 4rzwA, 0.6815, 2.92, 0.226, 251, 243, CRYSTAL STRUCTURE OF BRAF (R509H) KINASE DOMAIN BOUND TO AZ628
4836, 2c30A, 0.6815, 3.66, 0.180, 289, 256, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 6
4837, 5x3fB, 0.6814, 3.83, 0.163, 348, 263, CRYSTAL STRUCTURE OF THE YGJG-PROTEIN A-ZPA963-PKA CATALYTIC DOMAIN
4838, 5uitA, 0.6814, 3.19, 0.211, 284, 247, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 14
4839, 5t1sD, 0.6814, 3.09, 0.216, 281, 245, IRAK4 KINASE - COMPOUND 1 CO-STRUCTURE
4840, 5lxcB, 0.6814, 3.25, 0.176, 385, 250, CRYSTAL STRUCTURE OF DYRK2 IN COMPLEX WITH EHT 5372 (COMPOUND 1)
4841, 2r5tA, 0.6814, 3.44, 0.169, 284, 254, CRYSTAL STRUCTURE OF INACTIVE SERUM AND GLUCOCORTICOID- REGULATED KINASE 1 IN COMPLEX WITH AMP-PNP
4842, 1yxsA, 0.6814, 3.45, 0.174, 274, 253, CRYSTAL STRUCTURE OF KINASE PIM1 WITH P123M MUTATION
4843, 5j1vC, 0.6813, 3.23, 0.185, 314, 249, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW29 (COMPOUND 13)
4844, 4xs2D, 0.6813, 3.06, 0.209, 277, 244, IRAK4-INHIBITOR CO-STRUCTURE
4845, 3mygA, 0.6813, 3.10, 0.190, 252, 247, AURORA A KINASE COMPLEXED WITH SCH 1473759
4846, 2xruA, 0.6813, 3.07, 0.190, 253, 247, AURORA-A T288E COMPLEXED WITH PHA-828300
4847, 2qr8A, 0.6813, 2.96, 0.180, 298, 244, 2.0A X-RAY STRUCTURE OF C-TERMINAL KINASE DOMAIN OF P90 RIBOSOMAL S6 KINASE 2 (RSK2)
4848, 1mruA, 0.6813, 3.18, 0.161, 269, 249, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
4849, 6b5jA, 0.6812, 2.81, 0.205, 263, 239, TNNI3K COMPLEXED WITH A 46-DIAMINOPYRIMIDINE
4850, 5m51A, 0.6812, 3.01, 0.168, 260, 244, NEK2 BOUND TO ARYLAMINOPURINE COMPOUND 8
4851, 4y83A, 0.6812, 3.43, 0.169, 299, 254, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(2-AMINO-5- (QUINOLIN-3-YL)PYRIDIN-3-YL)-134-OXADIAZOLE-2(3H)-THIONE
4852, 4f6sA, 0.6812, 3.61, 0.187, 328, 256, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 7 (1-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]UREA)
4853, 3zfyA, 0.6812, 3.26, 0.312, 260, 247, CRYSTAL STRUCTURE OF EPHB3
4854, 3lokB, 0.6812, 2.74, 0.301, 242, 239, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR PD168393
4855, 3d7tA, 0.6812, 2.91, 0.302, 249, 245, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
4856, 2b9hA, 0.6812, 3.13, 0.157, 337, 249, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM STE7
4857, 1x8bA, 0.6812, 3.07, 0.158, 259, 247, STRUCTURE OF HUMAN WEE1A KINASE: KINASE DOMAIN COMPLEXED WITH INHIBITOR PD0407824
4858, 6aydA, 0.6811, 3.33, 0.167, 272, 252, PIM1 COMPLEXED WITH N-(6-(4-HYDROXYPHENYL)-1H-INDAZOL-3-YL) CYCLOPROPANECARBOXAMIDE
4859, 5x17B, 0.6811, 3.90, 0.148, 289, 263, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
4860, 4mq2A, 0.6811, 3.36, 0.151, 343, 252, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
4861, 3v3vA, 0.6811, 3.28, 0.199, 351, 251, STRUCTURAL AND FUNCTIONAL ANALYSIS OF QUERCETAGETIN A NATURAL JNK1 INHIBITOR
4862, 2bheA, 0.6811, 2.76, 0.180, 274, 239, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 5-BROMO-INDIRUBINE
4863, 2b9fA, 0.6811, 3.16, 0.149, 337, 249, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED FUS3
4864, 5o13A, 0.6810, 3.21, 0.177, 270, 249, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
4865, 4y83B, 0.6810, 3.48, 0.176, 302, 255, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(2-AMINO-5- (QUINOLIN-3-YL)PYRIDIN-3-YL)-134-OXADIAZOLE-2(3H)-THIONE
4866, 4xhgA, 0.6810, 4.00, 0.149, 357, 268, STRUCTURE OF C. GLABRATA HRR25 BOUND TO ADP (FORMATE CONDITION)
4867, 4ek6A, 0.6810, 3.04, 0.193, 278, 243, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
4868, 3fpmA, 0.6810, 2.90, 0.148, 283, 243, CRYSTAL STRUCTURE OF A SQUARATE INHIBITOR BOUND TO MAPKAP KINASE-2
4869, 2hwoB, 0.6810, 2.71, 0.290, 242, 238, CRYSTAL STRUCTURE OF SRC KINASE DOMAIN IN COMPLEX WITH COVALENT INHIBITOR
4870, 5texA, 0.6809, 3.44, 0.174, 274, 253, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
4871, 5mqvF, 0.6809, 3.79, 0.146, 286, 261, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
4872, 5hhwA, 0.6809, 3.45, 0.299, 306, 254, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH CIS-(R)-7-(3-(AZETIDIN-1-YLMETHYL)CYCLOBUTYL)-5-(3-((TETRAHYDRO-2H- PYRAN-2-YL)METHOXY)PHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE.
4873, 5acbD, 0.6809, 3.79, 0.160, 319, 263, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
4874, 4mygA, 0.6809, 3.17, 0.185, 335, 249, MAPK13 ACTIVE FORM
4875, 3we8A, 0.6809, 3.34, 0.171, 273, 252, PIM-1 KINASE IN COMPLEX WITH RUTHENIUM-BASED INHIBITOR
4876, 2b9jA, 0.6809, 3.11, 0.157, 337, 249, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM FAR1
4877, 1gznA, 0.6809, 3.20, 0.167, 271, 246, STRUCTURE OF PKB KINASE DOMAIN
4878, 1f5qA, 0.6809, 3.49, 0.148, 296, 256, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
4879, 6fykB, 0.6808, 3.40, 0.161, 349, 254, X-RAY STRUCTURE OF CLK2-KD(136-496)/INDAZOLE1 AT 2.39A 
4880, 5hi2A, 0.6808, 2.80, 0.224, 247, 241, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH SORAFENIB
4881, 4joaA, 0.6808, 3.12, 0.283, 250, 244, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 7-AZAINDOLE BASED INHIBITOR
4882, 4ic7A, 0.6808, 3.48, 0.156, 355, 256, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
4883, 6fypA, 0.6807, 3.50, 0.149, 348, 255, X-RAY STRUCTURE OF CLK3-KD(GP-[275-632]; NON-PHOS.)/CX-4945 AT 2.29A 
4884, 5cs6B, 0.6807, 3.22, 0.153, 316, 248, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
4885, 5bvnA, 0.6807, 3.29, 0.297, 278, 249, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
4886, 4qp3B, 0.6807, 3.41, 0.165, 331, 254, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
4887, 1g5sA, 0.6807, 2.80, 0.183, 275, 240, CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH THE INHIBITOR H717
4888, 6b5jD, 0.6806, 2.84, 0.222, 257, 239, TNNI3K COMPLEXED WITH A 46-DIAMINOPYRIMIDINE
4889, 5n4oA, 0.6806, 3.25, 0.172, 271, 250, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE (E)-3-(P-TOLYL)ACRYLIC ACID
4890, 4fg9B, 0.6806, 3.20, 0.179, 279, 246, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-320 IN COMPLEX WITH ATP
4891, 3t9iA, 0.6806, 3.22, 0.165, 273, 249, PIM1 COMPLEXED WITH A NOVEL 36-DISUBSTITUTED INDOLE AT 2.6 ANG RESOLUTION
4892, 3m11A, 0.6806, 3.02, 0.187, 256, 246, CRYSTAL STRUCTURE OF AURORA A KINASE COMPLEXED WITH INHIBITOR
4893, 5mqvA, 0.6805, 3.74, 0.146, 286, 260, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
4894, 5e1sA, 0.6805, 3.28, 0.292, 284, 250, THE CRYSTAL STRUCTURE OF INSR TYROSINE KINASE IN COMPLEX WITH THE INHIBITOR BI 885578
4895, 4cxaC, 0.6805, 3.91, 0.162, 330, 266, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
4896, 3uokB, 0.6805, 3.28, 0.190, 265, 248, AURORA A IN COMPLEX WITH YL5-81-1
4897, 3tubA, 0.6805, 3.22, 0.352, 253, 250, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH 1-(5-(67- DIMETHOXYQUINOLIN-4-YLOXY)PYRIDIN-2-YL)-3-((1R2S)-2- PHENYLCYCLOPROPYL)UREA
4898, 3qrkA, 0.6805, 3.05, 0.347, 270, 245, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DP- 987
4899, 2c3iB, 0.6805, 3.27, 0.168, 266, 250, CRYSTAL STRUCTURE OF HUMAN PIM1 IN COMPLEX WITH IMIDAZOPYRIDAZIN I
4900, 5uq0B, 0.6804, 3.24, 0.313, 256, 246, FGFR1 KINASE DOMAIN COMPLEX WITH FRAGMENT 22-DIMETHYL-23- DIHYDROBENZOFURAN-7-CARBOXAMIDE
4901, 3a99A, 0.6804, 3.39, 0.175, 273, 252, STRUCTURE OF PIM-1 KINASE CRYSTALLIZED IN THE PRESENCE OF P27KIP1 CARBOXY-TERMINAL PEPTIDE
4902, 1o6yA, 0.6804, 3.03, 0.167, 260, 246, CATALYTIC DOMAIN OF PKNB KINASE FROM MYCOBACTERIUM TUBERCULOSIS
4903, 4ztnB, 0.6803, 3.13, 0.213, 282, 244, IRAK4-INHIBITOR CO-STRUCTURE
4904, 2a4lA, 0.6803, 3.20, 0.179, 286, 246, HUMAN CYCLIN-DEPENDENT KINASE 2 IN COMPLEX WITH ROSCOVITINE
4905, 5j1wB, 0.6802, 3.52, 0.176, 337, 255, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW31 (COMPOUND 14)
4906, 4f6wA, 0.6802, 3.47, 0.180, 330, 255, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 1 (N-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-4-[2-({[3-TERT-BUTYL- 1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]CARBAMOYL}AMINO)ETHYL]PIPERAZINE- 1-CARBOXAMIDE)
4907, 3f69A, 0.6802, 3.15, 0.138, 270, 246, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
4908, 2c47B, 0.6802, 3.77, 0.138, 289, 261, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
4909, 1z57A, 0.6802, 3.51, 0.180, 333, 255, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH 10Z-HYMENIALDISINE
4910, 5oktB, 0.6801, 3.74, 0.146, 281, 260, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH IWP-2 
4911, 4yljA, 0.6801, 3.41, 0.146, 346, 253, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-IODO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLINE-6-CARBOXYLIC ACID INHIBITOR 5J
4912, 4iaaA, 0.6801, 3.31, 0.167, 272, 251, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE
4913, 2z2wA, 0.6801, 3.12, 0.161, 260, 248, HUMAND WEE1 KINASE COMPLEXED WITH INHIBITOR PF0335770
4914, 2bikB, 0.6801, 3.29, 0.171, 272, 251, HUMAN PIM1 PHOSPHORYLATED ON SER261
4915, 5xd6B, 0.6800, 2.85, 0.224, 282, 237, CARK1 PHOSPHORYLATES ABA RECEPTORS
4916, 4yu2A, 0.6800, 3.42, 0.142, 348, 253, CRYSTAL STRUCTURE OF DYRK1A WITH HARMINE-DERIVATIZED ANNH-75 INHIBITOR
4917, 4fg9A, 0.6800, 3.14, 0.188, 278, 245, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-320 IN COMPLEX WITH ATP
4918, 6ft8A, 0.6799, 3.52, 0.176, 338, 255, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH INHIBITOR 8G 
4919, 6cqhB, 0.6799, 3.98, 0.124, 316, 266, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N- PROPYNYL-N-ETHYL-DIHYDROPTERIDINE INHIBITOR
4920, 4mq2D, 0.6799, 3.18, 0.141, 329, 248, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
4921, 2o65A, 0.6799, 3.60, 0.173, 274, 255, CRYSTAL STRUCTURE OF PIM1 WITH PENTAHYDROXYFLAVONE
4922, 1h24A, 0.6799, 3.65, 0.159, 293, 258, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
4923, 1h01A, 0.6799, 3.25, 0.174, 286, 247, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
4924, 5tkdB, 0.6798, 2.59, 0.210, 247, 238, CRYSTAL STRUCTURE OF TYROSINE KINASE 2 JH2 (PSEUDO KINASE DOMAIN) COMPLEXED WITH 6-[(35-DIMETHYLPHE NYL)AMINO]-8- (METHYLAMINO) IMIDAZO[12-B]PYRIDAZINE-3-CARBO XAMIDE
4925, 5aagA, 0.6798, 3.09, 0.186, 253, 247, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14B)
4926, 4tw9B, 0.6798, 3.89, 0.144, 289, 264, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
4927, 4fg8B, 0.6798, 2.92, 0.189, 268, 243, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-315 IN COMPLEX WITH ATP
4928, 4cqgA, 0.6798, 3.18, 0.190, 313, 247, THE CRYSTAL STRUCTURE OF MPK38 IN COMPLEX WITH OTSSP167 AN ORALLY-ADMINISTRATIVE MELK SELECTIVE INHIBITOR
4929, 4bcqC, 0.6798, 3.51, 0.165, 292, 255, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
4930, 3c51B, 0.6798, 3.90, 0.183, 461, 263, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 3.55A
4931, 2w96B, 0.6798, 3.01, 0.185, 267, 243, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
4932, 5jznB, 0.6797, 3.26, 0.179, 266, 251, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
4933, 3uokA, 0.6797, 3.21, 0.190, 265, 247, AURORA A IN COMPLEX WITH YL5-81-1
4934, 2izsA, 0.6797, 4.00, 0.131, 298, 267, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
4935, 5o11A, 0.6796, 3.21, 0.165, 268, 248, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
4936, 5hd7A, 0.6796, 3.53, 0.161, 347, 255, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT MUTANT SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
4937, 4o0rB, 0.6796, 3.55, 0.193, 282, 254, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
4938, 4i93A, 0.6796, 3.23, 0.150, 281, 246, STRUCTURE OF THE BSK8 KINASE DOMAIN (SEMET LABELED)
4939, 4btkA, 0.6796, 3.75, 0.162, 287, 260, TTBK1 IN COMPLEX WITH INHIBITOR
4940, 3uohB, 0.6796, 3.21, 0.190, 264, 247, AURORA A IN COMPLEX WITH RPM1722
4941, 3uohA, 0.6796, 3.21, 0.190, 264, 247, AURORA A IN COMPLEX WITH RPM1722
4942, 3uixA, 0.6796, 3.29, 0.164, 266, 250, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4943, 3le6A, 0.6796, 3.17, 0.176, 283, 245, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A PYRAZOLOBENZODIAZEPINE INHIBITOR
4944, 5aafA, 0.6795, 3.18, 0.190, 254, 248, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14A)
4945, 4xhlA, 0.6795, 3.81, 0.134, 330, 262, STRUCTURE OF S. CEREVISIAE HRR25 1-394 (K38R MUTANT)
4946, 4ibmA, 0.6795, 3.56, 0.286, 301, 252, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH AN INHIBITOR IRFIN-1
4947, 2eu9A, 0.6795, 3.46, 0.142, 345, 254, CRYSTAL STRUCTURE OF CLK3
4948, 5w84A, 0.6794, 2.93, 0.212, 279, 241, CRYSTAL STRUCTURE OF IRAK-4 WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 4)
4949, 4medA, 0.6794, 3.32, 0.167, 272, 251, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE DERIVATIVES
4950, 4fksA, 0.6794, 2.91, 0.191, 275, 241, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
4951, 1yi4A, 0.6794, 3.34, 0.175, 267, 251, STRUCTURE OF PIM-1 BOUND TO ADENOSINE
4952, 6gdqA, 0.6793, 3.41, 0.166, 339, 253, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
4953, 6fykC, 0.6793, 3.44, 0.154, 349, 254, X-RAY STRUCTURE OF CLK2-KD(136-496)/INDAZOLE1 AT 2.39A 
4954, 5lvpA, 0.6793, 3.65, 0.198, 275, 257, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN HM-PEPTIDE BOUND TO THE PIF-POCKET
4955, 4byiA, 0.6793, 3.21, 0.189, 254, 249, AURORA A KINASE BOUND TO A HIGHLY SELECTIVE IMIDAZOPYRIDINE INHIBITOR
4956, 3etaB, 0.6793, 3.42, 0.308, 292, 250, KINASE DOMAIN OF INSULIN RECEPTOR COMPLEXED WITH A PYRROLO PYRIDINE INHIBITOR
4957, 5w4wC, 0.6792, 3.93, 0.148, 284, 263, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
4958, 5uiuA, 0.6792, 3.34, 0.221, 286, 249, CRYSTAL STRUCTURE OF IRAK4 IN COMPLEX WITH COMPOUND 30
4959, 5obrA, 0.6792, 3.18, 0.177, 255, 248, AURORA A KINASE IN COMPLEX WITH 2-(3-CHLORO-5-FLUOROPHENYL)QUINOLINE- 4-CARBOXYLIC ACID AND JNJ-7706621
4960, 4q9sA, 0.6792, 3.30, 0.337, 252, 249, CRYSTAL STRUCTURE OF HUMAN FOCAL ADHESION KINASE (FAK) BOUND TO COMPOUND1 (35-DIHYDRO[124]TRIAZINO[34-C][14]BENZOXAZIN-2(1H)- ONE)
4961, 3k5uA, 0.6792, 3.14, 0.190, 260, 248, IDENTIFICATION SAR STUDIES AND X-RAY COCRYSTAL ANALYSIS OF A NOVEL FURANO-PYRIMIDINE AURORA KINASE A INHIBITOR
4962, 2vtqA, 0.6792, 2.79, 0.184, 274, 239, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4963, 2izuA, 0.6792, 3.99, 0.124, 297, 266, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
4964, 1y6bA, 0.6792, 3.32, 0.306, 266, 248, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 2-ANILINO-5-ARYL-OXAZOLE INHIBITOR
4965, 5hvyA, 0.6791, 3.62, 0.187, 335, 257, CDK8/CYCC IN COMPLEX WITH COMPOUND 20
4966, 4zloA, 0.6791, 3.54, 0.182, 277, 253, SERINE/THREONINE-PROTEIN KINASE PAK1 COMPLEXED WITH A DIBENZODIAZEPINE: IDENTIFICATION OF AN ALLOSTERIC SITE ON PAK1
4967, 4bidA, 0.6791, 2.71, 0.208, 254, 240, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4968, 5ih9A, 0.6790, 3.12, 0.191, 308, 246, MELK IN COMPLEX WITH NVS-MELK8A
4969, 4qp1B, 0.6790, 3.39, 0.162, 343, 253, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
4970, 4f7jA, 0.6790, 3.46, 0.178, 326, 253, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 3 (1-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-3-(2-HYDROXYETHYL) UREA)
4971, 4bfmA, 0.6790, 3.20, 0.190, 313, 247, THE CRYSTAL STRUCTURE OF MOUSE PK38
4972, 1unlA, 0.6790, 3.55, 0.141, 292, 256, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
4973, 6fyrA, 0.6789, 3.47, 0.142, 355, 254, X-RAY STRUCTURE OF CLK3-KD(GP-[275-632]; NON-PHOS.)/CPD-2 AT 1.42A 
4974, 4yljD, 0.6789, 3.37, 0.135, 347, 252, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-IODO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLINE-6-CARBOXYLIC ACID INHIBITOR 5J
4975, 4rc3A, 0.6789, 3.30, 0.172, 271, 250, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
4976, 3w55A, 0.6789, 3.04, 0.163, 335, 246, THE STRUCTURE OF ERK2 IN COMPLEX WITH FR148083
4977, 5mqvE, 0.6788, 3.78, 0.146, 287, 260, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
4978, 3en6B, 0.6788, 2.62, 0.281, 239, 235, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP102 A MULTITARGETED KINASE INHIBITOR
4979, 1ywnA, 0.6788, 3.38, 0.301, 279, 249, VEGFR2 IN COMPLEX WITH A NOVEL 4-AMINO-FURO[23-D]PYRIMIDINE
4980, 6f3eB, 0.6787, 3.22, 0.228, 282, 246, IRAK4 IN COMPLEX WITH INHIBITOR 
4981, 5hd4A, 0.6787, 3.55, 0.165, 347, 255, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT WILD TYPE SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
4982, 3q4zB, 0.6787, 3.47, 0.166, 279, 253, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
4983, 4yljC, 0.6786, 3.39, 0.143, 346, 252, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-IODO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLINE-6-CARBOXYLIC ACID INHIBITOR 5J
4984, 4jbqA, 0.6786, 3.23, 0.189, 257, 249, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
4985, 3nr9C, 0.6786, 3.58, 0.152, 347, 256, STRUCTURE OF HUMAN CDC2-LIKE KINASE 2 (CLK2)
4986, 3nr9A, 0.6786, 3.59, 0.160, 341, 256, STRUCTURE OF HUMAN CDC2-LIKE KINASE 2 (CLK2)
4987, 2zv2A, 0.6786, 3.17, 0.179, 256, 246, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2 BETA CAMKK2 KINASE DOMAIN IN COMPLEX WITH STO-609
4988, 4ic7D, 0.6785, 3.53, 0.156, 353, 256, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
4989, 1dm2A, 0.6785, 2.85, 0.175, 274, 240, HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR HYMENIALDISINE
4990, 5eymB, 0.6784, 3.41, 0.202, 292, 252, MEK1 IN COMPLEX WITH BI 847325
4991, 5cwzC, 0.6784, 2.90, 0.170, 271, 241, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
4992, 5aaeA, 0.6784, 3.14, 0.190, 252, 247, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14D)
4993, 3uo6A, 0.6784, 3.16, 0.191, 264, 246, AURORA A IN COMPLEX WITH YL5-083
4994, 2vtnA, 0.6784, 2.79, 0.176, 274, 239, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
4995, 1jowB, 0.6784, 3.08, 0.163, 277, 246, CRYSTAL STRUCTURE OF A COMPLEX OF HUMAN CDK6 AND A VIRAL CYCLIN
4996, 4z7hB, 0.6783, 3.34, 0.189, 388, 249, CRYSTAL STRUCTURE OF HUMAN IRE1 CYTOPLASMIC KINASE-RNASE REGION - COMPLEX WITH IMIDAZOPYRIDINE COMPOUND 3
4997, 4bckC, 0.6783, 3.55, 0.165, 293, 255, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
4998, 3uo6B, 0.6783, 3.16, 0.191, 264, 246, AURORA A IN COMPLEX WITH YL5-083
4999, 2xngA, 0.6783, 3.04, 0.188, 253, 245, STRUCTURE OF AURORA-A BOUND TO A SELECTIVE IMIDAZOPYRAZINE INHIBITOR
5000, 1wzyA, 0.6783, 3.44, 0.173, 350, 254, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A PYRAZOLOPYRIDAZINE DERIVATIVE
